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Abstract
Nance-Horan Syndrome (NHS) is an X-linked developmental syndrome characterised by 
congenital cataract, dental anomalies, and dysmorphological features often associated with 
mental retardation. The NHS locus on Xp22.13 is encompassed by the disease locus for X- 
linked congenital cataract (CXN). Analysis of microsatellites within the CXN family 
resulted in refinement of the CXN disease interval, reducing the region of overlap between 
the CXN and NHS disease loci. Candidate genes in the overlapping intervals were 
identified bioinformatically and their genomic structures evaluated. Patient DNA was 
screened by direct sequencing, resulting in the identification of mutations within a novel 
gene in four British families with NHS, but not the CXN family. This novel gene, named 
NHS, is encoded by at least 10 exons transcribed into at least five mRNA isoforms A, B, C, 
D, and E (encoding a putative 1,630 a.a., 1,335 a.a., 1,474 a.a., 1,453 a.a., and 1,473 a.a. 
protein, respectively). All mutations identified are truncating and three mutations have been 
identified in exon 1, which are only expressed in isoform A. This implies that mutations in 
isoform A are sufficient to cause disease in families with NHS. Functional clues for the 
NHS protein were investigated resulting in identification of three new genes with 
significant homology to NHS (NHS-Like 1 (NHSL1), NHSL2 and NHSL3). All four genes 
share a conserved genomic structure. Fetal expression analysis of NHS, NHSL1 and NHSL2 
suggests that NHSL1 and NHSL2 are more ubiquitous than NHS. Analysis of the NHS 
family of proteins revealed significant homology to members of the WASP family, which 
consists of WASP, N-WASP and WAVE 1-3. The WASP protein family play a crucial role 
in regulating actin dynamics, directly linking small GTPase signalling to actin 
polymerisation through activation of the Arp2/3 complex. An anti-peptide antibody to the 
C-terminus of NHS, completely conserved across species, was raised and characterised. A 
major NHS isoform (approximately 170 kDa) was detected in several cell lines. Subcellular 
localisation studies in MTLn3 cells showed localization of endogenous NHS to the leading 
edge of lamellipodia, a localisation pattern reminiscent of the Arp2/3 complex. Endogenous
NHS also localised to some actin stress fibres. Homology to the WASP protein family and 
localisation of endogenous NHS to the leading edge of lamellipods strongly supports a role 
for NHS in actin cytoskeletal dynamics during development.
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1.1 Structure of the eye
The human eye consists of three basic layers, a fibrous (corneoscleral) coat, the uvea or 
uveal tract (formed from the choroid, ciliary body and iris) and the neural layer (the 
retina). As shown in figure 1.1, the human eye contains numerous structures. The pupil 
forms the central aperture of the iris, a pigmented circular muscle. The iris controls the 
amount of light passing through the lens by controlling the size of the pupil. Due to the 
absorbing pigments of the retinal pigment epithelial cells in the retina, the pupil appears 
black. The cornea, forming the fibrous coat, is responsible for most of the refractive 
power of the eye. The cornea is transparent, covering the lens and the iris, and presents 
a tough physical barrier to trauma and infection. The sclera, which is continuous with 
the cornea, is a dense fibrous opaque white outer coat, forming part of the fibrous coat.
The lens (comprised of the capsule, lens epithelium and the lens fibres) is suspended in 
the eye by zonular ligaments between the aqueous humour and the vitreous body. The 
zonular ligaments cause the lens to change shape by contracting and relaxing (known as 
accommodation), thereby allowing a sharp image to be formed on the retina.
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Figure 1.1 A cross-sectional view of the human eye
(Adapted from Fight for Sight, http://www.fightforsight.org.uk/)
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1.2 Lens development and cataract morphology
1.2.1 Lens development
Human lens organogenesis can be detected at 3-4 weeks gestation (4-mm embryo). 
Surface ectoderm cells overlying the developing optic vesicle starts thickening to form 
the epithelial cells of the lens placode (figure 1.2). The lens placode then begins to 
invaginate towards the developing optic cup forming the lens pit (figure 1.2), whilst the 
lens stalk retains a temporary connection with the surface ectoderm. By the 8 or 9 mm 
stage (beginning of week 6) the lens stalk is pinched off creating a lens vesicle about 0.2 
mm in diameter (Snell and Lemp, 1989; Jaffe and Horwitz, 1992; Brown and Bron, 
1996).
Upon formation of the lens vesicle, the nuclei of cells lining the posterior wall assume 
an anterior location as they elongate to form the primary lens fibres. Elongation of 
these cells leads to the obliteration of the cavity of the vesicle by the 18 mm stage (end 
of week 7, figure 1.2). At the end of the seventh week of fetal life the synthesis of 
primary lens fibres is complete, and it is this part of the lens that in later development 
becomes the “embryonic nucleus.” By this stage the lens is primarily spherical and is 
0.35 mm in diameter (Jaffe and Horwitz, 1992).
Cells not induced to form primary lens fibres, form the cuboidal monolayer of lens 
epithelial cells. Only cells lying within a narrowly defined area positioned anteriorly to 
the lens equator, known as the germinative or proliferation zone (figure 1.2, B), are able 
to divide and differentiate (Jaffe and Horwitz, 1992). After the 25 mm stage (week 8) 
of development, secondary lens fibres are formed through division of cells within the 
germinative zone and are continued to be produced throughout life (Brown and Bron, 
1996). During the elongation process, lens cells expel their nuclei, mitochondria, golgi 
bodies, and rough and smooth endoplasmic reticulum leading to mature lens fibres that 
are unable to divide and have minimal turnover of protein constituents (McAvoy, 1981).
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Figure 1.2 The developing lens
A) A developing mouse eye lens shown as histological sections at embryonic day (E) 9.5, El 1.5, E15.5, and Postnatal day (P) 7. At E9.5 the lens placode (formed from the 
thickening of the surface ectoderm, overlying the optic veiscle) invaginates forming the lens pit (LP). At El 1.5 the lens pit has closed over to form the lens vesicle (LV). 
The lens vesicle detaches from the surface ectoderm and the primary lens fibres (PLF) begin to elongate from the posterior part of the lens, filling the lumen. By El 5.5, the 
PLF have completely filled the lumen, which is followed by division and migration of epithelial cells to the lens equator (LE). At the lens bow (LB) they differentiate into 
secondary lens fibres cells and elongate to form lamellae surrounding the embryonic nucleus. At P7 the eye is developed and the lens (L) is free of cellular organelles. IL, 
inner layer; OL, outer layer; OS, optic stalk; C, cornea; NFL, nerve fibre layer; ON, optic nerve; R, retina. B) Following the PLF completely filling the lumen of the lens 
vesicle, secondary lens fibres (SLF) elongate at the lens bow region. The points at which the SLF meet at the posterior and anterior poles gives rise to the lens sutures. Taken
from Graw and Loster, 2003.
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Sutures are formed at points where secondary lens fibres come into apposition (figure 
1.2; Kuszak et al., 1984). Sutures start to appear at about the 35 mm stage (8-9 weeks 
of fetal life). Until birth, addition of lens cell layers gives rise to a suture plane, with a 
symmetrical Y pattern in the anterior section and a symmetrical inverted Y pattern at the 
posterior section. Following birth, the formation of sutures becomes complex and 
irregular leading to various zones of discontinuity (Jaffe and Horwitz, 1992).
The human lens capsule is a transparent basement membrane, completely encompassing 
the lens, and continues to grow throughout life. At the 13 mm developmental stage 
(start of week 7), epithelial cells secrete the anterior portion of the capsule whilst the 
elongating fibre cells secrete the posterior portion (Jaffe and Horwitz, 1992). The lens 
capsule plays an important role in modelling the shape of the lens as its volume 
continues to increase throughout the life of the lens.
1.3 Morphology of congenital cataracts
Cataract is an opacity of the lens, which varies in morphology, can be either static or 
progressive, and is frequently confined to a specific area of the lens. Inherited 
congenital cataract can occur as an isolated anomaly or may be associated with an 
inherited disease syndrome. Examples of X-linked inherited syndromic cataract and 
their loci include, Alport syndrome at Xq22 (Atkin et al., 1988; Szpiro-Tapia et al., 
1988), Lowe Syndrome at Xq26.2 (Silver et al., 1987; Nussbaum et al., 1997; Reilly et 
al., 1990), Oculofaciocardiodental syndrome at Xpll.4, and Nance-Horan Syndrome at 
Xp22.2 (Lewis, 1989; Stambolian et al., 1990; Zhu et al., 1990; Wilkie et al., 1993; 
Bergen et al., 1994; Aalfs et al., 1996; Toutain et al., 1997).
Variation of type and severity of lens opacities is great. They range from dense, total 
opacities involving different structures of the lens leading to total blindness, to a minute 
white dot in the anterior capsule (Amaya et al., 2003). Only those of relevance to this 
project are referred to below.
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1.3.1 Total cataracts
These types of cataract have been reported in families with autosomal dominant and X- 
linked modes of inheritance (Semina et al., 1998; Francis et al., 2002).
Cataracts affecting the whole of the lens usually have an early onset, requiring early 
surgical intervention if they have a dramatic effect on vision. General opacity of all lens 
fibres is commonly referred to as a total cataract. Total cataract may develop from 
lamellar or nuclear cataracts and in some cases the lenses are found to be totally opaque 
upon first diagnosis (figure 1.3). Whole lens cataracts are seen in Down syndrome and 
syndromes, as well as familial or sporadic cases. Less common are congenital 
Morgagnian cataracts. These are total, dense cataracts in which the outer zones of the 
lens become liquefied whilst the nucleus remains intact. A third type of total cataract 
are disk-like and membranous cataracts, representing varying stages of reabsorption of 
the lens leaving either a disk of lens material or a bag of milky or crystalline substance 
that is either dense and completely opaque or thin and transparent (Amaya et al., 2003).
Figure 1.3 Total cataract (Taken from Reddy et at., 2004)
1.3.2 Central cataracts
Nuclear cataracts consist of opacities of the majority of the embryonic or fetal nucleus 
(figure 1.2, B). They are static and vary from fine dots to a dense white and chalk-like, 
central cataract. The cataract is usually bilateral and is commonly associated with 
opacified cortical fibres encircling the nuclear opacity, known as riders. Nuclear 
cataracts are also on occasion combined with opacities of the sutures (Amaya et al., 
2003). Other central cataracts include lamellar or zonular cataracts, central pulverulent 
cataracts, cortical cataracts and cerulean, floriform or coronary cataracts.
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1.3.3 Sutural cataracts
Sutural cataracts (figure 1.4) consist of opacities around or involving the sutures of the 
fetal nucleus (figure 1.2), are very common, stationary and usually bilateral and 
familial. Their morphology ranges from an increased density of the sutures to a variety 
of whitish or cerulan dots clustered around the sutures which may progress and form 
nuclear or central cataracts (Amaya et al., 2003). Sutural cataracts may be the only 
phenotype observed in asymptomatic relatives. They are reported to be inherited in 
autosomal dominant and X-linked recessive modes and are seen in female carriers of 
Nance-Horan Syndrome (Zhu et al., 1990).
E dw ard  S. H a rk n e ss  Eya Institu te  
Columbia University
Figure 1.4 Sutural cataract (Taken from http://dro.hs.columbia.edu/antsutural.htm)
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1.4 Genetics of congenital cataract
A large proportion of inherited non-syndromic cataract exhibits an autosomal- 
dominant mode of inheritance (table 1.1), although autosomal recessive and X-linked 
inheritance have been reported (Francois, 1982; Francis et al., 2002). A number of 
chromosomal structural abnormalities have also been associated with congenital 
cataract such as, Wilms tumour, aniridia, genitourinary anomalies, and mental 
retardation (WAGR syndrome, Pinna et al., 2004).
Cataract is an extremely heterogenous disease and the number of genes and mapped loci 
associated with cataract is ever increasing (tables 1.1, 1.2, and 1.3). Genes implicated in 
cataract, include those encoding transmembrane and structural proteins, and 
transcription factors.
1.4.1 Transmembrane proteins in the lens
Terminally differentiated lens fibre cells are metabolically inactive and therefore are 
dependent on the lens epithelium for adequate nutrition. The removal of waste products 
is also essential to the survival of the lens fibres. The presence of fully functional gap 
junctions and channels is imperative to prevent the precipitation of cell structural 
proteins, causing cataract formation (He and Li, 2000).
1.4.1.1 Connexins
In 1968, Donahue and colleagues assigned the Duffy blood group to chromosome one, 
such that, the cosegregation of cataract with the Duffy blood group locus became the 
first genetically linked autosomal disease in man (Renwick and Lawler, 1963). The 
Duffy Blood group locus was later refined to lq22-23 (Matthew et al., 1994) aiding the 
identification of a mutation in the connexin 50 gene (GJA8) in a family with autosomal 
dominant pulverulent cataract (Shiels et al., 1998). GJA8 is primarily and abundantly 
expressed in human lens (White et al., 1992).
Connexin proteins mediate intercellular transportation of small biomolecules (<1 kDa), 
such as second messengers, ions and metabolites (Goodenough, 1992). In addition, 
connexin proteins allow adjacent cells to coordinate their activities and movements.
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Consequently, their function in the lens is important for homeostasis and maintaining 
lens fibre transparency (Goodenough, 1992).
Connexins form a superfamily of proteins, which associate to form heterogeneous 
oligomeric transmembrane structures called connexons. Connexons form between lens 
fibre cells allowing the flow of ions, metabolites, and second messengers (Goodenough, 
1980), as well as preserving lens fibre cell homeostasis (Mathias et al., 1997). Of the 
connexins, connexin 43 (encoded by GJA1\ connexin 46 (encoded by GJA3) and 
connexin 50 (encoded by GJA8) are expressed within the lens. There have been many 
reports of connexins (when mutated or knocked out) causing a wide spectrum of 
phenotypes. For example, absence of connexin 43 expression leads to dominantly 
inherited severe heart malformations (Reaume et al, 1995), loss of connexin 50 leads to 
dominant zonular pulverulent cataracts (White et al., 1998) and a mutation in connexin 
46 was found in two families with dominant pulverulent cataract (table 1.1; Mackay et 
al, 1999).
1.4.1.2 Aquaporin/MIP
The Major Instrinsic Protein, MIP (MIP26/AQP0) present in lens fibre cells, was the 
first member of the aquaporin family identified. Aquaporins facilitate the transport of 
water across the plasma membrane of cells by acting as channel proteins (Heymann et 
al., 1998). Expression of MIP has been found to be strongest in elongating fibre cells in 
the bow region of the lens (Shiels and Griffin, 1993). Mutations in the MIP gene have 
been identified in two unrelated families (Berry et al., 2000, table 1.1). Each family had 
a different missense mutation giving rise to two distinct forms of cataract. One family 
exhibited polymophic bilateral discrete progressive punctate lens opacities limited to 
mid and peripheral lamellae with additional asymmetric polar opacification. The 
second family were reported to have non-progressive lamellar cataract (Berry et al., 
2000). Functional studies implied that the mutated proteins were not targeted to the cell 
membrane, which may have been a result of misfolding.
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Mode of 
Inheritance Gene Nomenclature Locus Phenotype OMIM Reference
Autosomal
Dominant
Beaded filament structural protein 2, 
Phakinin
BFSP2 3q22.1 Congenital and Juvenile 
Y-sutural
MIM:604219 Conley et al., 2000 
Jakobs et al., 2000 
Zhang et al., 2004
Crystallin, beta A I CRYBA1 17ql 1.2 Congenital zonular, 
with sutural opacities
MIM:600881 Kannabiran et al., 1998
Crystallin, beta B2 CRYBB2 22q 11.23 Congenital cerulean type 2 MIM:601547 Litt et al., 1997
Crystallin, beta B l CRYBB1 22ql2.1 Pulverulent cataract MIM:600929 Mackay et al., 2002
Crystallin, alpha A CRYAA 21q22.3 Congenital Zonular central 
nuclear
MIM: 123580, 
604219
Litt et al., 1998
Crystallin, alpha B CRYAB 1 lq23.1 Congenital posterior polar - Berry et al., 2001
Crystallin, gamma C CRYGC 2q33.3 Coppock-like/ variable zonular MIM: 123680 Heon et al., 1999
Crystallin, gamma D CRYGD 2q33.3 Punctate, progressive juvenile- 
onset
Congenital crystalline 
aculeiform cataract
MIM: 123690 
MIM: 115700
Stephan et al., 1999 
Heon et al., 1999
Crystallin, gamma S CRYGS 3q27.3 Progressive cortical cataract - Sun et al., 2005
Gap junction protein 
alpha 3, 46 kD (Connexin 46)
GJA3 13ql2.11 Zonular pulverulent type 3 MIM:601885 Mackay et al., 1999
Gap junction protein 
alpha 8, 50 kD (Connexin 50)
GJA8 1q21.1 Zonular pulverulent type 1 MIM: 116200 Shiels et al., 1998
Major Intrinsic protein MIP 12q 13.3 Polymorphic/Lamellar MIM: 154050 Berry et al., 2000
Heat shock transcription factor 4 HSFA 16q21 Lamellar cataract MIM: 116800 Bu et al., 2002
v-M af musculoaponeurotic 
fibrosarcoma oncogene homologue
MAF 16q23.2 Juvenile -onset +/- 
microcomea/coloboma
MIM: 177075 Jamieson et al., 2002
Paired-like homeodomain 
transcription factor 3
PITX3 10q24.32 Total MIM:602669 Semina et al., 1998
Paired-like homeobox-containing gene 
6
PAX6 1 lp l3 Congenital cataract “ Glaser et al., 1994
Table 1.1 Disease genes implicated in autosomal dominant cataract
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Mode of 
Inheritance Gene Nomenclature Locus Phenotype OMIM Reference
Autosomal Recessive Lens Intrinsic membrane protein 2 (19 kD)
LIM2 19ql3.41 Late-onset pulverulent cortical MIM: 154045 Pras et al., 2002
Heat shock transcription factor 4 HSFA 16q21 Congenital
Congenital, total white cataract
“ Forshew et al., 2005, 
Smaoui et al., 2004
Crystallin, alpha A CRYAA 21q22.3 Congenital - Pras et al., 2000
Crystallin, beta B3 CRYBB3 2q 11.23 Congenital, nuclear with cortical 
riders
“ Riazuddin et al., 
2005a
Glucosaminyl (N-acetyl) transferase GCNT2 6p24 Congenital - Pras et al., 2004
Syndromes
£
Ferritin Light Chain FTL 19q 13.33 Hyperferritinemia-cataract
syndrome
MIM:600886 Beaumont et al., 1995
Oculocerebrorenal syndrome o f  
Lowe
OCRL Xq25 Congenital MIM:309000 Leahey et al., 1993
Protein-O-mannosyltransferase 2 POMT2 14q24.3 Lamellar “ Van Reeuwijk et al., 
2005
BCL-6 interacting corepressor BCOR X pll.4 Congenital cataract MIM:300166 Ng et al., 2004
Table 1.2 Disease genes implicated in autosomal recessive cataract and syndromal cataract.
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These mutants were also found to have a dominant-negative effect on wildtype protein 
(Francis et al., 2000). The CatLop mouse mutant (Lens opacity) also has a single amino 
acid substitution in the Mip gene, which inhibits targeting of its protein product Mip, to 
the cell membrane (Shiels and Griffin, 1993; Shiels and Bassnett, 1996).
1.4.1.3 Lens intrinsic membrane protein 2, Lim2
The lens intrinsic membrane protein 2 (Lim2, also referred to as MIP 19) is one of the 
most abundant integral membrane protein in lens fibre cells. Its role within the lens is 
believed to involve the exchange of ions and metabolites between lens fibres, epithelial 
cells, and the extracellular matrix. Expression analysis of the Lim2 gene in mouse 
embryos identified its presence in the head region from embryonic day 12 leading to the 
hypothesis that it plays an important role in lens development (Zhou et al., 2002). A 
missense mutation in the human LIM2 gene was identified in a family with autosomal 
recessive presenile cataract (Pras et al., 2002; table 1.2). A missense mutation in the 
mouse Lim2 gene, results in a total opacity with a dense cataract, which is also 
associated with micophthalmia in homozygotes (Steele et al., 1997).
1.4.2 Structural proteins of the lens
1.4.2.1 Crystallins
Crystallins are contained within lens fibre cells. They maintain lens fibre transparency 
through the formation of tightly packed stable oligomers, which interact with the 
surrounding cytoskeleton (Carter et al., 1995). The three major classes of crystallins 
(a-, p-, y-) account for the majority of proteins of the human lens with approximately 
90% of water-soluble proteins being crystallins. The P- and y- crystallin polypeptides 
are part of a superfamily of proteins. They share a common two-domain structure, each 
domain consisting of four torqued p-pleated sheets referred to as “Greek key” motifs 
(Lubsen et al., 1988). The a- crystallin family includes aA- and a-B crystallin and 
both are considered to be molecular chaperones and members of the small heat-shock 
protein family (Graw, 1997).
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Numerous mutations in the crystallin genes have been implicated in autosomal 
dominant cataract (table 1.1), the most recent being the gamma-S crystallin gene 
(CRYGS). A missense mutation in exon 2 of the CRYGS gene was found to co- 
segregate with dominant progressive cortical cataracts in a large six-generation family 
(Sun et al., 2005). Another crystallin gene recently implicated in autosomal recessive 
cataract was crystallin beta, B3 (table 1.2; Riazuddin et al., 2005a).
The a-crystallin complexes are composed of two subunits: aA- and aB-crystallin, 
encoded by two genes CRYAA and CRYAB, respectively. Both a  A- and aB-crystallin
are highly expressed in the developing and mature lens. Mutations in the CRYAA gene 
have been implicated in both autosomal dominant and autosomal recessive forms of 
cataract (tables 1.1 and 1.2; Litt et al., 1998; Pras et al., 2000).
A mutation in the CRYAB gene has been reported to cause autosomal dominant 
congenital posterior polar cataract (Berry et al., 2001).
The p- and y- crystallins are coded for by a p/y crystallin superfamily consisting of six 
p- and seven y-crystallin genes (CRYB and CRYG, respectively). The p-crystallins 
constitute the majority of the water soluble protein in the lens. In mammals the y- 
crystallins are expressed in the lens and retina (Jones et al., 1999). A number of 
mutations within the P-crystallin genes are implicated in autosomal dominant cataract 
(table 1.1). Mutation of the CRYBB2 gene has been found to cause congenital cerulean 
cataract (Litt et al., 1997), whereas mutation of the CRYBB1 is associated with 
pulverulent cataract (Mackay et al., 2002). A splice site mutation in CRYBA1, which 
codes for pA3 crystallin, has been found to cause dominant zonular cataract with sutural 
opacities (Kannabiran et al, 1998). A missense mutation in the CRYGD has been 
associated with autosomal dominant "coral-like" cataract (Mackay et al., 2004).
1.4.2.2 Cytoskeletal proteins
Crystallin proteins interact with the cytoskeleton of lens cells thereby maintaining their 
structural framework. Some of the cytoskeletal proteins found within the lens include: 
Filensin, vimentin, and CP49 (phakinin/beaded filament structural protein 2). The two 
intermediate filament proteins CP49 and filensin form the beaded filament, a structure 
unique to the lens. Beaded filaments were first identified back in 1972 by Maisel and
13
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Perry, and have since been found to be the major cytoskeletal component of the lens. 
Filensin and CP49 are encoded by the BFSPJ and BFSP2 genes, respectively. 
Mutations within the BFSP2 gene have been associated with autosomal dominant 
cataracts in humans (table 1.1; Conley et al., 2000; Jackobs et al., 2000). The cataract 
phenotype observed from mutations in the BFSP2 gene, were of a juvenile-onset 
progressive cataract in one family (Conley et al., 2000). Apart from two affected 
individuals exhibiting congenital nuclear cataract, the majority of the affected members 
from this family had lamellar cataract. The second family with mutations in the BFSP2 
gene had pulverulent and spoke-like cortical opacities from birth (Jakobs et al., 2000). 
Recently, Zhang and colleagues reported that a mutation within the BFSP2 was the 
cause of Y sutural cataract in a Chinese family (table 1.1; Zhang et al., 2004).
1.4.2.2.1 Oculocerebrorenal Syndrome o f Lowe (OCRL)
Lowe Oculocerebrorenal Syndrome (OCRL, MIM 309000) is a rare X-linked disorder 
characterised by bilateral congenital cataract, neonatal hypotonia, severe mental 
retardation, and renal Fanconi syndrome (a defect in solute and protein re-absorption in 
the proximal tube, resulting in progressive kidney wasting and eventually end-stage 
renal disease). Mutations within the OCRL1 gene have been identified in patients with 
Lowe Oculocerebrorenal syndrome (Suchy et al., 1995; Zhang et al., 1995). The 
OCRL1 gene encodes a phosphoinositide 5-phosphatase, with preference for the 
substrate phosphatidylinositol 4,5-bisphosphate PI(4,5)P2 and Phosphatidylinositol 3,4- 
5-trisphosphate PI(3,4,5)P3 (Zhang et al., 1995; Schmid et al., 2004).
Two protein isoforms, A (901 aa) and B (893 aa), which differ by 8 amino acids 
(EDSFLEKE), are coded for by OCRL1. Both isoforms are expressed in all tissues with 
the exception of brain, in which only isoform A is expressed (Johnson et al., 2003). 
Within the OCRL1 protein sequence are two conserved domains; a Rho GAP domain 
located at the C-terminus and an inositol polyphosphate 5-phosphate domain (figure 
1.5).
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EDSFLEKE,
OCRL1
Isoform a 
901 aa
Isoform b 
893 aa
5-phosphatase RhoGAP
Figure 1.5 The human Oculocerebrorenal syndrome of Lowe 1 (OCRL1) protein
The OCRL I gene encodes two isoforms, A (901 aa) and B (890 aa), which differ by the presence/absence 
of eight amino acids (EDSFLEKE). The 5-phosphatase and RhoGAP domains are highlighted. Adapted
from Lowe, 2005.
Kidney proximal tubules and fibroblast cell lines derived from Lowe Oculocerebrorenal 
syndrome patients and therefore devoid of OCRL1, have an elevated concentration of 
phosphatidylinositol 4,5-bisphosphate PI(4,5)P2 (Zhang et al., 1998; Wenk et al., 2003). 
PI(4,5)P2 has a crucial role in cell signaling, polymersiation of the actin cytoskeleton, 
and protein trafficking (Berridge and Irvine, 1989; Toker, 1998; Raucher et al., 2000).
The first observation that the actin cytoskelton of fibroblasts was abnormal in Lowe 
Oculocerebrorenal syndrome patients, was made by Suchy and Nussbaum in 2002. 
Suchy and Nussbaum described the actin cytoskeleton in these fibroblasts to exhibit a 
reduced number and length in actin stress fibres, along with an altered response to 
depolymerising agents and an altered distribution of gelsolin and a-actinin, two actin- 
binding proteins.
Over the last ten years, the OCRL1 protein has been localised to the 7nms-Golgi 
network (TGN) of fibroblasts and epithelial cells (Suchy et al., 1995; Dressman et al., 
2000) and more recently, OCRL1 has been implicated in regulating protein trafficking 
between the TGN and endosomes (Choudhury et al., 2005). OCRL1 was found to be 
present in clathrin-coated vesicles operating between the TGN and endosomes, and has 
been shown to bind the terminal domain of clathrin-heavy chain (CHC) through its
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LIDLE motif residing between the 5-phosphatase and RhoGAP domains (ter Haar et al., 
2000; Ungewickell et al., 2004; Choudhury et al., 2005).
Following their recent work showing that activated GTP bound Rac forms a stable 
complex with the RhoGAP domain of ORCL1, and that endogenous Rac colocalizes 
with OCRL1 to the TGN (Faucherre et al, 2003), Faucherre and colleagues 
demonstrated that a fraction of ORCL1 is transported to the plasma membrane upon 
Rac activation (Faucherre et al., 2005). Further, OCRL1 colocalized with polymersized 
actin in membrane ruffles suggesting a role in regulating actin polymersiation 
(Faucherre et al., 2005). PI(4,5)P2 was also found to accumulate in plasma membrane 
ruffles of patient dermal fibroblasts compared with controls (Faucherre et al., 2005). 
Whether the RhoGAP domain of OCRL1 is a fully functional GTPase-activating 
domain is under question. Firstly, the RhoGAP domain of OCRL1 has a glutamine in 
place of the critical catalytic arginine residue in other Rho GAPs. Secondly, binding of 
the RhoGAP domain in OCRL1 to GDP- and GTP-bound Rac was found to be of equal, 
with only weak GAP activity to the GTP-bound form (Jefferson and Majerus, 1995).
1.4.3 Transcription factors
Transcription factors regulate the formation of the lens throughout development.
1.4.3.1 Pituitary homeobox 3 (PITX3)
Mutation of the pituitary homeobox 3 (PITX3) gene, a member of the RIEG/PITX 
homeobox gene family, has been found to cause anterior segment mesenchymal 
dysgenesis (ASMD) and congenital cataracts in humans (table 1.1; Semina et al., 1998). 
A 17-bp insertion in the 3’ -end of the coding sequence and resulting in a frame shift, 
was identified in a patient with ASMD and cataract. In addition a G—>A transition in 
exon 2 (resulting is a serine being replaced for asparagine) was identified in a patient 
with congenital cataract.
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1.4.3.2 Paired-like homeobox-containing gene 6 (PAX6)
Paired-like homeobox-containing gene 6 (PAX6) is essential for early eye development, 
specification of ocular tissues and normal eye development in vertebrates (Hill et al., 
1992). PAX6 contains a paired domain/homeodomain and is believed to have a role in 
regulating lens crystallin expression (Duncan et al., 1998). Mutations in the human 
PAX6 gene have been found to cause congenital cataracts, aniridia, anophthalmia and 
central nervous system defects (table 1.1; Glaser et al., 1994; Jordan et al., 1992; 
Hanson et al., 1994; Martha et al., 1995).
1.43.3 The bZIP transcription factor family (MAF)
The MAF family are basic leucine zipper (bZIP) transcription factors expressed in the 
lens placode and primary lens fibres (Shimada et al., 2003). MAF proteins bind as 
homo- or heterodimers to MAF responsive elements (MAREs) found in the promoters 
of the crystallin encoding genes and PITX3 (Ogino and Yasuda, 1998; Semina et al., 
2000).
A family reported to have cataract associated with microcomea and iris coloboma (table 
1.1), were found to harbour a mutation affecting the DNA-binding domain of the MAF 
gene (Jamieson et al., 2002). The cataract phenotype within this family was one of 
pulverulent, autosomal juvenile-onset (Jamieson et al., 2002).
1.4.3.4 Heat shock transcription factor 4 (HSF4)
A regulator of small and large heat shock proteins is the heat shock transcription factor 
4 (HSF4). Small heat shock proteins such as aB crystallin have an inherent chaperone 
activity that is not ATP-dependent, unlike the larger heat shock proteins. Larger heat 
shock proteins also have the capability of refolding denatured proteins and protecting 
those newly synthesized proteins from misfolding (Bagchi et al., 2002). Mutation of 
the DNA binding domain of HSF4 is associated with autosomal dominant lamellar 
cataract (table 1.1; Bu et al., 2002). More recently, mutation of HSF4 has been 
implicated in autosomal recessive congenital cataract (table 1.2; Smaoui et al., 2004; 
Forshew et al., 2005).
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1.4.3.5 BCL-6 interacting corepressor (BCOR)
Recently, several families with Oculofaciocardiodental (OFCD, OMIM 300166) were 
found to contain a range of mutations (ffameshifts, deletions, and nonsense mutations) 
in the BCL-6 interacting corepressor (BCOR) gene (Ng et al., 2004). OFCD is a 
distinct form of syndromic microphthalmia associated with congenital cataracts, narrow 
face, broad nasal tip with separated cartilage, cleft palate, and cardiac and dental 
anomalies. OFCD is inherited in an X-linked dominant pattern with male lethality. In 
addition, a family with Lenz micropthalmia (MAA2) was found to have a missense 
mutation in the BCOR gene, substituting a conserved proline (Ng et al., 2004). The 
authors proposed that the two diseases result from defects in alternative functions of the 
BCOR protein (Ng et al., 2004).
1.4.4 Cataract disease loci
In addition to the aforementioned genes already implicated in autosomal dominant, 
recessive and syndromic forms of cataract, a number of disease loci have been mapped 
for which a novel disease gene is yet to be identified. Table 1.3 summarises cataract 
disease loci mapped over the last few years.
Mode of 
Inheritance Locus Phenotype Reference
Autosomal dominant lp36.13-36.21
Total congenital cataract McKay et al., 2005
2p35-pter Coralliform cataract Gao et al., 2005
15q22.33-
24.2
Anterior polar cataract (associated with 
keratoconus)
Hughes et al., 2003
Autosomal
Recessive
9q13-22 Congenital cataract Forshew et al., 
2005
19q 13 Nuclear cataract Riazuddin et al., 
2005b
Table 1.3 Recently mapped disease loci for autosomal dominant and recessive forms of cataract
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1.5 The Human and Mouse Genome Projects
1.5.1 The Human Genome Project and the role of bioinformatics
A major achievement of the human genome project was the publication of the draft 
sequence in the February 2001 issue of Nature (The Human Genome, 2001, Nature 409: 
745-964). Subsequently, international efforts concentrated on converting the draft 
sequence into finished sequence, which was announced by the human genome 
sequencing consortium in April 2003. The overall goal of the Human Genome project 
was to produce a single continuous sequence for each of the 24 human chromosomes 
and to delineate the positions of the genes and genetic markers (Wolfsberg et al., 2001). 
The International Human Genome Sequencing Consortium constructed the working 
draft by putting together sequence segments derived from over 20,000 large-insert 
clones (YACs, BACs, and PACs), and these results were made available on the web by 
numerous international centres including the Sanger Centre (www.sanger.ac.uk), the 
University of California at Santa Cruz (UCSC; www.genome.ucsc.edu), and The 
National Centre for Biotechnology Information (NCBI: 
www.ncbi.nlm.nih.gov/genome/guide/human/).
The finished sequence covers 99 % of the human genomes gene-containing regions 
(euchromatin) sequenced to an accuracy of 99.99 %. Finished sequence is a technical 
term meaning that the sequence is highly accurate (less than 1 error per 10,000 letters), 
and highly contiguous (with remaining gaps corresponding to difficult regions including 
400 stretches of repetitive DNA and centromeres). The average DNA letter now sits on 
a stretch of 27,332,000 base pairs of uninterrupted, high quality sequence (-334 x 
longer than the working draft; Pennisi, 2003).
Closing the gaps in the human genome will not be completed through the industrial- 
scale efforts of the Human Genome Project, but instead will be slowly filled through 
individual research projects and the development of new technologies. Interestingly, 
the total number of genes within the human genome is yet to be determined, with rough 
estimates of 30,000 genes compared to the 35,000 -  45,000 estimates from the release 
of the draft sequence (Pennisi, 2003), and pre-draft estimates of about 100,000.
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A number of resources are available for analysing the human genome. There are 
currently at least three sites, NCBI, Ensembl or UCSC, displaying genomic viewers and 
web-searchable datasets which allow analysis of the human genome sequence without 
the need to run complex software locally (Bimey et al, 2001, Kent et al., 2002). The 
sequence is continually being functionally annotated by the human genetics community, 
in search of molecular mechanisms of genetic diseases by means of gene prediction 
programs, SNP detection (for analysis of human genetic diversity and to identify genes 
for polygenic diseases), and characterisation of novel transcripts. More sophisticated 
software programs have been developed to fully utilise the genome sequence as it 
becomes more contiguous. BLAT, a DNA/Protein Sequence Analysis program, written 
by Jim Kent at UCSC identifies the location of a query sequence within a genome. 
BLAT is designed to quickly find sequences of 95% and greater similarity and is 
especially useful for establishing exon/intron organisation of cDNA sequences using the 
latest genome freeze available.
A wealth of data and software is available that can be used to predict genes. 
Information on expressed sequences (i.e. expressed sequence tags (ESTs) defined from 
complementary DNAs, cDNAs) and proteins from humans and other organisms can 
provide a fast, accurate resource for resolving gene structures against the vast genomic 
background; these, in conjunction with sequence alignment programs such as BLAST 
(Basic Local Alignment Search Tool), can determine the complete structure of a single 
gene (Altschul et al, 1990, Bimey et al., 2001). With BLAST, users input either a 
nucleotide or amino acid query sequence, and search a nucleotide or amino acid 
sequence database. The program returns a list of the sequence “hits”, alignments to the 
query sequence and statistical values (Wolfsberg and Madden, 1999).
Genes can be found through an implied relationship to something else -  for example, 
being a putative ortholog or paralog (see section 1.8; Wolfsberg et al., 2001).
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1.5.2 Annotating the human genome sequence
Following the completion of a working draft for the human genome, it was imperative 
that the human genome be annotated fully in order to utilise the vast amount of 
sequence data generated. Annotation of the human genome sequence involves labelling 
those areas of the genome with biological significance. To annotate the human genome 
sequence (or other genomes), involves correctly positioning known genes on the human 
genome sequence, and predicting new genes. To correctly position known genes, 
messenger RNAs (mRNAs) are aligned with the genomic template using computer 
software. In addition, single nucleotide polymorphisms (SNPs) and sequence tagged 
sites (STSs) are also positioned within the human genome sequence.
Predicting new genes is achieved through the alignment of expressed sequence tags 
(ESTs), which also highlight whether a gene is alternatively spliced. The validity of a 
gene prediction by gene prediction software is greatly enhanced from alignment of 
ESTs to such novel gene predictions. Comparative genomics is also a powerful tool for 
identifying new genes. Confidence in gene predictions arises upon identifying an 
ortholog in closely related species, such as the mouse. Further, comparison of orthologs 
will help to resolve the genomic structures of newly identified genes.
1.5.3 The Mouse Genome Project
Since the release of the human genome draft sequence in early 2001, scientists have 
been keen to fully annotate the human genome. A powerful means by which this task 
can be undertaken involves comparative genomics. The laboratory mouse, Mus 
musculus, provides a model organism for human biology. The mouse has many 
similarities to humans with respect to physiological homeostasis, whole-organ systems, 
reproduction and more importantly disease, which are reflected in their genomes.
Human and mouse lineages diverged approximately 75-125 million years ago and as a 
consequence of evolution, their genome sequences have diverged at a rate of nearly one 
substitution for every two nucleotides through the deletion and insertion of sequences. 
Orthologous sequences within the two genomes can be aligned due to the slow rate at 
which the sequences have diverged. However, the divergence rate has been great
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enough to allow functionally important elements within the two genomes to be 
recognised through their greater degree of conservation (Waterston et al, 2002).
1.5.3.1 The Mouse Genome Sequencing Consortium (MGSC)
The MGSC, originally comprised of three large sequencing centres (the 
Whitehead/Massachusetts Institute of Technology (MIT) Centre for Genome Research, 
the Washington University Genome Sequencing Centre and the Wellcome Trust Sanger 
Institute), who made a concerted effort to sequence the entire mouse genome 
(http://www.sanger.ac.uk/Projects/M_musculus/).
The mouse genome draft sequence was generated by assembling about sevenfold 
sequence coverage from female mice of the C57BL/6J strain. The C57BL/6J strain was 
selected based on its predominant role in mouse genetics and sequence from a female 
mouse was selected in order to obtain equal coverage of the X chromosome and the 
autosomes. Consequently the Y chromosome was omitted from the genome sequencing 
effort.
1.5.3.2 Sequencing the mouse genome using a hybrid strategy
A hybrid strategy consisting of four components, was employed for sequencing the 
mouse genome:
(1) Production of a B AC-based physical map of the mouse genome by 
fingerprinting and sequencing the ends of clones of a BAC library
(2) Whole genome shotgun (WGS) sequencing to approximately sevenfold 
coverage and assembly to generate an initial draft genome sequence
(3) Hierarchical shotgun sequencing of BAC clones covering the mouse genome 
combined with the WGS data to create a hybrid WGS-BAC assembly
(4) Production of a finished sequence by using the BAC clones as a template for 
directed sequencing.
Hierarchical shotgun sequencing was employed to overcome the difficulties 
encountered when sequencing genomes containing highly repetitive sequences.
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1.5.3.3 Conservation of synteny between human and mouse genomes
Initial comparative analysis indicates that the mouse genome is about 14 % smaller than 
the human genome (2.5 Gb compared to 2.9 Gb, respectively). Further, over 90 % of 
both the mouse and human genomes can be partitioned into corresponding regions of 
synteny (Waterston et al., 2002).
The extent of synteny varies between the individual chromosomes except for the X 
chromosome, which is represented as single reciprocal syntenic blocks (Figure 1.6). 
Comparisons between the newly generated sequence-based map of conserved synteny 
and the most recent map based on 3,600 loci, has identified many more conserved 
syntenic segments (342 compared with 202) and a few conserved syntenic blocks (217 
compared with 170). The new sequence-based map of conserved synteny highlights 
numerous rearrangements of segments within blocks, especially on the X chromosome.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 X
Human H 1  ■ ■ ■ ■  ■ ■ ■ ■ ■ ■ ■ ■  ■ ■ ■ ■  ■
1 2 3 4 5 6 7 8 9  10 11 12 1314 15 16 17 18 19 20 21 22 X
Figure 1.6 Synteny between the human and mouse genomes.
Segments and blocks > 300 Kb in size with conserved synteny in human are superimposed on the mouse 
genome. Each colour corresponds to a particular human chromosome. The 343 segments are separated 
from each other by thin, white lines within the 217 blocks of consistent colour (taken from Waterston et
al., 2002).
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1.5.4 Other genome projects
A number of other genome projects are available for viewing and comparative analysis 
with the human genome. The closest human living evolutionary relative, the 
chimpanzee (Pan troglodytes), has a genome that differs by roughly 1.4 % to that of 
humans. The Broad Institute and Genome Sequencing Centre at the Washington 
University school of Medicine made the Pan troglodytes genome available on the public 
domain back in December 2003. The chimpanzee genome consists of 23 pairs of 
autosomes and a pair of sex chromosomes. The chimpanzee genome has been 
humanised in the sense that it was assembled using the human genome as a guide. 
Consequently, sequences such as insertions/deletions, and gene duplications are subject 
to incorrect representation by the current assembly (www.ncbi.nlm.nih.gov/Genomes/). 
A new chimpanzee chromosome naming system was adopted following a recent 
proposal (McConkey, 2004). This new system names the chimpanzee chromosomes to 
correspond to their syntenic human chromosomes, thus enabling comparisons between 
chimpanzee and human genomes. Table 1.4 highlights the newly adopted naming 
system for the chimpanzee chromosomes, compared with the original naming system. 
It should be noted that the UCSC genome browser currently uses the old naming 
system.
Two genome assemblies released in July 2004, were of Canis familaris (dog) and Danio 
rerio (zebrafish). The Dog genome sequencing consortium released a 7.6x WGS 
assembly of a female boxer dog. The dog genome consists of 38 pairs of autosomes and 
a pair of sex chromosomes (Breen et a i, 1999). More recently (May 2005), a second 
version of the dog genome assembly was released by the Broad Institute of 
MIT/Harvard and Agencourt Bioscience (www.ncbi.nlm.nih.gov/Genomes/). The 
Zebrafish genome project was led by the Wellcome Trust Sanger Institute, which 
released a 5.7 x coverage (Zv4) of the zebrafish genome. The Wellcome Trust Sanger 
Institute generated the zebrafish genome by whole genome shotgun and fingerprinted 
BAC clone sequencing (www.ncbi.nlm.nih.gov/Genomes). The zebrafish genome 
consists of 25 pairs of chromosomes (Endo and Ingalls, 1968; Daga et al., 1996) and a 
genome size of 1.7 Gb (http://www.ncbi.nlm.nih.gov).
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June 2005 saw the release of a 6.2 x WGS assembly of the bovine (Bos Taurus) 
genome, generated by the Human Genome Sequencing Center at Baylor College of 
Medicine. Genome assembly was based on the Hereford breed, and build 2.1 included 
the complete mitochondrial genome, derived from a Korean native cow. The Bovine 
genome is organised into 29 pairs of autosomes and a pair of sex chromosomes, X and 
Y.
Human chromosome 
designations
NEW Chimpanzee 
chromosome designations
Original Chimpanzee 
chromosome designations
1 1 1
2 2A 12
2 2B 13
3 3 2
4 4 3
5 5 4
6 6 5
7 7 6
8 8 7
9 9 11
10 10 8
11 11 9
12 12 10
13 13 14
14 14 15
15 15 16
16 16 18
17 17 19
18 18 17
19 19 20
20 20 21
21 21 22
22 22 23
X X X
Y Y Y
Table 1.4 Summary of the human chromosome naming system, the original chimpanzee naming 
system, and the new chimpanzee naming system
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1.6 Identifying human disease genes through positional 
cloning
Identifying disease genes through positional cloning requires only the approximate 
chromosomal location of the gene to be known. This is in contrast with previous 
position-independent methods whereby knowledge of the protein product or the DNA 
sequence was required.
The disease must initially be genetically mapped within a family or families. 
Frequently, genetic mapping results in a candidate region of 10 Mb or more which is 
often too large for positional cloning and therefore requires refinement. For positional 
cloning, small disease intervals of less than 1 Mb are preferable, so that the number of 
candidate genes does not exceed 10 (average 10 genes per Mb). In order to refine a 
disease interval dense coverage of polymorphic markers across the interval is sought. 
Such markers (microsatellites and single nucleotide polymorphisms, SNPs) can be 
found through database searching for known polymorphic markers or by screening 
BACs, YACs and cosmids covering the candidate region. Polymorphic markers can 
then be typed within a family to construct individual haplotypes, which are used to 
identify potential crossovers between markers and disease (see section 1.6.3.1).
The release of the human genome draft sequence has had a considerable impact on 
disease gene identification. Prior to the availability of the human genome draft 
sequence, a high-resolution physical map of the disease interval had to be compiled 
from YACs, BACs, PACs and cosmid contigs, often a laborious task. With the advent 
of the human genome sequence, known genes within the candidate region can be 
identified through database searching and those considered as potential candidates for 
disease can be screened for pathogenic mutations. If no promising candidate is 
identified within the disease interval, novel genes are sought through a combination of 
computational and experimental methods (see section 1.4.1).
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1.7 Genetic maps
Genetic maps are based on recombination frequencies between genetic markers at 
meiosis. The unit of scale for a human genetic map is the centimorgan (cM), defined as 
a recombination fraction (see below) of 0.01. In physical distance, 1 cM roughly 
corresponds to between 0.7 and 1 Mb of DNA sequence.
Unless located in the same region of the genome, genetic markers have a tendency to 
recombine freely at meiosis. Markers not recombining freely are referred to as linked. 
Genetic markers recombine during prophase of meiosis I, where pairs of homologous 
chromosomes synapse and exchange segments. If such an exchange (crossover) occurs 
between the positions of two markers (loci), two recombinant and two nonrecombinant 
chromatids result. Very rarely does a recombination separate loci lying in close 
proximity to one another on a chromosome. Conversely, the greater the distance 
separating two markers on a chromosome, the greater the chance of a crossover 
occurring leading to the separation of the two loci.
The recombination fraction (0) is a measure of the genetic distance between two loci. If 
two loci segregate independently, there is a 50 % chance that the offspring will be 
recombinant between the two markers and a 50 % chance they will be nonrecombinant, 
resulting in a recombination fraction of 0.5. Loci which are syntenic and tightly linked 
will segregate together not resulting in recombinants and will have a recombination 
fraction of 0. Any two or more markers which are not tightly linked, will have a 
recombination fraction ranging between 0 and < 0.5.
Sets of alleles located in the same small interval of a chromosome are usually 
transmitted as a block (haplotype) through a pedigree because their close proximity 
makes it unlikely they will undergo recombination.
1.7.1 Genetic markers
Mapping human disease genes is dependent on markers. The requirement of such 
markers is that they are sufficiently polymorphic so that a randomly selected individual 
is likely to be heterozygous and therefore informative for linkage. In addition, linkage 
requires markers to be spaced throughout the genome at intervals < 20 cM. The
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informativness of a marker is measured by the mean heterozygosity (equation 1) of the 
marker in question, that is - the chance that a randomly selected person is heterozygous 
for that marker.
Equation 1: H = 1 - Xpi2 
(for alleles Al, A2, A3, with gene frequencies of p i, p2, p3, the proportion of 
heterozygotes is equal to 1 -  (p l2 + P22 + P32))
The types of markers currently used for mapping human disease genes are 
microsatellites and single nucleotide polymorphisms (SNPs). Microsatellites are 
tandem repeats (often (CA)„ repeats) of 1 -  6 bp, consisting of 10 -  50 copies. 
Advantages of microsatellites over their ‘minisatellite variable number tandem repeat’ 
(VNTR) predecessors are attributed to their distribution throughout the genome 
(VNTRs are not evenly distributed) and the advent of the polymerase chain reaction 
(PCR; Saiki et al, 1988).
SNPs are now the latest generation of genetic markers. Like restriction fragment length 
polymorphisms (RFLPs), they are a 2 allele system but do not always result in the 
creation or abolishment of a restriction site. They have the advantage of being scored 
on solid-state arrays whereas previous genetic markers have been dependent on gel 
electrophoresis (Wang et al., 1998). SNPs are widely distributed throughout the human 
genome and millions of SNPs have been identified since the completion of the human 
genome sequence (http://www.ncbi.nlm.nih.gov/). Such a large number of SNPs 
compensates for their lower informativeness in comparison to microsatellites.
1.7.2 HapMap, a haplotype map of the human genome
Trying to understand the connection between heritable inter-individual variation (e.g. 
disease susceptibility and appearance) and variation in DNA sequence has stemmed 
from the completion of the human genome project. The majority of human sequence 
variation takes the form of SNPs and in October 2002, the International HapMap 
Project was launched to genotype over one million SNPs in 269 individuals from four 
ethnic origins (The International HapMap Consortium, 2005, Altschuler et al., 2005). 
The HapMap project has been divided into two phases. Phase I aimed to genotype one
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or more common SNPs for every 5 Kb of genomic sequence from 269 DNA samples. 
Phase II aims to genotype an additional 4.6 million SNPs in each of the HapMap 
samples (The International HapMap Consortium, 2005, Altschuler et al., 2005). A total 
of 11,500 SNPs residing within the coding region of genes, and which code for different 
amino acids (non-synonymous cSNPs) were successfully genotyped in Phase I (The 
International HapMap Consortium, 2005, Altschuler et al., 2005).
Comparisons between the genome-wide resource to a more complete database of 
common variation, in which all common SNPs and numerous rare SNPs have been 
previously discovered and tested, were made (The International HapMap Consortium, 
2005, Altschuler et al., 2005). Ten representative regions of 500 Kb in length were 
selected from the Encyclopedia of DNA Elements (ENCODE) Project (The ENCODE 
Project Consortium, 2004), and sequenced in 48 individuals. Identified SNPs within 
these 48 individuals were combined with known SNPs on the database and genotyped in 
all 269 DNA samples used in the HapMap project (The International HapMap 
Consortium, 2005, Altschuler et al., 2005).
The ENCODE data revealed that SNPs perfectly correlate with several nearby SNPs 
(i.e. one SNP provides information on a neighbouring SNP), and partially correlate with 
numerous other SNPs (The International HapMap Consortium, 2005, Altschuler et al., 
2005). Thus, the presence or absence of a SNP at one site will provide information on a 
neighbouring SNP (serves as a proxy for other SNPs), allowing for a reduction in the 
total number of SNPs to be genotyped (Kruglyak, 2005, figure 1.7). Thus several 
hundred thousand proxies can capture the majority of common variants through strong 
correlations.
S ~ A %
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T Reference SNPs Y SNPs captured by proxy J  Uncaptured SNPs
Figure 1.7 Schematic demonstrating SNPs acting as a proxy for several other nearby SNPs when
testing for association with a phenotype
Red SNPs are genotyped directly, whilst the orange SNPs are captured through correlation (linkage 
disequilibrium) with the red SNPs. Blue SNPs are not genotyped or correlated with any genotyped SNP 
resulting in them not being associated with the phenotype in question. Adapted from Kruglyak, 2005.
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HapMap data will allow for comprehensive genome-wide association studies to be 
conducted, aiding the identification of the causative genes and pathways involved in 
human disease. It will also help to identify alleles conferring susceptibility or resistance 
to common diseases, and perhaps establish inter and intra-familial phenotypic variations 
in disease due to differences in genetic background. This will ultimately aid in creating 
a better understanding of disease framework (The International HapMap Consortium, 
2005, Altschuler et al., 2005).
1.7.3 Linkage analysis
Identifying informative markers and typing them within families in which a mendelian 
disease segregates is the first step to determining whether linkage exists between those 
markers and the segregating disease. Seldom do families, in which a disease segregates, 
allow for the phase of the alleles within the heterozygous parents to be determined. 
Consequently, scoring each meiosis as recombinant or nonrecombinant becomes 
ambiguous.
Such problems are overcome by calculating the overall likelihood of linkage, on the 
basis that the loci are either linked (recombination fraction 0 = 0) or not linked 
(recombination fraction 0 = 0.5). The odds of linkage is given by the ratio of these two 
likelihoods, the logarithm of which is the lod score. The lod score (log of the odds, z) is 
the most efficient statistic for evaluating pedigrees for linkage and is calculated as a 
series of 0 ranging from 0 to 0.5.
Linkage analysis results in a table of lod scores at various recombination fractions. 
Positive lod scores are evidence in favour of linkage whereas negative lod scores are 
evidence against linkage. The threshold of significance for the autosomal traits is Z = 
3.0 (1000:1 odds), with a 5 % chance of error. Linkage is rejected if Z < - 2.0 and Z 
values between -2 and 3 are inconclusive. A lod of 2 is the threshold of significance for 
establishing linkage between an X-linked trait and a marker residing on the X- 
chromosome. A lower threshold exists for X-linked traits due to the increased 
probability that two loci chosen at random should prove to be linked for only the X 
chromosome, compared to two loci chosen at random from the 22 autosomes.
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1.7.3.1 Haplotype analysis
Once a disease gene has been mapped to a chromosomal region, it may be necessary to 
refine the genetic interval in order to reduce the total number of possible candidate 
genes. Gene rich regions may contain up to 10 genes per 1 cM of genomic DNA 
(approximately 1 Mb of genomic sequence). Therefore, for disease intervals greater 
than 1 Mb, an attempt is usually made to refine the interval through genotyping with 
additional informative markers within the family for which the disease interval has been 
mapped. Segregation of markers typed in this way, are followed through the family to 
try and identify any potential crossovers between the markers and the disease locus. 
Following the typing of additional markers, new haplotypes are constructed for the 
individuals within the family by minimising the total number of crossover events in 
each sidship.
In some circumstances there may be promising candidate genes within the mapped 
disease interval, which are preferentially screened and excluded before the interval is 
further refined by genotyping with additional markers.
1.8 Orthologs and Paralogs
The most commonplace definition for describing relationships between two entities of 
common decent is homology and such entities, which are homologous, are referred to as 
homologs. The phrase, homology, was coined by Richard Owen in 1843 when he used 
the phrase to designate “the same organ in different animals under every variety of form 
and function”.
The term homolog is further divided into two subcategories, orthologs and paralogs. 
Genes described as orthologs are related through vertical decent (figure 1.8). They are 
related by speciation and are therefore derived from a single ancestral gene of the last 
common ancestor of the species in question. Generally, orthologs exhibit equivalent 
functions. Genes that are paralogs, are related through duplication (figure 1.8). Walter 
Fitch introduced the terms orthologs and paralogs back in 1970 (Fitch, 1970).
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Events leading to gene duplication are classified into four main events:
(1) Vertical decent (speciation) with modification
(2) Gene duplication, followed by vertical decent and modification
(3) Horizontal gene transfer (HGT)
(4) Fusion, fission, and other rearrangements of genes
The first event gives rise to orthologs, and the second to paralogs (figure 1.8). The 
latter two events, which have been mainly recognised since the release of completed
sequenced genomes, add complexity to determining whether two entities are orthologs
or paralogs of one another.
Gene duplication, which gives rise to paralogs, is considered to be the main process 
responsible for bringing about emerging novel functions through evolution (i.e. one of 
the paralogs sidesteps the confines of purifying selection, thereby evolving a novel 
function).
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Figure 1.8 Phylogenetic tree illustrating orthologous and paralogous relationships.
A, B, and C represent different species, with each branch representing the inheritance of each gene, 
(X, Y, and Z) from the last common ancestor. The common ancestor of the entire gene family (genes 
X, Y, and Z) existed prior to the last common ancestor of all three compared species (A, B, and C). 
The last common ancestor of each of the three compared species already encoded three paralogous 
genes (X, Y, and Z). Each of these paralogs then became the progenitors of the three branches of the 
tree. Consequently, each gene in branch 1 is a paralog to each gene in branches 2 and 3 due to only 
vertical inheritance occurring via evolution from the last common ancestor. The same applies for 
branch 2 compared with branches 1 and 3, and branch 3 compared to branches 1 and 2. The genes in 
different species (A, B, and C) are orthologs to one another in each individual branch. For example, 
XA, XB, and XC are orthologs of each other in branch one, whilst YA, YB, and YC are orthologs to
one another in branch 2.
Adapted from Koonin, 2005.
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1.9 The actin cytoskeleton
The role of the actin cytoskelton within cells is diverse. Cellular events such as 
adhesion, division, spreading, and motility are all underpinned by the regulation of the 
actin cytoskeleton. Actin constitutes approximately 5-10 % of total protein in 
nonmuscle cells and around 20 % in striated muscle cells. It is an ATP-binding protein, 
which exists either as a monomer (G-actin or globular-actin) or as part of a filament (F- 
actin or filamentous actin). Self assembly into long polymers is an important property 
of actin, allowing it to form F-actin under physiological conditions. Assembly of actin 
filaments is through reversible head-to-tail polymerisation of ATP-bound G-actin 
(figure 1.9; Wegner, 1976), which is associated with ATP hydrolysis and the release of 
inorganic phosphate (Pi; Carlier, 1990). ADP eventually dissociates from the filament 
and exchange bound ADP for ATP (figure 1.9). Coupling of ATP hydrolysis to the 
formation of filaments generates ends which are kinetically different. At one end, there 
is an ATP-actin cap (the barbed end, see below), and an ADP-actin protomer at the 
other (Carlier, 1990). The assembly kinetics therefore, differs at both ends, where the 
ATP-bound end form the site of preferential addition of new monomers (ATP-actin). 
The opposite end exhibits dissociation of ADP-acitn (the pointed end). The equilibrium 
concentration for both types of monomers also differs, referred to as the critical 
monomer concentrations (Carlier, 1990).
Due to the nonequilibrium conditions, at high monomeric actin concentrations, 
molecules assemble at both the barbed and pointed ends at different rates causing the 
filaments to grow. The opposite is true for low monomeric actin concentrations, where 
the filaments shrink due to protomers dissociating from both ends. Intermediate 
concentrations leads to the treadmilling of actin filaments (Small et al., 1993; Small, 
1994; Small, 1995), and results from addition of protomers at the barbed end, and 
dissociation of protomers at the pointed end (figure 1.9, Neuhaus et al., 1983).
Generated actin filaments are polar, containing a fast-growing end (barbed end or plus 
end), and a slow-growing end (pointed end or minus end). Polymersiation of actin takes 
place mainly at the fast-growing (barbed) end. Actin polymersiation is regulated 
through monomer- and filament-binding proteins, which maintain the
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Figure 1.9 Actin polymersiation
The actin cycle shown by the incorporation o f ATP-bound actin (denoted by actin monomers with a red 
asterisk) into the barbed end of a growing actin filament and dissociation of ADP-bound actin at the 
pointed end. ATP is hydrolysed by actin once incorporated into the actin filament, releasing inorganic
phosphate (Pi).
monomer pool, organise filament formation and arrange filaments into arrays, and 
depolymerise filaments to regenerate the G-actin pool.
Members of the thymosin p family of proteins and profilins, play an essential role in 
maintaining a reserve of unpolymerised actin for subsequent incorporation into existing 
filaments or for de novo polymerisation. Thymosin p proteins are actin-sequestering 
proteins (Devineni et al., 1999). When bound to actin thymosin p proteins are 
mobilised by the action of profilins. Profilins, which catalyse the exchange of ADP for 
ATP in actin monomers, sequester actin when the fast-growing end of an actin filament 
is capped (Goldschmidt-Clermont et al., 1991). This is achieved through the binding of 
profilin to dissociated actin molecules from the slow growing end, keeping them in 
reserve. Conversely, if an actin filament is uncapped, actin-bound profilin adds to the 
fast-growing end as efficiently as actin alone. The affinity of profilin for actin is ten 
times greater than thymosin p-actin. Thus in the presence of profilin, actin is removed 
from thymosin p and added to the filament ends. This results in faster elongation as the
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concentration of actin available for polymerisation, is higher in the presence of profilin 
compared to actin and thymosin p alone.
Cells contain a cortical network of actin filaments, which can be polymerised in a 
spatially restricted manner to generate the necessary force to drive membrane protrusion 
during cell motility. These protrusive structures formed at the leading edge of a cell 
attach to the substratum and are followed by a retraction of a tail, thus allowing the cell 
to migrate (Mitchison and Cramer, 1996). The different protrusive structures formed at 
the leading edge include lamellipodia and pseudopodia, ruffles, filopodia, and 
microspikes. Lamellipodia are large, relatively flat semicircular extensions supported 
by orthogonal actin networks (figure 1.10), whilst filopodia are narrow membrane 
protrusions supported by parallel actin bundles (figure 1.10). Pseudopodia are non-flat 
and larger in structure. Ruffles are formed from upward folding of lamellipodia, and 
microspikes are classed as smaller versions of filopodia. In each case, the filaments are 
orientated with their fast-growing (barbed) ends to the membrane (Small et al., 1998). 
The rapid addition of actin monomers to existing filaments at the interface between the 
barbed end and the membrane generates the force for pushing the membrane forward. 
Stationary cells can often be found to form hemispherical blebs on their surface. 
Lamellipods and filopodia are formed from the activation of small guanosine 
triphosphate (GTP)-binding proteins cdc42 and Rac, respectively (Small et al., 2002).
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Figure 1.10 Actin within migrating fibroblasts visualised by fluorescently-labelled phalloidin 
(upper cell) and a scanning electron micrograph (lower cell), taken from http://www.els.net/).
Stress fibres can be seen in the tails of the migrating fibroblasts. To the left of the migrating fibroblasts 
are schematic representations of a lamellpodium and filopodium.
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1.10 The actin-related protein (Arp) 2/3 complex
The human actin-related protein (Arp) 2/3 complex is the only cellular factor known to 
nucleate new actin filaments with free barbed ends. Arp2/3 is composed of seven 
highly conserved subunits: p41, p34, p21, p20, p i6, and the actin related proteins, Arp2 
and Arp3 (figure 1.11, Machesky and Gould, 1999). Machesky and colleagues first 
isolated the Arp2/3 complex in 1994, from Acanthamoeba castellani (Machesky et al., 
1994). Since then, the Arp2/3 complex has also been isolated from a number of 
vertebrates including humans (Welch et al., 1997), and from Saccharomyces cerevisiae 
(Winter et al., 1997), and has been found to be highly conserved throughout. Although 
Arp2 and Arp3 are designated actin-related proteins, their actual amino acid sequence 
and the majority of their surface residues differ to that of actin. Arp2 and Arp3 are 
however, predicted to share the same fold as actin (Kelleher et al., 1995).
...
p20 } p34
Arp2 
p41
Figure 1.11 The Arp2/3 complex
The Arp2/3 complex is composed of seven highly conserved subunits: p41, p34, p21, p20, pi 6, and Arp2
and Arp3.
The Arp2/3 complex has an intrinsic ability to enhance actin nucleation, albeit weakly. 
The Arp2 and Arp3 subunits form a stable dimer that mimics actin-actin dimers, thus 
providing a substrate for rapid elongation of actin (Kelleher et al., 1995).
The intrinsic nucleating capability of the Arp2/3 complex is enhanced through the 
binding of nucleation-promoting factors. Nucleation-promoting factors have been 
identified in the majority of eukaryotes studied to date, and in Listeria monocytogenes 
(ActA), an enteropathogenic bacterium (Welch et al., 1998). The most intensively 
studied nucleating-promoting factors are the WASP protein family (section 1.11).
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Known nucleation-promoting factors (NPFs) of the Arp2/3 complex are summarised in 
table 1.5.
Additional activators of the Arp2/3 complex include actin filaments themselves when in 
the presence of nucleation promoting factors such as the WASP protein family. 
Binding of the Arp2/3 complex to the side of an actin filament increases the affinity five 
fold for binding to a WASP protein family member (Marchand et al., 2001). Such 
activation of the Arp2/3 complex results in the formation of Y-shaped branches on pre­
existing actin filaments and is referred to as the “dendritic nucleation” model of Arp2/3 
activity (Pollard et al., 2000). The newly nucleated ‘daughter filament’ projects at a 70° 
angle from the original, mother filament (Mullins et al., 1998; Blanchoin et al., 2000). 
The formation of Y-shaped branches are seen in actin meshworks of leading edge 
lamellipodia in motile cells (figure 1.12, Svitkina and Borisy, 1999; Bailly et al., 1999). 
Interestingly, the Arp2/3 complex is localised to the leading edge of motile cells and 
spreading cells (Machesky et al., 1994; Welch et al., 1997; Machesky et al., 1997).
The importance of the Arp2/3 complex to cells is highlighted in Saccharomyces 
cerevisiae and Schizosaccharomyces pombe, in which deletion of the Arp2/3 complex 
leads to severe growth defects and lethality (Lees-Miller et al., 1992; McCollum et al., 
1996; Schwob and Martin 1992; Winter et al., 1997; Winter et al., 1999). Further, 
Drosophila Arp3, and Arpcl mutants do not survive to adulthood (Hudson and Cooley
2002) and have been found to have defects in embryonic actin structures in addition to 
nervous system development (Zallen et al., 2002).
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Class of NPF NPF Identified in Function Reference
Class I ActA L. monocytogenes 
L. ivanovii
Bacterial
pathogenesis,
intracellular
motility
Welch et al., 
1998
RickA Rickettsia conorii Bacterial
pathogenesis,
intracellular
motility
Gouin et al., 
2004
WASP S. cerevisiae 
(Lasl7p/Beelp)
S. pombe (Wsplp) 
metazoans
Cell signalling, 
endocytosis
Yarar et al., 
1999, Winter et 
al., 1999
N-WASP metazoans Endocytosis Rohatgi et al., 
1999
Scar/WAVE D. discoidium (Scar) Lamellipodia
formation,
phagocytosis,
endocytosis.
Machesky et 
a l ,1999
Myosin I S. cerevisiae 
(Myo3p, Myo5p) 
S. pombe (Myolp)
Cell polarisation Lechler et al, 
2000,
Evangelista et 
al, 2000, Lee 
et al, 2000,
Class II Cortactin Metazoans Cortical
cytoskeleton,
endocytosis
Weed et al, 
2000, Weaver 
et al, 2001
Abplp S. carevisiae 
Metazoans
Endocytosis Goode et al, 
2001
Unknown class Pan 1 p/Eps 15 S. cerevisiae 
Metazoans
Endocytosis Duncan et al, 
2001
Table 1.5 Nucleation-promoting factors (NPFs) of the Arp2/3 complex
40
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Figure 1.12 Schematic of actin nucleation through activation of the Arp2/3 complex at the leading edge of a motile cell.
Nucleating-promoting factor WAVE2 binds to and activates the Arp2/3 complex leading to formation of Y-shaped branches. Green arrow denotes direction of extending
membrane.
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1.11 The WASP family of proteins
In mammals the WASP family of proteins is comprised of the founder member WASP, 
its homologue neural WASP (N-WASP), and three WASP family verprolin homologous 
(WAVE) proteins (WAVE 1-3). WASP was originally identified as the mutated gene in 
patients with Wiskott-Aldrich syndrome (WAS, Derry et al., 1995). Wiskott-Aldrich 
syndrome is an X-linked disorder characterised by thrombocytopenia, eczema, and 
immunodeficiency.
Expression of WASP is exclusive to hematopoietic cells, whereas N-WASP is 
ubiquitously expressed, with strongest expression in neural cells. Similarly, WA VE2 is 
widely expressed, but WAVE1 and WAVE3 are predominantly expressed in the brain 
(Bear et al., 1998; Suetsugu et al., 1999; Benachenhou et al., 2002; Soderling et al.,
2003). Just prior to the identification of the WAVE proteins, Bear and colleagues 
identified a new gene (SCAR) essential for actin reorganisation during chemotactic 
movement of Dictyostelium cells in response to cAMP stimulation (Bear et al., 1998). 
The SCAR gene proved to be the homolog of the WAVE1 gene in mammals. A 
SCAR/WAVE protein is also present in Caenorhabditis elegans and Drosophilia 
melanogaster.
The WASP protein family link Rho GTPases with actin assembly (Suetsugu et al., 
1999; Takenawa and Miki, 2001). Following activation of small Rho GTPases (Cdc42 
and Rac), the WASP protein family stimulate the nucleating activity of the Arp2/3 
complex. This subsequently results in the formation of filopodia by N-WASP following 
activation by CDc42, and lamellipodia by WAVE proteins following activation by Rac 
(Miki et al., 1998; Rohatgi et al., 1999; Kim et al., 2000; Takenawa and Miki, 2001). 
WASP is also a direct effector of Cdc42.
The WASP protein family have a common molecular organisation (figure 1.13). All 
members (WASP, N-WASP, and WAVE1-3) contain a verprolin homology/WASP 
homolgy (V/WH2), central (C), and acidic (A) domain (VCA/WCA) at the carboxy 
terminus. In addition, all members have a proline rich region preceded by a basic motif, 
upstream of the WCA domain. The WASP protein family can then be placed into 
subcategories based on the sequence at their N-terminus. The WASP-like category
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consists of WASP and N-WASP, and the three WAVE proteins compose the remaining 
category. WASP and N-WASP contain a central GTPase binding domain (GBD) and 
an N-terminal WASP homology domain 1 (WH1), also referred to as Ena-VASP 
homology domain 1 (EVH1, Callebaut et al., 1998). These domains (GBD and WH1) 
are absent from the WAVE proteins. Instead, the WAVEs have a SCAR homology 
domain (SHD), also referred to as a WAVE homology domain (WHD).
WASP
N-WASP
WAVE 1- ~ 1 I P
D□
□
WASP HOMOLGY 
1 (WH1/EVH1)
BASIC
REGION
GTPase
BINDING DOMAIN 
(GBD)
PROLINE
RICH
□
D
□□
WASP HOMOLGY 
2 (WH2A/)
ACIDIC 
REGION (A)
CENTRAL 
REGION (C)
WAVE HOMOLGY 
DOMAIN (WHD/SHD)
cl WCA domain
Figure 1.13 Domains within the WASP protein family members.
Note, the WCA domain in N-WASP contains two WH2 domains.
The variation in the domains at the N-terminus of the WASP protein family results in 
differential regulation of the two subcategories. The GBD domain of WASP and N- 
WASP binds directly to GTP-Cdc42, whilst the basic region binds PIP2 (figure 1.14, 
Symons et al., 1996; Miki et al., 1998; Rohatgi et al., 2000; Higgs and Pollard, 2000; 
Prehoda et al., 2000). In the absence of GTP-Cdc42, WASP and N-WASP are
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autoinhibited by an intramolecular interaction between the WCA and GBD domains 
(Miki et al., 1998; Rohatgi et al., 1999; Higgs and Pollard, 2000; Kim et al., 2000). The 
WAVE proteins do not directly interact with the small GTPase Rac. Regulation of the 
activity of WAVES is believed to result from their interaction within a pentameric 
complex including PIR121 (p53 inducible messenger RNA), Napl (Nck-associated 
protein), Abi (Abl interactor, see section 1.13), and HSPC300 (Eden et al., 2002). 
PIR121 shares sequence identity with a Rac effector, pl40Sra-l (specifically Racl- 
associated protein, Kobayashi et al., 1998), and so is thought to mediate the link 
between the pentameric complex and Rac. Abi links PIR121/Napl to the WAVE 
proteins through binding to the WHD domain of the WAVES (figure 1.15, Echarri et 
al., 2004; Gautreau et al., 2004; Innocenti et al., 2004; Leng et al., 2005).
The WCA domain common to all members of the WASP protein family (figure 1.13) is 
essential for the binding to, and activation of, the Arp2/3 complex (section 1.10). The V 
domain facilitates binding actin monomers, whilst the A and C domains are responsible 
for binding the Arp2/3 complex (Miki and Takenawa, 1998; Machesky and Insall, 1998; 
Rohatgi et al., 1999; Machesky et al., 1999).
Intramolecular binding between the WCA and GBD domains of WASP and N-WASP 
inhibits their function thereby regulating their function (Kim et al., 2000; Prehoda et al., 
2000; Rohatgi et al., 1999; Rohatgi et al., 2000). Additional regulators of the WASP 
and N-WASP proteins include the Src kinases. Phosphorylation of tyrosine residues 
near the GBD domain is thought to release the autoinhibition (Cory et al., 2002; 
Suetsugu et al., 2002). Other regulators include the SH3 domain containing proteins, 
Grb2/Ash, Nek, and WISH, which have all been shown to activate N-WASP by binding 
the proline-rich region (Carlier et al., 2000; Fukouka et al., 2001; Rohatgi et al., 2001).
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Figure 1.14 Schematic representation of WASP regulation leading to Arp2/3 complex activation
Following extracellular stimuli, the autoinhibition of N-WASP is relieved through the binding of either, Cdc42 and PIP2, an SH3 containing protein. Phosphorylation of 
tyrosine by Src kinases enhances N-WASPs ability to activate the Arp2/3 complex. Adapted from Bompard and Caron, 2004.
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Figure 1.15 Schematic representation of WAVE regulation leading to Arp2/3 complex activation
Following extracellular stimuli, the pentameric complex containing WAVE2 is localised to the membrane 
and activates the Arp2/3 complex either in the presence (A) or absence (B) of the remainder o f Rac- 
GTP/PIR121/NAP1/Abil. Adapted from Bompard and Caron, 2004.
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1.12 Nucleation promoting factors
In addition to the WASP protein family, other nucleation promoting factors are known 
to activate the Arp2/3 complex, as outlined in table 1.5. Characterised examples are 
described in more detail below.
1.12.1 ActA
ActA, a nucleation promoting factor from the intracellular pathogenic bacterium 
Listeria monocytogenes, has been shown to bind the same three subunits of the Arp2/3 
complex as the WASP family. Further, two domains of Act A with sequence similarity 
to the WH2 domain, have been found to bind two actin monomers (Zalevsky et al., 
2001). ActA, is a transmembrane protein required for the pathogenic bacterium to 
utilise the host cells actin polymerisation machinery in order to assemble a comet tail 
for motility (Dramsi et al., 1998). Branched actin filaments have been shown to be 
formed in cell extracts in the presence of ActA coated on the surface of beads (Cameron 
et al., 1999), thus further implicating it as an Arp2/3 complex activator.
1.12.2 Myosin I
The C-terminus of fungal myosin-Is (from budding yeast, fission yeast, and the 
filamentous fungus Aspergillus), resembles that of the C and A motifs in the WASP 
family. Although activation was found to be weak compared to the WASP family 
WCA, constructs of the C-termini of the fungal myosin-Is have been shown to bind the 
Arp2/3 complex (Lee et al., 2000). In addition, the tail of S. pombe Myolp has been 
found to activate the Arp2/3 complex (Lee et al., 2000).
1.12.3 Cortactin
Cortactin contains an N-terminal acidic domain and an F-actin binding domain, which 
have been shown to be necessary to activate the Arp2/3 complex (Weed et al., 2000; 
Uruno et al., 2001; Weaver et al., 2001). Cortactin binds the Arp2/3 complex via the 
Arp3 subunit (Weaver et al., 2002) and is localised at the leading edge of lamellipodia 
in metazoans. Cortactin appears to stabilise the branches formed by the Arp2/3 
complex (Weaver et al., 2001), thereby possibly prolonging the lifetime of dendritic 
networks. Recently, cells in which cortactin had been knocked down, exhibited a defect
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in the persistence of lamellipodial protrusions, thus implying that cortactin does have a 
role in enhancing lamellipodial protrusions (Bryce et al., 2005).
1.12.4 Abplp
Like cortactin, Abplp does not contain a G-actin binding domain, but instead has an F- 
actin binding domain. Abplp was the first actin associated protein to be identified in 
yeast (Drubin et al., 1990) and consist of an ADF/cofilin homology domain (ADF/F-H), 
a helical region, a proline-rich domain, and an SH3 domain. Overexpression of Abplp 
leads to severe defects in cellular actin organisation (Drubin et al., 1990), which 
corresponds with the localisation of Abplp to cortical actin patches (Drubin et al., 
1990). Activation of the GTPase Rac results in the translocation of Abplp to the 
leading edge of cells (Kessels et al., 2000). Abplp contains two acidic motifs, which 
are essential for activation of the Arp2/3 complex (Goode et al., 2001). The ADF-H 
domain mediates F-actin binding (Goode et al., 2001). Binding to F-actin filaments and 
to the Arp2/3 complex, enables Abplp to recruit the Arp2/3 complex to the sides of 
filaments and possibly link endocytosis with actin filament dynamics.
1.12.5 RickA
RickA was recently identified as a protein expressed on the surface of Rickettsia 
conorii, which activates the Arp2/3 complex leading to the generation of long- 
unbranched actin filaments (Gouin et al., 2004). The protein sequence of RickA 
contains a central proline-rich region, an N-terminal G-actin binding domain, and a C- 
terminal CA domain. In vitro studies of the RickA protein confirmed activation of the 
Arp2/3 complex, but with less efficiency than ActA (see section 1.12.1), and expression 
of RickA at the inner face of the plasma membrane in mammalian cells, was found to 
result in the formation of filopodia (Gouin et al., 2004). RickA is the most closely 
related bacterial nucleation promoting factor to the WASP protein family.
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1.13 The Abelson (Abl)-interactor (Abi) family of proteins
First identified as a substrate and a binding partner for Abelson tyrosine kinases (Dai 
and Pendergast, 1995; Shi et al., 1995; Juang and Hoffmann, 1999), the Abi proteins are 
instrumental in the intracellular reorganisation of actin through the regulation of Rac- 
dependent pathways. Members of the Abi family include mammalian Abil, Abi2, and 
Abi3/NESH (New molecule including SH3), Drosophila melanogaster Abi (dAbi), 
Xenpous laevis Xlan4 (Xenopus laevis animal 4), Dictyostelium discoideum Abi, and 
Caenorhabditis elegans Abi (Reddy et al., 1992; Dai and Pendergast; 1995; Shi et al., 
1995; Juang and Hoffmann, 1999; Miyazaki et al., 2000).
The amino- and carboxy-terminal regions of the Abi proteins are well conserved across 
species, whilst the middle portion of the molecule varies considerably (Echarri et al.,
2004). Conserved domains amongst the Abi proteins include an SH3 domain within the 
carboxy terminus, a homeodomain homologous region, and SNARE and WAVE- 
binding (WAB) domains at the amino terminus (Dai and Pendergast; 1995; Shi et al., 
1995; Stradal et al., 2001; Echarri et al., 2004).
Abi proteins are localised to sites of actin polymerisation in protrusive membrane 
structures in particular; Abil and Abi2 have been shown to localise to the leading edge 
of lamellipodia and filopodia in highly motile B16 melanoma cells (Stradal et al.,
2001). The cellular localisation pattern observed for Abil and Abi2 is comparable to 
the cellular localisation pattern observed with the WAVE proteins (Hahne et al., 2001, 
Stradal et al., 2001). Two recent reports showed Abil to regulate the localisation of 
WAVE1 and WAVE2 to the leading edge of lamellipodia (Echarri et al., 2004; Leng et 
al., 2005). In addition WAVE1 levels were also found to be regulated by Abil (Echarri 
et al., 2004).
Abil and Abi2 act as scaffolding proteins, leading the assembly of various multi- 
molecular complexes (Innocenti et al., 2003; Stradal et al., 2004; Disanza et al., 2004). 
One such complex is the WAVE2-Abil-NAP1-PIR121 complex (figure 1.16; Innocenti 
et al., 2004). Abil directly binds WAVE2 forming the platform on which NAP1 and 
PIR121 associate (figure 1.16; Innocenti et al., 2004). Abi2 has been reported to form a 
complex with WAVE1, Nap-1, HSPC300, and PIR121 (Eden et al.,
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Figure 1.16 Abil directly binds WAVE2 forming the platform on which NAP1 and PIR121
associate
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2002). Other known interactors of the Abi proteins include the adapter protein Eps8, 
Spectrin, the Sos guanine nucleotide exchange factor, and Grb4 (Biesova et al., 1997; 
Ziemnicka-Kotula et al., 1998; Scita et al., 1999; Fan and Goff, 2000; Cowan and 
Henkemeyer, 2001).
The Abi family of proteins link to the signalling pathway, involving the Rac GTPase, is 
exemplified by Abi Is association with Eps8 and the Sos GEF in a trimeric complex, 
which was found to exhibit GEF activity towards the small GTPase, Rac (Scita et al., 
2001). Further, over expression of Abil leads to the activation of Rac through an Eps8- 
dependedent mechanism (Innocenti et al., 2002), whilst down regulation of Abil 
through use of RNA interference inhibits Rac-dependent membrane ruffling (Innocenti 
et al., 2004).
Two recent reports demonstrated the Abi family to play a role in the regulation of 
WASP and N-WASP mediated processes (Bogdan et al., 2005; Innocenti et al., 2005). 
The Drosophila melanogaster Abi homologue is reported to bind WASP through its 
carboxy terminal domain and induces formation of F-actin (Bogdan et al., 2005), whilst 
the SH3 domain of Abil facilitates its binding to N-WASP resulting in its attuning of 
N-WASP activity during endocytosis and vesicular transport (Innocenti et al., 2005).
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1.14 Aims of this thesis
At the outset of this study, a family with X-linked congenital cataract (CXN) had been 
mapped to the short arm of the human X chromosome (Francis et al., 2002). The CXN 
locus resided within the locus for Nance-Horan syndrome (NHS) for which a similar 
cataract phenotype in affected males is seen. It had therefore been previously 
hypothesised that X-linked congenital cataract and Nance-Horan syndrome were 
possibly allelic. In strength of this hypothesis, an X-linked congenital cataract locus in 
the mouse had been mapped to the distal end of the mouse X chromosome (Stambolian 
et al., 1994), syntenic with the portion of the human X chromosome for which CXN and 
NHS had been mapped. Thus, the aim of this thesis was to identify the disease 
causative gene(s) in the CXN family and families with NHS, through positional cloning. 
Following identification of the causative gene(s) for CXN and NHS, functional analyses 
of the protein product(s) would be initiated to unravel the mechanisms of lens 
development and cataract formation.
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- Chapter Two -
Materials and Methods
2.1 Materials
All reagents were purchased from ABgene, UK, Amersham Biosciences, UK, 
Invitrogen, UK, Promega, UK, and Sigma, UK, and QIAGEN, UK, unless otherwise 
stated.
2.1.1 Reagents and Buffers
2.1.1.1 Tissue culture reagents
All tissue culture reagents were purchased from Invitrogen (Paisley, UK; see table 2.5). 
Phosphate buffered saline (PBS): 10 mM phosphate, 0.9 % (w/v) NaCl, pH 7.4
2.1.1.2 Plasmid DNA
X-gal: 20 mg/ml stock 
IPTG: 100 mM stock
LB broth: 1 % (w/v) Tryptone, 1 % (w/v) NaCl, 0.5 % (w/v) Yeast extract. Made up 
with distilled water and autoclaved before use.
LB agar: LB broth with 1.5 % (w/v) agar, autoclaved prior to use.
2.1.1.3 Protein purification, electrophoresis, and Western blotting reagents
Coomassie stain: 0.2 % (w/v) Coomassie blue, 50 % (v/v) methanol, 10 % (v/v) acetic 
acid.
Coomassie de-stain: 45 % (v/v) methanol, 10 % (v/v) acetic acid.
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Cells and tissue homogenisation buffer: 100 mM Tris-HCl, 2 % (v/v) glycerol, 1 % 
(w/v) SDS, 1 % (w/v) 2-p mercaptoethanol
Ponceau S stain: 3 % (v/v) Trichloroacetic acid, 0.2 % (w/v) Ponceau S
SDS-PAGE sample buffer (5x): 125 mM Tris-HCl (pH 6.8), 4 % (v/v) SDS, 20 % (v/v)
glycerol, 10 % (v/v) 2-mercaptoethanol and 0.2 % (w/v) bromophenol blue.
SDS-PAGE running buffer (lx): 25 mM Tris-HCl, 190 mM glycine, 3.5 mM SDS. 
Tris-acetate EDTA buffer (TAE, lx): 40 mM Tris-HCl, 40 mM acetic acid, 1 mM 
EDTA
Western blotting transfer buffer (lx): 25 mM Tris-HCl, 190 mM glycine, 20 % (v/v) 
methanol
Western blotting blocking buffer: 5 % (w/v) “Marvel” milk powder, 0.05 % (v/v) 
Tween-20, in 1 x PBS.
Western blotting wash buffer: 0.05 % (v/v) Tween-20 in 1 x PBS.
Lysate buffer: 150 mM NaCl, 10 mM sodium phosphate (pH 7.0), 1 % (v/v) Triton X- 
1:100 dilution of protease inhibitor cocktail, in 1 x PBS.
2.1.1.4 Actin assay reagents
General actin buffer: 5 mM Tris-HCl (pH 8.0), 0.2 mM CaCh, 0.2 mM ATP, 0.5 mM 
DTT
Actin polymerisation buffer (10 x): 100 mM Tris-HCl (pH 7.5), 20 mM MgC^, 10 mM 
ATP, and 0.5 M KC1.
2.1.1.5 General reagents
1 M Tris-HCl (pH 7.5, or 8): adjusted pH to 7.5 or 8.0 with 5 M NaOH, autoclaved 
before use.
5 M NaOH: prepared with SDW.
10 % (w/v) SDS: prepared with SDW.
Unless otherwise stated, room temperature was approximately 21-23°C.
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2.2 Molecular Biology Techniques
2.2.1 Polymerase Chain Reaction (PCR)
A typical PCR mix (25 pi) consisted of 50-150 ng DNA, 2 pmol of each primer, 200 
pM of each dNTP, 1 . 5 - 3  mM MgCl2, 1 x NH4 reaction buffer, 0.5 U BIOTAQ- 
polymerase (Bioline). PCRs were carried out on Techne Genius PCR thermocylers 
equipped with heated lids thus eliminating the necessity to overlay PCR reactions with 
mineral oil to prevent evaporation. Cycling conditions consisted of an initial 
denaturation step of 95°C for 5 minutes followed by 30 to 40 cycles of 95°C for 30 
seconds, 52°C -  64°C (depending on the required annealing temperature) for 30 seconds 
and 72°C for 30 seconds (extension time varied depending on the size of the amplicon). 
A final cycle of 72°C for 5 minutes completed the extension.
In addition to the standard PCR mix mentioned above, a 2 x ReddyMix™ PCR Master 
Mix (Abgene, Epsom, UK) was used. The Abgene master mix consisted of 1.25 U 
Thermoprime Plus DNA Polymerase, 75 mM Tris-HCl (pH 8.8 at 25°C), 20 mM 
(NH4)2S0 4, 1.5 mM MgCl2, 0.01% (v/v) Tween® 20, 0.2 mM each of dATP, dCTP, 
dGTP and dTTP, precipitant and red dye (for electrophoresis), 2 pmol of each primer 
and 5-150 ng DNA. For templates that were difficult to amplify, the Abgene Extensor 
Hi-Fidelity PCR Master Mix was used and consisted of consisting of 1.25 U 
Thermoprime Plus DNA Polymerase, 2.25 mM MgCl2, 500 pM each of dATP, dCTP, 
dGTP, and dTTP.
2.2.2 Primer design and determination of annealing temperatures
Annealing temperatures for newly designed primer pairs were approximated from their 
melting temperatures (Tm). To calculate the Tm, which is dependent on a primer 
nucleotide sequence, the following formula was used:
4(G + C) + 2(A+T) = Tm 
Equation 1 Formula for calculating the melting temperature of primers
By lowering the value obtained by 2-5°C, an annealing temperature could be assigned 
(e.g. a Tm of 60°C would indicate an annealing temperature of 57-58°C).
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In order to design primer pairs for PCR amplification, several rules were followed: 
random base distribution and similar GC content for both primers, an anchoring C or G 
at the 3’ end of each primer, minimal secondary structure (i.e. self-complementary) and 
low complementarity to each other, especially in the 3’ region as to avoid the incidence 
of ‘primer dimer’ formation, no greater than 4°C difference between the Tm values of 
both primers and, bearing in mind the above constraints, a primer length of at least 20 
nucleotides- to increase the sequence specificity.
2.2.3 Reverse Transcription (RT) PCR
Synthesis of cDNA from RNA extracted from tissue was performed using M-MLV 
Reverse Transcriptase (Promega, Southampton, UK). First strand cDNA synthesis 
reactions (20 pi) consisted of M-MLV Reverse Transcriptase 5 x buffer, 200 pM of 
each dNTP, 0.5 ug Oligo (dT)is primer, 20 U RNasin® Rnase inhibitor, 100 U M-MLV 
Reverse Transcriptase Rnase H Minus, and 2-3 pg of total RNA.
Reverse transcription was performed in a Techne Genius PCR thermocyler at 55 °C for 
1 hour followed by 10 minutes at 65 °C. The double stranded cDNA was then either 
used immediately as a template for PCR or stored at -20°C.
2.2.4 Colony PCR
Identification of colony forming units transformed with the required vector and insert 
was carried out using colony PCR. Following plating out of transformed bacterial 
cultures and incubation overnight at 37 °C, white forming colonies were picked using a 
sterile pipette tip and used as a template for PCR (section 2.2.1). The sterile tip 
containing the picked colony was dipped in a 0.2 ml eppendorf tube containing 25 pi of 
PCR mix and then stored for subsequent propagation. PCRs were carried out on Techne 
Genius PCR thermocylers.
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2.2.5 Size Fractionation of DNA
2.2.5.1 Agarose gel electrophoresis
PCR products, vectors, clones, and enzyme digests were size-fractionated on an 
appropriate % agarose gel depending on the fragment size (0.8 - 1 % for 2 - 20 Kb 
fragments, 1 - 2 % for 1 - 2 Kb fragments and 3 % for 70 bp -  1 Kb fragments). 
Agarose gels were prepared by weighing out the appropriate amount of agarose (% w/v) 
in a conical flask and adding the correct volume of 1 x TAE. The flask contents were 
mixed by gentle swirling and heated in a microwave to dissolve the agarose. The 
dissolved agarose was left to cool to approximately 60 °C before the addition of 5 pi of 
0.5pg/ml ethidium bromide. The melted agarose was then poured into an appropriate 
pre-sealed casting plate containing a well comb. Agarose gels were left to set for 20-30 
minutes at room temperature.
Generally, 5 pi of PCR product or DNA was mixed with 1 pi blue/orange 6 x gel 
loading dye (Promega, Southamton, UK) and loaded into the well (except for where 2 x 
ReddyMix™ PCR Master Mix was used). An appropriate DNA size marker was also 
loaded, depending on the anticipated size of the DNA fragments (see table 2.1).
<}X174/HaeUI 1 Kb DNA ladder
1,358 10,000
1,078 8,000
872 6,000
602 5,000
310 4,000
281 3,000
271 2,500
234 2,000
194 1,500
118 1,000
- 750
- 500
- 250
Table 2.1 DNA marker sizes (bp) for, <|>X174/HaeIII and 1Kb DNA ladder
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2.2.6 QIAquick Gel Extraction
Inserts digested out from vectors, or PCR products were electrophoresed on a 0.5 % 
(w/v) agarose gel, gel extracted, and purified. DNA in the range of 70 bp to 10 Kb was 
extracted and purified using the QIAquick gel extraction kit according to the 
manufacturers guidelines.
Upon resolving DNA on an agarose gel, the band of interest was excised from the gel 
and the gel slice weighed. Three volumes of buffer QG was then added to one volume 
of gel (100 mg is equivalent to 100 pi) and incubated at 50 °C for ten minutes with 
gentle vortexing every two to three minutes. For DNA fragments outside the range of 
500 bp to 4 Kb, one gel volume of isopropanol was added to the sample and mixed. A 
QIAquick spin column was then placed in a 2 ml collection tube and the DNA bound to 
the membrane by applying the sample to the column and centrifuging for one minute at 
approximately 17,900 x g. The flow through was discarded and 750 pi of buffer PE 
added and centrifuged for one minute at approximately 17,900 x g. The flow though 
was then discarded and an additional centrifuge step performed for one minute at 
approximately 17,900 x g in order to remove any residual buffer. The column was then 
transferred to a sterile 1.5 ml microcentrifuge tube. 50 pi of sterile distilled water was 
then applied to the centre of the QIAquick membrane and centrifuged for one minute at 
approximately 17,900 x g to elute the DNA.
2.2.7 Genotyping
Microsatellite markers were selected and primer sequences obtained from the genome 
database (http://www.gdb.org). Novel microsatellite markers were identified using an 
in-house nucleotide repeat locator (World-wide Webster web designs 2000) and 
available genomic sequence. Primers for microsatellite markers were labelled with 
either 6-FAM (blue) or HEX (green) probes (Genosys Biotechnologies Ltd., 
Cambridgeshire, UK). Microsatellites were amplified from patient genomic DNA by 
standard PCR (section 2.2.1) with appropriate annealing temperatures (table 3.2). PCR 
products were then loaded and analysed on an ABI 3100 genotyper according to 
manufacturers instructions (Applied Biosystems). Genotypes were determined in a 
double-blind manner.
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2.2.8 WAVE® Nucleic Acid Fragment Analysis System
Denaturing high-performance liquid chromatography (DHPLC) allows the automated 
detection of single base substitutions, insertions and deletions. Their detection is based 
around the formation and separation of double-stranded DNA fragments containing 
mismatched bases (heteroduplexes). The WAVE system (Transgenomic, Inc., San Jose, 
CA) allows the separation of heteroduplexes from homoduplexes in the absence of 
radioactivity, acrylamide gels or chemical denaturants. Mismatched bases within a 
heteroduplex begin to separate at a critical temperature whilst the matched bases within 
homoduplexes remain intact. Consequently, a lower percentage of organic mobile 
phase (acetonitrile) is required to disrupt the interactions between heteroduplexes and 
the column matrix as opposed to the interactions between homoduplexes and the 
column matrix. Heteroduplex DNA subsequently elutes earlier in the gradient and is 
detected by additional peaks in the chromatogram. Additional peaks within the 
chromatogram compared to a reference “wild type” DNA amplicon indicate the 
presence of a sequence variant.
A 6 pi volume of PCR product was made up to 10 pi with H2O and subjected to an 
additional 5 min 94°C denaturing step followed by gradual reannealing from 94°C to 
65°C over a 30 minute period to allow formation of heteroduplexes. PCR amplicons 
were then loaded (5 pi) on a DNASep column packed with Ci8 alkylated, polystyrene- 
divinylbenzene polymeric beads (Transgenomic Inc., San Jose, CA). The appropriate 
temperature for resolving heteroduplex molecules was calculated using the DHPLC 
melting algorithm. Hetero- and homo-duplexes were eluted with a linear acetonitrile 
gradient at a flow rate of 0.9 ml/min and detected at 260 nm.
2.2.9 RNA extraction
RNA was extracted from various mouse tissues using the Ambion Totally RNA kit. 
Samples were weighed and homogenised in 10 volumes of denaturation solution using 
an electronic homogeniser. An equal volume of Phenol:Chloroform:IAA was added to 
the lysate (starting volume), vortexed vigorously for 1 minute and stored on ice for 10 
minutes. The suspension was then centrifuged at 4°C for 15 minutes at 17,900 x g. The 
upper aqueous phase was transferred to a new vessel and 1/10 the aqueous phase
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volume of sodium acetate solution was added and inverted for about 10 seconds. One 
starting volume of Acid-Phenol:Chloroform was then added and vortexed vigorously 
for 1 minute. The resulting suspension was stored on ice for 10 minutes and centrifuged 
at 4 °C for 15 minutes at 17,900 x g. The upper aqueous phase was transferred to a new 
RNase-free vessel and an equal volume of isopropanol added, and mixed thoroughly. 
The preparation was then stored at -20 °C for 30 minutes. The precipitation mixture 
was centrifuged at 4 °C for 15 minutes at 17,900 x g and the supernatant carefully 
removed and discarded. The RNA pellet was then washed in 200 pi of 70 % ethanol, 
gently vortexed, followed by centrifugation at 4 °C for 5 minutes at 9,000 x g. The 
ethanol supernatant was removed and discarded and the RNA pellet resuspended in 30 - 
50 pi of DEPC water/EDTA. Resuspended pellets were stored at -80 °C until further 
use.
2.2.10 Automated DNA sequencing
Both, PCR products and cloned DNA fragments were sequenced using ABI BigDye 
terminator cycle sequencing chemistry version 3.1 on an ABI 3100 automated 
sequencer (Applied Biosystems). Before sequencing, PCR products were purified, 
removing unincorporated primers and dNTPs. An aliquot of the amplification product 
(2 pi) was purified by the addition of 23 pi dEhO, 1 U shrimp alkaline phosphatase 
(SAP, Amersham LifeScience, Buckinghamshire, UK) and 1 U Exonuclease I (United 
States Biochemical, Ohio, USA) in SAP buffer, and incubated at 37 °C for 15 minutes 
followed by 80 °C for 15 minutes. A 13 pi aliquot of purified PCR product was then 
used for cycle sequencing. Cycle sequencing reactions (20 pi) consisted of 1 pi 
BigDye, 1 pi of 1 pmol sequence specific primer, 13 pi of purified PCR product, and 5 
pi TM buffer (200 mM Tris.HCl pH 9.0, 5 mM MgCb). For cycle sequencing of 
cloned DNA fragments, 2 pi of (100-250 ng) cloned DNA, 2 pi of 1 pmol sequence 
specific primer, 2 pi BigDye and 3 pi TM buffer was made up to a total volume of 20 
pi. Cycle sequencing reactions (30 cycles of, 96°C for 30 seconds, 50°C for 15 seconds 
and 60°C for 4 minutes) were carried out in a Techne Genius PCR thermocyler. The 
DNA was then precipitated by addition of 26 pi precipitation solution (50 ml 95% (v/v) 
Ethanol, 2 ml 3 M NaOAc pH 5.2), vortexed and left on ice for 10 minutes before 
centrifugation at 17,900 x g for 30 minutes. The supernatant was then aspirated and 200
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pi of 70 % ethanol was added to the DNA pellet and centrifuged at 17,900 x g for 10 
minutes. The supernatant was removed and the tubes heated (with the lids open) at 
65°C for 1-5 minutes. The DNA pellet was then resuspended in 11 pi formamide before 
being loaded onto the ABI 3100 automated sequencer.
2.2.11 Restriction enzyme digest
Single and double digests of mini- and maxi-prepped plasmid DNA was carried out in a 
total volume of 10 pi. Restriction enzyme digests consisted of 2 pi of mini/maxi- 
prepped DNA, 1 pi of 12 U/pl restriction enzyme for single digests or 0.5 pi of each 
enzyme for double digests, and 1 pi 10 x Buffer (Promega, Southampton, UK). Digests 
were incubated for 2 hours at 37 °C in a Techne Genius PCR thermocyler and then 
resolved on a 0.5 % (w/v) agarose gel (section 2.2.5.1).
2.2.12 Quantification of DNA and RNA
Following DNA/RNA purification, the concentration was determined by measuring 
absorbance at 260 nm on a spectrophotometer. 5 pi of DNA was made up to 1 ml with 
sterile water. The sample was then placed in a cuvette and absorbance read at 260 nm. 
An absorption of 1 OD (A) is equivalent to 50 pg/ml dsDNA, 33 pg/ml ssDNA, or 40 
pg/ml RNA. These standards were used to calculate the concentration of DNA, 
factoring in the dilution factor. To check for purity, DNA absorption was also 
measured at 280 nm. The ratio A[260]/A[280] is used as an estimate of the purity of 
nucleic acids as contaminating proteins absorb at 280 nm. Pure DNA has a ratio of 
approximately 1.8 and pure RNA, a ratio of approximately 2.0.
2.3 DNA Plasmid Preparation
2.3.1 Ligation reaction
Digested DNA fragments were purified (section 2.2.6) and ligated into the appropriate 
plasmid vector pre-digested with the same sites, in a 3:1 molar ratio. The ligation 
reaction contained 2 x rapid ligation buffer (Promega, Southampton, UK), 
approximately 500 ng of plasmid vector DNA, 3 Weiss units of T4 DNA ligase
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(Promega, Southampton, UK) and x ng of insert DNA, in a total volume of 20 pi. 
Ligation reactions were incubated at 4 °C overnight.
2.3.2 Transformation of competent cells
JM109 high efficiency competent cells (Promega) were thawed on ice and gently 
mixed. 50 pi of JM109 cells were then transferred to a 1.5 ml eppendorf tube 
containing 5 pi aliquot of the ligation reaction, and gently mixed. The cells were then 
heat shocked for 45-50 seconds at 42°C and immediately returned to ice. 950 pi of 
room temperature SOC medium (Invitrogen) was added and the cells incubated for 1.5 
hours at 37°C with shaking at 200 rpm. 100 pi of the transformation culture was plated 
onto an LB/ampicillin plate and incubated overnight (16-24 hours) at 37 °C.
Single colonies were picked and used to inoculate 5 ml LB broth (containing the 
appropriate antibiotic) and grown overnight with vigorous shaking at 37 °C. Plasmid 
DNA was then harvested from the overnight cultures as described in section 2.3.3 and 
digested with appropriate restriction enzymes to confirm the presence of an insert. 
Minipreps containing inserts were sequence verified to check for PCR induced errors 
before being stored at - 20 °C. 750 pi of the overnight culture was mixed with an equal 
volume of 50 % (v/v) glycerol and stored at -80°C as glycerol stocks.
2.3.3 Purification of plasmid DNA
Plasmid DNA was extracted and purified from bacterial cells using either the Genelute 
plasmid mini-prep kit (Sigma) or the HiSpeed Plasmid Maxi kit (QIAGEN).
2.3.3.1 Purification of plasmid DNA using the Genelute Plasmid Mini-Prep kit
Cells were pelleted by centrifuging 1.5 ml of overnight culture at 12,000 x g and the 
supernatant discarded. Cells were resuspended in 200 pi resuspension solution and 
vortexed. 200 pi of lysis solution was added to the resuspended cells and the tube 
gently inverted 4 - 6  times to mix. The lysed cell suspension was left to clear for 
approximately 4 minutes. 350 pi of neutralization solution was then added, the tube 
inverted 4-6 times and centrifuged at 17,900 x g for 10 minutes. To a binding column,
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500 ml of column preparation solution was applied, centrifuged at 17,900 x g for 1 
minute, and the flow-through discarded. The clear lysate was then transferred into the 
binding column and centrifuged for 1 minute at 17,900 x g. The flow-through was 
discarded and 750 pi of wash solution was added to the binding column and centrifuged 
for 1 minute at 17,900 x g. The flow-through was discarded and the column centrifuged 
for an additional 1 minute at 17,900 x g to remove excess flow through. The column 
was then transferred to a clean sterile 1.5 ml microcentrifuge tube and the DNA eluted 
by the addition of 50 pi of water and a final centrifugation step at 17,900 x g for 1 
minute.
2.3.3.2 Purification of plasmid DNA using the HiSpeed Plasmid Maxi kit
A single colony from a freshly streaked selective plate was picked and used to inoculate 
a starter culture of 5 ml LB medium (see section 2.3.2) containing the appropriate 
antibiotic. The inoculated culture was incubated overnight at 37 °C with vigorous 
shaking (200 rpm). The starter culture was then diluted 1/1000 into 250 ml medium 
containing the appropriate antibiotic, and grown overnight at 37 °C with vigorous 
shaking (200 rpm). Overnight cultures were then centrifuged at 6000 x g for 15 minutes 
at 4 °C to pellet the cells. The bacterial pellet was then resuspended in 10 ml buffer PI, 
to which 10 ml of lysis buffer P2 was added, mixed gently and incubated at 
approximately 22 °C for 5 minutes. 10 ml of chilled neutralisation buffer P3 was then 
added to the lysate, mixed immediately and transferred to a QIAfilter Cartridge. The 
lysate was then filtered through the QIAfilter Cartridge into a HiSpeed Tip previously 
equilibrated with 10 ml QBT buffer. The cleared lysate was allowed to enter the resin 
by gravity flow and was washed with 60 ml buffer QC. The DNA was then eluted with 
15 ml buffer QF. The eluted DNA was precipitated by incubating with 10.5 ml 
isopropanol at approximately 22 °C for 5 minutes. The eluate/isopropanol mixture was 
transferred to a 30 ml syringe connected to a QLAprecipitator. The eluate/isopropanol 
mixture was then filtered throught the QLAprecipitator. The bound DNA was washed 
by passing 2 ml 70 % (v/v) ethanol through the QIAprecipitator. The QLAprecipitator 
membrane was dried twice, by passing air through it quickly, and attached to a new 5 
ml syringe. 1 ml of sterile water was passed through the QIAprecipitator into a sterile 
1.5 ml microcentrifuge tube. The eluate was then passed through the QIAprecipitator a 
second time to ensure maximum yield.
63
Chapter Two -  Materials and Methods
2.3.4 Cloning
2.3.4.1 TA cloning into pGEM-T Easy
Constructs to be TA cloned were PCR amplified (section 2.2.1) using template specific 
primers, resolved by gel electrophoresis (section 2.2.5) and purified (section 2.2.6). 
Purified inserts were then ligated (section 2.3.1) into the pGEM-T Easy vector 
(Promega,), transformed into JM109 electro competent cells (section 2.3.2) and grown 
overnight on IPTG/X-gal/AMP LB plates. White colonies were selected and the 
plasmid DNA harvested (section 2.3.3.1). Clones were sequenced (section 2.2.10) to 
check for PCR introduced errors using vector and insert primers.
2.3.4.2 Generating GST-tagged proteins
The C-terminus of human NHS was directly cloned into pGEX-2T for characterisation 
of the C-terminal peptide antibody. A 607 bp fragment was amplified using primers 
engineered with restriction enzyme sites (see table 2.2). Both the PCR product and 
pGEX-2T vector were digested (section 2.2.11) with the appropriate restriction enzymes 
(see tables 2.2 and 2.3), ligated and transformed into JM109 electro competent cells 
(section 2.31 and 2.3.2). Clones were sequenced to check for PCR introduced errors 
using vector and insert primers.
Engineered
Primer name Sequence 5 *-39 restriction
__________________________________________________________ enzyme site
NHSC1 F CGGGATCCTCCAAGAGGAAAGTACTTGG BamHI
NHSC1 R CGGAATTCTCTATGTTGAACTCTGGGAG EcoRI
NHSC2 R CGGAATTCTGGTACAGGCAGTCTATGTTGAACTC EcoRI
NHS-CA1 F CGGGATCCAGCAGCTCCACGTGCCC BamHI
NHS-CA1 R CGGAATTCGT A ATTCC ACTCACTGTC AC EcoRI
NHS-CA2 F CGGGATCCGTTGGCGCTAAACCCTCAG EcoRI
NHS-CA2 R CGGAATTCCCCACTCCAGTTGCCACT________________ BamHI
Table 2.2 Primer sequences used to clone various NHS fragments into prokaryotic and mammalian
expression vectors.
For individual expression vectors into which the above fragments were cloned into refer to table 2.3.
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2.3.4.3 Generating Myc-tagged proteins
The NHSC2 construct of the human NHS protein (see figure 6.7), was amplified using 
primers engineered with restriction enzyme sites (see table 2.2). NHSC2 spanned exon 
6 to exon 8 of the NHS gene and threrefore, was amplified from a mRNA (accession 
number CR936788) obtained from RZPD Deutsches Ressourcenzentrum fur 
Genomforschung GmbH (Germany).
Amplicons were TA cloned into the pGEM-T Easy vector (section 2.3.4.1) and 
sequenced using vector and internal primers to check for PCR introduced errors. 
Following confirmation of the correct sequence, inserts were digested out of the pGEM- 
T Easy vector (section 2.2.11), sized fractionated on a 0.5 % (w/v) agarose gel (section 
2.2.5.1) from which the relevant insert was excised and gel purified (see section 2.2.6). 
Purified inserts were then ligated into pCMV-Tag3b (Stratagene, UK section 2.3.1) 
previously digested with the appropriate restriction enzymes (see table 2.3).
Vector Ligated with
Digested 
with 
restriction 
enzymes -
Buffer
Incubation
temperature
<°C)
Incubation
period
(Hours)
pCMV-
Tag3b
NHSC2 BamHI and 
EcoRI
E 37 2
pGEX-2T NHSC1 BamHI and 
EcoRI
E 37 2
pGEX-2T NHSC2 BamHI and 
EcoRI
E 37 2
Table 2.3 Vectors, restriction enzymes, and conditions used for subcloning of relevant PCR
generated fragments.
Note, all restriction enzymes and buffers used were obtained from Promega (UK) except where indicated 
(*) in which case the restriction enzymes and buffers were obtained from Amersham Biosciences (UK).
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2.4 Protein Based Techniques
2.4.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)
2.4.1.1 Resolving protein samples by SDS-PAGE
Protein samples were analysed by SDS-PAGE using the Mini-PROTEAN II 
electrophoresis cell (Bio-Rad, Hemel Hempstead, Hertfordshire). Casting gels had 
dimensions of 9 cm x 7 cm, and were 0.75 mm thick. Samples were loaded onto a 
stacking gel (125 mM Tris-HCl pH 6.8, 0.1 % (w/v) SDS, 0.05 % (w/v) ammonium 
persulphate (APS), 4.0 % (v/v) acrylamide, 0.1 % (v/v) bisacrylamide) overlaying the 
resolving gel.
Up to 20 pi of denatured protein sample was loaded in each well. Molecular weights of 
sample proteins were determined by loading 10 pi of a molecular weight marker per gel 
(Precision Plus Protein™ Standards, Bio-Rad). The Precision Plus Protein Standard 
contained ten protein bands of 10 kD, 15 kD, 20 kD, 25 kD, 37 kD, 50 kD, 75 kD, 100 
kD, 150 kD, and 250 kD.
Proteins were separated by electrophoresis in usually, a 12 % (v/v) acrylamide gel (375 
mM Tris-HCl pH 8.8, 12.0 % (v/v) acrylamide, 0.3 % (v/v) bisacrylamide, 0.15 % APS, 
0.1 % (w/v) SDS, 0.08 % (v/v) TEMED, as described above unless otherwise stated) in 
1 x electrophoresis running buffer (section 2.1.1.3). Samples were run at 200 volts for 
approximately 45 minutes.
2.4.2 Coomassie Staining
Protein samples resolved by SDS-PAGE were stained with Coomassie blue stain 
(section 2.1.1.3) for 1 hour. Excess stain was removed by washing the gel for 20 
minutes, two to three times with de-staining solution (section 2.1.1.3) with gentle 
agitation. Gels were then placed in water containing glycerol for 30 minutes and dried 
using a Bio-Rad drying system according to manufacturers instructions.
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2.4.3 Western blotting
Following separation of the protein samples by SDS-PAGE, the proteins were 
transferred to a nitrocellulose membrane (BioRad) ready for detection with a specific 
primary antibody. Protein blotting was performed using a semi dry transfer cell (Bio- 
Rad). The gel was placed on a piece of nitrocellulose membrane (0.45 pm thick, Bio- 
Rad) and sandwiched between blotting paper soaked in 1 x transfer buffer (section
2.1.1.3). The entire sandwich was then placed within the semi dry transfer cell 
according to manufacturers instructions. Proteins were transferred from the gel to the 
nitrocellulose membrane at 0.8 Amps for 20 minutes at 20 volts.
After transfer of the resolved protein samples onto the nitrocellulose membrane, non­
specific binding was abolished by blocking the membrane with blocking buffer (section
2.1.1.3) at 4°C overnight.
The membrane was then incubated in blocking buffer containing primary antibodies 
(table 2.4, A) at specific concentrations (as described in the relevant sections) for 1 hour 
at approximately 22 °C on a shaking platform. The nitrocellulose membrane was 
washed 5 times in 1 x PBS containing 0.05 % (v/v) Tween-20 (pH 7.4). Secondary 
antibody was then diluted (see table 2.4, B for working dilutions of secondary 
antibodies) in fresh blocking buffer, added to the membrane, and incubated at room 
temperature for 1 hour on a shaking platform. Excess, unbound secondary antibody was 
removed by washing the membrane 5 times in 1 x PBS containing 0.05 % (v/v) Tween- 
20 (pH 7.4).
Secondary antibody binding was detected using the ECL Plus Western Blotting 
Detection Reagents (Amersham Biosciences) in accordance with the manufacturers 
instructions. The ECL Plus Western Blotting Detection system is based on the 
combined HRP and peroxide catalyzed oxidation of a Lumigen PS-3 Acridan substrate. 
The resulting light was detected using Fuji films (Jet X-ray, UK).
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Name Mono/Polyclonal Specificity Affinity
purified
Raised in Supplier Western blot 
Titre
Immunocytochemistry
titre
SG1703 Polyclonal
(C-terminus peptide)
NHS peptide 
sequence
No Rabbit Sigma Genosys 1:1000 1:1000
Myc Monoclonal Myc peptide 
sequence
Yes “ Mouse Sigma-Aldrich 1:1000 1:2000
p34 Polyclonal p34 subunit of 
the Arp2/3 
complex
Yes Rabbit 1:50
(B)
Specificity Affinity
purified
Raised in Supplier Conjugate Western blot 
Titre
Immunocytochemistry
titre
Goat IgG 
(H+L)
Yes Rabbit Jackson
ImmunoResearch
Peroxidase-
conjugated
1:30,000 -
Rabbit IgG 
(H+L)
Yes Donkey Jackson
ImmunoResearch
Cyanine 3- 
congugated
- 1:100
Mouse IgG 
(H+L)
Yes Donkey Jackson
ImmunoResearch
Cyanine 2- 
congugated
- 1:100
Table 2.4 (A) List of primary antibodies used and, (B) secondary antibodies used to detect primary antibodies
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2.4.4 Expression and Purification of Glutathione-S-Transferase (GST) 
Fusion Proteins
2.4.4.1 Initial analysis of GST-fusion proteins
A 5 ml aliquot of LB broth containing ampicillin was inoculated with the relevant 
pGEX-2T clone and grown overnight at 37°C with vigorous shaking (transformant 
culture). The transformant culture was then diluted 1 in 100 into 10 ml fresh LB broth 
containing ampicillin, and incubated with vigorous shaking at 37°C for 2 hours. 1 ml 
aliquot from each liquid culture was removed and placed on ice for use as non-induced 
control samples. To the remaining 9 ml of culture, IPTG at a final concentration of 1 
mM was added, and the cultures incubated with vigorous shaking at 37°C for 3 hours. 
Following incubation, 40 pi of each of the induced and uninduced cultures were 
transferred to a sterile 1.5 ml eppendorf tube, to which 10 pi of 5 x SDS sample buffer 
was added. Samples were then denatured by heating at 95°C for 5 minutes before 
loading onto a 12 % SDS-PAGE gel (see section 2.4.1). The remaining induced 
cultures, were centrifuged at 4,000 xg for 10 minutes to pellet the cells. The 
supernatant was then aspirated and the pellets stored at -  20 °C for future use.
2.4.4.2 Purification of GST fusion proteins
Milligram quantities of GST fusion protein were purified following initial confirmation 
that the fusion protein was being expressed (see section 2.4.4.1).
Starter cultures (section 2.4.4.1) were diluted 1:100 into 100 ml LB/ampicillin and 
grown at 37 °C with vigorous shaking for 12 to 15 hours. The culture was then diluted 
1:10 into 1 litre fresh LB/ampicillin medium, which was split between two 2-litre flasks, 
and grown at 37 °C with vigorous shaking for 1 hour. A 5 ml volume was then removed 
and transferred to a clean sterile universal tube. To the remaining culture, 100 mM 
IPTG was added to a final concentration of 0.1 mM and the induced culture grown for 
an additional 3 hours. The 5 ml volume taken out prior to the addition of IPTG (the 
uninduced control sample), was also grown for an additional 3 hours. The induced 
culture was then centrifuged for 10 minutes at 5,000 x g, at approximately 22°C to 
pellet the cells. The supernatant was discarded and the pellet resuspended in 20 ml 1 x 
PBS containing protease inhibitor cocktail as mentioned previously (section 2.1.1.3).
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Resuspended cells were then lysed on ice using a 5 mm diameter probe sonicator. 10 % 
(v/v) Triton X-100 was then added to the lysed cells to 1 % final concentration and 
mixed. Lysed cells were then centrifuged at 10,000 x g for 5 minutes at 4 °C, and the 
supernatants collected. The supernatant was transferred to a tube containing 1.5 ml 50 
% slurry of glutathione-agarose beads (Amersham Biosciences) and mixed by end-over- 
end rotation for 5 minutes at approximately 22 °C.
The slurry was then washed by adding up to 50 ml ice-cold 1 x PBS, mixed, and 
centrifuged for 10 seconds at 500 x g, approximately 22 °C. PBS was aspirated and the 
wash repeated an additional three times. The beads were resuspended in 1 ml ice-cold 1 
x PBS and transferred to a clean sterile 1.5 ml microcentrifuge tube. The sample was 
centrifuged at 500 x g, approximately 22 °C, to pellet the beads. The supernatant was 
then aspirated and the fusion protein eluted by the addition of 1 ml 50 mM Tris-HCl 
(pH 8.0)/10 mM reduced glutathione. The sample was mixed gently for 2 minutes, 
centrifuged for 10 seconds at 500 x g, approximately 22 °C, and the supernatant 
collected. The elution step was repeated twice. Samples were analysed by SDS-PAGE 
(section 2.4.1) and stored long term at -  80 °C in 10 % glycerol.
2.5 Cell Based Techniques
All cell culture lines were grown in an atmosphere of 5 % CO2 at 37 °C and were 
passaged every two to three days, or when approximately 90 % confluent.
2.5.1 Cell Culture Maintenance
2.5.1.1 Adherent cells
Table 2.5 lists the media used to maintain all the mammalian cell lines used in this 
work. Except for MTLn3 cells, all cells were cultured in the presence of 10 % (v/v) 
foetal bovine serum and 50 pg/ml gentamycin. MTLn3 cells were cultured in 5 % (v/v) 
foetal bovine serum 50 pg/ml gentamycin.
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Cell type Abbreviation Morphology Media
Human Caucasian 
colon 
adenocarcinoma
Caco-2 Epithelial DMEM (lx) liquid + L- 
Glutamine, 4500 mg/L D- 
Glucose, 110 mg/L Sodium 
Pyruvate
Chinese hamster 
ovary
CHO - DMEM/F12 (lx) liquid + 
GlutaMAX I
Monkey African 
Green Kidney
COS-7 Fibroblast DMEM/F12 (lx) liquid + 
GlutaMAX I
Dog cocker spaniel 
kidney
MDCK Epithelial DMEM (lx) liquid + L- 
Glutamine, 4500 mg/L D- 
Glucose, 110 mg/L Sodium 
Pyruvate
Metastatic rat 
mammary 
adenocarcinoma
MTLn3 Epithelial MEM-a (lx) liquid + Earl salts 
and L-Glutamine. No 
ribonucleosides or 
Deoxyribonucleosides
Table 2.5 Adherent cell lines, their morphology, and media used.
2.5.2 Storage of cells
Cells to be stored in liquid nitrogen were pelleted, resuspended in 2 mis cell culture 
freezing media (Gibco, UK) and placed in 100 % (v/v) ethanol in a cell freezing 
container at -  80 °C for 24 hours before freezing in liquid nitrogen.
2.5.3 Reviving Stored Cells
Cell aliquots frozen in liquid nitrogen were removed and thawed quickly in a water bath 
at 37 °C. The thawed cells were then immediately transferred to pre warm media and 
left at 37 °C in an atmosphere of 5 % CO2.
2.5.4 Determination of total cell counts and viable cell number
Viable cells in culture were counted using Trypan Blue. Trypan Blue only crosses the 
membrane of dead (non-viable) cells therefore appearing dark blue. Adherent cells 
were treated with Trypsin (Gibco, UK) and resuspended in 4 ml medium. A 50 pi 
aliquot was transferred to a separate tube containing 50 pi of 0.4 % (w/v) Trypan Blue 
solution, mixed and left to stand for 5 minutes. A cover slip was placed on a clean 
hemocytometer and the Trypan Blue-cell suspension transferred to each chamber by
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capillary action. Viable and non-viable cells were counted in the 1 mm centre square of 
chamber 1 followed by the four 1 mm comer squares, and was repeated for chamber 2. 
Non-viable cells were then counted as a percentage of viable cells.
2.5.5 LipoFectamine Plus
LipoFectamine Plus, a cationic lipid, was used to transfect mammalian cells with 
plasmid DNA. In order to achieve maximum transfection efficiency, the following 
conditions were optimised: cell number, plasmid DNA and lipofectamine
concentrations, and the length of exposure of cells to DNA-liposome complexes.
2.5.5.1 Transfection of CHO cells using LipoFectamine Plus
CHO cells were seeded at a density of approximately 30,000 cells per well on an eight 
well chamber slide, and left to grow and adhere for one to two days before transfecting. 
Once the cells were approximately 80 % confluent, they were transfected with the 
plasmid DNA construct of interest. Two solutions (A and B) were prepared. Solution 
A consisted of 100 ng of plasmid DNA, 1 pi of Plus reagent, and 25 pi of serum free 
DMEM/F12 media. Solution B contained 0.5 pi Lipofectamine and 100 pi of serum 
free DMEM/F12 media. Both solutions were mixed separately and left at 22 °C for 
fifteen minutes. The two solutions were then mixed together and left at 22 °C for an 
additional fifteen minutes to allow the DNA-liposome complexes to form. The 
CHO/MTLn3 cells to be transfected were then washed twice in Hanks’ Balanced Salt 
Solution (HBSS), and a 100 pi of the DNA-liposome solution added to each well of the 
eight well chamber slide. The cells were then incubated for 3 - 4 hours at 37 °C in an 
atmosphere of 5 % CO2. Following the incubation period, an equal volume of 
DMEM/F12 containing 20 % (v/v) fetal calf serum (10 % (v/v) final concentration), and 
2 % (v/v) streptomycin/penicillin (1 % (v/v) final concentration), was added to each 
well of the eight well chamber slide and the cells incubated for 24 hours at 37 °C with 5 
% CO2. Transfected cells were then stained and analysed (see section 2.5.6.1).
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2.5.6 Immunocytochemistry
2.5.6.1 Adherent cells
Glass chamber slides and cover slips were pre-treated prior to seeding MTLn3 cells by 
first washing in 1M HC1 for 3-5 minutes followed by two washes with sterile lx PBS. 
PBS was then aspirated away and 95 % (v/v) ethanol overlaid on the chamber 
slide/cover slip for 1-2 minutes. A second wash with lx PBS was then carried out 
before seeding the cells. No pre-treatment was necessary for other cell types used in 
this study.
Transfected CHO cells seeded on 8 well chamber slides at a density of approximately 
30,000 and seeded MTLn3 cells, were rinsed twice in 1 x PBS and fixed in 4 % (w/v) 
paraformaldehyde in 1 x PBS for fifteen minutes at 22 °C. The cells were then washed 
twice in 1 x PBS and permeabilised by incubating the cells at 22 °C in 0.1 % (v/v) 
Triton X 100 in 1 x PBS for fifteen minutes. The cells were then washed twice in 1 x 
PBS for five minutes. To prevent non-specific binding, the cells were incubated in 
blocking buffer (1 % (w/v) bovine serum albumin (BSA), 10 % (v/v) donkey serum in 1 
x PBS) for 45 minutes at 22 °C. Seeded MTLn3 cells were incubated in blocking buffer 
for 45 minutes at 22 °C in the presence of either rhodamine-, Alexa Fluor 488-, or Alexa 
Fluor 647 phalloidin (see table 2.6) at a final concentration of 20 units/ml. The 
blocking buffer was then replaced with fresh blocking buffer containing the appropriate 
dilution of primary antibody (see table 2.4, A) and left at 22 °C for 1 hour. The cells 
were then washed five times with 1 x PBS. A 100 pi aliquot of fresh blocking buffer 
containing a 1:100 dilution of the appropriate secondary antibody conjugated with either 
cyanine-2 or -3 (see table 2.4, B) was added to each well and incubated at 
approximately 22 °C for 1 hour. The cells were then washed five times in 1 x PBS. On 
the penultimate wash, the 1 x PBS contained 4’-6 Diamidino-2-phenylindole (DAPI) at 
a concentration of 0.002 mg/ml. The final wash in 1 x PBS was aspirated and one drop 
of binding media (90 % glycerol in 1 x PBS) added to each well before overlaying a 
cover slip.
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Phallotoxin
probe
Conjugate Stock
concentration
(units/ml)
Working
concentration
(units/ml)
Alexa Fluor 
488 phalloidin
Green-fluorescent Alexa 
Fluor 488
200 20
Alexa Fluor 
647 phalloidin
Far-red fluorescent Alexa 
Fluor 647
200 20
Rhodamine
phalloidin
T etramethy lrhodamine 
(TRITC)
200 20
Table 2.6 List of conjugated phallotoxins used to stain the actin cytoskeleton of MTLn3 cells.
2.5.7 Epidermal growth factor (EGF) stimulation of MTLn3 cells
MTLn3 cells were seeded onto small glass cover slips placed within a 35 mm dish at a 
density of approximately 240,000 cells. Glass cover slips were pre-treated as stated in 
section 2.5.6. Seeded cells were left for 24 hours or until approximately 80 % 
confluent. Cells were then starved for a maximum of 3 hours by replacing the media for 
serum-free MEM-alpha media supplemented with 0.35 % (w/v) BSA. An equal volume 
of serum-free MEM alpha media containing 10 nM EGF solution was then added to the 
starved cells and left for 3 minutes to allow for formation of lamellipods. After 3 
minutes the media was removed and 4 % paraformaldehyde added to fix the cells. The 
cells were then fixed and stained accordingly (see section 2.5.6). Upon staining of the 
stimulated MTLn3 cells, a drop of binding media was added to each of the cover slips 
before being inverted and mounted onto a glass slide.
2.6 Actin polymerisation assay
Measuring polymerisation through fluorescence enhancement of pyrene-conjugated 
actin is a sensitive, versatile and quick assay to help determine if a protein activates the 
Arp2/3 complex. Control and test samples are mixed together with a small amount of 
pyrene-conjugated actin and the Arp2/3 complex and fluorescence measured using a 
spectrophotometer. Fluorescence is enhanced up to twenty fold by the association of 
actin monomer into the polymer form.
Bovine brain Arp2/3 complex and rabbit skeletal muscle actin (> 95 % purity), were 
purchased from Cytoskeleton Inc along with an Actin Polymerisation Biochem Kit. 
The Actin Polymerisation Biochem Kit contained: actin (> 99 % purity) modified to
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contain co-valently linked pyrene at cysteine 374, General Actin Buffer, Actin 
Polymerisation Buffer, 100 mM ATP pH 7.0, and 100 mM Tris-HCl pH 7.5.
To 1 ml General Actin Buffer, 2 pi of ATP solution was added and mixed (A buffer). 
225 pi and 605 pi aliquots of A buffer were then mixed with 5 pi pyrene-labelled actin 
and 20 pi actin respectively, and left at 22 °C for 1 hour. The actin monomer stocks 
were then centrifuged at 150,000 xg for 2 hours at 4°C and the top 80 % of supernatant 
aspirated for further use in the polymerisation assays. This step reduces the endogenous 
nucleation centres formed from freeze/thawing the actin samples and reduces the 
starting background level of fluorescence.
A control assay lacking the test substance was performed for each run. To a clean 
quartz cuvette ( 3 x 3  mm light path), 4.5 pi pyrene-labelled actin and 87.75 pi actin 
were added (5 % pyrene labelled actin). A 0.5 pi aliquot of Arp2/3 complex (13 nM 
final concentration) was then added to the cuvette followed by 9 pi of Actin 
Polymerisation Buffer, mixed thoroughly, and fluorescence measured immediately 
using a Perkin Elmer LS 5 0B luminescence spectrometer. Fluorescence was measured 
for a period of 10 minutes or until a plateau in signal strength was achieved. Excitation 
was set at a wavelength of 365 nm, with a bandwidth of 15 nm and the emission 
wavelength at 407 nm, with a bandwidth of 10 nm.
GST-tagged NHS constructs (in lOmM Tris pH 8.0, 50 mM NaCl; section 2.4.4) at 
varying concentrations, were then tested for their ability to compete with the WASP 
WCA domain for binding to the Arp2/3 complex. A competitive assay consisted of the 
above assay being performed in the presence of both GST-tagged WASP WCA (100 
nM, in 20 mM Tris pH 7.5, 25 mM KC1, 1 mM MgCl2, 0.5 mM EDTA, 0.2 % (w/v) 
dextran, 2 % (w/v) sucrose buffer, Cytoskeleton Inc.) and the GST-tagged NHS 
construct. GST-tagged WASP WCA was added after the addition of the GST-tagged 
NHS construct due to the WASP WCA domain being a potent activator of the Arp2/3 
complex.
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2.7 Bioinformatics and computational software
A series of bioinformatic tools were used to define the genomic interval Xp22.13 - 22.2, 
identify polymorphic markers and characterise genes within the region.
The main sites used for this study were as follows: 
o UCSC (http://genome.ucsc.edu/), 
o NIX and PIX (http://www.hgmp.mrc.ac.uk/), 
o UniGene (NCBI, http://www.ncbi.nlm.nih.gov/), 
o Genecards (http://bioinformatics.weizmann.ac.il/cards/), 
o Ensembl (http://www.ensembl.org/), 
o Sanger Institute (http://www.sanger.ac.uk/), 
o ExPASY (http://ca.expasy.org/).
Novel microsatellites residing within the CXN interval were sought using an in house 
nucleotide repeat locator programme (World-wide Webster web designs 2000).
2.7.1 UCSC genome browser
The UCSC genome browser allows users to visualise a number of genomes including 
human, mouse and rat. The browser displays assembly contigs and gaps, mRNA and 
EST alignments, multiple gene predictions, homologies to other species, single 
nucleotide polymorphisms, sequence-tagged sites and more as a series of tracks aligned 
with the genomic sequence of interest (Kent et al., 2002; Karolchik et al., 2003).
2.7.2 Nucleotide Identification of unknown sequences (NIX)
NIX, a WWW tool, runs numerous DNA programmes on a denoted DNA sequence 
allowing for a general consensus to be seen between the programmes. Such 
programmes include exon prediction programmes (GRAIL, Fex, Hexon, MZEF), gene 
prediction programmes (Genemark, Genefinder, FGene), BLAST, Polyah 
(polyadenylation-signal identifier), RepeatMasker and tRNAscan (transfer RNA 
identifier).
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2.7.3 Protein Identification of unknown sequences (PIX)
PIX allows users to view results of numerous peptide analysis programme’s run 
simultaneously on a peptide sequence of interest. The type of analysis runs on a query 
peptide sequence include predicting, secondary structure (e.g. Predator); coiled coil 
(coil), transmembrane (DAS), signal peptide (Signal) and helix-tum-helix (HTH) 
domains; and running Blast searches against sequence and the (SPTR, NRL3D) 
domain (SBASE, PRODOM) databases.
2.7.4 ExPASy tools
The ExPASy (Expert Protein Analysis System) proteomics server (Swiss Institute of 
Bioinformatics, SIB), provides databases and analysis programmes for protein 
sequences and structures (Gasteiger et al., 2003). A software programme used in this 
thesis included T-coffee, an alignment algorithm allowing multiple alignment of protein 
sequences. The PROSITE database (a database of protein families and domains) was 
used to identify potential protein domains and homologies to other proteins or classes of 
protein. Identified homologies to proteins or specific domains were then searched for in 
the Swiss-Prot protein knowledge database to elucidate their function and highlight 
conserved/functionally important residues.
2.7.5 DNAStar
Nucleic acid and protein sequences were analysed using DNAStar computational 
software (DNAStar, Inc., USA). Sequencing data obtained from clones or PCR 
products were analysed using SeqMan. EditSeq was used to analyse downloaded 
Genbank sequences. Pairwise and multiple sequence alignments were performed using 
MegAlign, whilst MapDraw was used to generate a map of restriction endonuclease 
sites present within a given nucleic acid sequence.
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- Chapter Three -
Refinement of the X-linked cataract locus 
(CXN) and gene analysis for CXN and 
Nance-Horan syndrome (NHS)
3.1 Introduction
The chromosomal region Xp22 harbours numerous eye disease genes including Nance- 
Horan Syndrome (NHS; nuclear cataract, microphthalmia and microcomea, MIM 
302350), X-linked congenital cataract (CXN; Francis et al., 2002), retinitis pigmentosa 
(RP23; Hardcastle et al., 2000, MIM 300424), and retinoschisis 1 (RSI, MIM 312700). 
The causative genes, for NHS, CXN, and RP23 are not yet known and remain to be 
identified. This research project focuses on two diseases which mapped to this genomic 
region, Nance-Horan Syndrome and X-linked congenital cataract.
3.1.1 X-linked congenital cataract (CXN)
An X-linked congenital cataract (CXN) locus was recently mapped within a five- 
generation family to a 3 cM interval on chromosome Xp22.13 -  22.2 flanked by 
markers DXS9902 and DXS999 (Zmax = 3.64 at 0 = 0 for marker DXS8036; figure 3.1; 
Francis et al., 2002).
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Figure 3.1 CXN pedigree showing haplotypes on Xp22.13 -  22.2
Boxed haplotypes of affected males and carrier females show recombination with markers DXS99902 
and DXS999, as drawn in original paper (Francis et a l 2002). Disease segregates with markers
DXS1195 and DXS8036.
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Within this five-generation family, males are severely affected with a total opacity of 
the lens and require cataract surgery within the first few months of life. Females have a 
milder form of disease consistent with an X-linked carrier status. The cataract 
phenotype in carrier females is one of sea-fan of nuclear opacity (figure 3.4A). Until 
the mapping of CXN to the X chromosome in this family there was only one other 
convincing X-linked pedigree in which males had sutural cataracts (Krill et al., 1969). 
Some of the affected males in the CXN family were found to suffer from cardiac 
abnormalities, i.e. ventriculoseptal defect (VSD). However, it is unclear whether or not 
the cardiac abnormalities completely segregate with the cataract phenotype in this 
family. Furthermore, it has not been documented whether the female carriers had 
cardiac abnormalities. Unfortunately, this family are no longer contactable by our 
clinical colleagues.
3.1.2 Nance-Horan Syndrome (NHS)
Nance-Horan Syndrome (MIM 302350) is a rare X-linked disease characterised by 
severe congenital cataract in males with microcomea and/or microphthalmia, distinctive 
dental anomalies including supernumerary incisors and crown shaped permanent teeth, 
characteristic facial features (anteverted pinnae, long face, prominent nasal bridge and 
nose) and mental retardation in approximately 30% of cases. In carrier females, 
cataracts are confined to the posterior Y sutures. Obligate carriers also have widely 
spaced cone or screwdriver shaped teeth (figure 3.4 B iii and C iii; Bixler et al., 1984; 
Seow etal., 1985).
Original linkage data mapped the NHS locus to a 30 cM interval on Xp22.13-22.31 
flanked by markers DXS143 and DXS451 (Stambolian et al., 1990; Zhu et al., 1990; 
Bergen et al., 1994, figure 3.2).
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Figure 3.2 Schematic diagram of the genomic intervals for CXN, NHS, and Xcat.
Note, the Xcat genomic interval mapping to the mouse chromosomal region syntenic with the Xp22.1-22,3 block, is superimposed on the human X chromosome for
comparison.
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3.1.3 X-linked congenital cataract of the mouse
Favor and Pretsch reported the finding of a dominant X-linked cataract mutation (Xcat) 
in mice (Favor and Pretsch, 1990). The Xcat mutation was recovered in an Fi female 
descendent from the cross T-stock female x an irradiated DBA/2 male. Both 
hemizygous males and homozygous females have a total lens opacity present at eye 
opening whilst the phenotype of heterozygous female carriers varies from barely 
noticeable to totally opaque lenses (Stambolian et al., 1994).
Favor and Pretsch originally mapped the Xcat mutation with respect to two mutations, 
tabby (Ta) and glucose-6-phosphate dehydrogenase (G6pd) on the mouse X 
chromosome (Favor and Pretsch, 1990). The Xcat interval was further refined by 
Stambolian and colleagues placing the Xcat gene distal to PDHA1 and approximately 3 
cM proximal to Amg (Stambolian et al., 1994). A panel of 700 backcross progeny from 
the cross DBA/2-Xcat x Mus spretus was generated, of which 140 were analysed for 
linkage to markers on the X chromosome. The new linkage data relocated the Xcat 
locus 3.5 cM distal to DXMit28 and 2.9 cM proximal to Amg, DXMitl2. No 
recombinants were detected between DXWas31, DXPasl8, DXMit20, DXMitl5, Grpr 
and Xcat (Stambolian et al., 1994).
The distal end of the mouse X chromosome to which the Xcat locus was mapped 
contains the conserved block Xp22.1-22.3 in humans and is the syntenic interval to 
which Nance-Horan Syndrome and X-linked congenital cataract have been mapped. In 
addition, there are phenotypic similarities of the cataract (total lens opacity in affected 
males at birth) in all three diseases implying that the Xcat mouse is likely to be an 
animal model for NHS and/or CXN. Interestingly however, other abnormalities seen in 
patients with Nance-Horan Syndrome (e.g. dental abnormalities) or X-linked congenital 
cataract (heart anomalies such as VSD), are not reported in the Xcat mouse.
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3.2 Results
3.2.1 Families and phenotypes
The CXN family previously mentioned in section 3.1.1 was included in this study, 
along with four families with a diagnosis of Nance-Horan syndrome (figure 3.3).
3.2.1.1 NHS family 1
A four generation family diagnosed with Nance-Horan Syndrome (NHS) was evaluated 
(figure 3.3, B). Two brothers were noted soon after birth to have bilateral dense 
congenital cataracts and microphthalmia (IV:2 and IV:3, figure 3.3, B). The youngest 
brother (IV:3) also had bilateral cleft palate, which was repaired in infancy. At a later 
age both brothers were found to have abnormal teeth and typical dysmorphic features 
(anteverted pinnae, long face, prominent nasal bridge and nose) consistent with a 
diagnosis of Nance-Horan syndrome (NHS). Their mother (111:3) had bilateral sutural 
lens opacities consistent with being an X-linked carrier of the disorder.
3.2.1.2 NHS family 2
Family two (figure 3.3, C) exhibited typical features of NHS. One affected son (111:2) 
exhibited dense central nuclear opacities along with large anteverted pinnae, typical 
NHS dysmorphism (long face, prominent nasal bridge and nose), diastema and 
prominent notching of incisors (figure 3.4, C iii-iv). The other affected son (111:1) 
displayed dense white central lens opacity with denser central star shaped opacity, but 
no typical NHS features were documented. The affected sons mother (11:1) had 
posterior polar and cortical cataract (figure 3.4, C i-ii), and it was reported she had poor 
dental enamel.
3.2.1.3 NHS family 3
The affected male (11:1) of family 3 (figure 3.3, D) displayed typical features of NHS 
(prominent teeth, anteverted pinnae, long face, and broad nasal bridge) in addition to 
severe mental retardation, epilepsy and hypotonia (figure 3.4, B i). The affected sons 
mother (1:1) had sutural cataract and displayed screwdriver shaped teeth (figure 3.4, B ii 
and iii).
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Figure 3.3 Pedigrees of X-linked congenital cataract and Nance-Horan Syndrome
CXN pedigree (A), NHS 1 pedigree (B), NHS 2 pedigree (C), NHS 3 pedigree (D), NHS 4 pedigree (E). 
Squares denote males and circles, females. Blackened squares are indicative of an affected individual and 
circles with black dots represent carrier females. Symbols with a diagonal line through them represent
deceased individuals.
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Figure 3.4 Specific clinical features of CXN and NHS.
Slit lamp view of a heterozygous 50 year old female from the CXN family, showing fan of nuclear lens opacification (A, i). Same eye at a lower magnification and with the 
lens in retroillumination (A, ii). An Affected male (11:1) with typical NHS features and severe developmental delay from NHS family 3 (B, i). Sutural cataract (B, ii) and 
screwdriver shaped teeth (B, iii) in a female carrier for NHS (1:1, NHS family 3). Slit lamp view (C, i) and lens retroillumination (C, ii) of a 34 year old carrier female (11:1, 
NHS family 2). Teeth anomalies in an affected male of NHS family 2 (111:2, C, iii). An Affected male (111:2) with typical NHS features from NHS family 2 (C, iv). Slit 
lamp view (D, i) of an affected mother in NHS family 4 (1:1). An Affected male (11:1) with typical NHS features from NHS family 4 (D, ii).
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3.2.1.4 NHS family 4
The affected male in this family (11:1, figure 3.3, E) had dense white central lens opacity 
along with an upside down Y sutural opacity with a milky lens opacity diffuse edge. 
The periphery of the lens was clear. The affected sons mother (1:1) exhibited fine dots 
at both posterior Y sutures and cortical wedges (figure 3.4, D i). Other typical NHS 
features were not documented, although the family do have a history of abnormally 
large ears as seen in the affected son (11:1, figure 3.4, D ii).
3.2.2 Genotyping
The CXN disease interval spans approximately 3.5 Mb of genomic sequence on 
Xp22.13 -  22.2 (Francis et al., 2002, figure 3.2). Prior to further genetic and genomic 
studies, segregation at Xp22 was confirmed through genotyping a total 46 known 
microsatellite markers (table 3.1) spanning the X chromosome, in 20 individuals of the 
CXN family. Genotyping of the 46 known microsatellite markers was outsourced to 
The John Vane Science Centre (Barts, London), the results were scored twice by two 
individuals and then compared with our own, previous data. The results (figure 3.5) 
confirmed disease segregation in the CXN family to chromosomal region Xp22.13 -  
22.2, with markers DXS1053-DXS8036-DXS1195 (figure 3.5).
Since the disease interval in the CXN family on Xp22.13-22.2 spans approximately 3.5 
Mb of DNA and the average gene density in humans is 1 gene per 100,000 bases, there 
was the potential for the CXN interval to harbour up to approximately 35 genes. In an 
attempt to refine the CXN interval and therefore reduce the number of potential 
candidate genes for analysis, additional and novel microsatellite markers were sought 
for genotyping in the CXN family. Microsatellite markers DXS1053, DXS1195, and 
AFMB343YD5, within the CXN disease interval were selected and primer sequences 
obtained from the genome database (http://www.gdb.org, table 3.2). In addition, a 
further 6 novel di-nucleotide repeats (SI, S2, S3, S4, S6, and S7), two tri-nucleotide 
repeat markers (S5 and S9), and one tetra-nucleotide repeat marker (S8), were identified 
from available genomic sequence within the disease interval using an in-house repeat 
locator programme (World-wide Webster web designs 2000).
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Marker name Chromosome location Heterozygosity
Genetic distances (Mb) 
marker to marker
DXSI060 Xp22.32 -
DXS1223 Xp22.31 0.75 2.83
DXS7108 Xp22.22 0.75 1.50
DXS9902 Xp22.2 - 4.88
DXS1053 Xp22.2 0.84 0.04
DXS8036 Xp22.2 0.74 1.28
DXS1195 Xp22.13 0.61 0.29
DXS999 Xp22.13 0.75 1.10
DXS7593 Xp22.11 0.70 3.36
DXS1061 Xp21.3 0.73 4.85
DXS1214 Xp21.2 0.79 3.62
DXS8090 Xp21.1 0.81 5.49
DXS1068 X pll.4 0.82 1.75
DXS8102 X pll.4 0.65 0
DXS8015 X pll.4 0.74 0.50
DXS993 X pll.4 0.79 1.16
DXS8080 X pll.3 0.68 2.90
DXS8083 Xpll.3 0.74 0.80
DXS1055 Xpll.3 0.72 0.98
DXS1039 Xp 11.23 0.61 2.78
DXS991 Xpll.21 0.82 6.04
DXS1216 Xql3.1 0.61 12.54
DXS986 Xq21.1 0.76 10.84
DXS1196 Xq21.31 0.79 7.11
DXS1217 Xq21.31 0.62 1.51
DXS8077 Xq21.33 0.60 6.68
DXS8020 Xq22.1 0.78 4.10
DXS1106 Xq22.2 0.67 2.96
DXS1059 Xq23 0.72 8.39
DXS8088 Xq23 0.62 1.83
DXS8055 Xq23 0.64 1.11
DXS8064 Xq24 0.56 2.38
DXS8067 Xq24 0.70 1.89
DXS1001 Xq24 0.82 0.28
DXS8009 Xq25 0.52 6.10
DXS1047 Xq26.1 0.81 2.70
DXS1062 Xq26.3 0.74 8.00
DXS984 Xq27.1 0.72 2.13
DXS1205 Xq27.1 0.72 0.43
DXS1227 Xq27.2 0.73 0.34
DXS8106 Xq27.3 0.69 1.18
DXS8043 Xq27.3 0.81 1.62
DXS8045 Xq27.3 0.49 1.29
DXS998 Xq27.3 0.57 0.90
DXS8069 Xq28 0.62 2.79
DXS1073 Xq28 - 3.88
Table 3.1 Micosatellite markers used for genetic characterisation of the CXN family
A total of 46 microsatellite markers spanning the X chromosome were genotyped in 20 members of the CXN 
family. Marker to marker distances were obtained from the GDB database (http://www.gdb.org/)
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Individual: 11:1 111:1 111:2 111:3 lll:4 IIIS 111:7
Status: C U U C C C C
Marker
DXS1060 ?/? 3 3 3/5 3/5 2/3 4/5
DXS1223 5/5 5 5 3/5 3/5 2/5 2/2
DXS7108 3/1 3 3 5/1 5/1 3/2 ?/?
DXS9902 2/1 2 2 4/1 4/1 1/4 3/1
DXS1053 1/2 1 1 3/2 3/2 2/2 3/2
DXS8036 3/3 3 3 3/3 3/3 3/3 2/3
DXS1195 1/2 1 1 2/2 2/2 3/2 2/2
DXS999 2/1 2 2 1/2 1/1 2/1 2/1
DXS7593 4/5 4 4 3/4 3/5 5/2 1/2
DXS1061 ?/? 3 3 2/3 2/4 4/1 3/2
DXS1214 2/2 2 2 2/2 2/2 2/4 2/2
DXS8090 2/2 2 2 5/2 5/2 4/4 2/4
DXS1068 1/2 1 1 2/1 2/1 2/1 2/1
DXS8102 1/2 1 1 4/1 4/1 2/4 3/1
DXS8015 1/1 1 1 4/1 4/1 4/3 3/1
DXS993 4/2 ? 4 1/4 1/4 4/2 7/7
DXS8080 2/3 2 2 3/2 3/2 3/3 2/2
DXS8083 1/3 1 1 2/1 2/1 3/1 1/1
DXS1055 1/2 1 1 4/1 4/1 2/1 1/1
DXS1039 1/1 1 1 2/1 2/1 1/1 7/7
DXS991 1/1 1 1 4/1 4/1 2/3 1/1
DXS1216 3/3 3 3 2/3 2/3 2/3 ?/?
DXS986 2/2 ? 2 2/2 2/2 7/7 2/2
DXS1196 3/4 3 3 2/3 2/3 1/2 1/1
DXS1217 ?/? 2 1 2/1 2/1 2/1 2/1
DXS8077 2/2 2 2 2/2 2/2 2/2 2/2
DXS8020 1/4 4 1 1/1 1/1 5/1 4/1
DXS1106 3/1 ? 3 2/3 2/3 3/3 3/3
DXS1059 ?/? 2 1 2/1 2/1 2/1 3/1
DXS8088 3/3 3 3 4/3 4/3 2/3 1/3
DXS8055 ?/? ? 7 2/3 7/7 1/3 ?/?
DXS8064 3/1 1 3 3/3 3/3 4/3 ?/?
DXS8067 3/4 4 3 2/3 2/3 3/3 4/3
DXS1001 ?/? 2 2 4/2 4/2 2/2 2/2
DXS8009 2/2 2 2 1/2 1/2 1/2 1/2
DXS1047 5/4 7 5 1/5 1/5 3/5 ?/?
DXS1062 3/3 3 3 3/3 3/3 2/3 ?/?
DXS984 5/2 2 5 1/5 1/5 4/5 ?/?
DXS1205 1/2 2 1 1/2 1/1 1/1 7/7
DXS1227 1/1 ? 1 1/1 3/1 1/3 1/1
DXS8106 2/3 3 2 6/3 6/2 4/2 3/3
DXS8043 4/4 4 4 5/4 5/4 4/4 2/1
DXS8045 2/2 2 2 2/2 2/2 2/2 ?/?
DXS998 1/2 2 1 3/2 3/1 2/1 3/2
DXS8069 2/2 2 2 2/2 2/2 1/2 1/2
DXS1073 2/2 7 2 1/2 1/2 2/3 7/7
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Figure 3.5 Haplotype analysis of the entire X chromosome in the CXN family.
Markers segregating with disease, DXS1053-DXS8036-DXS1195, are indicated (boxed red). NB.
Marker DXS1195 was found to be proximal to marker DXS8036 in the current genome assembly, 
compared to figure 3.1. Positions and distances between markers can be seen in table 3.1. A = affected 
male, C = carrier female, U = unaffected individual. Where known, both alleles are shown (separated by 
a virgule [/]) for female members of the CXN family. For individuals position in the pedigree please refer
to figure 3.1
IV:2 IV3 IVS IV:6 IV:7 V:1 V3 V:4 VS V:6 V:7
C A A C U A U A U U U
3/5 5 2 5/1 4/1 3 1 5 7 1 2/1
4/5 5 2 5/2 2/2 4 2 5 2 2 1/2
1/1 1 3 1/3 4/3 1 3 1 3 4 3/3
4/1 1 1 3/1 3/3 4 3 1 3 3 3/3
2/2 2>i 3/2 1 2 2 7 3 1/2
2/3 3/3 3/3 3 3 3 3 3/3
2/2 2/2 2 2 2 1/2
2/2 1 1 2/1 2/2 2 1 1 2 7 7/7
2/4 4 5 2/2 1/2 4 2 2 2 1 4/2
3/3 4 4 2/2 3/2 3 2 2 2 3 3/2
3/2 2 2 2/1 2/1 2 1 2 1 2 2/1
3/2 2 1 2/4 4/4 2 4 2 4 4 1/4
2/1 1 2 2/1 1/1 1 1 2 1 1 3/1
3/1 1 2 3/3 1/3 1 3 3 3 1 2/3
3/1 1 4 3/4 1/5 1 5 3 5 1 2/5
4/4 4 4 4/3 4/3 4 7 7 3 4 4/3
3/2 2 3 1/1 1/1 2 1 1 1 1 1/1
2/1 1 3 1/2 1/2 1 2 2 2 2 1/1
2/1 1 2 1/1 1/1 1 1 1 1 1 3/1
2/1 1 1 1/3 1/3 1 3 3 3 3 1/1
5/1 1 2 1/3 1/3 1 3 3 7 3 1/1
1/3 3 2 3/3 3/3 3 3 3 3 3 2/3
3/2 2 7 2/3 1/3 2 3 3 3 3 2/1
2/3 3 1 3/5 1/5 3 5 5 5 5 3/1
1/1 1 2 1/1 1/1 1 1 1 1 1 1/1
1/2 2 2 2/2 2/2 2 2 2 2 2 2/2
1/1 1 5 1/3 1/3 1 3 3 3 3 2/1
3/3 3 7 3/3 3/3 3 3 3 3 3 3/3
3/1 1 2 1/3 1/3 1 3 3 7 3 2/1
4/3 3 2 1/3 1/3 3 1 1 1 1 7/7
1/3 3 1 3/3 3/3 3 7 7 7 3 2/3
3/3 3 4 3/3 3/3 3 3 3 3 3 2/3
1/3 3 3 3/2 4/2 3 3 3 2 2 3/4
1/2 2 2 2/3 2/3 2 2 2 3 3 5/2
2/2 2 1 2/2 1/2 2 2 2 2 2 2/2
5/1 5 7 5/5 3/5 1 5 5 7 5 3/5
2/3 3 2 3/2 1/2 3 2 3 2 2 2/2
1/1 5 4 2/1 6/1 1 1 2 1 1 3/1
2/1 1 1 2/2 3/2 1 2 2 7 2 2/2
2/3 1 7 1/3 3/3 3 3 1 3 3 3/3
1/6 2 4 3/6 3/5 6 6 3 6 6 3/6
3/5 4 4 1/3 2/3 3 3 1 3 3 1/3
2/2 2 2 2/3 2/3 2 3 2 3 3 1/3
2/3 1 2 2/2 3/2 2 2 2 2 2 2/2
1/2 2 1 1/1 1/1 1 1 1 1 1 1/1
3/1 2 4 3/2 3/2 3 3 3 3 3 3/2
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The sequences of each of the novel microsatellite markers are shown in figure 3.6. 
Primers were designed (section 2.2.2) with appropriate fluorescent tags (table 3.2) and 
microsatellites were amplified using standard conditions (section 2.2.1) with specific 
annealing temperatures. The products were then loaded and analysed on an ABI 3100 
genotyper (section 2.2.7). Genotypes were determined in a double blind-manner. 
Novel microsatellite markers S6, S7, S8, and S9 (figure 3.6 and table 3.3) proved not to 
be polymorphic upon genotyping in the CXN family. Of the four novel microsatellites 
that proved not to be polymorphic, S7 consisted of an imperfect repeat (figure 3.6) 
whilst the repeat sequences of S8 and S9 (figure 3.6) consisted of only 12 repeats each. 
S5 (figure 3.6) consisted of 15 tri-nucleotide repeat units and was polymorphic. S7 was 
identical to SI in the type and number of repeats (figure 3.6), but only SI was 
polymorphic in the CXN family. In summary, five of the nine novel microsatellites 
(S1-S5) were polymorphic in the CXN family.
M ic ro sa te llite P r im e r S e q u e n c e  (5 ’-3 ’) T m °C D ye
la b e l
DXS1053 Forward
Reverse
TT AAGG A AG T AT G AGGCTCC A 
TTGGT GC A AAAGT AATC ACG
60
56
6-FAM
6-FAM
SI Forward
Reverse
TGTGATACCTGTTATTCACAAA G
TATCTGA CATTTTAAAG TGCAAG
62
60
6-FAM
6-FAM
AFMB343YD5 Forward GTGTCCATTTGTTGCCTACC 60 5-HEX
Reverse TGATTT AGATTCCCC AAGTTTT AC 64 5-HEX
S2 Forward TACATACAGCCCTTCAAAAACTG 64 5-HEX
Reverse AGCCAAGACAGGGGGATCAC 64 5-HEX
DXS1195 Forward TGCAAATGGACCCAAG 48 6-FAM
Reverse AT ATC AC AC AGGC AC AAAT G 56 6-FAM
S3 Forward TCAGTTCTTGA GTTTCAATTTG 58 6-FAM
Reverse T AACCC AG AT ATT AG A ACT AGC 60 6-FAM
S4 Forward TACTTGAGTGCATCTCCAGG 60 5-HEX
Reverse AAAGAGGTACAATTTCAGCCC 60 5-HEX
S5 Forward ATGTTCATAGCACTTACTATGG 62 5-HEX
Reverse AGTG A CTTTT AAGGGT AT ATGG 62 5-HEX
S6 Forward AAG AGT GT A TCTT ACTT GGT GC 62 5-HEX
Reverse AG AG TTCT GGGAG AAGTTAT AG 62 5-HEX
S7 Forward AG AT A A TT AG AT G AGCTC ACC AG 64 6-FAM
Reverse TTGT A ACCT AGATATGAGTGCTG 64 6-FAM
S8 Forward ATTTTCTGGCACTAGAATATGC 60 6-FAM
Reverse ATCCTGCTTTCTAATACCATTC 60 6-FAM
S9 Forward A AGTCT ATTTC AGTCC AG AC A AC 64 5-HEX
Reverse AGCG AT AAC ATC AGG AG AAAT AC 64 5-HEX
Table 3.2 Additional and novel microsatellite markers identified within the CXN disease interval.
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□ Novel microsatellite marker SI (24 di-nucleotide (GT) repeat):
g a g t c c g t g c  t g a a a a g g a g  g a tg g a g a a a  c t t a g g t c a a  t a c a g a c c a t
TGTGATACCT GTTATTCACA AAGGGACTCT TTCTCATCTT ATGCTAGGAG S1F
GGGAGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT
GTTTATTGAG GAGAAATGTG TTGAGAATGA AGAAAGTAAA ACATACATAA
AATATGTAAA AGCATATAAC AATTAGCACA CCGTCTTATA GGTAAAAAGC
TACAATTTTA CAGAAAGGCA ATCTTGCACT TTAAAATGTC A G A T A cattt SIR
c a a c a g g a c a  t t g t a a a a t a  g t t g t a a a a t  a g t t t a t c t c  c a g g t t c t c a
□ Novel microsatellite marker S2 (28 di-nucleotide (GT) repeat):
a g g c a t c t g t  g t g t t a c t t t  a t c t t g t t t t  c a a c t c a a a c  t t t a t a g t t t
TACATACAGC CCTTCAAAAA CTGCTATTTT TTTTTTAAAG ATTTTATTTT S2F
TCTTACTGCC TTTTGTTTTT TTTAAAAAAA AATTATGGAA AATTTCAAGC
TTAACAAAAA GTAGAGAGAT AATATAGCAC CTGGCTTCAG CAGATGAAAC
CGTAATTCCG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG
TGTGTGTGTG TGTGTATAGA GACAGTTTCT TGCTAAATTG CCCAGGCTGG
TCTTGAACTC CTGGGCTCAG GTGATCCCCC TGTCTTGGCT c c c c a a a g t g  S2R
c t g g g a t t g t  a g a t g t g a g c  c a c t g t a c a t  g g c t g a t a a t  t t c a t c t c t g
□ Novel microsatellite marker S3 (24 di-nucleotide (TG) repeat):
a t t c t g g t t a  a t t t t g t c c a  g t g a a t c t t t  t a c t t c a g a t  a t t g t a t t t t
TCAGTTCTTG AGTTTCAATT TGGCTCCTTT TTATCCTTTG TTTCTCCACT S3F
AAGATGGTCT TTTTAATCAG TACGATTGTG TGTGTGTGTG TGTGTGTGTG
TGTGTGTGTG TGTGTGTGTG TGTGTCTGTG TAATGTCATC GAAGACCAGT
TGAATAGCCA CTTTAAAATT TTTGTTTGCT AGTTCTAATA TCTGGGTTAT S3R
a c t t g g g t c t  g t c t c a g t t g  a t t t t c t t t t  t t c t t g a a a a  t a t t a t t c a t
□ Novel microsatellite marker S4 (21 di-nucleotide (GT) repeat):
a g c c t g g t c c  c t t t g g a a g c  a g t c a c g t g g  c c g c t g a c t t  t g c a g c c c a t
TACTTGAGTG CATCTCCAGG CCAGGAACAG AGCAGGGCTG GGGCAGAGAG S4F
CTGTGCTCAC GGCCAGTGCA TTGTCTCCCA GATTCGTGGC TCTGGGCTTG
CCTTCCCGGC TGAAAGGCAA AGCAGCCTGG CCCTGTTCTA GTTATTTCTT
TGTGTATATA TGTTTGTTTA TTTATTTAAG CAAGAGCTCT CTCTGCAGAG
TGGGGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTTTGT
GTGGGGTGCT TCAGAGAGGG CTGAAATTGT ACCTCTTTTC TTTCAGCCCT S4R
c t g c a t t t c c  c c a g a g a g a a  g g t t t t t t t c  t c g t c t t c a t  t t c c t t t g a a
□ Novel microsatellite marker S5 (15 tri-nucleotide (TTA) repeat):
c t a t a a t c t t  a c c a a g a c t g  a a t g a a a g t a  t t t g g t g c t t  a t a c t t t t t a
ATGTTCATAG CACTTACTAT GGCCAGGCAC AATGCCCAAG TGTTTTGCTT S5F
TATTATTATT ATTATTATTA TTATTATTAT TATTATTATT ATTATTTTCA
CAACAACCCA GCGAAACAGG TACTATTATT ATCCCCTTTT TGTAAATGAG
GAAACAGATT TCCATACTTG ACATTAACCT GCCCAAGGTC ACCCAGTTTG
GAAGTGGCAG GGCCAGGATT TGAAGCCGAA TATGTTCATT GTAAAGCCCA S5R
TATACCCTTA A A A g tca ctg  c a c g t c c a c g  t a t g g t a a t g  t g g t c a c a a t
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□ Novel microsatellite marker S6 (22 di-nucleotide (GT) repeat):
ATAATTTATT CTGATTTTTC TGGCTCACAT ATTGTGTCCC CAGTAGAAAC
AAGAGTGTAT CTTACTTGGT GCCATCGAAG TCTGTCCAAG TTTGAAGGGG S6F
TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTAGGGGAG
ACAACCTCAT GTGCTCATTC TCTATAACTT CTCCCAGAAC T C T tg t t tg t  S6R
t g a a t t g a t t  g t a c c t t g a g  a g a t g c t t t c  c c c t t t c a c a  c a c c t a c c t c
□ Novel microsatellite marker S7 (25 di-nucleotide (GT) repeat):
g t a g a a a t a c  a a a t t t g a a a  a t c a t t t g c a  t a t a a a c t g t  a t t t a a a g c c
AGATAATTAG ATGAGCTCAC CAGGGGATTA ATACAGGTTA GGGTTTCTCA S8F
GCCTTGGCAC TACTGACGTT TGGAGCCAGA ATGGGTGTGC GTGTGTGTGT
GTGTGTGTGT GTGTGTGTGC GCGTGTGTGT GTGTATGTGT ATTCTGTGCA
TTGTAGGATG TGAAGCAGCA CTCATATCTA GGTTACAAag c a t c a t t t c a  S8R
c t a c t c t c t t  c t c a g c a t c c  a a a a c c a a c t  t a t t c c c t t g  t c t t t g c c c t
□ Novel microsatellite marker S8 (12 tetra-nucleotide (TTTC) repeat):
c c t c c t c c t c  c t c c t t c t c t  c t c t c t c t t t  t t t t t t a a a c  c t a c t t c t t t
ATTTTCTGGC ACTAGAATAT GCTCCAGGCT CATCTTGTAC ATTTTTATGC S I I F
CCCAGTCCTA GTTTCAGCCA TTTCACCAAA GAGTCCTGGT TTCTTTCTTT
CTTTCTTTCT TTCTTTCTTT CTTTCTTTCT TTCTTTCTTT TGAGGCAGGG
CGTCACTCTC ACCCAGGCTG GAGTGCAGTT GCATGATCGC GGCTCACCAC
AGCCTTGACC TCCTAGGCTC AGGTGATCCT CCCACCTCAG CCTCCAGAGT
AACTGGGGCT ACAGGTGCGG GCCACCACAC CTGGCTAATT TTTGTATTTT
TTTTTTTTTT TTGTAGAGAA GGGGTTTTAC CATGTTGCCC AGGCTGGTCT
CGAACTCTTG GGCTCAAGTG ATCTGCCCGG CCTGTCTCCC AAAGTGCTAG
GATTACAGAC ATGAGCCACT GTGCCCGACT CCTGGTTTAT TTTTATCACA
GAATGGTATT AGAAAGCAGG A T c ta g g tg c  t a g g t g g g t g  c t a a t g a a t c  S11R
t t t c a t t t t g  g t t a t t t a c t  t t
□ Novel microsatellite marker S9 (12 tri-nucleotide (TTA) repeat):
t t t t t t t t t t  t t g t a t t a a t  g a a a c g a a a g  t t t a t t t c t t  g c t c a t a c a a
AAGTCTATTT CAGTCCAGAC AACTCCACAG GGAAATTGTC CTTCATGTAA S12F
TAGATCAGTA TTCCAGGTTA CTTAGTTATT ATTATTATTA TTATTATTAT
TATTATTATT ATGCTTTAAG TTCTGTGTTA CATGTGCAGA ACATGCAGTT
TTGTTACATA GGTATACAGG TGCCATGGTG GTTTGCTGCA CCCATCAACC
CATCACCTAC ATTAGGTATT TCTCCTGATG TTATCGCTCC CCTAGCCCCC S12R
c a c c c c a c a g  a g g c c c c a g t  g t g t g a t g t t  c c c c t c c c t g  t g a c c a t g t g
Figure 3.6 Sequences of novel microsatellite markers SI, S2, S3, S4, and S5.
The nucleotide repeat sequences are highlighted in green with primer sequences shown in red. The 
imperfect repeats in microsatellite marker S7 are underlined in green.
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Figure 3.7 shows examples of the ABI 3100 traces obtained for microsatellite marker 
AFMB343YD5 in a carrier female, her affected son, and an unaffected individual in the 
CXN family.
Novel m icrosatellite 
m a rk e r
T ype o f rep ea t R ep ea t sequence N u m b er o f  rep ea ts
SI Di-nucleotide GT 24
S2 Di-nucleotide GT 28
S3 Di-nucleotide TG 24
S4 Di-nucleotide GT 21
S5 Tri-nucleotide TTA 15
S6 Di-nucleotide GT 22
S7* Di-nucleotide GT 25
S8 Tetra-nucleotide TTTC 12
S9 Tri-nucleotide TTA 12
Table 3.3 Summary of all novel microsatellite markers genotyped in the CXN family
* denotes an imperfect repeat sequence
Peak: Scan 7916 Size 182.36 Height 64 Area 675i—■—i—i—i—I—i—i—i—i—i—i—i—i—i—i—i—i—i—i*h—i—i—i—i—i—i—i—r
175 180 185 190 195 200 205 210 215A
Simon.B.10.03.03A. 1fsa 1 Green 1 Carrier mother
-2000
-1500
-1000
.500
3 4
Peak: Scan 7908 Size 184.12 Height 105 Area 11481 i 1 1 ' 1 r 1 ■ ■ r ■ ■ ■ -» r f 1 i ■ » ■ ■ i ■ ■  ^ ■ i » ■  ........................ . ■
175 180 185 190 195 200 205 210 215
Simon.B.12.03.03. 7.fsa 7 Green 36 Affected son
-2000
-1500
-1000
-500
c 175 180 185 195 200 205 210190 215
Simon.B.12.03.03._.. 7.fsa 7 Green 84 Unaffected individual
3
Figure 3.7 ABI 3100 genotyping results for microsatellite marker AFMB343YD5.
Genotyping results obtained for a carrier female (A) and her affected son (B) in the CXN family 
compared to an unaffected individual (C) within the same family. The unaffected individual is 
homozygous for allele 3, whilst the affected son is hemizygous for allele 4 and the carrier female 
heterozygous for alleles 3 and 4. Allele 4 segregates with disease in the CXN family.
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Figure 3.8 depicts the pedigree with new haplotypes, indicating relative genetic 
positions of all microsatellites typed in relation to previously identified recombinant 
markers (DXS9902 and DXS999) and linked markers (DXS1053 and DXS1195). The 
reconstructed haplotypes confirm disease segregation with markers in Xp22.13-22.2 
(DXS1053-0.8Mb-S 1 -1.23Mb-AFMB343YD5-0.1 Mb-S2-1.07Mb-DXS 1195-0.84Mb- 
S3, figure 3.8). The proximal cross over was originally identified between markers 
DXS8036 and DXS999 (figure 3.1). Marker DXS 1195, which is linked with disease 
has now been localised proximal to DXS8036 after confirming relative positions of 
microsatellite markers in the latest genome build (UCSC, http://genome.ucsc.edu/). 
Novel microsatellite markers S4 (within intron 2 of PPEF1) and S5 (within intron 2 of 
CDKL5) were both found to be crossed over in individual III.3 and subsequent 
generations (IV: 1, IV:2, and V:l) thereby refining the proximal recombination to 
between S3 and S5 (figure 3.8). A recombination event defines the distal cross over 
between DXS9902 and DXS 1053 (seen in individual V:l). The disease interval has 
therefore been refined to an approximately 3.2 Mb interval between markers DXS9902 
and S5 (figure 3.8).
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Figure 3.8 CXN pedigree showing haplotypes on Xp22.13 with new microsatellites.
Boxed haplotypes of affected males and carrier females show recombination with markers S4, S5, 
DXS999, and DXS9902. Disease segregates with markers DXS1053-S1-AFMB343YD5-S2-DXS1195-
S3
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3.2.3 Candidate genes for CXN and NHS
The original disease interval for CXN (Francis et al., 2002) spanned 3.5 Mb of genomic 
sequence and was completely encompassed by the NHS and Xcat disease intervals 
(figure 3.2). As a result of genotyping novel microsatellite markers within the CXN 
interval (section 3.2.2, figure 3.8) in 20 members of the CXN family, the CXN disease 
interval was refined to approximately 3.2 Mb of genomic DNA (flanked by markers 
DXS9902 and S5).
During this study, the original NHS disease interval (figure 3.2) was also refined to 
approximately 1.3 Mb of genomic sequence on Xp22.13, flanked by markers DXS1195 
and DXS999 (Toutain et al., 2002, figure 3.9). These new data reduced the common 
interval for disease for NHS and CXN (figure 3.9), and both were encompassed by the 
Xcat disease interval (figure 3.9).
The similarity in cataract phenotype between the CXN family and patients with NHS, 
and their overlapping disease intervals, implied these diseases may be allelic. 
Furthermore, the mapping of the Xcat locus to a region of the mouse X chromosome 
containing the conserved block Xp22.1-22.3 in humans (the syntenic interval to which 
NHS and CXN were mapped), suggested that the Xcat mouse might be a disease model 
for CXN and/or NHS. In light of this, the causative gene for these diseases was likely 
to reside in the region of overlap between all three loci. However, the possibility 
remained that CXN and NHS may not be allelic and that any potential strong candidate 
gene identified within the CXN interval but outside of the region of overlap, should still 
be considered.
Twenty-two known genes (i.e., named and/or characterised at some level, as opposed to 
predicted, unconfirmed genes) were found to reside in the CXN interval at the outset of 
this project (table 3.4) based on the current genome database (genome version January 
2003 freeze). Three of the 22 known genes resided within the region of overlap 
between the CXN and NHS intervals: sex comb on midleg-like-1 and -2  (SCML1, 
SCML2), and Retinoic acid induced 2 (RAI2, figure 3.9).
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Figure 3.9 Revised schematic diagram of the refined genomic intervals for CXN and NHS.
Genomic intervals shown above are based on recent refinements for NHS (Toutain et al., 2002) and CXN (this study). Genes boxed blue have been excluded for CXN (this 
study), and NHS (Walpole et al., 1999; Toutain et al., 2002) whilst those boxed red were excluded for NHS (Toutian et al., 2002). The grey shaded area within the genomic
region Xp22.13 denotes the region of overlap between the CXN and NHS intervals.
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Gene Name
Gene location with respect to 
disease intervals Xcat, NHS 
and CXN
Screened in
NHS/CXN/Xcat Reference
ASBll Ankyrin repeat and SOCS box-containing 11 CXN, Xcat - -
PIGA Phosphatidylinositol glycan, class A CXN - -
FIGF c-fos induced growth factor (vascular endothelial growth 
factor D)
CXN, Xcat -
PIR (Belongs to the Pirin family) CXN - -
BMX BMX non-receptor tyrosine kinase CXN, Xcat - -
ACE2 Angiotensin I converting enzyme (peptidyl-dipeptidase A) CXN - -
NX17 kidney-specific membrane protein CXN . .
CA5B Carbonic anhydrase VB, mitochondrial CXN, Xcat - -
U2AF1-RS2 - CXN, Xcat - -
AP1S2 Adaptor-related protein complex 1, sigma 2 subunit CXN, Xcat - -
GRPR Gastrin-releasing peptide receptor CXN, Xcat - -
CTPS2 CTP synthase II CXN, Xcat - -
CALB3 Calbindin 3, (vitamin D-dependent calcium binding - 
protein)
CXN, Xcat - -
SYAP1 Synapse associated protein 1, SAP47 homolog 
(Drosophila)
CXN, Xcat - ■
CXORF15 - CXN -
RBBP7 Retinoblastoma binding protein 7 CXN, Xcat Xcat Huang et al., 2003 ARVO
REPS2 RALBP1 associated Eps domain containing 2 CXN, Xcat Xcat Huang et al., 2003 ARVO
SCML1 Sex comb on midleg-like 1 (Drosophila) CXN, NHS NHS Toutain et al., 2002
RAI2 Retinoic acid induced 2 CXN, NHS NHS/CXN/Xcat Walpole et al., 1999; Huang 
etal., 2003 ARVO;
SCML2 Sex comb on midleg-like 1 (Drosophila) CXN, NHS, Xcat NHS Toutain et al., (2002)
CDKL5 Cyclin-dependent kinase-like 5 CXN, NHS NHS Toutain et al., (2002)
RSI Retinoschisis (X-linked, juvenile) 1 CXN, NHS, Xcat NHS Toutain et al., (2002)
PPEF1 Protein phosphatase, EF hand calcium-binding domain 1 CXN, NHS NHS Toutain et al., (2002)
Table 3.4 Characterised genes within the CXN, NHS and Xcat loci.
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All three genes (SCML1, SCML2, and RAI2) were reported to have been excluded as 
disease causative for NHS (Toutain et al., 2002). The RAI2 gene had also been 
screened and excluded for CXN (Francis, unpublished data at the time). An additional 
two genes were reported to be excluded for NHS: protein phosphatase with E-F hand 
motif (.PPEF1), retinoschisis (X-linked, juvenile) I  (RSI), serine-threonine kinase 9 
(.STK9/CDKL5; Toutain et al., 2002). All three of these genes (PPEF1, RSI and 
STK9/CDKL5) have been excluded for CXN through the refinement of the CXN 
interval (section 3.2.2, figure 3.9) Due to all three characterised genes (SCML1, SCML2, 
and RAI2) within the region of overlap being excluded for either CXN, NHS, or both 
and since no gene predictions were found to reside in the region of overlap at the time, 
candidate genes within the entire CXN interval were sought for screening in the CXN 
family.
3.2.3.1 Identification, characterisation, and mutation screening of 
candidate genes
Identification of candidate genes within the CXN and NHS disease intervals were 
sought through a bioinformatic approach (section 2.7). A powerful strategy for 
identifying candidate genes in this study was through comparative genomics of the 
syntenic region on the mouse X chromosome containing the Xcat locus (figure 3.10). 
Gene prediction programmes (Twinscan and Syntenic Gene Prediction, SGP) based on 
human-mouse homology were used to identify novel candidate genes, and were 
analysed using NIX and PIX analysis programmes to determine any homologies to 
known genes/proteins, respectively.
Four candidate genes; one fully characterised gene (RBBP7, table 3.4) and three novel 
genes-7X7, CX43-L and NCG1) were identified and screened for mutations. RBBP7 
and TL1 resided within the CXN and Xcat intervals, whereas CX43-L and NCG1 
mapped within all three disease loci.
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Figure 3.10 Alignment of the human CXN, NHS, and mouse Xcat disease intervals.
Known and uncharacterised genes within the intervals are shown. Taken and adapted from the UCSC genome browser 2003 Freeze
(http://genome.ucsc.edu/cgi-bin/hgGateway)
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3.2.3.1.1 Taxilin-like 1 (TL1)
A novel candidate gene (CXorfl5, hereafter named Taxilin-like 1, TLT) predicted by 
gene prediction programmes in both human and mouse genomic sequence was found 
to reside in the CXN and Xcat loci. The human gene consists of at least 10 exons (table 
3.5, figure 3.11) predicted to code for a protein of 528 amino acids. The full coding 
sequence is contained within cDNA clone FLJ11209 (accession number AK002071) 
and is part of the UniGene cluster Hs.201624. Numerous ESTs and cDNAs 
representing this transcript have been sequenced and found to be expressed in a variety 
of tissues including: fetal heart and adult heart, brain, liver, kidney and lung.
PIX analysis of the predicted protein sequence revealed 61% identity over 327 amino 
acids to Taxilin. Taxilin is a novel binding partner of members of the syntaxin family 
(including syntaxin-la, -3 and -4) and is believed to be involved in Ca -dependent 
exocytosis in neuroendocrine cells (Nogami et al., 2003). TL1 also shows between 20- 
30 % identity to members of the myosin family
Exon Size Exon-intron junction Intron Size
(bp) Acceptor Donor (bp)
l 153 ggccctgcG A G A T T C T G G C A G A A G gtcagtca l 3 1 9 8 4
2 304 tc ttc ta g T T T G A A A T A A C T T T A G g ta a ta a t 2 1 2 8 4
3 92 a  c  c  a  t  cagGAAAAGAA C T G A T C T T g tg a g ta t 3 7 8 3 6
4 171 a a tttta g C T G G A G G A C G T T A A A G g tta g ttg 4 1 3 1 1
5 195 g t  a  a  t  aagGAGGAAAA G G G A A G A G gtaatggc 5 2 8 5 2
6 120 t  c  c  c  a  t  agCACAT T GA G A G A G T T T g taa g ttc 6 1 5 4 0
7 75 t t t tc ta g T T A T T A A A AACAGCAGgtaa c 1 1  c 7 3 2 3 5
8 93 tc c ta ta g C T T T C T C T T GGAAAAGgta111a c 8 2 1 3 5
9 96 a  11  c  a  cagATGACAAA C T GAAGAGgtg a  g a  t  g 9 1 5 1 1
10 7 4 6 t  c  11  a  cagAAAACAGT T A T T A T T C ag aaaaac 10
Table 3.5 Human TL1 genomic structure
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Figure 3.11 Schematic diagram of the genomic interval for CXN and NHS on Xp22.13.
Relative positions of excluded genes PPEF1, CDKL5, TL1, RBBP7 and RAI2 are shown with the current microsatellite map.
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Mutations within nonmuscle myosin heavy chain 9 (MYH9) gene have been identified in 
Fechtner syndrome (FTNS, MIM #153640; May-Hegglin/Fechtner Syndrome 
Consortium 2000). Peterson and colleagues first described FTNS as an autosomal- 
dominant platelet disorder characterised by macrothrombocytopenia, leukocyte 
inclusions, nephritis, deafness and congenital cataracts (Peterson et al., 1985).
TL1 was screened based on its expression in relevant tissues, its position within the 
CXN and Xcat intervals, and a 20-30 % similarity at the protein level to myosins. 
Primers were designed (section 2.2.2, table 3.6) to PCR amplify (section 2.2.1) and 
sequence (section 2.2.10) all 10 exons and splice sites in an affected male from each 
family. No sequence alterations were identified within the coding and non-coding 
regions sequenced.
G ene Prim er Sequence (5 ’-3 ’) Tm°C
TL1 IF  AGTCTCACATGCGGCGATTG 62
1R TGTTCGTCCCGTGGCTATAG 62
2F IT GTTAGTAG AATTTAC AGGTTAG 62
2R TGTACTTT AAG AAACTTATC AAGC 62
3F AGCTCTCATTATAATTCTAGCC 60
3R ATAGGCACAGGGTTGATTATG 60
4F AGCTTCTCTTGTGAGCATCTTC 64
4R  ACTTTAGGTATGAATGGTGACAC 64
5F CTGTAACTGCTGTGATGTTTCC 64
5R ATGTTTCAAATGGCCTCAGTTAC 64
6F TGTTTCATCTGTAGACCTGTGG 64
6R TAACCTAAATAAAGTGGAAAATACC 64
7F ATGCATTTCTGTGGGTTGTCAG 64
7R AGGATCACTAAAGAGAAAATGAAG 64
8F TGTACTGGGACAGGGAGTAG 62
8R AGTAGTGTTACAGCACACGTC 62
9F TGTCCAATATGGCTGAGCTGG 64
9R  ACCAATAGTTAACTACTAACAGAG 64
10F TGTTCCATTGCTTGTAAACATTG 62
10R TATCTGGGCTGCAGAAAACAC 62
Table 3.6 TL1 specific primers and conditions
3.23,1,2 Retinoblastoma binding protein-7 (RBBP7, RbAp46)
Retinoblastoma binding protein-7 (RBBP7, RbAp46) contains WD-repeats, which are 
known to have a variety of functions including signal transduction, pre-mRNA 
processing and cytoskeleton assembly (Qian and Lee, 1995). RBBP7 is a core 
component of at least two major co-repressor complexes, and is thought to have a role 
modulating transcriptional activity and chromatin remodelling (Vermaak et al., 1999;
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Parthun et al., 1996; Verreault et al., 1998; Ahringer, 2000). This 425 amino acid 
protein is highly conserved between human and mouse and is ubiquitously expressed. 
RBBP7 is expressed from embryonic day 9.5 through to adulthood and is detected in the 
developing brain, heart and eye amongst other tissues (Yang et al., 2002). The genomic 
structure of the gene (figure 3.11) is also conserved between human and mouse 
containing at least 12 coding exons. Since genes involved in chromatin remodelling 
have been implicated in developmental syndromes (e.g. the ribosomal protein s6 kinase, 
RSK2, in Coffin-Lowry syndrome), and RBBP7 maps within the disease intervals for 
CXN and Xcat, it was considered a candidate for disease. Primers were designed 
(section 2.2.2, table 3.7) to PCR amplify (section 2.2.1) and sequence (section 2.2.10) 
all 12 exons and splice sites in an affected male from each family. No nucleotide 
changes were identified in all coding and non-coding regions sequenced.
Gene Primer Sequence (5’-3’) Tm°C__________________________  ^ v 7_______________ size (bp)
RBBP7 IF  TCTTGGCTAACGAGAGGAGTC 64
1R ACGCCAATTCGCGCCTTTCG 64
2F TTCTGACTTTGATCTATCTCAGC 64
2R AACT AGGAAATTC AGAACGAC AG 64 263
3F ACAGTTGATGCTAAGTATATATTTG 64 1QO
3R TAAAGTCCTAGAAGTTAAATTACTG 64
4F TATTTTCCAGTGCAAAT GGGC 64
4R TT GAGGATGGTTATGGG ACC 55 520
5F TTCTCACCAGTTCTGATAAACAG 55
5R TATAGTACTCCTTCAGCACAGC 64
6F CAGTCTCTTATAGCCCTTGTTC 64
6R TGATGGTCATTCAGGTCACCC 64 265
7F TGCAGTGACAGTGATGTGAGG 64
7R ATCTGATTAAGGCACAAGAGAAC 64 266
8F TT G AAAA1TCTTAGGTA AAGC ATAG 64 180
8R TCCCTGGATTTCATTTCCTGAC 64
9F TTGAAAGTCGGGGACAAGAG 60
9R ACAGAACAAAGGCTCTTTAGG 60 360
10F TGTTCGTGCTACAAGAATTTCAC 64
10R AAAGAGATCAATGACAATCCAATC 64 171
1 IF  AATAGATTACTGAGCCTGTACC 62
11R ATGCAGAGATTTCTCCTGACC 62 488
12F ACATGACCATGTGAAAACCATAG 64
12R AATC AAGC ATTC ATGTAGC ATT AC 64 184
Table 3.7 RBBP7 specific primers and conditions
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3.2.3.1.3 Connexin 43-like (CX43-L)
Connexin proteins are major components of gap junctions, which mediate intercellular 
transportation of small biomolecules (<1 kDa) such as second messengers, ions, and 
metabolites. Connexin 43 is thought to play an important role in the synchronized 
contraction of the heart and in embryonic development (Britz-Cunningham et al., 1995).
Paznekas and colleagues recently reported the finding that mutations within the 
connexin 43 (GJAJ) gene, cause the pleiotropic phenotype of Oculodentodigital 
Dysplasia (ODDD [MIM 164200]; Paznekas et al., 2003). ODDD is an autosomal 
dominant disorder with intra- and interfamilial variability. The ODDD phenotype has 
many features in common with either Nance-Horan Syndrome or X-linked congenital 
cataract. Ophthalmic findings include cataract, microphthalmia, and microcomea. Most 
cases of ODDD have abnormal primary and permanent dentition, craniofacial anomalies 
and cleft palate. In addition, some families present mild mental retardation and cardiac 
abnormalities are observed on occasion (Paznekas et al., 2003).
Located in the disease intervals for CXN and NHS is a predicted connexin 43 
pseudogene. The pseudogene has 82.1 % sequence identity at the nucleotide level to 
connexin 43 and resides within intron 3 of the Cyclin-dependent kinase-like 5 (CDKL5) 
gene, but does not contain a single continuous open reading frame. The Xcat locus does 
not contain a connexin 43 pseudogene, but does contain a connexin 33 gene (Gja6).
Bioinformatic analysis of this genomic region containing the CX43 pseudogene led to 
the identification of a predicted gene (here named CX43-Like, CX43-L, figure 3.11) 
based on two gene prediction programmes (Genscan and the SGP), which shows an 82 
% identity to CX43. No EST or cDNA hits were found to align with this newly 
predicted four exon gene. In addition to these four exons forming a novel gene 
prediction, it was possible that these exons (except exon 2) may prove to be cryptic 
exons of the CDKL5 gene. Primers were designed (section 2.2.2, table 3.8) to PCR 
amplify (section 2.2.1) and sequence (section 2.2.10) the predicted exons in an affected 
male from each family due to its location within the CXN and NHS intervals and its 
similarity to connexin 43. No nucleotide changes were identified in the coding and non­
coding regions sequenced in either of the affected males. These exons were screened 
prior to obtaining the genotyping results in which microsatellite marker S5
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recombined with disease (section 3.2.2), therefore leading to the exclusion of CDKL5 as 
a candidate for disease.
Gene Primer Sequence (5’-3’) Tm°C Amplicon size (bp)
CX43-L IF AGATACCACGCATTTGCTGTC 62 2621R ATTCCAAAGAGATCTGAGAAGC 62
2F AGGGAGTC ATTTAATACTTC ATG 62 2852R AGGAATAACTAACTGTTCATTGC 62
3F ACCAGTCTTTGCCAATCTCC 60 2913R AAGATGACACCAATGGTACAC 60
4F
4R
AT ATTGCAAGACTCTGGATCC 
ATTCCCTGCCTGATGAGATC
60
60 364
Table 3.8 CX43-L specific primers and conditions
3.2.4 Discussion
The CXN locus was originally mapped to a 3.5 Mb interval on Xp22.13-22.2 (Francis et 
al., 2002). Segregation of disease to this genomic region was confirmed in this study by 
genotyping 46 known microsatellite markers spanning the human X chromosome. An 
attempt was then made to further refine the genomic interval in order to reduce the 
number of possible candidate genes for screening in the CXN family. Novel 
microsatellites markers were identified and genotyped in house. This resulted in the 
identification of a crossover in individual III.3 and subsequent generations with novel 
markers S4 and S5. The disease interval has therefore been refined to an approximately
3.2 Mb interval flanked by markers DXS9902 and S5. Microsatellite markers S4 and 
S5 were identified within intron 2 of PPEFland CDKL5 respectively. Therefore, the 
refinement of the CXN interval led to the exclusion of PPEF1, RSI and CDKL5 as 
candidates for disease in the CXN family.
The refined CXN interval overlaps the recently refined NHS disease interval, which 
spans approximately 1.3 Mb of genomic sequence flanked by markers DXS1195 and 
DXS999 (Toutain et al., 2002). If CXN and NHS are allelic then refinement of the 
CXN disease interval implies the disease causing gene now lies within approximately 1 
Mb of genomic sequence flanked by markers DXS1195 and S5 (figure 3.11). Further, 
exclusion of the PPEF, RSI and CDKL5 genes in the CXN family is in agreement with 
the exclusion of these genes as causative for NHS (Toutain et al., 2002).
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The possibility that CXN and NHS may not be allelic could not be overlooked, such 
that potential candidate genes for CXN were also sought outside the region of overlap. 
Two genes residing outside the interval of overlap, which were present in the Xcat 
locus, were 7X7 and RBBP7. Both genes were thought to be strong candidates for 
disease in the CXN family and were screened for mutations. No nucleotide alterations 
were identified in the coding and non-coding regions sequenced for either TL1 or 
RBBP7 resulting in their exclusion as disease causative for CXN. A third candidate 
gene (CX43-L) based on a gene prediction and displaying homology to CX43 was 
screened in the CXN and NHS families but no sequence variants were identified in both 
coding and non-coding regions sequenced. The CX-43-L gene prediction resided within 
intron 2 of the CDKL5 gene, which was excluded as disease causative for CXN through 
refinement of the CXN interval. Consequently, the refinement also excluded the CX43- 
L gene as a candidate. The total number of genes now excluded for CXN from this 
study is 6 (PPEF1, RSI, CDKL5, TL1, RBBP7, and CX43-L). In addition, the RAI2 
gene was previously excluded as disease causative for CXN.
To date a total of 6 genes have been reported to have been screened and excluded as 
disease causative in NHS (RBBP7, CDKL5, PPEF1, RAI2, RSI, SCML1 and SCML2; 
this study; Toutain et al., 2002; Walpole et al., 1999). Within the region of overlap 
between the refined disease loci for CXN and NHS, all known genes (SCML1, RAI2, 
and SCML2) have been screened and excluded for either CXN or NHS. Only SCML1, 
SCML2 have not been screened in the CXN family.
The mouse Xcat locus is syntenic with and completely encompasses the refined CXN 
and NHS loci. X-linked congenital cataract (Xcat) in the mouse displays a similar 
phenotype to that observed in CXN and NHS. Based on these observations, the Xcat 
mouse may prove to be a model of disease for either CXN and/or NHS. Recently, 
seven genes (Rai2, Rbbp7, Ctps2, Calb3, Grpr, Reps2, and Syapl) residing in the Xcat 
locus were reported to have been sequenced in the Xcat mouse and no mutations were 
identified (Huang et al., 2004). All seven genes reside within the CXN interval, but 
only RAI2 resides within the NHS interval and therefore within the region of overlap 
between CXN, NHS, and Xcat. If the Xcat mouse is a disease model for CXN, then the 
exclusion of RBBP7 in both CXN and Xcat supports this possibility, as does the
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exclusion of RAI2 in all three diseases. The RAI2 gene is currently the only gene 
screened and excluded for all three diseases (CXN, NHS and Xcat).
All known genes within the refined NHS locus have now been screened and excluded 
for NHS. This would imply that an uncharacterised gene residing in the NHS locus 
remains to be identified. The likelihood that CXN and NHS are not allelic, cannot be 
ignored and future candidate gene screening for CXN will be considerable due to the 
relatively large interval (currently 3.2 Mb of genomic sequence). The acquisition of 
new families with X-linked congenital cataract may help to refine the interval further 
and therefore reduce the size of the CXN locus in which candidate genes reside.
A recent publication by Ng and colleagues (2004) reported that distinct classes of 
mutations within the BCOR gene on X pll.4  (encoding BCL-6-interacting corepressor) 
result in the Oculofaciocardiodental (OFCD, MIM 300166) and Lenz microphthalmia 
syndromes. OFCD is a distinct form of syndromic microphthalmia associated with 
congenital cataracts, narrow face, broad nasal tip with separated cartilage, cleft palate, 
and cardiac and dental anomalies. There is considerable overlap between the CXN, 
NHS and OFCD phenotypes, emphasising genetic heterogeneity on the X-chromosome 
for these related developmental disease and raising the question as to whether mutations 
in BCOR could be disease causative in CXN and NHS. Currently only one family with 
congenital cataract has been mapped to Xp22.13-22.2 (Francis et al., 2002). The 
possibility that a double cross over occurring with the CXN family may have led to the 
wrong assignment of the CXN disease locus to Xp22.13-22.2 in the original study. 
However, the new haplotypes created in this thesis using novel microsatellites, 
confirmed segregation with Xp22.13-22.2. In addition, the typing of microsatellite 
markers spanning the X chromosome resulted in crossovers being observed between 
disease in the CXN family and all markers residing on Xpll.4, in particular 
microsatellite markers DXS8015 and DXS993. Microsatellite marker DXS8015 resides 
0.03 Mb upstream of the BCOR gene, whilst DXS993 resides 1.09 Mb downstream of 
the BCOR gene. Therefore disease segregation with X pll.4 was not identified from 
genotyping microsatellite markers in the CXN family in this study.
Since the families with Nance-Horan syndrome in this study are of a small size, 
haplotype analysis was not performed in order to confirm segregation of disease with
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markers on Xp22.13. It has not been possible therefore, to determine whether NHS is 
heterogenous by mapping NHS families to alternative loci. The possibility that some of 
the NHS families in this study may map elsewhere on the X chromosome and could 
harbour mutations within the BCOR gene cannot be ruled out.
The causative gene(s) for CXN and NHS remained to be identified.
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- Chapter Four -
Identification of the gene for Nance-Horan 
Syndrome (NHS)
4.1 Introduction
Following refinement of the CXN locus and the exclusion of 7 candidate genes (RAI2, 
TL1, RBBP7, CX43-L, PPEF1, RSI, and CDKL5) for CXN and/or NHS, a 
comprehensive genomic survey of the region of overlap between the NHS and CXN 
loci was performed (figure 3.11).
4.2 Results
4.2.1 Novel candidate gene 1 (NCG1), the Nance-Horan 
syndrome gene
Using comparative genomics and bioinformatic tools (section 2.7), novel genes were 
sought and partially characterised to identify potential candidates for disease. As a 
result, a novel gene distal to SCML1 and proximal to microsatellite marker DXS1195 
(AFM207ZD6) was identified and found to be highly conserved in mouse. The novel 
gene (NCG1) was predicted to contain at least 9 coding exons (table 4.1, figure 4.1) 
spanning at least 65 Kb of genomic sequence and coding for a 1,471 amino acid protein.
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Exon Size Exon-intron junction
(bp) Acceptor Donor
1 G T T G G C A G g tcag cat
2 152 c  c  c  t  q cagG T  GC CAAC A A G G G C C A gtqqcaqa
3 1 5 3 tc ttg c a g C C G T C T C C GC GCAGAGgtg a  c  a  q  a
4 134 c ttc tcag A A C A C C G G T T T T A A C G g ta a g tt t
5 1 9 3 g tttg c a g T C C C A T C C T G T T A C T G g ta tc q tt
6 132 ggttgcagG A G T T G G C A G A A A T A G g tq tg a ta
7 2 9 8 2 tg ccc tag A T T C T G A T A T T G A A A G g tcag tca
8 127 a tt t ta a g A A T C A T C A ATT C A CA G gtqa g g  c a
9 tc tcaaag A T C C A A G A GCAAATAAACGTGACT
Table 4.1 Human NCG1 genomic structure
The human gene prediction was supported by numerous EST hits (NCBI Unigene 
cluster Hs.444940) expressed in multiple tissues including fetal eye, brain, kidney, 
muscle, heart, liver, lung and colon. NIX analysis of the predicted gene identified a 
mRNA hit (accession number AK026164) joining together part of exon 7 with exon 8 
and the terminal exon (exon 9). In addition, part of this cDNA sequence had high 
homology to the myosin gene family.
mRNAAK026164
Figure 4.1. Genomic structure of the NCG1 gene.
Boxes represent exons, blackened boxes indicate the open reading frame (ORF), with sizes of the coding 
portions given below. Green asterisk denotes the methionine start codon.
Based on the position of NCG1 within all three disease loci (CXN, NHS and Xcat, 
figure 4.2), its expression in relevant tissues and its potential similarity to myosins, all 
coding exons and splice sites were screened in an affected male from the CXN family 
and all the NHS families. Primers were designed (section 2.2.2, table 4.2) to PCR 
amplify (section 2.2.1) all 9 predicted coding exons and splice sites.
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Figure 4.2 Identification of NCG1 within the region of overlap between disease loci CXN, NHS, and Xcat 
Relative position of the NCG1 gene prediction with relation to other genes on Xp22.13
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Gene Primer Sequence (5’-3’) Tm°C
NCG1 IF  TTAACTTGATTGCCTGCAACTG 62
1R TTCAGAGACTTTGAATGAGATAAG 62
2F TTGTGGAGTTTCCATCATAGG 60
2R TTGCAGTATTTCGAAAACTAGG 60
3F G ACTTTACTCCTGTCCTCTTC 62
3R ATGCCTGAGCATTTGCATATTG 62
4F TACAGCCTTTTGCTAACACTC 62
4R AGACAAACTGATGTTTCCTCAG 62
5F TGCTTATGTATAAACTATGATGGC 64
5R AAAAGCATATCGAACATCCTCTG 64
6F TATTTGTTCACAGGCTTAACCC 62
6R TTCTATTTCATCTCCCTATCATC 62
7Fa ACATAGCTCAGAATGTCTGTTG 62
7Ra AAGTGGTCATTGTATTGCTCTG 62
7Fb TCGGAGTTGTCACTAAACACAG 64
7Rb TGAATGGTGGAATATCCGAAGC 64
7Fc TTCTTGG ATAAACC AGAGT G AAC 64
7RC TGTCTTCAGTGGAGTATTGACG 64
7Fd ATTTAGAGGAAAGCACACTCAC 62
7Rd AATTCC AGGA AGT GCC ATGAG 62
8F TGAGTAAGCTTTGACAGGTATC 62
8R TTGCATTTGTGAGAAGTACCTG 62
9F TGAATGCGACTGAATACTTCAG 62
9R ATTCATTGCTTAGCAGTGATGC 62
7FBD CATAAC ATC AGCTGGTAGC AG 62
7RBD GTTCTAGAGTTTCGTCTGGAC 62
7FCD AAG AC C AAGC ATCTC TIT C AGG 64
7RCD TGAATGGTGGAATATCCGAAGC 64
Table 4.2 Primer sequences used to amplify NCG1
Amplification of each of the predicted coding exons of NCG1 in the affected males, was 
confirmed by electrophoresis of 5 pi of PCR product on a 2 % (w/v) agarose check gel 
(figure 4.3). Due to the large size of predicted exon 7, primers were designed so as to 
amplify and sequence exon 7 in four subffagments (7a-d, table 4.2). All exons 
amplified in each of the affected males were of the correct size and were sequenced as 
described in section 2.2.10.
Sequence covering the entire length of each of the amplified exons was obtained. From 
bioinformatic analysis of genomic sequence on the database, no stop codon was 
identified in the 3’ exon (exon 9) of the NCG1 gene prediction. Upon sequencing exon 
9 in the affected males and a control DNA sample it became evident that the stop codon 
was omitted from the current genomic sequence available (June 2003).
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Exon 7d Exon 9 Exon 8
 1,358 bp
 1,078 bp
  872 bp
  602 bp
  310 bp
Figure 4.3 Examples of PCR amplicons for NCG1 gene exons from an affected male from the CXN 
and NHS family 1, resolved on a 2 % (w/v) agarose gel.
CXN = affected male from the CXN family, NHS = affected male from NHS family 1; +, control DNA;
no DNA control. Anticipated sizes of individual exons are: 7d (790 bp), 8 (364 bp), 9 (807 bp). 
Molecular weight marker (M) was run alongside to confirm the size of PCR products, details of markers
are shown on the right hand panel
No mutations were identified in any of the exons for NHS families 2 and 4, or the CXN 
family. However, sequencing of fragment d of exon 7 of the NCG1 gene in NHS family 
1 (affected male IV:3, figure 3.3B) resulted in the identification of a 2 bp deletion 
(delTG) at position 3,261-3,262 bp of the NCG1 Genscan gene prediction. Deletion of 
the two bases (TG) resulted in a frameshift leading to the addition of 15 novel amino 
acids followed by a premature stop codon (figure 4.4).
Wildtype: caagtgcgtacagagactgagcctattccagaaaacacgccaacc
Q V R T E T E P I  P E N T P T  
NHS family 1: caagtgcgtacagagactgagcctattccagaaaacacgccaacc
Q V R T E T E P I  P E N T P T
**
Wildtype: aaaaactgtgcttttcccacagaaggatttcagagggtctctgct
K N C A F P T E G F Q R V S A  
NHS family 1: aaaaactgcttttcccacagaaggatttcagagggtctctgctgc
K N C F S H R R I S E G L C C
Wildtype: gcccgcccaaatgatttggatggtaaaataatacaatatggacct
A R P N D L D G K I  I Q Y G P  
NHS family 1: ccgcccaaatga
P P K *
Figure 4.4 Sequence of NCG1 in an affected male from NHS family 1 compared with wildtype
sequence
A 2 bp (TG) deletion identified in an affected male from NHS family 1 results in a frameshift leading to 
an additional 15 novel amino acids followed by a premature stop codon.
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A second mutation was also identified within exon 7 of the NCG1 gene in the affected 
male (11:1) from NHS family 3 (figure 3.3D). A lbp deletion (delA) at position 2,210 
bp of the Genscan gene prediction for NCG1 was identified in this family member. The 
1 bp deletion causes a frameshift resulting in the addition of 10 novel amino acids 
followed by a premature stop codon (figure 4.5).
Wildtype: c tg c c tc t tg a t t tc g c c a a c a c g c c t tc tc g a a tg g a a a a c g c c
L P L D F A N T P S R M E N A
NHS family 3: c tg c c tc t tg a t t tc g c c a a c a c g c c t tc tc g a a tg g a a a a c g c c
L P L D F A N T P S R M E N A
Wildtype: a a tc ttc c c a c c a a g c a g g a a c c ttc t tg g a ta a a c c a g a g tg a a
N L P T K Q E P S W I N Q S E
NHS family 3: a a tc t tc c c a c c a a g c a g g a a c c ttc t tg g a ta a a c c g a g tg a a c
N L P T K Q E P S W I N R V N
Wildtype: c a a g g c a tta a g g a a c c tc a g t ta g a tg c t tc g g a ta t tc c a c c a
Q G I K E P Q L D A S D I P P
NHS family 3: a a g g c a tta a g g a a c c tca g tta g  
K A L R N L S  *
Figure 4.5 Sequence of NCG1 in the affected male from NHS family 3 compared with wildtype
sequence
A 1 bp (A) deletion identified in the affected male from NHS family 3 results in a frameshift leading to an 
additional 10 novel amino acids followed by a premature stop codon.
Upon identifying deletion mutations within exon 7 of the NCG1 gene in two families 
with NHS (NHS families 1 and 3), segregation of the 2 bp deletion (delTG) with disease 
in family 1 was confirmed. It was not possible to test segregation of the 1 bp deletion 
(delA) identified in NHS family 3 as only one DNA sample for the affected son 
(individual 11:1, figure 3.3D) was available. Exon 7 (fragment d) was amplified (section
2.2.1) in each member of NHS family 1 for whom DNA was available.
Sequencing of exon 7d in each member of NHS family 1 confirmed segregation of the 2 
bp deletion (delTG) with disease in this family (figure 4.6). Identification of two 
deletions both causing ffameshifts, which are predicted to result in the addition of novel 
amino acids prior to a premature stop codon strongly implied that the NCG1 gene 
prediction is the NHS gene. To confirm the original 2 bp deletion observed in NHS
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family 1 was disease causing, 200 control chromosomes were screened for this 
sequence change.
Primers were designed (section 2.2.2; table 4.2, primers 7FBD and 7RBD) to amplify 
207 bp across the 2 bp (TG) deletion in NHS family 1. PCR amplification (section
2.2.1) across the 2 bp (TG) deletion was carried out on a carrier female and an affected 
male of NHS family 1. The amplicons were then analysed using the WAVE® Nucleic 
Acid Fragment Analysis System (Transgenomic) to detect heterodulplexes (section 
2.2.8). Upon establishing a particular WAVE pattern for the amplified fragment 
containing the 2 bp (TG) deletion, from an affected male and an affected female, from 
NHS family 1 (figure 4.7, B), 200 female control chromosomes were amplified and 
analysed on the WAVE® Nucleic Acid Fragment Analysis System (section 2.2.8). 
None of the 200 control chromosomes resulted in a WAVE pattern similar to the 
affected or carrier individuals of NHS family 1 (figure 4.7, A and 4.7, B).
The same method of screening control DNAs for the 2 bp deletion (delTG) identified in 
NHS family 1, was carried out for the 1 bp deletion (delA) identified in NHS family 3. 
Primers were designed (section 2.2.2; table 4.2, primers 7FCD and 7RCD) to amplify 
299 bp across the 1 bp (delA) in NHS family 3 (figure 4.8). The primers were then used 
to amplify across the 1 bp (A) deletion by PCR (section 2.2.1) in the affected male of 
NHS family 3 (DNA was not available for the carrier female in NHS family 3). Once a 
particular WAVE pattern for the amplified fragment containing the 1 bp (A) deletion 
was established, 200 control chromosomes were amplified (figure 4.8) and analysed on 
the WAVE® Nucleic Acid Fragment Analysis System (section 2.2.8). None of the 200 
control chromosomes resulted in a WAVE pattern similar to the affected male of NHS 
family 3.
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1:1
— © 
l:2
0
11:2 11:3
A A C T  G l T  Gl C T  T
o
IV:4
A A C T G l T  Gl C T  T
Figure 4.6 Segregation of a 2 bp deletion (delTG) with disease in NHS family 1.
Sequence chromatograms for two affected boys, one carrier female, and 5 unaffected individuals 
demonstrates segregation of the 2 bp deletion with disease in NHS family 1. The two bases, TG, deleted 
in the two affected boys and in the carrier female is boxed red in the unaffected individuals.
No DNA sample was available for individual 111:3.
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Figure 4.7 Chromatograms showing the WAVE patterns obtained from a heterozygous female from NHS family 1 and a control sample.
(A) WAVE pattern observed from a control female sample. (B) WAVE pattern observed from a heterozygous female from NHS family 1. The 2 bp deletion results in a 
heteroduplex, which elutes prior to the homoduplex resulting in two peaks. The same pattern was observed from an affected hemizygous male from the same family when
spiked with control DNA.
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Figure 4.8 Amplification across the 1 bp deletion identified in NHS family 3, and amplification of the same region in control DNAs.
(A) Amplification across the 1 bp deletion identified in NHS family 1, in the affected male. +, control DNA; M, marker. (B) Amplification of the same fragment in 8
control DNA samples; M, marker. All amplicons were resolved on a 2 % (w/v) agarose gel.
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4.2.2 Further characterisation of the genomic structure of 
NCG1, the Nance-Horan syndrome gene
Since NCG1 was evidently the Nance-Horan syndrome gene as two different 
frameshifting deletions had been identified in Nance-Horan syndrome families 1 and 3, 
further characterisation of the gene was required to determine the full genomic structure 
and identify further mutations in the two remaining NHS families and the CXN family. 
NCG1 is here after referred to as the NHS gene.
During further analysis of the gene structure for NHS, Burdon and colleagues reported 
the finding of a novel gene in which truncation mutations cause the pleiotropic effects 
of Nance-Horan syndrome (Burdon et al., 2003). The gene was predicted by gene 
prediction programmes and the transcript was further characterised through northern 
blot analysis and RT-PCR. The NHS gene they describe is the same gene as the novel 
gene identified here as the cause of NHS (NCG1). Burdon et al., reported the NHS gene 
to contain 9 exons of which 8 were coding. Exon la of NHS was found to be —350 kb 
upstream of exon 2. Exons 2, 3, 4, 5, 6 ,7 and 8 of the NHS gene proved to be exons 3, 
4, 5, 6, 7, 8 and 9 (respectively) of the NCG11NHS gene prediction described in this 
thesis (figure 4.1). In addition, an alternative 5’ exon (exon lb) is reported in the NHS 
gene, forming an alternative isoform (isoform b) containing exons lb and 4 -  8 of the 
NHS gene (Burdon et al., 2003). The genomic structure and isoforms of the NHS gene, 
with the new exon la and alternative exon lb is depicted in figure 4.9.
As a result of these additional data, exons la and lb of the NHS gene were amplified 
and sequenced in both the CXN family and NHS families 2 and 4. Primer sequences for 
the new exon la and exon lb of NHS were designed (section 2.2.2, table 4.3) from 
sequence available on the genome database.
Gene Primer Sequence (5’-3’) Tm°C Amplicon size (bp)
NHS laF TATCCGGACTGCCAGATCGC 64 815laR GAGTAGTAAGGTGC AAGCTGC 64
laFB AGGGACCTGGACGAGGTC 62
lbF AATGAAGCCTCTGGTGGTGG 60 446IbR ATGCCCTGTTGACTCAGAGG 62
Table 4.3 Primer sequences used to amplify exons la  and lb  of the NHS gene
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NHS gene
Isoform A 
Isoform B
la -3 5 0 Kb lc 2
565 bp
3 1b 3b 4
34 153 134 63 193 132
bp bp bp bp bp bp
2982 bp 127
bp
607 bp
Isoform C 
Isoform D
Isoform E
Figure 4.9 Genomic structure of the NHS gene.
A number of alternative isoforms have been identified on the database. Currently, there are five isoforms (isoforms A -  E). Blackened squares indicate the open reading 
frame (ORF), with sizes of coding portions given below. Exons 2, 3, 4, 5, 6, 7 and 8 of the NHS gene proved to be exons 3,4, 5, 6, 7, 8 and 9 (respectively) of the NCG1
gene prediction described prior to the publication of the Burdon and colleagues paper (Burdon et al., 2003).
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Using the primers designed to the new exon la and lb of the NHS gene, each exon was 
PCR amplified (section 2.2.1, figure 4.10) from an affected male from NHS families 2 
and 4, and from the CXN family. Amplicons were then sequenced directly (section 
2.2.10) in the hope of identifying a mutation in one of these exons in each affected 
male.
1,358 bp—  
1,078 b p -  
872 bp —
602 b p -
310 b p -
446 bp
Figure 4.10 PCR amplification of NHS exon lb  in an affected male from the CXN family, and NHS 
families 2 and 4, resolved on 2 % (w/v) agarose gel
M, marker; no DNA control
No sequence alterations were identified in the CXN family. However, a 1 bp deletion 
(400delC) was identified in exon la of NHS family 2, and is predicted to cause a 
frameshift resulting in a premature stop codon after the addition of 61 novel amino 
acids (figure 4.11), and a severely truncated protein product.
121
Chapter Four -  Identification of the gene for Nance-Horan syndrome (NHS)
Wildtype: 271 gctggcgaggagagcacggcggggatcccggaggcggcgcccgca
A G E E S T A G I P E A A P A  
NHS family 2: 271 gctggcgaggagagcacggcggggatcccggaggcggcgcccgca
A G E E S T A G I P E A A P A
Wildtype: 316 gccggcgaggcgtcctcggcggcggcggcggcggccgtgctgctc
A G E A S S A A A A A A V L L  
NHS family 2: 316 gccggcgaggcgtcctcggcggcggcggcggcggccgtgctgctc
A G E A S S A A A A A A V L L
Wildtype: 361 atgctggacctatgcgcggtcagcaacgccgctctggcccgtgtc
M L D L C A V S N A A L A R V  
NHS family 2: 361 atgctggacctatgcgcggtcagcaacgccgctctggccg£gtcc
M L D L C A V S N A A L A V S
Wildtype: 406 ctccggcagctctcggacgtggcccggcacgcttgcagcctcttc
L R Q L S D V A R H A C S L F  
NHS family 2: 406 tccggcagctctcggacgtggcccggcacgcttgcagcctcttcc
S G S S R T W P G T L A A S S
Wildtype: 451 caggagctcgagagcgacatccagctcacccaccgccgcgtctgg
Q E L E S D I Q L T H R R V W  
NHS family 2: 451 aggagctcgagagcgacatccagctcacccaccgccgcgtctggg
R S S R A T S S S P T A A S G
Wildtype: 496 gcgctgcagggcaagctcggcggcgtgcagcgcgtcctcagcacg
A L Q G K L G G V Q R V L S T  
NHS family 2: 496 cgctgcagggcaagctcggcggcgtgcagcgcgtcctcagcacgc
R C R A S S A A C S A S  S A R
Wildtype: 5 4 1  cttgaccctaagcaggaggcagtgcccgtctccaacctggacata
L D P K Q E A V P V S N L D I  
NHS family 2: 541 ttgaccctaagcaggaggcagtgcccgtctccaacctggacatag
L T L S R R Q C P S P T W T *
Figure 4.11 Sequence of NHS in an affected male from NHS family 2 compared with wildtype
sequence
A 1 bp (C) deletion (400delC) identified in exon la  of an affected male from NHS family 2, results in a 
frameshift leading to an additional 61 novel amino acids followed by a premature stop codon.
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Segregation of the 1 bp deletion (del400C) in NHS family 2 was confirmed by PCR 
amplification (section 2.2.1) and sequencing (section 2.2.10) exon la in members of the 
NHS family 2 for whom DNA was available. A newly designed primer NHS laFB 
(table 4.3) was designed (section 2.2.2) for amplification across the 1 bp deletion in 
NHS family 2 (figure 4.12).
1,358 bp 
1,078 bp 
872 bp
602 bp 
310 bp
Figure 4.12 PCR amplification of exon la  in the two affected males and carrier female of NHS 
family 2, resolved on a 2 % (w/v) agarose gel
+, control DNA; no DNA control. Anticipated size o f the PCR product was 560 bp.
Upon sequencing of amplicons in the second affected boy and the carrier female of 
NHS family 2, a 1 bp deletion in exon la was identified in both family members. The 
female, as expected, was found to be heterozygous for the mutation (figure 4.13).
Using the same primers (laFB with laR, size 560 bp) to amplify across the 1 bp 
deletion (400delC) in individuals of NHS family 2, 200 control chromosomes were PCR 
amplified (section 2.2.1) and sequenced (2.2.10) to determine whether the 1 bp deletion 
was a polymorphic variant. No sequence changes were identified in any of the 200 
control chromosomes.
M 11:2 111:1 111:2 +
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D O
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T T T N G C C C G T
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Sequence
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Sequence
C T G G C C G T
Figure 4.13 Segregation of a 1 bp deletion (delA) in exon la  of N H S  with disease in NHS family 2.
Sequence chromatograms for two affected boys and one carrier female demonstrates segregation of the 1 
bp deletion (400delC) with disease in NHS family 2. The base deleted in the two affected boys and in the 
carrier female is boxed in red in the wildtype sequence. No unaffected individuals in this family were 
available for this study. The wild type sequence is given above each chromatogram from the two affected
males and carrier females for comparison.
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Screening of exon la in an affected male from NHS family 4 revealed a nonsense 
mutation. A C-»T transition (figure 4.14) at the first position of codon 158 (472C->T) 
alters the sequence from a glutamine (Q) to a stop (figure 4.14). The introduction of a 
nonsense mutation in exon la of the NHS gene is predicted to result in a severely 
truncated protein product (figure 4.14).
E L E  S D  I Q L T H  R R V W A
Wild type: gag etc gag age gac ate cag etc ace cac ege ege gtc tgg geg
E L E  S D I .
NHS family 4: gag etc gag age gac ate tag etc ace cac ege ege gtc tgg geg
Figure 4.14 Sequence of NHS in an affected male from NHS family 4 compared with wildtype
sequence
A nonsense mutation at base pair 472 of NHS results in an aberrant protein product. The C—>T transition 
is highlighted red in the genomic sequence o f the affected male from NHS family 4.
The C—>T transition (figure 4.14) identified in exon la of an affected male in NHS 
family 4, was screened in 200 control chromosomes. Using primer pair laFB/laR, PCR 
amplification (section 2.2.1) and direct sequencing (section 2.2.10) in 200 control 
chromosomes did not identify any sequence changes. DNA for the carrier mother (1:1) 
of NHS family 4 was not available for screening.
Currently, there are five NHS isoforms (isoforms A-E, figure 4.9) entered on the 
database. Isoforms C-E contain alternative 5’ exons, and a cryptic exon 3b, which is 
spliced in, in isoforms C and E (figure 4.9). Primers were designed (section 2.2.2, table 
4.4) to PCR amplify (section 2.2.1) and sequence (section 2.2.10) these additional NHS 
exons for screening in an affected male from the CXN family.
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Gene Primer Sequence (5’-3’) Tm°C Amplicon size (bp)
NHS lcF AAGTCCCACTGCAACCTAAAC 62
lcR AAGTGGCTAC AGC AC AAGCC 62 489
3bF ATACACTGTGTTGTGTGCACG 62
3bR TCTGGACAGAGTGGGATAGG 62 171
Table 4.4 Primer sequences used to amplify altenative 5’ exons and exon 3b identified in isoforms
C-E of the NHS gene.
No sequence variants were identified in the alternative 5’ exon or exon 3b of NHS
isoforms C-E, in an affected male from the CXN family.
Figure 4.15 summarises all mutations identified in the NHS gene in all four NHS
families screened in this study. In addition, table 4.5 summarises all mutations
identified in the NHS gene from this thesis, along with those reported by Burdon and 
colleagues (2003) and by Ramprasad and colleagues (2005).
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NHS Family 1
0- 1— ©
II □ — —© □
III £  5  n - r - i
IV £ J i i
I
Wildtype \ )CW j O C
A A C T 5 T G C T T
Patient
(male)
A A C T G C T T
3738-3739delTG 
(Exon 6) 
C1246-A1247fsX 15
NHS Family 2
C T G G C C G T
400delC 
(Exon la) 
R134fsX61
NHS Family 3
III
T A A A C C A G A
T A A A C C G A G  
2687delA 
(Exon 6) 
Q896fsX10
NHS Family 4
■a
i i
A T C C A G C T C
A T C T A G C T C
472C->T 
(Exon la) 
Q158STOP
Figure 4.15 NHS families analysed in this study and corresponding sequence chromatograms highlighting mutations identified in the NHS gene
127
Chapter Four -  Identification of the gene for Nance-Horan syndrome (TSfHS)
Sequence change Exon/Intron Predicted protein Fam ily and phenotype
400delC'K Exon la R134fsX61 Family 2 with typical 
NHS features, this thesis
472C-»T Exon la Q158STOP Family 4 with typical 
NHS lens opacities, this 
thesis
115C->T0C Exon la Q39STOP
IVS2-3C->Gt* Intron 2
718insGt* Exon 3 E240fsX36
linC -J-T ’ Exon 5 R378STOP
3738-3739delTG Exon 6 C1246-A1247fsX 15 Family 1 with typical 
NHS features and 
bilateral cleft palate, this 
thesis
2687delA Exon 6 Q896fsX10 Family 3 with typical 
NHS features and severe 
mental retardation, 
epilepsy and hypotonia, 
this thesis
3459delCt Exon 6 L1154fsX28
2387insCt Exon 6 S797fsX35
Table 4.5 Summary of mutations identified in the NHS gene
* identified within the same family 
f Reported by Burdon and colleagues 
^ Also reported by Burdon and colleagues 
00 Reported by Ramprasad and colleagues
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4.2.2.1 Expression of NCG1/NHS
4.12.1.1 AK026164
Initial characterisation of the genomic structure of NCG1 was based on gene prediction 
programmes and comparative genomics, supported by ESTs and an mRNA 
(AK026164) aligning with predicted exons of the gene. Interestingly, on further 
analysis mRNA AK026164 (from human renal epithelial cells) was found to be a 
chimera. AK026164 (1,741 nucleotides in size) contained sequence from exons 7, 8 
and 9 of the NCG1 gene prediction (first 1,016 nucleotides), whilst the remaining 725 
nucleotides were found to match non-muscle myosin light chain alkali, on chromosome 
12. Therefore, the novel gene identified proved not to share homology with the myosin 
protein family.
4.2.2.1.2 Human fetal cDNA panel
As NHS is a developmental syndrome, the expression of the NHS gene in human fetal 
tissue was investigated. A human fetal multiple tissue cDNA (MTC) panel was 
obtained from BD Biosciences (UK), and primers were designed (section 2.2.2, table 
4.6) to amplify from exons 6-7 of the NHS gene, which is present in all isoforms. 
Amplification spanning intron 6 of the NHS gene allowed for contamination of the 
human fetal cDNA panel with genomic DNA to be tested. Amplification of NHS from 
cDNA was predicted to result in a PCR fragment of 268 bp, whereas amplification of 
NHS from contaminating genomic DNA should result in a product of 590 bp.
G ene Prim er Sequence (5 ’-3 ’) Tm°C
A m plicon  
size (bp)
NHScDNA6F TGCCTGGTACTATCAGCTATG 64 268NHScDNA7R TCCTCAGTTGTTCGAGGTTTG 62
Mouse Nhs 6F 
Mouse Nhs 6R
ACTGCAACCTCAGCTAGCAG 
TGCTGTACAGTGCCATCTGG
62
62 207
Table 4.6 Primer sequences used to amplify the NHS gene in a human fetal cDNA panel and mouse
tooth cDNA.
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Expression of the NHS gene in each of the 8 human fetal tissues (spleen, brain, liver, 
kidney, heart, lung, thymus, and skeletal muscle) was determined by attempting to PCR 
amplify exons 6-7 of the NHS gene using the newly designed primers mentioned above 
(table 4.6). A 268 bp fragment was amplified from human fetal brain, thymus, lung, 
and kidney (figure 4.16), demonstrating expression of the NHS gene in these tissues. 
Further, amplification of the NHS gene in these tissues was not a result of DNA 
contamination, as a 590 bp product was not observed.
Since tooth abnormalities are a typical clinical feature of Nance-Horan syndrome, 
expression of the mouse NHS orthologue in mouse tooth cDNA at postnatal day zero, 
P0, and postnatal day two, P2, was investigated. RNA was extracted from mouse teeth 
at P0 and P2 (section 2.2.9) and reverse transcribed (section 2.2.3). Primers were 
designed (section 2.2.2, table 4.6) to amplify a region within exon 6 of the mouse NHS 
orthologue (see chapter 5, section 5.2.1). PCR amplification (section 2.2.1) of the 
mouse Nhs gene from mouse tooth cDNA was successful at P0, but not P2 (figure 4.16).
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310 bp 
271/281 bp
Figure 4.16 PCR from human fetal cDNA (panel A) and mouse tooth cDNA (panel B) at P0 and P2
Primers were designed to amplify exon 6 -  8 of the NCG1 gene; +ve, genomic DNA control; -ve, no 
DNA control. PCR products were resolved on a 2 % (w/v) agarose gel.
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4.2.3 Discussion
Following the exclusion of all characterised candidate genes residing in the disease 
interval for Nance-Horan syndrome, novel candidate genes were sought in the region of 
overlap between the NHS and CXN disease loci. As a result a Genscan gene prediction, 
here named NCG1, was identified and screened in the four NHS families and the CXN 
family. Two deletion mutations, 3738-3739delTG and 2687delA, were identified 
within exon 6 of NCG1 in NHS families 1 and 3 respectively. However, no mutation 
was identified in the CXN family or NHS families 2 and 4. Since the two deletion 
mutations were found to segregate with disease in the respective families and since 
these changes were not identified in 200 control chromosomes, the NCG1 gene was 
clearly the disease causative gene for NHS. Further, the mutations identified in NHS 
families 1 and 3 disrupted the open reading frame resulting in an aberrant protein 
product.
Based on these findings, the NCG1 gene (named NHS), was further characterised in the 
hope of identifying additional exons to screen in the CXN family and NHS families 2 
and 4. Subsequently, Burdon and colleagues published their data (2003) detailing their 
findings of a novel gene harbouring truncating mutations in 5 of their 6 families with 
NHS. Closer inspection of their findings demonstrated that the NHS gene identified in 
this thesis was the NHS gene reported by Burdon and colleagues. Two additional novel, 
alternative 5’ exons (exon la and lb) reported by Burdon and colleagues (2003), which 
had not been screened in the CXN family and NHS families 2 and 4, were amplified and 
sequenced in an affected male from each of these families (Burdon et al., 2003).
A 1 bp deletion (400delC) was identified in exon la of NHS family 2, whilst a nonsense 
mutation (472C—>T) was found in exon la of NHS family 4. No sequence alterations 
were identified in either exon la or exon lb of the CXN family. The sequence changes 
identified in NHS families 2 and 4 (400delC and 472C-»T, respectively) were 
confirmed as disease causative in these families by screening 200 control chromosomes 
for these sequence variants. Neither change was observed in any of the 200 control 
chromosomes screened.
Burdon and colleagues identified truncating mutations in 5 independent NHS families. 
Within the index case of one family, a truncating mutation and a one base pair
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substitution at the 3’ acceptor splice site were identified in exon 3. This female with 
NHS is reported to display an unusually severe ocular phenotype. One of the NHS 
families reported by Burdon and colleagues appears to be the same family as NHS 
family 2, reported in this study. Their reporting of a 1 base pair deletion (AC) at the 
same position in exon la (base pair 400) and personal communications via a common 
clinical colleague, confirmed this.
A more recent paper by Ramprasad and colleagues (2005), reports the finding of a 
nonsense mutation (115C—>T) in exon la of the NHS gene. The nonsense mutation 
(115C—»T) was identified in a four-generation family containing 8 affected males, and 
results in the conversion of glutamine to stop codon (Q39X).
Interestingly, a total of 9 mutations in 9 independent families with NHS have been 
reported to date, all of which are truncating and are predicted to result in an aberrant 
protein product (table 4.5). Families who have truncating mutations in exon la, 2 or 3 
of the NHS gene (44 %; Burdon et al., 2003; this study; Ramprasad et al., 2005), are 
predicted to have a loss of the major NHS isoform (isoform A, figure 4.9). These 
families may still express full-length isoform B, however this requires further 
investigation. Those families who have truncating mutations in exons 4-8, are predicted 
to express truncated forms of all 5 NHS isoforms (Burdon et al., 2003; this study). 
Isoform A therefore appears to be the major isoform responsible for disease in families 
with mutations in the NHS gene.
It should be noted that for one Nance-Horan syndrome family screened for mutations in 
NHS (Burdon et al., 2003) no mutation was identified (Burdon et al., 2003). The 
authors conclude that the mutation may reside within either non-coding sequence of the 
NHS gene, or within regulatory sequence. It should not be ruled out however, that NHS 
may prove to be heterogeneous, or that the family suffer from a highly related X-linked 
developmental syndrome such as Oculofaciocardiodental syndrome (OMIM 300166).
Although a mutation within the NHS gene has not yet been identified in the CXN 
family, it is still possible that CXN and NHS are allelic. An attempt to identify alternate 
5’ ends or cryptic exons of the NHS gene may facilitate the identification of a mutation
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in the CXN family, and in the family with NHS for which a mutation has not yet been 
found (Burdon et al., 2003). Upstream and other regulatory regions of the gene should 
also be considered as mutation sites leading to disease.
At present, there does not appear to be any obvious phenotype/genotype correlation. 
The affected male of NHS family 3 in this study was reported to be severely 
developmentally delayed and was found to harbour a deleterious mutation in exon 6 of 
the NHS gene. Such a mutation in exon 6 is predicted to affect all known isoforms of 
the NHS gene (A-E, figure 4.9). In line with this observation, both NHS families 2 and 
4, which have truncating mutations in exon la  (predicted to affect isoform A only), 
there has been no report developmental delay. Contrary to this, NHS family 1 were 
found to harbour a truncating mutation in exon 6 and were also not reported to exhibit 
developmental delay. Therefore, questions arise such as: are truncated versions of the 
NHS protein expressed and if so, does the number of additional novel amino acids 
arising from a ffameshift have varying affects within the cell? Or, are genetic modifiers 
involved? The latter appears more likely as Burdon and colleagues reported one family 
with NHS, in which two of the four affected males had severe intellectual impairment 
(Burdon et al., 2003). Further acquisition of families with NHS and identification of 
potential NHS mutations, may help to highlight any potential genotype/phenotype 
correlation.
The NHS gene currently consists of 11 exons, of which 10 are coding. At present, there 
are 5 NHS isoforms on the database (figure 4.9). Isoform A codes for the full-length 
protein of 1,630 amino acids (aa). Isoforms B-E code for a protein of 1,335 aa, 1,474 
aa, 1,453 aa, and 1,473 aa, respectively. Four conserved putative monopartite nuclear 
localization signals were detected at amino acid positions 371-379 (RRRKLRRRK), 
438-444 (PSRRRIR), 822-825 (RKPK), and 1026-1034 (PGGSKRKPK) of the major 
isoform (isoform A, Burdon et al., 2003). Such monopartite nuclear localization signals 
imply that NHS may have a functional role within the cell nucleus.
Expression of NHS in this thesis was determined through PCR analysis of a human fetal 
multiple tissue cDNA panel, and mouse tooth cDNA (P0 and P2). Primers designed to 
amplify the human NHS gene, allowed for possibly amplification of all predicted NHS 
isoforms (isoforms A-E, figure 4.9). NHS transcripts were detected in mouse tooth
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cDNA at PO and human fetal brain, thymus, lung, and kidney. Primers used to amplify 
the mouse tooth cDNA were designed within exon 6 of the NHS gene. Thus, possible 
contamination of the mouse tooth cDNA with genomic DNA could not be verified. It is 
plausible therefore, that the PCR product detected at PO is in fact a result of genomic 
contamination, and primers spanning an intron of the mouse Nhs gene should be 
designed to resolve this. It is possible that the mouse tooth cDNA at PI may be of poor 
quality, explaining the reason for not being able to detect an Nhs transcript at PI. 
However, failure to amplify an Nhs transcript from mouse PI tooth cDNA may be a 
result of the Nhs gene being switched off. A house keeping gene could also be used as a 
control to determine the quality of the PO and PI mouse tooth cDNA samples.
Elegant expression data for the NHS gene was reported by Burdon and colleagues 
(2003). RT-PCR analysis of all five NHS transcripts (A-E, figure 4.9), detected in adult 
and fetal brain, lens, retina, retinal pigment epithilium, placenta, lymphocytes and 
fibroblasts (Burdon et al., 2003). Transcript levels of NHS in retinal pigment 
epithilium, placenta, lymphocytes and fiboblasts were reported to be very low. The 
developmental expression pattern of NHS in mouse brain was investigated by probing a 
mouse northern blot containing brain RNA from various developmental stages. A probe 
was generated from the 3’ end of the Nhs gene, thereby allowing for detection of all 
possible Nhs isoforms. Their results showed the mouse Nhs gene to be broadly 
expressed throughout brain development and in adult mouse brain from E l7.5 until age 
12 months, with transcript levels varying. In addition, Burdon and colleagues 
performed in situ hybridisation of mouse embryo sections using probes designed to 
exon 1 of isoform A and exon 6 (all Nhs isoforms). Expression was detected in 
midbrain, lens, retina, tooth primordia, the olfactory epithelium, the whisker follicles, 
the choroid plexus, and heart. Expression in the choroid plexus and heart were only 
detected using the probe designed from exon 6 of the Nhs gene. In light of this, and the 
absence of a mutation within the CXN family in which cardiac anomalies are 
documented, a mutation in the CXN family may reside in some regulatory region of the 
isoforms, which do not contain exon la-3.
Expression of Nhs (driven by the Nhs promoter) throughout development, was studied 
further by Burdon and colleagues using a mouse line containing a lacZ reporter-gene 
cassette inserted in the Nhs locus. Insertion of the cassette occurred within intron one
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and therefore was likely to be driven by promoters upstream of exon 2. Consequently, 
any observed expression was most likely representative of isoform A. Strong 
expression was detected in the developing lens and relatively high expression was also 
detected in some tissues of the developing and early postnatal brain. Expression in the 
olfactory bulbs, olfactory epithilium and the limbic system were most prominent and 
expression in the heart, apical ectoderm ridge and the olfactory tubercle was also 
observed.
The preliminary expression studies of NHS in this thesis, did not detect the presence of 
any of the five NHS transcripts (A-E, figure 4.9) in human fetal heart. Northern blot 
results reported by Burdon and colleagues in multiple human fetal and adult tissues are 
not shown and tissues in which low levels of expression were detected are not specified. 
Interestingly however, expression of Nhs (all potential isoforms) in heart was detected 
through mouse in situ hybridisation and analysis of a mouse Nhs lacZ insertion mutant. 
This may imply that the human fetal heart cDNA sample used in this study was of poor 
quality. Since cardiac anomalies have been reported in four of the six affected males of 
the CXN family and CXN and NHS may still prove to be allelic, it is important to 
determine whether or not the NHS gene is expressed (and which isoforms) in human 
fetal and adult heart. The degree of conservation between vertebrate species (in 
particular mouse, rat and human, see chapter 5) and the results of Nhs expression in the 
mouse, imply that the human NHS gene is likely to be expressed in human heart and 
therefore remains a strong candidate for CXN.
Prior to cloning the NHS gene, Burdon and colleagues were able to refine the disease 
interval for NHS to ~1.3 Mb flanked by markers DXS1195 and DXS999. Toutain and 
colleagues also reported the same refinement of the NHS disease interval in a different 
family with NHS (Toutain et al., 2002). Interestingly, the truncating mutations 
identified within exon la of families with NHS reside outside the refined NHS disease 
interval, emphasising the need for caution when refining disease intervals using 
multiple pedigrees for positional cloning.
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- Chapter Five -
The NHS gene family, orthologs and 
paralogs
5.1 Introduction
The NHS gene, which was found to harbour truncating mutations in all NHS families in 
this study, codes for a relatively large full-length protein of 1,630 amino acids (isoform 
A, figure 4.9). To date, no sequence similarity to any known protein or class of protein 
has been reported for the NHS protein. Thus, there are no clues as to the function of the 
NHS protein. Only four putative monopartite nuclear localisation motifs have been 
described (Burdon et al., 2003). To help gain a greater insight into the function of the 
NHS protein, NHS orthologs were sought. In particular, a mouse NHS ortholog was 
identified as part of the positional cloning strategy (chapter four) since the Xcat mouse 
was believed to be a model for Nance-Horan syndrome (section 3.1.3).
5.2 Results 
5.2.1 NHS orthologs
Bioinformatic analysis of the NHS protein has revealed NHS orthologs in a number of 
vertebrate species (for methods see section 2.7). Using the NHS partial and full-length 
protein sequence (isoform A) as query, BLAST algorithms were performed against the 
protein database at NCBI.
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NHS orthologs were found in mouse (Mus musculus), Rat (Rattus norvegicus), 
Chimpanzee (Pan Troglodytes), Dog (Canis familaris), Orangutan (Pongo pygmaeus, 
partial), chicken (Gallus gal I us, partial), Cow (Bos Taurus, partial), frog (Xenopus 
laevis, partial), zebrafish (Danio rerio, partial), and pufferfish (Tetradon nigroviridis, 
partial). A full alignment of the NHS protein in all these species and humans (Homo 
sapiens) can be seen in figure 5.1, which highlights the conserved domains of the NHS 
protein. Orthologs in yeast and plants were sought, but none have been identified to 
date. The level of protein identity between the human NHS protein and its orthologs is 
summarised in table 5.1.
O rtholog species
Protein  
length (aa)
Protein  
identity to 
H om o sapiens 
N H S protein
(% )
Protein  
similarity to 
H om o sapiens 
NH S protein
(% )
Genomic contigs 
and/or cDNAs 
accession no.
Canis familaris* 1628 91 94 NW _879562
Mus musculus* 1626 88 91 CN531035/AI874417
Rattus norvegicus* 1627 87 91 NW _048040
Pan Troglodytes* 1606 95 95 N W 1 2 1 6 7 9
Pongo pygmaeus 856 (partial) 99 99 CAH89962
Gallus gallus 1328 (partial) 71 80 NW _060228
Bos Taurus 1349 (partial) 90 93 BF776631
Xenopus laevis 1443 (partial) 62 74 AAH85022
Danio rerio 
Tetradon
1256 (partial) 55 67 AL926872
nigroviridis
1527 (partial) 39 52 CAF95442
Table 5.1 Orthologs of the NHS protein and the percentage sequence identity with human NHS 
protein. * denotes identified full length orthologs for which genomic structures are deduced in fig 5.2.
The NHS protein is highly conserved at the very N- and C-terminus across species 
(figure 5.1). In the middle of the protein, the level of conservation remains relatively 
high, with two blocks of highly conserved sequence across all species residing at amino 
acid positions 550-653 and 924-1043, of the human protein sequence (figure 5.1). A 
few additional, smaller blocks of highly conserved sequence across all species can be 
seen throughout the length of the protein sequence (figure 5.1).
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H . 1 MPFAKRIVEPQWLCRQRRPAPGPAVDASGGSAEPPPPLQPPGRRDLDEVEAPGPEEPARAVPAPSGLPPPPPP-LPAPADQTQPPHGEASVAGEESTAGIPEAAPAAGEA 109
P . 1 MPFAKRIVEPQWLCRQRRPAPGPAVDASGGSAEPPPPLQPPGRRDLDEVEAPGPEEPARAVPAPSGLPPPPPP-LPAPADQTQPPHGEASVAGEESTAGIPEAAPAAGEA 109
C . 1 MPFAKRIVEPQWLCRQRRPAPGPAEDANGGSADPPPPLQPPGRRD--EAVAPGPEDPPRAPPAPPG-PPPPPP-LPAPTDQAQPPHGEAPAAGEESAAGVAEAASAAGEA 107
M . 1 MPFAKRIVEPQW LCRQRRPAPGPDEDTSGGSVEPPPPLQPPGRRE--EAEAPEPEEPPRVPPAPLPLPPLPPS-LPAPAEQDQQPPSEAREAGEESVAGVSEAASAPGET 107
R. 1 MPFAKRIVEPQWLCRQRRPAPGPDEDTSGGSVEPPPPLQPPGRRE— EAEATEPDEPPRVPPAPLPLPPPPPPSMPAPAEQDQQPPSEAREAGEESVAGVPEAASATGEA 108
B . -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Pp. .................................................................................................. .........................................................................................................................................
G. --------------------------------------------------------------------------------------------------------------------
T. --------------------------------------------------------------------------------------------------------------------
X . -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------D. -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Exon 1 Exon 2
T *H . 110 SSAAAAAAVLLMLDLCAVSNAALARVLRQLSDVARHACSLFQELESDIQLTHRRVWALQGKLGGVQRVLSTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPATR 219
P . 110 SSAAAAAAVLLMLDLCAVSNAALARVLRQLSDVARHACSLFQELESDIQLTHRRVWALQGKLGGVQRVLSTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPATR 219
C . 108 SSAAAAA-VLLMLDLCAVSNAALARVLRQLSDVARHACSLFQELESDIQLTHRRVWALQGKLGGVQRVLGTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPATR 217
M. 108 SEASAEA-VLLMLDLCAVSNAALARVLRQLSDVARHACSLFQELESDIQLTHRRVWALQGKLGSVQRVLSTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPATR 217
R . 109 SEAAAEA-VLLMLDLCAVSNAALARVLRQLSDVARHACSLFQELESDIQLTHHRVWALQGKLGSVQRVLNTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPVTR 218
B .  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PP. --------------------------------- ------------- -----------------------------------------------------------------------------------------------------
G .    —-----------------------------------—
T . -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------VSNLDIESKLSLHYQAPWHQQHNVFHPCSR
X . -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------VSNLDAESKLDVFYKSSWHQQRNIFLPITR
D . -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------VSNLDIESKLTSHYQAPWHQQHNLFHTCTR
Exon 2   Exon 3
H. 220 PPCVEELHRHARQS LQALRR^- — -----------------------------------EHRSRSDRREQRAAAPLSIA-APPLPAYPPAHSQRRREFKDRH
P . 220 PPCVEELHRHARQSLQALRRGDRSWAWGLLRETTRRLSHPEHRSRSDRREQRAAAPLSIA-APPLPAYPPAHSQRRREFKDRH
C . 218 PPCVEELHRHARQSLQALRR------------------------------------------- EHRSRSDRREQRAAAPLSVA-APPLPAYPPAHSQRRREVKDRH
M. 218 PPCVEELHRHARQS LQALRR--------------------------------------------EHRSRSDRREQRAAAPLPIA-APPLPAYPPAHSQRRREAKDRH
R . 219 PPCVEELHRHARQS LQALRR--------------------------------------------EHRSRSDRREQRAAAPVPIA-APPLPAYPPAHSQRRREAKDRH
B. --------------------------------------------------------------------------------------------------------------------------------------
PP.  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G . —  — ---------- —--------  --------------
T . PPCVEELHRTAQFSLRALHRD----------------------------------------- EPAQRSASRERNRVTIAISV-APPM PTFPSPHSIRRQQRSRLA------RAQ----------------------------------------------
X . PICVEELHRHAKQSLRSMRK------------------------------------------- EQRIRADNRERRFQGSI -  FT-APPLPTYPAVNNLKRQEIKERH------WQFNRTRSHSPTECCHLTPWSRK
D. PACLEELHRHAKLNLRALHR--------------------------------------------DHLSRSTSRE-RSRVTISISVAPPMPTFPSTHKLRRREQRGRHSRMYQR----------------------------------------------
 FLT-----------------------284
 FLT-----------------------304
 FLT-----------------------282
 FLT-----------------------282
 LLT-----------------------283
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EDEDTD-- VMLGQRPK— NPIHNIPSTLDKQTNWSKALPLPTPEEKMKQDAQVISSCIIPIN$T(4v(!fDREASIRCSLVHSQSVLQRR 372
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G . ----------------------------------------- ----------------------------- --------------------------------------------------------------------
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X. AHAP----------------- QEED-D INIGQRPK— NPIPNVPSTLDKQTNWNKALPLPTPDEKMKQESQVITSCIIPINVSGVGFDREASIRCSLVHSQSVLQRR
D. SRSP-SPVQCCYFIPWIRKAGTNTETDGELQVMSHRPK— CPVPNAPTTLDKQTNWSKALPLPTPEERIKNDSQVISSCIIPINVSGVGFDREASARCSLVHSQSVLQRR
Exon 5 Exon 6
H. 373 RKLRRRKTISGIPRRVQQ^-DStteSPVARERNVIVHTNP------DPSNTVN-------- RISGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL 4 65
P. 369 ---------------------- DSDESPVARERNVIVHTNP------DPSNTVN-------- RISGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL 441
C. 371 RKLRRRKTISGIPRRVQQEI-DSDESPVARERNVIVHTNP------DPSNTVN-------- RRSGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL 4 63
M. 371 RKLRRRKT I SG IPRRVQQEI - PS DE S PV ARERN V IVHTN P------DPSNTVN-------- RRSGTRDSECQTEDI LI A-APSRRRIRAQRG-QSIAASLSHSAGNI SAL 4 63
R. 372 RKLRRRKT I SG I PRRVQQE I - PS DE S P VARERN VIVHTN P------DPSNTVN-------- RRSGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL 4 64
B. RKLRRRKTISGIPRRVQQEI-DSDESPVARERNVIVHTNP-------DPSNTVN------- RRSGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL
Pp. RKLRRRKT I SGI PRRVQQE I-DSDESPVARERNVIVHTNP-------DPSNTVN------- RISGTRDSECQTEDILIA-APSRRRIRAQRG-QSIAASLSHSAGNISAL
G.  RCVQKDAQDSDESPVARERNVIVHANP-------DFSSASS------- RRSGTRDSECQTEEILIA-APSRRRIRAQRG-QSWASLSHSAGNILVL
T. --------------------- DSDESPVARERTVIIHANPHQLSLCQEDLSIGG------- RLHHTRDSGCQTDDFLIASAPSRRRIRAQRGHQGIPASLSHSTGNI SSL
X. RKLRRRKT I SG I PRRVQQE I - PS DE S PVARDRNVIVHANP-------E LAS SAN------- RRSGTRDTECQTDDILIA-APSRRRIRAQRG-QGIAASLSHSAGNIAAL
D. RKLRRRKTITGIPKRVQQDM-PS DES PVARERTV11 HAN P-------HKSHEWHEELSLSGRVLHTKDSGCQTDDFLIT-APSRRRIRAQRG-QGIPASLSHSTGNITSL
H. 4 6 6 ADKGDTMFTPAVS— SRTRSRSLPREGNRGGDAEPKVGAKPSAYEEGESFVGDHERTPNDFSE-APSSPSAQ-------- DHQPTLGLACSQHLH--------------- 54 9
P. 442 ADKGDTMFTPAVS— SRTRSRSLPREGNRGGDAEPKVGAKPSAYEEGESFVGDRERTPNDFSE-APSSPSAQ-------- DHQPTLGLACSQHLH---------------- 525
C. 4 64 ADKGDTMFTTAVS— SRTRSRSLPREGNRSGDAEPKVGVKPAAYEEGEPFMGDQERTPNDCSE-APSSPSAQ-------- EHQPALGLACSQHLH---------------- 547
M. 4 64 ADKGDTMFTPWS— SRTRSRSLPREGNRGGDAEPKVGAKPSAFEEGERFVGDHERTPNDCSE-APSSPSTQ-------- EHQPALGLACSQHLH---------------- 547
R. 4 65 ADKGDTMFTPWS— SRTRSRSLPREGNRGGDAEPKVGAKPSAFEEGEHFVGDHERAPNDCGE-APSSSSTQ-------- EHQPTLGLACSQHLH---------------- 548
B. ADKGDTVFTTAVS— SRTRSRSLPREGNRGGDAEPKVGAKPSAYEEGEPFVGDQERTLTDCSE-APNSPSAQ-------- EHQPALSLACSQHLH---------------
Pp. ADKGDTMFTPAVS— SRTRSRSLPREGNRGGDAEPKVGAKPSAYEEGESFVGDHERTPNDFSE-APSSPSAQ-------- DHQPTLGLACSQHLH---------------
G. ADNGDAVFAAAVS— NRIRSRSLPREGARASEGDTAATTKSSAYE-AECFLASQERHPKKGKE-VLSKQGSQ-------- EHQP-LGLTCPQHLH---------------
T. GDQSDSTYTSVTTHGGRLRSRSLPREGGRLMDSDED— DDDDNYDDDDE DEELSPYEAEDFIPSGPSPRMKMMMMKDEEESTDDQAAPEPLQLGSLKRLQRSGERDR
X. TESGDQMFKNTVS— SRIRSRSLPRESARESN-DHDCSAQSSTYEE-DCYMPCTERILKKDKD-SLTSQESP-------- DHQP-LGLTYSQHRH---------------
D. PDRSDTVYAAASA— TRVRSRSLPREGGRLLDEDQDDNEELSPYEAEDFLPGPGQRIPKDEEES-TDDQAMPE---------LQFG-SLKRMQHSE---------------
Exon 4
H. 2^5 ISH^P---------
P. 305 SHPP------
C. 283 SHPP------
M. 283 SHSP------
R. 284 SHSP------
B. SHPP------
Pp. SHPP------
140
H. 550 ------ SPQHKLSERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPH 653
P. 526 ------ SPQHKLSERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPH 629
C. 548 ------ SPQHKLNERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPH 651
M. 54 8 ------ SPQQKLSERGRSRLSRMAADSGSCDISSNSDTFGSPVHCISTASVLLSSHMDQKEDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPN 651
R. 549 ------ SPQQKLSERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTASVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPN 652
Bt  SPQHKLNERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPH
Pp.  SPQHKLSERGRSRLSRMAADSGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPH
8 .  SPEHSIGERGRSRLSRMA-DSGSCEISSNSDTFGSPIHSISTAGVLLSSHMDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPN
T. GCGGGGSPEHSWMERGRSRLPRKA-DMGSCEISSSSDTFSSPIHSVSAAGVL-GSHVDHKEDHQSSSGNWSGSSSTCPSQTSESIPPPSSPPLTGSSHCDSELSLNTVPN
x<  SPQLHLNERGRSRLSRM-ADSGSCDISSNSDTFGSPVHSISAAGVLLSTHIDQKDDHQSSSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPN
D.  SPDHTWIERGRSRLPRKV-DMGSCEISSSSDTFSSPIHSASTTGVL-GSQIDHKEDHQSSSGNWSGSSSTCPSQTSETLPPAASPPLTGSSHCDSELSLNTGSH
H. 654 ANEDASVFVTEQY-NDHLDKVRGH— RANSFTSTVADLLDDPNNSNTSDSEWNYL— HHHHDASCRQDFSPERPKADSLG— CPSFTSMATYD----- SFLEKSPSDKAD 751
P. 630 ANEDASVFVTEQY-NDHLDKVRGH--RANSFTSTVADLLDDPNNSNTSDSEWNYL— HHHHDASCRQDFSPERPKADSRG— CPSFTSMATYD----- SFLEKSPSDKAD 727
C. 652 ANEDANVFVTEQY-NDHLDKVRGH--RANSFTSTVADLLDDPNNSNTSDSEWNYL--HHHHDASCRQDFSPERPKADSLG— CPSFTSMATYD----- SFLEKSPSDKAD 759
M. 652 ANEDASVFVTEQY-NDHLDKVRGH--RTNSFTSTVADLLDDPNNSNTSDSEWNYL--HHHHDASCRQDFSPERPKADSLG--CPSFTSMGTYD----- SFLEKSPSDKAD 759
R . 653 ANEDASVFVTEQY-NDHLDKVRGH— RTNSFTSTVADLLDDPNNSNTSDSEWNYL— HHHHDASCRQDFSPEHPKADSLG— CPSFTSMGTYD------SFLEKSPSDKAD 7 60
B. ANEDTSVFVTEQY-NDQLEKVRGH— RTNSFTSTVADLLDDPNNSNTSDSEWNYL— HHHHDASCRQDFSPERPKADSLG— CPSFTSMATYD SFLEKSPSDKAD
Pp. ANEDASVFVTEQY-NDHLDKVRGH— RANSFTSTVADLLDDPNNSNTSDSEWNYL— HHHHDASCRQDFSPERPKADSLG— CPSFTSMATYD SFLEKSPSDKAD
G. ANEDSSVFITEQY-GDHVDKVRGH--RASSFTSTVADLLDDPNNSNTSDSEWNYL--HHHHDASCRQDFSPERTKADSLG— CPSFTSMGTYD----- SFLEKSPSDKAD
T. ATDDGFSLDPSYH-SDLRPQGQGH— RSSSFTSSATDQLDDAGVSTASEGEWTYPPDQDQTDQDTETDQSRTLNRCQDLP REYNSKEGQENQVCFSDIKSSNVDK-D
X. AGEDSNVFITEQYSDDHIDSIRGH--RASSFTSTVADLLDDP-NSNTSDSEWNYL--HHHHDASCHQDFSPQHLKTDRLA--CPSFTSMGTYD----- SFLEKPASEKAD
D. VIDDNTGFIIDPY HIDKPQGQGQRSNSFTSSATDQMDDAGVSTASDGEWNCA— QDQQDQSCTQDFSPKRSREDESGVSCPSYSSGETYE----- SFSDQASARKSE
H. 752 TSSHFSVDTEGYYT-SMHFDCGLKGNKSYVCHYAALGPENGQGVGASPGLPDCAWQDYLDHKRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI------SEKKEPKIS 855
P. 723 TSSHFSVDTEGYYT-SMHFDCGLKGNKSYVCHYAALGPENGQGVGASPGLPDCAWQDYLDHKRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI------SEKKEPKIS 826
C. 760 TSSHFSVDTEGYYT-SMHFDCGLKGNKSYVCHYAALGPENSQGIGVPPTLPDCTWQDYLDHRRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI------SEKKEPKIS 863
M. 760 TSSHFSVDTEGYYT-SMHFDCGLKGNKTYVCHYAGLGPENGQGVGVPPALPDCAWQEYLDHRRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI------SEKKEPKIS 863
R. 761 TSSHFSVDTEGYYT-SMHFDCGLKGNKTYVCHYAGLGPENGQGVGVPPALPDCAWQEYLDHRRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI------SEKKEPKIS 864
B. TSSHFSVDTEGYYT-SMHFDCGLKGSKNYVCHYAALGPENSQGIGVPPALSDCAWQDYLDHRRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADT----- SEKKEPKTS
Pp. TSSHFSVDTEGYYT-SMHFDCGLKGNKSYVCHYAALGPENGQGVGASPGLPDCAWQDYLDHKRQGRPSISFRKPKAKPTPPKRSSSLRKSDGNADI----- SEKKESKIS
G. TSSHFSVDTEGYYT-SMHFDCGLKGNKSYICNYAAAGSESGQMASMTSSLADCTWQECISHRRQGRQGISLKKPKAKPAPPKRSSSLRKSEGSMDL----- PEKKEPKIS
T. PSSNYSSDTEGFYTSSVHFGECNQGYRGYMYNYADPGPDCAQSNTTAAPYPQHMADSRGGTMTLGRTCRSLRKPKVKPPPPKRTSSLKEPVCSVDVETNTQTEQDQPKMA
X. TGSHFSVDTEGYYT-SMHFDCGLNTGRSYIYNYAPTGSERDQGRGISSMNTDNAWQCYMDQENEGNQNISFKKPKARPTPPKRSSSLRKSDNNTDI----- LEKKEPKIV
D. M— HYIVDTEGFYS-SMHFDSGLKGSRSYY-NYAAIDPDCGPSGNIAPGMTEYPQPEYRATRTLGRPCLSLRKPKAKPPPPKRSSSLKETSSDVNV----- PEQNEPKIT
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H. 856 SG-QHLPHSSREMKLPL— DFANTPSRMENANLPTKQEPSW INQSEQGIKEPQLDASDIPPFKDEVAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI 957
P. 827 SG-QHLPHSSREMKLPL— DFANTPSRMENANLPTKQEPSW— INQSEHGIKEPQLDASDIPPFKDEVAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI 928
C. 864 SG-QLLPHSSREMKLPL— DFSNTPSLMENANLAIKQESSW MNQSEHGIKEPQLDTSDIPPFKDEGAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI 965
M. 864 SG-QHLPHSSREMKLPL— DFSNTPSRVENANLPAKLDSSW-— INQSEHAIKEPQLDTPDISPFKDEGAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI 965
R. 865 SG-QHLPHSSREMKLPL— DFSNTPSRVENANLPAKLDSSW— ISQSEHAIKEPQLDTTDISPFKDEGAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI 966
B. SG-QLLPHSSREMKLPL— DFSNTPSLMENANLPTKPEPSW MNQNEHGIKEPQLDTPDVPPFKDEGAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI
Pp. SG-QHLPHSSREMKLPL— DFANTPSRMENANLPTKQEPSW— INQSEHGIKEPQLDASDIPPFKDEVAESTHYADLWLLN-DLKTND-PYRSLSNSSTATGTTVIECI
G. SG-QHTSHTAREMKLPL— EFSNTPSRAEASSLPPKPELPW VSQSDGGMKDTQFDMADMPSFKDDGAEQPHYADLWLLN-DLKSGD-PYRSLSNSSTATGTTVIECI
T. TE-QEDTLSSTDTNLELEQDLESAPEPLQTACLVAEPLGTWGMGLHETVDIVEPMSFSSADTHSFKDEGAVQSDYADLWLHNTDLKCNNGEYTSMSNSSTATGTTVMECM
X. CGQQQVIHSSREMKLPL— EMSNIPSRVENFATPNQQEIPW VNQDDNDLKSTQFLTTDVPSFKYESGEQSHYADLWLVN-DLKTSD-PYRSLSNSSTATGTTVIECI
D. CE-LPLPLSSREMKLQL— DLADSAGHLETAGLESLGAWGV ENVRDMLDCSSPFSSSDTHSFKDEGAVQADYADLWLHN-DLKSND-PYRSLSNSSSATGTTVIECI
H. 958 KSPESSESQT-------- SQSESRATTPSLPSVDNEFKLASPEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL-QQPSL  1047
P. 929 KSPESSESQT-------- SQSESRATTPSLPSVDNEFKLASPEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL-QQPSL  1018
C. 966 KSPESSESQT--------SQSESRATTPSLPSVDNEFKIASPEKLAGLASPS8 GYSSQSETPTSSFPT— AFFSGPLSPGGSKRKPKVPERKSSL----- QQPSL 1055
M. 966 KSPESSESQT-------- SQSESRATTPSLPSVDNEYKLASPEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL-QQPSL  1055
R. 967 KSPESSESQT-------- SQSESRATTPSLPSVDNEYKLASPEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPQSPGGSKRKPKVPERKSSL-QQPSL  1056
B. KSPESSESQT-------- SQSESRATTPSLPSVDNEFKLASPEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL---------QQPSL--
Pp. KSPESSESQT-------- SQSESRATTPSLPSVDNEFKLAS PEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL---------QQPSL--
G. KSPESSESQT-------- SQSGSRATTPSLPSVDSEFKLAS PEKLAGLASPSSGYSSQSETPTSSFPT--- AFFSGPLSPGGSKRKPKVPERKSSL---------QQPLT--
T. KSPESSSSSTEASTQALSKASDTRAASPPLPSGD— FKLGSPEKLAGLASPSSGYSSQSETPTSTLPSSSGAFFPGPQSPSTGKRKPKVPERKSSL------- PSLQHFS
X. KSPESSESQM-------- SQSESRATSPSLPSVENEFKLSSPEKLAGLASPSSGYSSQSETPTSSFPT--- PFFSGPLSPGGSKRKPKVPERKSSL---------QHPSA--
D. KSPERSETHT-------- CQPRSRPSSPTLPPPESEFKLASPEKLAGLASPSSGYSSQSETPTSSFPS-AFFPGPLSPTSGKRKPKVPERKSSLCSLQQQQLSV-------
H. 1048 KDGTISLS--KDLELPIIPPTHLDLSALH-----NVLNKPFHHRHPLHVFTHNKQNTVG------ ETLRSNPPPS------------ LAITPTILKSVNLRSINK—  1127
P. 1019 KDGTISLS--KDLELPIIPPTHLDLSALH-----NVLNKPFHHRHPLHVFTHNKQNTVG------ ETLRSNPPPS------------ LAITPTILKSVNLRSINK 1098
C . 1056 KDGALSLS--KDLELPI I PPTHLDLSALH-----SVLNKPFHHRHPLHVFTHSKQNPVG------ ETLRSNPPPS------------ LAITPTVLKSVNLRSISK 1135
M. 1056 KDGALSLS--KDFELPIIPPSHLDLSALH------VLNKPFHHRHPLHVFTH-KQNTVG------ DMPRSNPAPS------------ LAITPTVLKSVNLRSISK 1133
R. 1057 KDGALSLS-— KDFELPIIPPSHLDLSALH------VLNKPFHHRHPLHVFTH-KQNTVG-------DMLRSNPPPS------------ LAITPTVLKSVNLRSISK-- 1134
B. KDGALSLS--- KDLELPI IPPTHLDLSALH-----NVLNKPFHHRHPLHVFSHNKQNTVG------ ETLRSNPPPS------------ LAITPTVLKSVNLRSISK---
Pp. KDGTISLG--- KDLELPI IPPTHLDLSALH-----NVLNKPFHHRHPLHVFTHNKQNTVG------ ETLRSNPPPS------------ LAITPTILKSVNLRSINK—
G. KDGTMSAS--- KDLELPI I PPTHLDLSALH-----SVLNKPFAHRHQLHAFNPSKHSAVG------ EALSPSHPSA------------ LAITPSVLKSVHLRAINR---
T. RDGTSISSGYRRDPDFP-PPPSQLDLNILHGGYIRHTLSHRTHHMHTLHHNKHRATNWATGAKFVTEVSNANQSASSNLSQTSASTSVSVITPSVPRSVQFHPVSQPTA
X. KCCNVLGG--- KELELPTIPPTNLDLSALH------VLHKPLPYRPHIHAFSHNNQNMSE------ DQFDSNSSTA------------ LAITPSVLKSVQLRSVNK—
D. RDPGISCR— RETDFYAIPPSHLDLSALH TRTRQQKVPRCAKDIVTRETKTRFE-------STIAARP-------------------------------------
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H. 1128 -SEEVKQKEENNTDLPYLEESTLT TAALSPSKIRPHTANKSVSRQYSTEDTILSFLDSSAVEMGPDKLHLEKNSTF------- DV---- KNRCDPET-ITSAGSSL 1220
P. 1099 -SEEVKQKEENNTDLPYLEESTLT— TAALSPGKIRPHTANKSVSRQYSTEDTILSFLDSSAVEMGPDKLHLEKNSTF------- DV---- KNRCDPET-ITSAGSSL 1191
C. 1136 -SEEVKPKEGNNTDLPYLEDNTLT MAALSPGKIKPHMAKKSVSRQYSTEDTILSFLDSSAVEMGPDKLQLEKKRTF------- DV---- KNHCDPETATTSAGSNL 1229
M. 1134 -SEEVRQKEGNNTDLPYLEENAATAASVASLSPSKARPHTAKKSISRQYSAEDTLLPFLDSSVAEMGPEK-HLEKNPNF------- DG---- KSHGDPET-ATSASSNL 1228
R. 1135 -SDEVKQKEGNNTDLPYLEENAVTVASVASLSPSKARSHTAKKSISRQYSAEDTLMPFLDSSVGEMGPEK-HLEKNPTF------- DG---- KSHGNPET-VASASSNL 1229
B. -SEEVKQKEGNNTDLPYLEESTLT-- T GKIRPHVIKKSLPCQYTTEDTILSFLDSSAVEMGPDKLQLEKKHTF---------DV KHHCDPET-VTSAGSNL
Pp. -SEEAKQ------------------------------------------------------------------------------------------------------------
G. -PEEMKQK-GSIPDLLCIQEPTLL-- AGDVSPGKMRPLLAKKPVSRQYSTEEAIMSYIDSSPAETGPGKPSLEKSSSF---------SG QSNCEQEI-VPSAGVAL
T. SAATTEPEVANVAETAIRPKCPPS-- APTLAPPHTRPLPPRRPPPRPPIHDNT SSPEHLQPPPPGRHPDGPPSY---------ESLLFRQDRYGPGT-FW-AMTAF
X. -QHK-KSKQRETCNIVCSQDPTIT VDTYTTEKTIVTSARKSILRQFSTEEVILPYIDSSPVDTSPQSMFFDKCELFTGHGMYRQDK GTNIFGVT-KE PWTHEI
D.--------------------------------------------------------------------------------------------------------------------------
H. 1221 LDSNVTKDQVRTETEPI PENTPTKNCAFPTE------------GFQRVSAARP------------ NDLDGKIIQYGPGPDETLEQVQKAPSAGLEE— VAQPESVDVITS 1304
P. 1192 LDSNVTKDQVRTETEPIPENTPTKNCAFPTG------------GFQRVSAARP------------ NDLDGKIIQYGPGPDETLEQVQKAPSAGLEE— VAQPESVDVITS 1275
C. 1230 LDSSVTKDQIQMESEPIPENTPSKNCDFPTE------------GFQMVSVAHP------------ NDLDGKVLQYGGGPDGAVAQLQKPSSADWEG--AAHPESVDVLTA 1312
M. 1229 PDSNVMKEQIQMESELISENILSKNCGFST-------------GFQRVSASRP------------ SDLGSKMIQYGASPDGTVQQGQKAPSGVREE— GGKPESVDGITL 1311
R. 1230 PDSNVMKDQIQMESELIPESIPSKNCGFST-------------GFQRVSASRP------------ SDLGNKMIQYGASPDGAIQQGQKVPSGVGEE— GGKPESVDGITL 1312
B. LDSSVTRDQMHMESEPVSENKPSKSCDFLTE-------------GFQRVSAARP----------- NDSDGKTLQYGAGPDGALAQVQKLSFVDREE— AAPPESVDVLTP
p p . --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G. VEMKTVKDQISPATEHLPDSALNQTCAVSTE-------------GFQKGSALLT----------- GDHEAENENRGAEPESRLEHAQAQP E— LCGSEQQLELGM
T. RTRMEASSELSEDSSPLHRPVPRAPHPSPVDLHTHIHSHREFRGLTQSTSAHPEFRVLGERSFSQDDDDDD DDDDDEEEEQMKEPPLAACSR— V--------- SL
X. VQETVFLAQPETTTTTFQEYYEKKNC-----------------------------------------NEI— AVEQCGHVQED— NQLKLTPDIHIQDDVMTIPEPIKEITT
D.
Exon 6 Exon 7
H. 1305 QSDSPTRA— TDVSNQFKHQFVMSRHHD-------- KVPG-TISYESEITSVNSF PEKCSKQEN-IASGISAKSASD— NSKAEETQGNVDEASLKESSPSDDSI 1395
P. 1276 QSDSPTRA— TDVSNQLKHQFVMSRHHD KVPG-TISYESEITSVNSF PEKCSKQEN-IASGISAKSASD— NSKAEETQGNVDEASSKESSPSDDSI 1366
C. 1313 QSNSPTRP— TDISSQLKHQLGMSRHHD-------- KVPG-NISYEAELSSANSC PEKCSEQEN-IASGISAQSASD— NSGAEETQGSVDEVSLKESSPSDDSM 1403
M. 1312 QANSSTRV— TDISSQYKHQRVISRHHD-------- KVPV-TIRHESEMSTVNSF PEKCSEQEN-IASGISPQSASD— NSRAEETQGSMDETSLKESSPSDDSI 1402
R. 1313 QANSSTRV— TDISSQYKHQRWSRHHD-------- KVPV-TIRHESEPSTVNSF PEKCSEQEN-IASGISPKSASD— NSGAEETQGRMDETALKESSPSDDPI 1403
B. QSDSPTRV— TDIGYQLKPQLGMSHHHD-------- KVPG-NISSEAEISTINPC-----PEKCSEQEN-IASGISAKSASD— NSGAEETQGSVDEVSLKESSPSDDSV
pp.-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G. AGDS PAQAEGADV S DQLKHQLDLSHH----------- VPG-NISYESETAAVNLL-----SEASCKQEN-VTSGIPTRSASG— TSRADETAGGTEEPSLKESSPSDDSI
T. RSDHPPPP— A------- YDFAAGYHIDSGPWASPVKVPG-TRSETSHPYLISDARRGG-KDEKEDDQK-VTSG-ATRSAHHLLESKDDSTTPDTEDYFSKDSTPSDNS-
X. EFALQDNAA— EKFLSHDNEPDLS-NND-------- KVPGNTLSFESELSTVYSL-----SDECPEQESEFVSGIPTKSASE— DNRSYDPSENMEDTSEKESSQSEDYL
D.-----------------------------------------------------FNTVHVFGQHNATPCLYDVQGREEDYETSGVATRSASQ— DIREEESTPDTEDYFSKDSTPSDN-S
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Exon 7 Exon 8
H. 1396 ISPLSEDSQAEAEGVFVSPNKPRTTEDLFA^HjlS^KVLGRKDSGDMSVRSK— SRAPLSSSSSS-ASSI— TSPSSNVTTP-------NSQRSPGLIYRNAKKSNTSN 1493
P. 1367 ISPLSEDSQAEAEGVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMSVRSK— SRVPLSSSSSS-ASSI— TSPSSNVTTP-------NSQRSPGLIYRNAKKSNTSN 14 64
C. 1404 ISPLSEDSQAEAEGVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMSARSK— SRASLGSSSSSNAGSV— TLPNSSVTSP-------NSQRSPGLIYRNAKKSNTSN 1502
M. 1403 TSPLSEDSQAGAEGVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMSVRSK— SRVPLGSSSSS-ANSV— TSPSSNVTAG-------TSQRSPGLIYRNAKKSNTSN 1500
R. 1404 ASPLSEDSQAEAEGVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMSVRSK--SRVPLGSSSSS-ANSV--TSPSSNVTTG-------ISQRSPGLIYRNAKKSNTSN 1501
B. ISPLSEDSQAEAESVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMSVRSK--SRASLGSSSSNSAGSV--TSPNSNVTTP-------NSQRSPGLIYRNAKKSNTSN
pp. ------------------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------------------------------------------
G. MSPLSEDSQAEAEDVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDLSVRNR— LRASSGTSSQL-PTSS— TLPASSTSSASSTGAPMNSQRSPGLIYRNAKKSNTSN
T. LSPLMDDAKADDDIIITSPNKSRTTEDLFAMIHRSKRKVLGRKDSGDLNVKSRLCPPAPVAPVPTV-SVPP--APPLTSQVPAG------- SQRAPVPIYRSAKKSTTSN
X. ISPMSEDSQADTDDVFVSPNKPRTTDDLFAAIHRSKRKVLGRKDSGDSTVKNK--SRPLTGSSGAS-AA-----------------------SQRSPGLIYRSAKKSNTSN
D. SSPLTDDSRLD-DDVFPSPNKLRTTEDLFAMIHRSKRKVLGRKDSGEVSGKGR— PWPPVTTPVS-NPTVCPVIPAPPVPSN-------NSQRASGPIYRSAKKSSTSS
H. 1494 EEFKLLLLKKGSRSDSSYRMSATEILKSPILPKPPGELTAESPQSTDDAHQGS-QGAEALSPLSPCS PRVNAEGFSSKSFATSASARVGRSRAPPAASSSRYSVR 1597
P. 14 65 EEFKLLLLKKGSRSDSSYRMSATEILKSPILPKPPGELTAESPQSTDDAHQGS-QGAEALSPLSPCS PRVNAEGFSSKSFATSASARVGRSRAPPAASSSRYSVR 1568
C. 1503 EEFKLLLLKKGSRSDSSYRMSATEILKSPILPKPPGELTAESPQSTQEAHQGA-PGAEALSPLSPCS PRVNAEGFSSKNFATSAAARVGRSRAPPAASSSRYSVR 1606
M. 1501 EEFKLLLLKKGSRSDSSYRMSATEILKSPVLPKPPGEFTAESPQSPDDTHQGT-PGTEALSPLSPCS PRVNAEGFSSKNFATSASARVGRSRVPPVASSSRYSVR 1604
R. 1502 EEFKLLLLKKGSRSDSSYRMSATEILKSPVLPKPPGEFTAESPQSPDDTHQST-PGTEALSPLSPCS PRVNAEGFSSKNFATSASARVGRSRAPPVASSSRYSVR 1605
B. EEFKLLLLKKGSRSDSSYRMSATEILKSPILPKPPGDLTAESPQSPHEAHQGS-PGTEALSPLSPCS PRVNAEGFSSKNFATSASARVGRSRAPPVASSSRYSVR
pp. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G. EEFKLLLLKKGSRSDSSYRMSATEILKSPILPKSPGELTADASQSQDECPPVT— SPDASSPLSPCS PRVNAEGFSSKSFPMSASSRVGRSRAPPAASSSRYSVR
T. EEFKLLLLKKGSRSDSSYRMSATEILKSPITPKLPGDSVQEGWRQSEESLSA-LQEPPMSGLEPIQIPGLFPRANSESFTPKTMPMSAASRQGRSRIPPVANSSRYSTR
X. EEFKLLLLKKGSRSETSYRMSATEILKSPVTPKSLVDLALDSSSSSEDGSQLS-PGSDAFSPISPCS PRVISEGFSAKSGTMSAASRVGRSRVPPAASSSRYSVR
D. EEFKLLLLKKGSRTDSSYRMSATEILKSPITPKTQAELLLEAMRQPEEIPLPQLDSTSSGDPLPSPF PKANSEGFSPKTLTMSAASRQGRSRIPPAANSSRYSTR
H. 1598 CRLYNTPMQAISEGETENSDGSPHDDRSSQSST 1630 
P. 1569 CRLYNTPMQAISEGETENSDGSPHDDRSSQSST 1601
C. 1607 CRLYNAPMQAISEGETENSDGSPHDDRSSQSST 1639 
M. 1605 CRLYNTPMQAISEGETENSDGSPHDDRSSQSST 1637 
R. 1606 CRLYNTPMQAISEGETENSDGSPHDDRSSQSST 1638
B. CRLYNAPMQAISEGETENSDGSPHDDRSSQSST
pp. --------------------------------------------------------------
G. CRLYNTPMQAISEGETENSDGSPHDDRSSQSST
T. SRLYTAPMQAISEGETENSDGSPHDDRSS----
X. CRFYNAPMQAISEGETENSDGSPHDDRSSQSSM
D. SRLYTAPMQAISEGETENSDGSPHDDRSS----
Figure 5.1 Alignment of the human NHS protein with identified NHS orthologs. H, Homo sapiens', M, Mus musculus; Rat, Rattus norvegicus; P, Pan Troglodytes', C, 
Canis familaris', Pp, Pongo pygmaeus (partial); G, Gallus gallus (partial); B, Bos Taurus (partial); X, Xenopus laevis (partial); D, Danio rerio (partial); T, Tetradon 
nigroviridis (partial). Amino acids 100 % conserved are highlighted red. Blue arrows denote exon boundaries. Conserved sequence motifs are in bold and underlined.
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Stretches of amino acid sequence (490-549, 856-924, and 1121-1395 of the human NHS 
protein sequence) were found not to be very conserved across all species (figure 5.1). 
However, the NHS protein sequence of human (Homo sapiens), mouse (Mus musculus), 
Rat (Rattus norvegicus), Chimpanzee (Pan Troglodytes), and Dog (Canis familaris), is 
much more highly conserved throughout the entire length of the NHS protein. Only on 
addition of the remaining species, in particular the partial protein sequence of frog 
(Xenopus laevis), zebrafish (Danio rerio) and the pufferfish (Tetradon nigroviridis) is 
the level of conservation reduced. The pile up of the NHS protein sequences from all 
species however, highlights important functional domains of the NHS protein sequence.
To date, all the above NHS protein sequences from each species is based solely on 
prediction. There is little expression evidence currently available to support these 
predictions, as highlighted in figure 5.2. Full-length protein sequence was identified 
only for Mus musculus, Rattus norvegicus, Pan Troglodytes, and Canis familaris based 
on genome assemblies. As a result, the genomic structure of each of these predicted 
genes was examined. Figure 5.2 depicts the genomic structure for Mus musculus, 
Rattus norvegicus, Pan Troglodytes, and Canis familaris.
Limited expression data was available for the Mus musculus homologue. Two unigene 
clusters (Mm.328515 and Mm.336313) were identified for the Nhs gene from Mus 
musculus. Unigene cluster 328515 contains two ESTs from adult male kidney and 
mouse E l4.5 retina, which align with exon 1 of the Nhs gene (figure 5.2). Additional 
ESTs were identified in unigene cluster Mm.336313 and align with the 3’ end of the 
Nhs gene. A kidney EST AI874417 from unigene cluster Mm.336313 joins exon 4 of 
the Mus musculus Nhs gene with an exon 3b equivalent of the Homo sapiens NHS gene. 
Therefore exon 3b of the Homo sapien NHS gene (isoforms C and E; chapter 4 section
4.2.2, figure 4.9) was found to be present in the Mus musculus Nhs gene. An additional 
two EST hits are present in unigene cluster Mm.336313. The first, CB722921 from 
whole brain, aligns with exon 6 of the Nhs gene (figure 5.2). The second EST joins 
exons 6, 7, and 8 of the Mus musculus Nhs gene (figure 5.2), similar to mRNA 
AK026164 of the Homo sapien NHS gene (chapter 4 section 4.2.1, figure 4.1). No EST 
or mRNA hits were identified for exons 2, 3, or 5 of the
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Figure 5.2 Predicted genomic structures of the Nhs gene in Mus musculus, Rattus novegicus, Pan troglodytes, and Canis familaris.
The genomic structure o f the NHS gene in Homo sapiens is given at the top o f the figure for comparison of exons and their sizes. Exons are numbered with respect to the 
human sequence. EST/cDNA hits are depicted below the corresponding genomic structures (for data on human NHS expression and isoforms see chapter four). Genomic
structures for each of the NHS orthologs are not to scale.
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Mus musculus Nhs gene. Further, the alternative 5’ exons observed in isoforms B-E of 
the Homo sapiens NHS gene (chapter 4 section 4.2.2, figure 4.9) have not yet supported 
by ESTs in the Mus musculus Nhs gene.
The deduced genomic structures of the Rattus norvegicus, Pan Troglodytes, and Canis 
familaris Nhs genes can also be seen in figure 5.2. Exon sizes amongst the various 
species appears to be highly conserved. Sizes of exons 3,4, and 5 are identical amongst 
the Homo sapiens, Mus musculus, Rattus norvegicus, Pan Troglodytes, and Canis 
familaris NHS genes. Exon 2 differs only in Pan Troglodytes, although this may prove 
to be an error as the sizes of exons 1 and 3-7 are identical between Homo sapiens and 
Pan Troglodytes. Furthermore, exon 2 is 100 % conserved between these two species 
(amino acids 189-240 of the Homo sapien NHS protein, figure 5.1), except for the 
additional sequence in Pan Troglodytes, which is absent in all other species. Currently, 
there is no expression data to confirm the presence of these predicted exons in Rattus 
norvegicus, Pan Troglodytes, and Canis familaris, and the genomic structures (figure
5.2) are based purely on analysis of genome assemblies for each of these species.
5.2.2 NHS paralogs
After identifying orthologs of the human NHS protein through bioinformatic analysis, 
significant homology to sequence K1AA1357 located on chromosome 6q24.1 
(www.ncbi.nlm.nih.gov/, using BLAST algorithms) was detected. This sequence was 
predicted to be a novel gene by computational analysis of supporting mRNA and EST 
evidence (including UniGene cluster Hs. 170162) from multiple tissues, including adult 
and fetal brain, fetal eyes, and adult lens, kidney, liver, and intestine.
Inspection of the genomic interval (http://genome.ucsc.edu) revealed the structure of 
this novel gene, hereafter named NHSL1 (NHS-Like 1), on chromosome 6, with striking 
resemblance to the genomic structure of the NHS gene (figure 5.3).
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Figure 5.3 NHSL1 genomic structure.
Blackened squares indicate the open reading frame (ORF), with sizes of coding portions given below.
Genomic structure not to scale.
NHSL1 is predicted to be alternatively spliced with at least four alternative 5’ exons (la­
id) and a cryptic exon 5 (figure 5.3). Exon la  lies 196 Kb upstream of exon 2. 
Similarly, exon 1 of NHS is found 350 kb upstream of exon 2. In addition, exon la  of 
NHSL1 has sequence homology at the protein level to NHS exon la  (figure 5.5). Exons 
2, 4, and 5 of the NHS and NHSL1 genes are identical in size and show a high degree of 
protein homology, however, the large exon 6 of both genes is divergent. Exon 3, again 
is similar in size in both genes but encodes different protein sequences.
Interestingly, REPS1 and REPS2 lie telomeric to NHSL1 and NHS respectively. REPS1 
and REPS2 are close paralogs sharing 32 % protein sequence identity, implying that 
Xp22.13 and 6q42.1 are derived from a duplicated genomic sequence.
The identification of NHSL1 prompted a wider search (through bioinformatic analysis), 
for additional NHS paralogs using conserved domains between the protein sequences of 
NHS and NHSL1 as query. This resulted in significant homology to sequence 
BC033261 mapping to chromosomal region Xql3.1. Further computational analysis of 
Xql3.1 revealed a genomic structure highly similar to that of the NHS and NHSL1 
genes (figure 5.4). This newly identified paralog on Xql3.1 (named NHS-Like 2, 
NHSL2) has supporting mRNA and EST evidence (UniGene cluster Hs. 397836) from 
brain, mammary gland, and tongue. Exon la, like NHS and NHSL1, is found far 
upstream of exon 2, approximately 221 Kb. NHSL2 consists of 8 putative coding exons, 
predicted to code for a 1189 amino acids and like NHSL1, EST evidence suggests 
splicing out of exon 5 (figure 5.4). In addition, from available expression data, it 
appears that exons 2-4 are also spliced out of one isoform (figure 5.4). To date, no
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alternative 5’ exons have been identified for the NHSL2 gene and there is no supporting 
expression data for exon 2, although exon 2 of NHS and NHSL1 is highly conserved at 
the protein sequence level with the NHSL2 gene. Exon 3, which is divergent between 
NHS and NHSLl, is also different in NHSL2, although there is no EST or mRNA 
supporting evidence to confirm its expression. However, the splice sites of NHSL2 and 
NHS are similar for exon 3 implying that this particular exon is likely to form exon 3 of 
the NHSL2 gene.
Figure 5.4 NHSL2 genomic structure.
Blackened squares indicate the open reading frame (ORF), with sizes o f coding portions given below.
Genomic structure not to scale.
A pile up of the protein sequences for NHS, NHSLl and NHSL2 (figure 5.5), revealed 
regions of homology (figure 5.6) indicating specific protein domains for this protein 
family. In particular, sequence motifs SPSSGYSSQSXTPT, PXVPERKSSL, and 
RTTEDLFXXIHRSKRKXLG. These motifs were used as query sequence to try and 
identify any additional family members of the NHS gene family. As a result of this 
additional search, an alignment of the sequence motif SPSSGYSSQSXTPT with a 
partial human brain mRNA AB040955 mapping to chromosomal region 1 p35.1, was 
identified (figure 5.7). The sequence motif SPSSGYSSQSETPT in NHS is also 
conserved across species (located within exon 6, figure 5.1).
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Homology domain 1
NHS (Exon 1) 1 MPFAKRIVEPQWLCR 15
NHSLl (Exon la) 1 MPFHQRTLEPARLRR 15
NHSL2 (Exon la) 1 MPFYRRTWPQRLC-  14
NHS (Exon 1) 123 DLCAVSNAAIiARVLRQLSDVARHACSLFQELESDIQLTHRRVWALQGKLGGVQR 17 6
NHSLl (Exon 1) 31 SLEQV S SHALGCLLAQLADLSRCAGDIFGELE GQAAALGHRTAALHRRLDALQA 84
NHSL2 (Exon 1) 24 ELRDVSHLAALSLLRQLADLCGHSLALLEDLE GHLLALGRRTD SLYRRTVRLRR 77
Homology domain 2
NHS (Exon 2) 190 VSNLDIES-KLSVYYRAPWHQQRNIFLPATRPPCVEELHRHARQSLQALRRE 24 0
NHSLl (Exon 2) 98 VSNLDEES-RWTVHYTAPWHQQENVFLPTTRPPCVEDLHRQAKLNLKSVLRE 14 8
NHSL2 (Exon 2) 95 AAN S GRE NAT AT AH S RS SWRQ PVNVFL S S GR P P S VE E LLRE AQLNLQ S LLQE 14 6
Homology domain 3 : : : : :  :
NHS (Exon 4) 310 STLDKQTNWSKALPLPTPEEKMKQDAQVISSCIIPINV 347
NHSLl (Exon 4) 216 SDLNTQTNWTKSLPLPTPEEKMRQQAQTVQADWPINI 253
NHSL2 (Exon 4) 215 TTADKQTAWNSLFPLPILEEKRWPQLCSTQSDIVPINI 252
Homology domain 4 : : '
NHS (Exon 5) 348 TGVGFDREASIRCSLVHSQSVLQRRRKLRRRKTI SGI PRRVQQEI 392
NHSLl (Exon 5) 254 TGENFDRQASLRRSLIYTDTLVRRPKKVKRRKTITGVPDNIQKEL 298
NHSL2 (Exon 5) 266 TGQQFDKHASLRHSLFNTETAVNPKSTLRRRRTIIGFSNFSQRDQ 310
Homology domain 5
NHS (Exon 6 ) 818 SISFRKPKAKPTPPKRSSSLRK 839
NHSLl (Exon 6 ) 739 NISLKKAKKPPLPPSRTDSLRR 760
NHSL2 (Exon 6 ) 571 SISLRKAKKKPSPPTRSVSLVK 592
Homology domain 6 : :  * ’ :
NHS (Exon 6 ) 972 SRATTPSLPSVDNEFK-LASPEKLAGLASPSSGYSSQSETPTSS 1014
NHSLl (Exon 6 ) 897 SRATMPQVPGGSVKPK-IMSPEKSHRVISPSSGYSSQSNTPTAL 939
NHSL2 (Exon 6 ) 695 SRATTPSQLSIEVEAREISSPGRPPGIMSPSSGYSSQSETPTPT 738
Homology domain 7
NHS (Exon 6 ) 1027 GGSKRKPKVPERKSSL 1042
NHSLl (Exon 6 ) 953 GKGKPKPKVPERKSSL 969
NHSL2 (Exon 6 ) 753 SSVRVRPWPERKSSL 768
Homology domain 8
NHS (Exon 7-8) 1418 RTTEDLFAVIHRSKRKVLGRKDSGDMS 1444
NHSLl (Exon 7-8) 1428 RTTEDLFAAIHRSKRKVLGRRDSDDDH 1454
NHSL2 (Exon 7-8) 1102 RTTEDLFTVTHRSKRKLLGWKEPGSGS 1128
Homology domain 9
NHS (Exon 8 ) 14 93 NEEFKLLLLKKGSRSDSSYRMSATEI LKS 1521
NHSLl (Exon 8 ) 14 93 SDNFKALLLKKGSRSDTSARMSAAEMLKN 1521
NHSL2 (Exon 8 ) 1137 NDDFKALLQKKGSKATPRSRPSAAELLKT 1165
Figure 5.5 Alignment of NHS, NHSLl, and NHSL2 protein sequences.
Amino acids 100 % conserved are highlighted in red. Homology domains 1-9 can be seen schematically 
in figure 5.6. Protein sequences for NHSLl and NHSL2 are shown in appendix A.
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Figure 5.6 Schematic representation of the regions of homology between the NHS protein family.
Positions of homology domains 1-9 (HD 1-9) within NHS, NHSLl, and NHSL2 are shown. NHSL3 was found to only contain parts of homology domains 1, 5, 6 and 7.
Note, homology domain 9 in NHS and NHSLl was found to reside in the exact same location. Please refer to figures 5.5 and 5.10 for more detail of the homology domains
between the members of the NHS protein family.
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NHS
NH SLl
NHSL2
9 7 2  SRATTPSLPSYDNEFK-LRSPEKLAGLASPSSGYSSQSETPTSSFPTAFFSGPLSP— GGSKRKPKVPERKSSL 1 0 4 2  
8 9 7  SRATMPQYPGGSYKPK-1MSPEKSHRYXSPSSGYSSQSNTPTALTPVPVFTKSVSPflHGKGKPKPKVPERKSSL 9 6 9  
6 9 3  SR flTTPSQ LSIEY EflR EISSPG R PPG IM SPSSG Y SSQ SETPTPTV SM SLTIG H IPPPSSSV RV R PW PER K SSL 7 6 6
V  JY
Highly conserved 
m otif used as q u ay
I
TBLASTN algorithm performed at Ensembl Human 
(http://www.ensembl.org/Homo_sapiens/index.html)
I
Qiery: l
SPSSGYSSQS TPT 
Sbjct: 1 3 5 1 1 1  SPSSGYSSQSGTPT 1 3 5 1 5 2
SPSSGYSSQSETPT 14
Figure 5.7 Identification of NHSL3.
The highly conserved sequence motif SPSSGYSSQSXTPT within NHS, NHSLl, and NHSL2 was used 
as query sequence to search for additional family members. Homology with human mRNA AB040955
mapping to lp35.1 was identified.
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Human mRNA AB040955 contains a complete open reading frame spanning 7 coding 
exons and encoding a 1035 amino acid protein. AB040955 forms part of UniGene 
cluster Hs.528659, containing numerous mRNA and EST sequences derived from 
various tissues such as the eye, brain, lung, colon, kidney, liver, heart, mammary gland, 
and tongue. The gene prediction (referred to from here on as NHSL3) supported by 
various mRNA’s and EST sequences at this genomic interval, has a similar genomic 
structure to the rest of the NHS gene family (figure 5.8). NHSL3 is predicted to consist 
of 9 coding exons of which three are alternative 5’ exons (figure 5.8). Exon 3 of the 
NHSL3 is spliced out in one of the potential isoforms. To date no 5’ exon sharing 
homology with the 5’ exon (exon la) far upstream of exon 2 of the NHS, NHSLl, and 
NHSL2 genes, has been identified in NHSL3. In addition, only one exon (the 3’ 
terminal exon) is located downstream of the large exon 6 equivalent of the other NHS 
gene family members.
Figure 5.8 NHSL3 genomic structure.
Blackened squares indicate the open reading frame (ORF), with sizes o f coding portions given below.
Genomic structure not to scale.
The genomic structures and their chromosomal locations are summarised in figure 5.9.
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NHSL3 (1p35.1) NHSLl (6q24.1)
NHSL2 (Xq13.1)NHS (Xp22.13)
Figure 5.9 Genomic structure, chromosomal localisation, and alternative transcripts of members of the NHS gene family.
Genomic structures not to scale.
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Homology between all members of the NHS gene family identified (NHS, NHSLl, 
NHSL2, and NHSL3) at the protein level is shown in the alignment in figure 5.10. 
Homology between NHSL3 and the rest of the NHS protein family is weakest, with 
NHSL3 being the most similar to NHSLl (22 % identity over 1272 aa). NHSL2 and 
NHSL3 were found to be 23 % identical over 894 aa, whilst the homology between 
NHS and NHSL3 was even lower (23 % over 309 aa). Table 5.2 summarises the level 
of identity between each of the NHS family proteins, whilst figure 5.11 shows a 
preliminary phylogenetic tree for the NHS protein family.
Within Exon 2 of NHS/NHSL1 /NHSL2/NHSL3 (homology domain 1)
NHS 212 NIFLPATRPPCVEELHRHARQSLQALRR 239 
190 147
NHSLl NVFLPTTRPPCVEDLHRQAKLNLKSVLR
NHSL2 118 NVFLSSGRPPSVEELLREAQLNLQSLLQ 145
NHSL3 48 NVFFPSGRPPHLEELHTQAQEGLRSLQH 75
-sir •  ie •  •  •  -k • ★  * *  J  # ★  j  j  j  •
Within Exon 6 of NHS/NHSL 1/NHSL2/NHSL3 (homology domain 5)
NHS 818 SISFRKPKAKPTPPKRSSSL 837
NHSLl 739 NISLKKAKKPPLPPSRTDSL 758
NHSL2 571 SISLRKAKKKPSPPTRSVSL 590
NHSL3 429 SVSLRKLKRPPPPPRRTHSL 448 
. * . . * * * ** * . * *
(homology domain 6)
NHS 999 SPSSGYSSQSETPTSS 1014
NHSLl 924 SPSSGYSSQSNTPTAL 939
NHSL2 723 SPSSGYSSQSETPTPT 738
NHSL3 520 SPSSGYSSQSGTPTLP 535 
* * * * * * * * * *  * * *
(homology domain 7)
NHS 1 0 2 6 PGGS— KRKPKVPERKSSL 10 4 2
NHSLl 9 5 1 PANGKGKPKPKVPERKSSL 9 6 9
NHSL2 7 5 0 PPSSSVRVRPWPERKSSL 768
NHSL3 5 4 6 P---- GKAQPPKPERVTSL
* : :* ** ★ : * *
5 6 0
Figure 5.10 Partial Alignment of NHS, NHSLl, NHSL2, and NHSL3 protein sequences 
highlighting conserved domains within the family.
Note, the majority of conserved domains in figure 5.5 are lost when the NHSL3 protein sequence is 
included. Homology domains 1, 5-7 can be seen schematically in figure 5.6. Protein sequences for 
NHSLl, NHSL2, and NHSL3 are shown in appendix A.
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Protein NHS NHSLl NHSL2 NHSL3
NHS 100 % 28%(474/1694)
25%
(364/1454)
23%
J71/309)
NHSLl 28%(474/1694) 100 %
23%
(368/1599)
22%
(280/1272)
NHSL2 25%(364/1454)
23%
(368/1599) 100 %
23%
(206/894)
NHSL3 23%(71/309)
22%
(280/1272)
23%
(206/894) 100 %
Table 5.2 Summary of the level of identity between each of the NHS protein family members.
The number of identical residues over a given stretch o f amino acids is shown in brackets.
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Figure 5.11 A phylogenetic tree of the NHS protein family
The length o f each pair o f branches represents the distance between sequence pairs, while the units at the 
bottom o f the tree indicate the number of substitution events. The dotted line on the phenogram indicates 
a negative branch length, a common product o f averaging
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Following the identification of the NHS family of proteins in Homo sapiens, the 
possibility that N H S L l, NHSL2, and NHSL3 may also reside within other species was 
investigated. In this study, the genome of Mus musculus was analysed for potential 
NHSLl, NHSL2, and NHSL3 orthologs. Using each of the protein sequences for 
NHSLl, NHSL2, and NHSL3 in Homo sapiens as query, BLAST was performed. 
Perhaps not surprisingly, orthologs for each NHSLl, NHSL2, and NHSL3 were 
identified in Mus musculus. An N H SL l, NHSL2, and NHSL3 ortholog were identified 
on chomosomes 10qA3, XqC3, and 4qD2.2, respectively. Each of these chromosomal 
regions are syntenic with the corresponding Homo sapiens chromosomal bands in 
which the N H SL l, NHSL2, and NHSL3 genes reside. For each of the Mus musculus 
N H SLl, NHSL2, and NHSL3 genes, a number of mRNAs were found in the database 
supporting the expression of each of these genes. Unigene cluster Mm. 158390 
supported the expression of N H SL l, with mRNAs derived from embryonic cerebellum, 
eye, thymus, kidney, and mammary gland. Exons 1, lb, 2-4, and 6-8 of the Nhsll gene 
were found to be expressed (figure 5.12).
Expression of exons 1, lb, lc, and 2-8 of the Nhsl2 gene were confirmed by mRNA 
sequences from whole brain, liver, pancreas, kidney, and ear, and formed UniGene 
cluster Mm.336186 (figure 5.12). Expression of the Mus musculus Nhsl3 gene was 
supported by four mRNAs representing four different isoforms of Nhsl3 (figure 5.12). 
Unigene cluster Mm331907 represented Nhsl3, with cDNAs derived from whole brain, 
ganglia, cortex, intestine, stomach, liver, pancreas, eye, heart, respiratory system, 
thymus, mammary gland, muscle, bladder, kidney, skin, endocrine system, and ear. 
Translation begins in exon 4 of isoform 1, and in exons lb, lc, and Id of isoforms 2, 3, 
and 4, respectively (figure 5.12). Sizes of exons 2, 3, 5, and 7 are identical between 
Homo sapiens and Mus musculus. The genomic structures for the Mus musculus N hsll, 
Nhsl2, and Nhsl3 genes are represented in figure 5.12, whist an phylogenetic tree 
summarising orthologous and paralogous relationships between the NHS protein family, 
is shown in figure 5.13.
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Nhsll (10qA3)
289 bp 202 58 153 128 193 132
bp bp bp bp bp bp
3288 bp 133 733 bp
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Nhsl2 (XqC3)
i  lii i i  ■ ! ■  ■■
282 bp 69 156 128 196 171 2274 bp 133 322 bp
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Figure 5.12 Predicted genomic structures of the Nhsll, Nhsl2, and Nhsl3 genes in Mus musculus.
Exons are numbered with respect to the corresponding human genes. EST/cDNA hits are depicted below 
the corresponding genomic structures. Genomic structures not to scale.
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Family ancestor
NHS , NHSLI^ NHSL2 NH^
Last common ancestor
Hs. Mm. 
88 % identity 
(1442/1633)
Hs. Mm.
76 % identity 
(1290/1692)
Hs. Mm.
82 % identity 
(1006/1225)
Hs. Mm. 
80 % identity 
(834/1037)
Figure 5.13 A phylogenetic tree illustrating the orthologous and paralogous relationship between
the NHS family of proteins.
Each of the four branches denotes the descendants of the four ancestral genes (NHS, NHSL1, NHSL2, 
and NHSL3) in Homo sapiens (Hs.) and Mus musculus (Mm.). Percentage identity between orthologs is 
indicated below each of the four branches, with the number of identical residues over a given stretch of
amino acids shown in brackets.
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5.2.2.1 Expression of the NHS gene family
To confirm and compare expression of the NHS family of genes (with the exception of 
NHSL3, which was only recently identified), exons 6-8 of NHS, NHSL1, and NHSL2 
were amplified from a human fetal multiple tissue cDNA (MTC) panel (BD 
Biosciences, figure 5.14). Primers were designed (section 2.2.2) to amplify from exon 
6-7 of each of the NHS, NHSL1, and NHSL2 genes (table 5.3). Amplification across 
intron 6 of each of the NHS, NHSL1, and NHSL2 genes, controlled for genomic DNA 
contamination of the human fetal cDNA panel. Amplification of NHS, NHSL1, NHSL2 
from cDNA was predicted to result in PCR fragments of 268 bp, 212 bp, and 347 bp, 
respectively. Amplification of NHS, NHSL1, and NHSL2 from contaminating genomic 
DNA was anticipated to result in product sizes of 590 bp, 762 bp, and 1807 bp, 
respectively. Amplification of the NHS gene was also previously described in section
4.2.2.1.2.
Gene Primer Sequence (5’-3’) Tm°C Amplicon size (bp)
NHS NHScDNA6F TGCCTGGTACTATCAGCTATG 64 268NHScDNA7R TCCTCAGTTGTTCGAGGTTTG 62
NHSL1 NHSLlcDNA6F AGCAGAGTGGAAGCCAATGTC 62 212NHSLlcDNA7R ACCTCATCATTCCCGTCTTCC 62
NHSL2 NHSL2cDNA6F AAGGCAAGATTCCACCTCCC 62 347NHSL2cDNA7R ATCTTCAGTTGTGCGTGAAGC 62
Table 5.3 Primer sequences used to amplify the NHS, NHSL1, and NHSL2 genes in a human fetal
cDNA panel.
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NHS
NHSL1
NHSL2
602 bp —
310 bp 
271/281 bp
872 bp 
602 bp
234 bp 
194 bp
1,358 bp
602 bp 
310 bp
< - 5 9 0  bp 
< - 2 6 8  bp
< -  762 bp
< - 2 1 2  bp
1807 bp
347 bp
Figure 5.14 Expression analysis of NHS, NHSL1, and NHSL2 in a human fetal cDNA panel.
Primers were designed to amplify exon 6 -  8 of each of the NHS, NHSL1, and NHSL2 genes; +ve, 
genomic DNA control; -ve, no DNA control. Products were resolved on a 2 % (w/v) agarose gel.
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As described previously (section 4.2.2.1.2), NHS was found to be expressed in human 
fetal brain, thymus, lung and kidney. NHSL1 and NHSL2 appear to be much more 
widely expressed and were detected in all 8 tissues of the human fetal multiple tissue 
cDNA (MTC) panel (figure 5.14).
5.2.3 Discussion
NHS orthologs were identified through bioinformatic analysis, in Canis fam ilaris , Mus 
musculus, Rattus norvegicus, Pan Troglodytes, Pongo pygm aeus, Gallus gallus, Bos 
Taurus, Xenopus laevis, Danio rerio, and Tetradon nigroviridis. The NHS protein is 
highly conserved across species (87-95 %) for which a full length Homo sapiens NHS 
isoform A, protein sequence was determined (Canis fam ilaris , Mus musculus, Rattus 
norvegicus, and Pan Troglodytes). The level of conservation between NHS and the 
partial orthologous sequences identified in Pongo pygm aeus , Gallus gallus, Bos Taurus, 
Xenopus laevis, Danio rerio, and Tetradon nigroviridis, ranges from 39-99 %.
The genomic structure for all the predicted full length NHS orthologs (Canis fam ilaris , 
Mus musculus, Rattus norvegicus, and Pan Troglodytes) was deduced and found to be 
conserved (figure 5.2). Each of these orthologs (except for Pan Troglodytes, which is 
currently missing exon 5) have been found to contain all of the 8 coding exons of NHS 
isoform A (figure 4.9), although expression data to support these predicted exons in the 
different species is only partially available for Mus musculus. However, some of the 
available mRNA sequences for Mus musculus does support the presence of an Exon 3b, 
which forms part of isoforms C and E of the NHS gene. Exon sizes for the 5 orthologs 
(Homo sapiens, Canis fam ilaris , Mus musculus, Rattus norvegicus, and Pan 
Troglodytes) are identical for exons 2, 3, 4, 5, and 7 (except for exons 2 and 5 of Pan 
Troglodytes). An exon 5 equivalent in Pan Troglodytes has not yet been identified, 
which may be a result of incomplete genomic sequence. Further, exon 2 appears to be 
larger compared to its orthologs. The size of exon 2 in Pan Troglodytes is most likely to 
be an error in the genomic sequence as exon 2 was found to be the most highly 
conserved exon across species at the protein level. The large (over 2.9 kb) exon 6 
exhibits the greatest variability in size and sequence amongst species (figures 5.1 and
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5.2), although the size of exon 6 is identical between primates (Homo sapiens and Pan 
Troglodytes) and between rodents (Mus musculus and Rattus norvegicus). Since the 
genomic structures of Canis familaris, Mus musculus, Rattus norvegicus, and Pan 
Troglodytes are only predictions with little or no supporting mRNAs or ESTs, 
individual exon sizes may prove to be identical across all species with the possible 
exception of the largest exon, exon 6.
Together, the expression data presented in chapter 4 of this thesis (detailing the presence 
of NHS in fetal tissue) and the conservation of the NHS protein across species, supports 
a role for the NHS protein in development.
The most interesting NHS ortholog identified to date, and the only ortholog for which 
there is EST and mRNA data to support its expression, is the mouse (Mus musculus) 
Nhs protein. The Xcat mouse is believed to be a disease model for either CXN and/or 
NHS due to the similarities in the lens phenotype between CXN, NHS and Xcat. 
Further, the Xcat mutation has been mapped to an interval on the mouse X chromosome 
syntenic with Xp22 (to which the CXN and NHS loci are mapped). In light of this, the 
mouse (Mus musculus) Nhs gene is an excellent candidate gene for Xcat. Full 
characterisation of the mouse Nhs gene may elucidate additional exons not currently 
identified in the human NHS gene. Such newly identified exons could then be screened 
in the CXN family and any NHS families for which a mutation in the NHS gene has not 
been identified. An advantage of looking for disease genes in mouse models is the 
possibility of using tissue to compare the level of expression of candidate genes 
between, for example, control and Xcat mice. If the Xcat mouse results from a mutation 
in some regulatory sequence of the Nhs gene, then notable differences in the expression 
of Nhs between Xcat and control mice should be detected.
Following the identification of NHS orthologs, the human NHS gene was found to form 
a new gene family through the discovery of three NHS paralogs, NHSL1, NHSL2, and 
NHSL3. Residing on chromosome 6q24.1, NHSL1 was the first of the three paralogs 
identified (figure 5.9). NHS shares 28 % protein sequence identity with the predicted 
NHSL1 protein, 25 % sequence identity with NHSL2, and 23 % with NHSL3 (table
5.2). The genomic structure of NHS, NHSL1, NHSL2, and NHSL3 are highly similar,
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providing further support that NHSL1, NHSL2, and NHSL3 are paralogs of the NHS 
gene.
Initial pile up analysis of the NHS, NHSL1, and NHSL2 protein sequences highlighted 
conserved domains across the NHS family. One such conserved domain (sequence 
motif, SPSSGYSSQSXTPT) led to the identification of the NHSL3 gene (figure 5.7). 
A second alignment of all four protein sequences (NHS, NHSL1, NHSL2, and NHSL3), 
highlighted fewer conserved domains amongst the NHS protein family, with the 
SPSSGYSSQSXTPT motif being the most highly conserved (only amino acid 
designated X differs between each of the four members of the NHS protein family). 
Therefore, the sequence motif SPSSGYSSQSXTPT must play a crucial role in the 
function of the NHS protein family. Initial bioinformatic analysis of this sequence 
motif (SPSSGYSSQSXTPT) has not provided any clues as to its potential function. 
Other conserved domains amongst NHS, NHSL1, and NHSL2 (figure 5.5), may also be 
of significant importance to the function of this protein family and should be 
investigated further.
Initial phylogenetic analysis of the NHS family of proteins revealed NHS and NHSL2 
to be the most closely related (figure 5.11). Both NHS and NHSL2 are located on the X 
chromosome at Xp22.13 and Xql3.1, respectively. NHSL1 appears to have resulted 
from a duplication event prior to the duplication event of NHS, which resulted in 
NHSL2.
Interestingly, the NHS and NHSL1 genes lie on paralogous duplicated chromosomal 
intervals on Xp22 and 6q24, highlighted by the presence of the paralogs REPS1 and 
REPS2, which reside telomeric to NHS and NHSL1 respectively. Thus, the 
chromosomal region on Xp22 harbouring NHS and REPS1, arose from duplication of 
the chromosomal region 6q24 (containing NHSL1 and REPS2), or vice versa. The 
NHSL3 protein and its gene on chromosome lp35.1 is the most distantly related of the 
NHS family.
Based on preliminary investigation into the NHS gene family, it would appear that NHS, 
NHSL1, NHSL2, and NHSL3 are not confined to Homo sapiens. As one might expect, 
all four members of the NHS gene family were also identified in Mus musculus. It is
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clear therefore, that the NHS gene family did not arise solely from gene duplication in 
the Homo sapiens lineage following divergence of primates and rodents. Thus, the 
common ancestral gene of the NHS gene family existed prior to the last common 
ancestor of primates and rodents. Duplication of the common ancestral gene for the 
NHS gene family therefore resulted in paralogous genes prior to the last common 
ancestor of rodents and primates, which went on to become progenitors of the primate 
and rodent lineages. Subsequently, each NHS gene family member in Homo sapiens 
and Mus musculus is a paralog of each of the remaining NHS gene family members in 
both species. For example, the NHS gene in Homo sapiens is a paralog of NHSL1, 
NHSL2, and NHSL3 in both Homo sapiens and Mus musculus, and is an ortholog of the 
NHS gene in Mus musculus. Since only four NHS gene family members (NHS, NHSL1, 
NHSL2, and NHSL3) have been identified in Homo sapiens and Mus musculus, it would 
appear that evolution from the last common ancestor of both lineages has been of 
vertical inheritance only.
Expression analysis of the NHS, NHSLJ, and NHSL2 in a human fetal cDNA panel, 
revealed NHSL1 and NHSL2 to be more widely expressed (transcripts were detected in 
all eight of the fetal tissues tested), whilst expression of NHS was only detected in fetal 
brain, kidney, lung, and thymus.
Combining the preliminary expression data of NHS, NHSL1, and NHSL2 in this thesis 
with the knowledge that each of these proteins arose from gene duplication prior to the 
common ancestor of Homo sapiens and Mus musculus and that the sequence is well 
conserved between these species, all members of the NHS family of proteins are likely 
to play key roles in development. This is likely for NHSL3, as available mRNA data 
supporting its expression are derived mainly from embryonic tissues.
The rodent lineage split 12 to 24 million years ago into separate lines that gave rise to 
the rat and mouse, whereas primates and rodents diverged around 80 million years ago. 
Since all four NHS family members were identified in humans and mice, all four 
members are likely to be present in rat and other primates such as the chimpanzee. It 
will be important to determine how far back in evolutionary terms, the four members of 
the NHS protein family (NHS, NHSL1, NHSL2, and NHSL3) go. For example, the 
WAVE (WASP family verprolin homologous) proteins involved in regulating actin
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dynamics, are present as 3 members (WAVE 1-3) in mammals. In Drosophila however, 
only one WAVE homolog (Scar) is currently known (Bear et al., 1998). Paralogs 
generally perform distinct biological functions, albeit through the same mechanism. 
Understanding in more detail the mechanisms through which the NHS protein acts may 
shed light on the roles of the remaining NHS family members.
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- Chapter Six -
Functional analyses of the NHS protein
6.1 Introduction
To date, five potential transcripts for the human NHS gene have been identified from 
databases (figure 4.9), which are predicted to encode proteins of 1,630 aa (isoform A), 
1,335 aa (isoform B), 1,474 aa (isoform C), 1,453 aa (isoform D), and 1,473 aa (isoform 
E). All isoforms differ in the 5’ exon except for isoforms C and D, which differ by the 
alternative splicing of exon 3b (present in isoform C). Apart from the differing 5’ exon 
between the isoforms, all (with the exception of isoform B), contain exons 2-8 of the 
NHS gene (figure 4.9). Translation of the NHS protein in isoform B has been predicted 
to start in exon 4 at the first methione and continue through exons 5-8 (Burdon et al., 
2003). It should be noted, however, that there are currently no published experimental 
data demonstrating protein expression of any isoform in any tissue or cell type.
Burdon and colleagues reported no significant homology between the NHS protein and 
any other protein or class of proteins. The only sequence motifs identified in NHS 
(Burdon et al., 2003) were four potential monopartite nuclear localisation signals (NLS) 
at amino acid positions: 371-379 (RRRKLRRRK), 438-444 (PSRRRIR), 822-825 
(RKPK), 1026-1034 (PGGSKRKPK).
As the function of the NHS protein is currently unknown, homologies and functional 
clues were sought through bioinformatic analysis as detailed in this chapter. A 
powerful approach to identifying any potentially significant domains came from
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identifying the NHS paralogs, NHSL1, and NHSL2 (section 5.2.2). Alignment of the 
protein sequences of NHS, NHSL1, and NHSL2 (figure 5.5) highlighted conserved 
domains, which were used to perform BLAST algorithms against the NCBI database. 
Importantly, this resulted in the identification of sequence similarity at the protein level 
of NHS, NHSL1, and NHSL2 with the WAVE homology domain, WHD (also referred 
to as the SCAR homology domain, SHD; figure 6.1).
This chapter describes protein similarities identified and strategies carried out to address 
their significance. An anti-NHS peptide antibody was raised and characterised for use 
in immunocytochemistry experiments and competitive actin polymerisation assays were 
conducted to test the potential function of identified domains within the NHS protein.
6.2 Results
Monopartite NLS motifs are characterised by a cluster of around five basic residues. 
The putative monopartite nuclear signals identified in NHS (Burdon et al., 2003) are 
conserved across species (this thesis, figure 5.1) and the monopartite motif residing at 
amino acid position 822-825 in NHS is quite well conserved between NHS, NHSL1, 
and NHSL2 (this thesis, figure 5.5).
Bipartite nuclear localisation signals are characterised by the presence of two adjacent 
basic amino acids (Arg or Lys), a spacer of any 10 residues followed by at least three 
basic residues in the five positions after the spacer region. In this thesis, analysis of the 
NHSL1, NHSL2, and NHSL3 proteins identified potential bipartite nuclear localisation 
signals at amino acid positions 265-281 (NHSL1, RRSLIYTDTLVRRPKKV), 63-79 
and 54-75 (NHSL2, RRTDSLYRRTVRLRRRL and RRORSKSISLRKAKKKP. 
respectively; see appendix A). No bipartite nuclear localisation signals have been 
identified in NHSL3 at present. Predicted amino acid sequences for NHSL1, NHSL2, 
and NHSL3 are shown in appendix A.
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6.2.1 Homology to the Wiskott Aldrich Syndrome (WASP) 
family of proteins
6.2.1.1 The WAVE homology domain, WHD
Through in silico analysis, identity shared between the N-termini of NHS, NHSL1, and 
NHSL2 (coded for by exons la-2) and the WHD of the WAVE proteins, was identified 
by BLAST analysis using the amino acid sequences of NHS, NHSL1, and NHSL2 as 
query. Within the WHD the NHS protein contains an intervening amino acid sequence 
(amino acids 22-119, figure 6.1, table 6.1) coded by exon 1, with no similarity to the 
WHD, which contains a number of proline residues (25 % proline). The potential 
importance of the putative WHD in the NHS protein is highlighted not only by the 
conservation between the paralogs but also the N-terminus of NHS is highly conserved 
amongst its orthologs (74 % identity from amino acids 1-219; figure 5.1).
The high proline content (amino acids 22-119) of the NHS protein is present in all full- 
length NHS protein orthologs identified (figure 5.1). The level of conservation over this 
stretch of amino acids (22-119) however, is lower when compared with the remainder of 
the putative NHS WHD (amino acids 1-21 and 119-219, figure 5.1). The high proline 
content is not present at the N-terminus NHSL1 or NHSL2, although NHSL1 does 
contain a proline-rich region (38 % proline over 145 amino acids, see table 6.1) in the 
centre of its full-length protein sequence. To date, no proline-rich region has been 
identified in NHSL2.
Proteins known to contain a WHD also have proline-rich regions. The WHD has been 
described in the WAVE (WASP family Verprolin homology protein; Suetsugu et al., 
1999) family of proteins (also called SCAR and WASF, section 1.11). WAVE proteins 
1, 2 and 3 are part of a larger family of proteins called the WASP family, which also 
includes WASP and N-WASP, as discussed in chapter 1.11. Members of this family 
have a conserved C-terminal region consisting of a proline-rich segment, one or two 
WASP homology 2 domains (WH2, also known as Verprolin homology
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Family Protein Size (a.a.) Domain and position
WH1 Basic GBD Proline rich WH2 Central/Acidic WHD Alanine rich Serine rich
WASP WASP 502 38-144 225-249 237-250 312-421 431-447 465-502 - - -
N-WASP 505 34-138 165-181 203-216 277-392 405-422
433-450
466-505 - - -
WAVE1 559 - 173-206 - 275-492 497-514 526-559 1-165 - -
NHS NHS 1630 - 364-387 - 22-119 1418-1438 545-615
665-704
1-219* 88-133 1440-1629
NHSL1 1683 - 265-285 - 999-1143 1428-1448 1512-1558 1-127 - 967-991
NHSL2 1189 - 564-586 - - 1102-1122 339-407 1-126 - 664-814
NHSL3 1035" - 144-169 - 447-1006 - 301-368 - - 328-440
Table 6.1 Domain organisation of the WASP and NHS protein families.
♦Also contains the high proline content within the WHD of NHS at amino acids 22-119 inclusive
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domain), a central basic motif and an acidic region (table 6.1 and figure 6.2, section
1.11). The N-terminus of these proteins differ, with WASP and N-WASP both 
containing a WASP homology I (WH1) region and a GTPase binding domain (GDB; 
figure 6.2). In contrast, WAVEs share a WHD at the N-terminus (table 6.1 and figure
6.2).
It is interesting to note that the protein sequence of NHS, NHSL1 and NHSL2 that share 
sequence homology with the WHD are expressed only within isoform A of the NHS 
gene (figure 4.9) and most likely within only one isoform of the NHSL1 and NHSL2 
genes. Isoform A also appears to be the major isoform responsible for disease in 
Nance-Horan syndrome patients (as discussed in chapter four).
Until recently no function had been attributed to the WHD of the WAVE proteins. New 
evidence has shown that the WHD can act as a binding domain for the Abelson 
Interactor (Abi) protein family (Echarri et al., 2004; Leng et al., 2005, section 1.13). 
The putative WHD in NHS was therefore examined for key amino acid residues which 
are conserved across species in the Abi-binding domain of the WAVE protein family. 
Of the ten key amino acid residues spanning the Abi-binding domain of the WAVE 
protein family (figure 6.1), five are completely conserved amongst the NHS protein 
family (figure 6.1). The remaining five amino acids are substituted with residues that 
are highly similar in their biochemical properties (figure 6.1), implying that a potential 
Abi-binding domain may exist within the putative SHD of the NHS protein family 
(NHS, NHSL1, and NHSL2).
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WAVE 1 1 MPLVKRNIDPRHLCHTALPRG 21 22 IKNELECVTH-ISLANIIRQLSSLSKYAEDIFGELFNEAH 60
WAVE 2 1 MPLVTRNIEPRHLCRQTLPS- 20 21 VRSELECVTN-ITLANVIRQLGSLSKYAEDIFGELFTQAN 59
WAVE 3 1 MPLVKRNIEPRHLCRGALPEG 21 22 ITSELECVTN-STLAAIIRQLSSLSKKAEDIFGELFNEAN 60
NHS 1 MPFAKRIVEPQWLCRQRRPAP 21 120 LMLDLCAVSN-AALARVLRQLSDVARHACSLFQELESDIQ 158
NHSL1 1 MPFHQRTLEPARL RRPEA 18 28 LFRSLEQVSS-HALGCLLAQLADLSRCAGDIFGELEGQAA 66
NHSL2 1 MPF YRRTWPQRLCP-RNPPQ 20 21 QLAELRDVSHLAALS-LLRQLADLCGHSLALLEDLEGHLL 59
I  QL L r  L
« •  • • • • • • • • • • • • • • •
WAVE 1 61
WAVE 2 60
WAVE 3 61
NHS 159
NHSL1 67
NHSL2 60
SFSFRVNSLQERVDRLSVSVTQ-LDPK EEELSLQDITMRKAF RSSTIQDQQLFDRKTL 117
TFASRVSSLAERVDRLQVKVTQ-LDPK EEEVSLQGINTRKAF------RSSTIQDQKLFDRNSL 116
NFYIRANSLQDRIDRLAVKVTQ-LDST— -VEEVSLQDINMKKAF------KSSTVQDQQWSKNSI 117
LTHRRVWALQGKLGGVQ-RVLSTLDPK-QEAVPVSNLDIESKLSVYY----RAPWHQQRNIFLPATR 219
ALGHRTAALHRRLDA1QAAAAR-LDHR-RVKIPVSNLDEESRWTVHY----TAPWHQQENVFLPTTR 127
ALGRRTDSLYRRTVRLRRRLPCRLLGPEEDRBRT.GAANSG-RENATATAHSRSSWRQPVNVFLSSGR 125 
R L R L
★ t ★ • • ★ • • •
Figure 6.1 Alignment of the N-termini of NHS, NHSL1, and NHSL2 with the WHD of the WAVE protein family.
Amino acids highlighted in red are conserved; blue residues are completely conserved in the WAVEs and in at least one of the NHS family proteins. Green residues indicate 
amino acids present in at least one WAVE protein and at least one NHS protein family member. Those residues highlighted in pink underneath are conserved in mammalian
WAVEs, Drosophila SCAR, and Dictyostelium SCAR. The Abi binding domain is underlined.
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Figure 6.2 Comparison of the domain organisation of the WASP protein family with the NHS
protein family.
Note: The WASP protein family and their domains are drawn roughly to scale with respect to one 
another, as are the NHS protein family. However, comparison of the WASP protein family with that of 
the NHS protein family is not to scale. Amino acid positions and size of each of die above domains in 
both the WASP and NHS protein family are shown in table 6.1.
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6.2.1.2 The WCA (WASP-homology, central region, acidic region) 
domain
Identification of homology to the WHD of the WAVE proteins prompted a thorough 
search for other possible domains shared between the WASP protein family and the 
NHS family. Using the SIM alignment tool at ExPASy (section 2.7.4), the NHS protein 
was aligned with the WCA (WASP-homology, central region, acidic region) domain of 
the various WASP family proteins (section 1.11). A stretch of approximately 40 amino 
acids of the NHS protein (NHS CA1 amino acids 670-709) was found to align 
uninterrupted with the central (C) and acidic (A) regions of N- WASP (figure 6.3).
A tryptophan residue in the CA domain that has been reported to be conserved amongst 
members of the WASP family and is though to be essential for binding the Arp2/3 
complex (Marchand et al., 2001, section 1.10), was conserved within this putative NHS- 
CA1 domain (figure 6.3). The conserved tryptophan residue in NHS is preceded by a 
number of acidic residues (aspartic and glutamic acid, and asparagine) and several 
serine residues. Aspartic and glutamic acid residues constitute a large portion of the 
acidic region preceding the conserved tryptophan residue in proteins of the WASP 
family. In addition, WAVE proteins also contain a number of serine residues in the 
acidic domain. The acidic domain appears to be variable in length and content (figure
6.3).
Within the central (C) region of all known Arp2/3 activators (except cortactin) lies a 
conserved arginine residue (R477 in WASP) that is also conserved within this stretch of 
40 amino acids of the NHS protein (figure 6.3). The central region in members of the 
WASP protein family also contains conserved long-chain aliphatic residues such as 
Leucine, Isoleucine and Valine (figure 6.3). Together with the conserved arginine 
residue, these aliphatic residues have been reported to form a sequence motif that 
interacts with the Arp2/3 complex leading to its activation (Panchal et al., 2003). The 
putative central region in NHS (NHS CA1 670-688) also contains the conserved leucine 
residue, which when mutated abolishes the ability of an Arp2/3 activator to activate the 
Arp2/3 complex (figure 6.3, Panchal et al., 2003).
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WAVE3-Hum 471
WAVE2-Hum 4 65
WAVE1-Hum 528
N-WASp-Hum 4 68
WASp-Hum 4 67
SCAR-Dros 578
ACTA-Lis-Mono 138 
RICKA-Rconorii 443 
BEEl-Sacch 4
CORTACTIN-Hum ____
Central Acidic
GNDVATILSRRIAVE Y SD------------------------------------ SDDDSEFDENDWSD 502
GNDVATILSRRIAVEYSD---------------------------------- SEDDDSSEFDEDDWSD 4 98
ENDVATIL S RRI AVE Y S D------------------------------------ SEDDSEFDEVDWLR 559
VGALMEVMQKRSKAIHSS------------------------------ DEDEDEDDEEDGEDDDEWED 505
VGALMHVMQKRSRAIHSS--------------------------------DEGE DQAGDEDE DDEWDD 502
PLDVASILARRVAIE LSE SEDSDSEDDSEGWME 607
PSDSAAEIKKRRKAIASSD 158 33 DSEDSSLNTDEWEE 46
L S GLE SIFARRAVIKVS DSSSSESDSGNWSD 473
LNSSDKEIIKRALPKAS NK11 DVT VARL YI AY P DKNEWQ Y 43
___ 1 MWKASA---------------------------------------GHAVSIAQDDAGADDWET 24
NDHLDKVRGHRANSFTST------------------------------ VADLLDDPNNSNTSDSEWNT 709
LHSPQHKLSERGRSRLSRMAAD-SGSCDISSNSDTFGSPIHCISTAGVLLSSHMDQKDDHQSSSGNWSG 615
AAEMLKNT D PRFQRS RSE------------------------ PSPDAPESPSSCSPSKNRRAQEEWAK 1558
HGRVAVGQDARFPSLTSPVLRTPSSEPDEPHQARSGPNPPGMESMGMVYSVPSSCNGPTESTFSTSWKG 407 
DWALGRCSLRTLSRCSL HSASPASVRSLGRFSSVSSPQPRSRHPSSSSDTWSH 368
NHS, CAl-Hum 670
NHS, CA2-Hum 548
NHSLl-Hum 1518
NHSL2-Hum 339
NHSL3-Hum 315
Figure 6.3 Multiple protein alignment of the central and acidic regions (CA) for known activators of the Arp2/3 complex with the NHS protein family
Lis-Mono = Listeria monocytogenes, Sacch = Saccaromyces cerevisiae, RConorii = Rickettsie conorii. Key amino acids within the CA domains, which are highly conserved
are highlighted in red.
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A second putative CA domain was also identified within the NHS protein (NHS CA2 
amino acids 545-615). By comparison with the first CA domain identified in NHS, 
however, it is less conserved with the WASP protein family CA domains (figure 6.3). 
Both CA domains in NHS are highly conserved across species, with the tryptophan and 
arginine being 100 % conserved (figure 5.1).
The SIM alignment tool at ExPASy was used to identify potential central/acidic (CA) 
regions in NHSL1, NHSL2, and NHSL3 (section 2.7.4). Putative CA domains were 
identified in each protein at amino acid positions 1512-1558, 339-407, and 301-368, 
respectively (table 6.1, figures 6.2 and 6.3). The putative CA domains in the NHS 
protein family are not conserved amongst one another, however all of them do contain 
the essential conserved tryptophan and arginine residues found in Arp2/3 activators.
6.2.1.3 The actin binding domain of the WASP protein family
(WASP homology domain 2, WH2)
The presence of potential WHD and CA domains in the NHS protein family led to a 
search for putative actin binding domains, in particular the actin-binding (WH2) 
domains present in the WASP protein family (section 1.11). The SIM alignment tool at 
ExPASy was used to align the WH2 domain of the WASP protein family with the 
protein sequences of the NHS protein family. This resulted in alignment of the WH2 
domain in the WASP protein family with a highly conserved domain in the NHS protein 
family (except NHSL3, figure 6.4). This region in NHS lies within a stretch of 29 
amino acids (SPN K PR T T E D L FA V IH R SK R K V L G R K D SG ) over which there is 90 % 
identity across species (amino acids 1412-1440, figure 5.1).
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NWASP WH2a ALLDQI RQGIQL-KS
NWASP WH2b ALLDQI REGAQL-KK
WASP ALLDQI RQGIQL-NK
WAVE1 VLLEAI RKGIQL-RK
WAVE 2 DLLSAI RQGFQL-RR
WAVE 3 DLLAAI RMGIQL-KK
NHSL1 DLFAAIHRSKRK— VLGRR
NHS DLFAVIHRSKRK— VLGRK
NHSL2 DLFTVIHRSKRK— LLGWK
Figure 6.4 Alignment of the WH2 domain in the WASP protein family with the NHS protein
family.
Note, no alignment to NHSL3 could be obtained. Amino acids highlighted in red are completely 
conserved. Blue residues are found in at least one member of each family (WASP and NHS).
6.2.1.4 Additional dom ains w ithin the NH S protein fam ily
The homologies identified between the WASP protein family, in particular the WAVE 
subfamily, and the NHS protein family are striking and imply that the NHS protein 
family are functionally related to the WAVE subfamily. In addition to the WHD 
domain, WH2 domain, and the central and acidic domains, the WASP protein family 
have a basic region at their N-terminus (table 6.1 and figure 6.2, section 1.11). A 
GTPase binding domain also resides within the protein sequence of WASP and N- 
WASP, but is absent in the WAVE protein subfamily (figure 6.2, section 1.11). 
Analysis of the NHS protein family using the ExPASy database (section 2.7.4) of 
protein families and domains (prosite: http://ca.expasy.org/prosite/) revealed basic 
regions within each of the NHS family proteins (table 6.1 and figure 6.2). The basic 
region, like the WAVE subfamily, is located N-terminally in NHS, NHSL1 and 
NHSL3, and towards the centre of the NHSL2 protein. No potential GTPase binding 
domain was found in the NHS protein family strengthening the idea that they are more 
closely related to the WAVE subfamily rather than WASP and N-WASP.
Through the prosite database (section 2.7.4), an alanine rich region was identified 
within the WHD of the NHS protein (table 6.1 and figure 6.2) but is absent in the rest of 
the NHS protein family members. Furthermore, a serine rich region (25 % serine) was 
found in each of the NHS protein family members, which varies in size from 189 aa in 
NHS to 24 aa in NHSL1 (table 6.1 and figure 6.2). Such serine rich domains are absent 
from the WASP protein family.
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6.2.2 Characterisation of an anti-NHS antibodies
6.2.2.1 G eneration o f an anti-N H S antibodies
Polyclonal antisera were raised against a synthetic peptide derived from the C-terminus 
of the NHS protein (figure 6.5), which is present in all NHS isoforms (figure 4.9) and is 
completely conserved across species (figure 5.1). The very C-terminus of NHS 
however, is not conserved amongst the NHS protein family. The NHS protein family 
C-termini differ between all four members. Peptide production, conjugation and 
generation of polyclonal rabbit anti-NHS antisera was provided commercially by Sigma 
Genosys, UK. The last 14 amino acids of the NHS protein (figure 6.5) were selected to 
generate an NHS peptide sequence. A cysteine residue was positioned at the N- 
terminus of the peptide sequence (CDGSPHDDRSSQSST) for conjugation with 
keyhole lympet hemocyanin (KLH, a carrier protein). Conjugation was achieved 
through MBS (3-maleimidobenzoic acid n-hydroxysuccinimide ester) chemistry, 
whereby the KLH carrier protein is conjugated via the thiol group on the cysteine. Two 
rabbits (SGI703 and SGI704) were immunised with the synthetic peptide, and the pre- 
immune and immune antisera provided by Sigma Genosys, UK.
MPFAKRIVEPQWLCRQRRPAPGPAVDASGGSAEPPPPLQPPGRRDLDEVEAPGPEEPARAVPAPSGLPPPPPPLPA 
PADQTQPPHGEASVAGEESTAGIPEAAPAAGEASSAAAAAAVLLMLDLCAVSNAALARVLRQLSDVARHACSLFQE 
LESDIQLTHRRVWALQGKLGGVQRVLSTLDPKQEAVPVSNLDIESKLSVYYRAPWHQQRNIFLPATRPPCVEELHR 
HARQSLQALRREHRSRSDRREQRAAAPLSIAAPPLPAYPPAHSQRRREFKDRHFLTSHPPEDEDTDVMLGQRPKNP 
IHNIPSTLDKQTNWSKALPLPTPEEKMKQDAQVISSCIIPINVTGVGFDREASIRCSLVHSQSVLQRRRKLRRRKT 
ISGIPRRVQQEIDSDESPVARERNVIVHTNPDPSNTVNRISGTRDSECQTEDILIAAPSRRRIRAQRGQSIAASLS 
HSAGNISALADKGDTMFTPAVSSRTRSRSLPREGNRGGDAEPKVGAKPSAYEEGESFVGDHERTPNDFSEAPSSPS
a q d h q p t l g l a c s q h l h s p q h k l s e r g r s r l s r m a a d s g s c d i s s n s d t f g s p i h c i s t a g v l l s s h m d q k d d h q s
SSGNWSGSSSTCPSQTSETIPPAASPPLTGSSHCDSELSLNTAPHANEDASVFVTEQYNDHLDKVRGHRANSFTST
VADLLDDPNNSNTSDSEWNYLHHHHDASCRQDFSPERPKADSLGCPSFTSMATYDSFLEKSPSDKADTSSHFSVDT
EGYYTSMHFDCGLKGNKSYVCHYAALGPENGQGVGASPGLPDCAWQDYLDHKRQGRPSISFRKPKAKPTPPKRSSS
LRKSDGNADISEKKEPKISSGQHLPHSSREMKLPLDFANTPSRMENANLPTKQEPSWINQSEQGIKEPQLDASDIP
PFKDEVAESTHYADLWLLNDLKTNDPYRSLSNSSTATGTTVIECIKSPESSESQTSQSESRATTPSLPSVDNEFKL
ASPEKLAGLASPSSGYSSQSETPTSSFPTAFFSGPLSPGGSKRKPKVPERKSSLQQPSLKDGTISLSKDLELPIIP
PTHLDLSALHNVLNKPFHHRHPLHVFTHNKQNTVGETLRSNPPPSLAITPTILKSVNLRSINKSEEVKQKEENNTD
LPYLEESTLTTAALSPSKIRPHTANKSVSRQYSTEDTILSFLDSSAVEMGPDKLHLEKNSTFDVKNRCDPETITSA
GSSLLDSNVTKDQVRTETEPIPENTPTKNCAFPTEGFQRVSAARPNDLDGKIIQYGPGPDETLEQVQKAPSAGLEE
VAQPESVDVITSQSDSPTRATDVSNQFKHQFVMSRHHDKVPGTISYESEITSVNSFPEKCSKQENIASGISAKSAS
DNSKAEETQGNVDEASLKESSPSDDSIISPLSEDSQAEAEGVFVSPNKPRTTEDLFAVIHRSKRKVLGRKDSGDMS
VRSKSRAPLSSSSSSASSITSPSSNVTTPNSQRSPGLIYRNAKKSNTSNEEFKLLLLKKGSRSDSSYRMSATEILK
SPILPKPPGELTAESPQSTDDAHQGSQGAEALSPLSPCSPRVNAEGFSSKSFATSASARVGRSRAPPAASSSRYSV
RCRLYNTPMQAISEGETENSDGSPHDDRSSQSST
Figure 6.5 Amino acid sequence of the NHS protein (isoform A).
Antisera to a C-terminal peptide (NHSC1, highlighted red) was raised in rabbit. The very C-terminus of 
NHS is present in NHS isoforms A-E and is completely conserved across species.
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6.2.2.2 Characterisation of anti-NHS antibody SGI703
In order to characterise the antisera, a GST-NHS fusion protein (NHSC1, figures 6.6 
and 6.7) containing the 201 amino acids C-terminal of NHS, was generated. Primers 
with engineered in frame restriction endonuclease sites were designed (section 2.2.2, 
table 6.2) to PCR amplify (section 2.2.1) a 607 bp fragment from exon 8 of the NHS 
gene using genomic DNA as template.
Gene Primer Sequence (5’-3’)
Annealing
temperature
(°C)
Amplicon 
size (bp)
NHS NHSC1F CGGG ATCCTCC AAG AGG AAAGTACTTG 63 607NHSC1R cg^ a a t t c t c t a t g t t g a a c t c t g g g a g 63
NHSClFseq TCCAAGAGG AAAGT ACTTG 55
NHSClRseq TCTATGTTGAACTCTGGGAG 55
Table 6.2 Primer sequences used to amplify a 607 bp fragment from exon 8 of the NHS gene.
Restriction endonuclease sites engineered into the primer sequences are highlighted in bold and 
underlined (GGATCC -  BamHI, GAATTC -  EcoRI).
After amplification of the 607 bp fragment, PCR products were double digested with 
BamHI and EcoRI (section 2.2.11) and ligated (section 2.3.1) into the pGEX-2T vector 
(pre-digested with BamHI and EcoRI).
Two clones containing the correct insert were identified (figure 6.6) and sequenced 
(section 2.2.10) to check for any PCR induced errors using internal primers 
(NHSClFseq/NHSClRseq, table 6.2). No sequence changes were identified in either of 
the two clones.
Following successful cloning of the C-terminus of NHS, expression of the GST-NHS 
fusion protein (NHSC1) was induced in JM109 cells (section 2.4.4.1). Total lysates of 
induced and uninduced cell cultures were resolved by SDS-PAGE (section 2.4.1), 
transferred to a nitrocellulose membrane (section 2.4.3), and immunoreactive bands 
detected using the immune, final bleed anti-sera from both rabbits (rabbit 1, SGI703 
and rabbit 2, SGI704). Primary antibodies were visualised using a goat anti-rabbit 
secondary antibody conjugated to horse radish peroxidase (1:30,000, Pierce, UK), and 
detected using the ECL Plus detection reagent (Amersham Biosciences). The predicted
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molecular weight of NHSC1 was 50.1 kDa. No immunoreactive band was observed 
corresponding to GST-NHSC1 with the immune anti-serum SG I704.
1,358 bp—  
1,078 bp—  
872 bp —
602 bp —
4948 bp 
(Linearized peEX-2T)
607 bp 
NHSC1 Insert
Figure 6.6 Double digest of pGEX-2T clones containing the NHSC1 fragment
The NHSC1 fragment (607 bp) was amplified using primer pair NHSC1F/NHSC1R and cloned into 
pGEX-2T. Two clones containing the correct insert were identified. M, molecular weight marker; 1,
clone 1; 2, clone 2.
In contrast SGI 703 detected an immunoreactive band of the predicted molecular weight 
(approximately 50 kDa, see arrow in figure 6.8) was detected (figure 6.8, B, section
2.4.3). Immunoreactive bands of approximately 50 kDa were detected in both the 
induced and uninduced cells, although a much stronger immunoreactive band was 
observed in the induced lanes at approximately 50 kDa (figure 6.8. B). This 50 kDa 
band was not detected by the pre-immune sera (figure 6.8, A).
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N-terminally tagged with GST 
N-terminally tagged with Myc
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Figure 6.7 NHS constructs generated.
Putative domains in NHS were cloned either into prokaryotic or mammalian expression vectors for subsequent functional analysis. Refer to table 1 in appendix B for more
detailed information on NHS constructs generated.
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A) B)
M M 1
kDa kDa
75 75
50
37
50
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25 25
20 20
Figure 6.8 Immunoblots of CHO cells transform ed with the NHSC1 construct as detected by
SG1703 immu noreactivity
A) Pre-immune sera: M, molecular weight marker; 1, 5 gl induced total lysate; B) Immune sera: M, 
molecular weight marker; 1, 5 jj.1 induced total lysate. Pre-immune and immune sera from rabbit 1
(SG1703) were used at 1:1000 dilution.
The specificity of the anti-NHS antibody SGI 703 was determined through peptide 
blocking of a specific band of approximately 170 kDa. detected through Western blot 
analysis of endogenous NHS in various cell lines (section 6.2.3.1). Anti-NHS antibody 
SGI703 was, therefore, used in subsequent experiments.
6.2.2.3 Im m unocytochem istry on transiently transfected CH O  cells
The specificity of the anti-peptide antisera SGI 703 was tested as mentioned above 
(section 6.2.2.2), and successful detection of recombinant protein on immunoblots, the 
antibody was subsequently used for sub-cellular localisation studies in transiently 
transfected CHO cells.
6.2.2.3.1 Generation of NHSC2
A cDNA (accession number CR936788) available through RZPD (Berlin, Germany) 
representing isoform D of the NHS gene and containing exons lc, 2, 3, and 4-8 (figure
4.9) was used as a template for cloning the NHSC2 construct (figure 6.7).
Primers with engineered restriction endonuclease sites for in frame cloning into pCMV- 
Tag3b, were designed (section 2.2.2, table 6.3) to PCR amplify (section 2.2.1) the C- 
terminal half of the NHS gene (exons 6-8, amino acids 471-1630, figure 6.7, table 1 in 
appendix B).
with NH SC2
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Gene Primer Sequence (5’-3’)
Annealing
temperature
(°C)
Amplicon 
size (bp)
NHS NHSC2F CGGGATCCACCATGTTTACTCCTGCAGTGAGCAG 57 3,496NHSC2R CGGAATTCTGGTACAGGCAGTCTATGTTGAACTC 57
NHSC2 Fb TGAAGCAGAGGGTGTGTTCG 55
7Fb TCGGAGTTGTCACTAAACACAG 55
NHSC2 Fc ATCCTCACTACAGCAACCCTC 55
NHSC2 Fd AAGACCAAGCATCTCTTTCAGG 55
NHSC2 Fe TGCCTGGTACTATCAGCTATG 55
NHSC2 Rb TCCTCAGTTGTTCGAGGTTTG 55
Table 6 3  Primer sequences used to amplify a 3,496 bp fragment from exon 6-8 o f the NHS gene.
Restriction endonuclease sites engineered into the primer sequences are highlighted in bold and 
underlined (GGATCC -  BamHI, GAATTC -  EcoRI).
Using the primers listed in table 6.3, a 3,469 bp fragment from exons 6-8 of the NHS 
gene (coding for the last 1,160 aa o f the NHS protein, amino acids 471-1630) was 
amplified and TA cloned into the pGEM-T Easy vector (section 2.3.4.1). Clones with 
the correct molecular weight insert were identified through restriction endonuclease 
digestion of minipreped DNA (section 2.3.3.1), and sequenced (section 2.2.10) using 
vector sequencing primers (M l3 forward and reverse) and internal sequencing primers 
to check for PCR induced errors.
Following confirmation of the correct sequence for NHSC2, the insert was released 
from the pGEM-T Easy vector through digestion with restriction endonucleases; Pvul, 
BamHI, and EcoRI. Since the molecular weight of the pGEM-T Easy vector (3,015 bp) 
and NHSC2 insert (3,496 bp) were similar, the pGEM-T easy vector was first cut with 
Pvul. The Pvul restriction endonuclease cut pGEM-T Easy at two sites. This resulted 
in the release of a 1,099 bp pGEM-T Easy vector fragment, leaving the NHSC2 insert 
and the remainder of the pGEM-T Easy vector (1,916 bp). Fragments from the digested 
clone were resolved on a 0.5 % (w/v) agarose gel (section 2.2.5.1) and the larger 
fragment containing the NHSC2 insert and the remainder o f the pGEM-T Easy vector, 
excised and purified (section 2.2.6). The purified fragment was digested (section
2.2.11) with BamHI and EcoRI (sites engineered into the NHSC2 primer sequences) to 
release the 3,496 bp NHSC2 insert (figure 6.9). The fragments resulting from this 
second, double digest were resolved on a 0.5 % (w/v) agarose gel (figure 6.9; section 
2.2.5.1) and the NHSC2 insert excised and purified (section 2.2.6).
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10 kbp _
2.5 kbp —
1.5 kbp —
Linearized 
pGEM-T Easy
1 kbp —
0.75 kbp —
0.50 kbp — |
Figure 6.9 Digested pGEM-T Easy/NHSC2 clone, resolved on a 0.5 %  (w/v) agarose gel.
M, marker; 1, release of the NHSC2 insert from pGEM-T Easy (pre-digested with Pvul) following
digestion with BamHI and EcoRI.
The excised, purified NHSC2 insert was then subcloned in frame (section 2.3), into a 
mammalian expression vector (pCMV-Tag3b) pre-digested with BamHI and EcoRI. 
Clones containing the correct insert were verified through digestion with BamHI and 
EcoRI.
6.2.23.2 Expression of the NHSC2 construct in CHO cells
Cloning of the NHSC2 insert into the pCMV-Tag3b vector with N-terminal Myc-tag 
allowed for expression of an NHSC2 construct (figure 6.7, table 1 in appendix B) and 
the C-terminal epitope for the anti-NHS antibody SGI703 described in section 6.2.2.1. 
The pCMV-Tag3b/NHSC2 construct was transiently transfected into CHO cells (section
2.5.5). Transfected cells were then fixed, permeabilised and stained (section 2.5.6) for 
NHSC2 expression using both SGI703, and a monoclonal antibody to the Myc tag 
epitope (mAb 9E10, Sigma-Aldrich, UK). Primary antibody binding was visualised 
using goat anti-rabbit Cy3 and donkey anti-mouse Cy2 for SGI703 and 9E10, 
respectively. Nuclei of the CHO cells were counterstained with DAPI (section 2.5.6). 
Images of transfected CHO cells with the Myc-NHSC2 construct were taken using a
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Zeiss LSM 510 confocal microscope (figure 6.10). Excitation wavelengths were, 354 
nm (DAPI), 488 nm (mAh 9E10), 543 nm (SG1703 Ab).
Expression was confirmed through detection of the Myc tag using mAB 9E10. SGI 703 
(section 6.2.2), but not the pre-immune antisera (data not shown), also detected 
expression of the Myc-NHSC2 construct in transiently transfected CHO cells (figure
6.10). Detection of the Myc-NHSC2 construct using SGI 703 revealed brighter staining 
on Myc positive cells only. Results from immunostaining with secondary antibody 
only, did not result in a signal (data not shown). From these studies, the NHSC2 
construct (amino acids 471-1630) appeared to be excluded from the nucleus (nuclei 
were counterstained with DAPI in figure 6.10).
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Anti-Myc Ab SGI 703 Ab Merge
Anti-Myc Ab SGI 703 Ab Merge
Figure 6.10 Immunofluorescent confocal microscopy of transiently transfected CHO cells with the
pCMV-Tag3b/NHSC2 construct.
Anti-NHS antibody SG I703 (1:1000 dilution) detected expression of Myc-NHSC2 in CHO cells. 
Expression was confirmed by detection of the myc tag with mAb 9E10 (1:1000 dilution). Panel A is of a 
lower magnification than panel B. Scale bars 10 pm.
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6.2.3 Localisation of NHS in metastatic rat mammary 
adenocarcinoma (MTLn3) epithelial cells
Anti-NHS antibody SGI 703 successfully detected NHS construct expression by 
immunocytochemistry (section 6.2.2.3) and western blot analysis (section 6.2.2.2) the 
sub cellular localisation of NHS in MTLn3 cells was investigated. MTLn3 cells have 
been used extensively for studying the actin cytoskeleton, including the localisation of 
the Arp2/3 complex with an anti-p34 subunit antibody (Bailly et al., 1999). Arp2/3 
localises at the leading edge of lamellipods in MTLn3 cells (Bailly et al., 1999, sections 
1.9 and 1.10), which can be easily stimulated through the use of epidermal growth 
factor (EGF).
The homology identified between the NHS family of proteins and the WASP family of 
proteins (section 6.2.1) has highlighted putative WH2 and CA domains within the NHS 
protein (figures 6.2, 6.3, and 6.4). The CA domain within the WASP family of proteins 
facilitates the binding to and activation of the Arp2/3 complex, whilst the WH2 domain 
binds G-actin bringing actin monomers into close proximity with the Arp2/3 complex. 
MTLn3 cells provided a useful tool, therefore, for studying the localisation of NHS due 
to the clarity visualising the actin cytoskeletal structures, and the Arp2/3 localisation 
studies previously carried out on these cells.
6.23.1 Detection of endogenous NHS through immunoblotting
A range of cell lines (CHO, COS-7, Caco-2, MDCK, and MTLn3) were cultured as 
described in section 2.5.1.1, and grown to confluency. The cells were then lysed and 
the cell lysates collected. Equal volumes of total cell lysates were then resolved by 
SDS-PAGE (section 2.4.1.1), blotted (section 2.4.3), and immunoreactive bands 
detected using anti-NHS antibody SGI703. A strong immunoreactive band of an 
apparent molecular weight of approximately 170 kDa was detected with SGI703 in all 
cell lines used in this study (figure 6.11). No immunoreactive band of the same size 
was detected with the pre-immune serum for each cell line. The predicted molecular 
weights of the NHS isoforms without any post-translational modifications were: 195.6 
kDa (isoform A), 160.2 kDa (isoform B), 176.9 kDa (isoform C), 174.4 kDa (isoform 
D), and 176.8 kDa (isoform E).
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The immunoreactive band detected with SGI703 (figure 6.11, indicated by the arrow) 
has an apparent molecular weight of approximately 170 kDa. It is unclear which NHS 
isoform this may represent (A to E) or if it represents a novel alternative isoform. To 
confirm the specificity of the SGI 703 antibody, peptide competition with SGI 703 was 
performed. SGI703 was incubated in the presence of 50 pg/ml of the NHS antigen 
peptide, for two hours at 4°C with end-on-end rotation (referred to from here as the 
peptide-blocked immune antiserum). Total cell lysates, from all five cell lines (CHO, 
COS-7, Caco-2, MDCK, and MTLn3) were resolved by SDS-PAGE (section 2.4.1.1), 
blotted (section 2.4.3), and immunoreactive bands detected using the peptide-blocked 
immune antiserum. The immunoreactive band running at approximately 170 kDa 
detected by the SG I703 antibody in each cell line, was found to be significantly reduced 
in intensity (figure 6.11, indicated by the arrow) in contrast to other inmmunoreactive 
bands (figure 6.11, indicated by the asterisks). This data strongly suggested that all five 
cell lines contain an isoform of endogenous NHS that migrates with an apparent 
molecular weight o f 170 kDa.
6.23.2 Immunolocalisation of NHS in MTLn3 cells
The Arp2/3 complex is recruited to the membrane of the extending lamellipod in 
MTLn3 cells following stimulation with epidermal growth factor (EGF; Bailly et al., 
1999). The homology between the NHS family of proteins and the WASP family of 
proteins (section 6.2.1) suggests that NHS may have a role in binding and activating the 
Arp2/3 complex. To test this hypothesis stimulated and unstimulated MTLn3 cells were 
immunostained for endogenous NHS.
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Figure 6.11 Immunoblotting of mammalian cell lysates with anti-NHS antibody SG1703
Red arrow indicates an immunoreactive band corresponding to NHS, migrating at an apparent molecular weight of 170 kDa. Note the intensity of the immunoreactive band 
corresponding to the NHS protein (indicated by the red arrow) is reduced following peptide competition in contrast to the remaining immunoreactive bands highlighted by 
red asterisks. CHO, Chinese hamster ovary; COS-7, Monkey African Green Kidney; Caco-2, Human Caucasian colon adenocarcinoma; MDCK, Dog cocker spaniel kidney;
MTLn3, Metastatic rat mammary adenocarcinoma.
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6.23.2.1 Immunofluorescent confocal microscopy of stimulated and 
unstimulated MTLn3 cells
MTLn3 cells were cultured in MEM alpha containing 5 % (v/v) fetal calf serum, in an 
atmosphere of 5 % CO2 at 37°C (section 2.5.1.1). Cells were seeded onto cover slips 
(section 2.5.7). Once approximately 70 % confluent, MTLn3 cells were starved in 
starvation media (serum-free MEM alpha/0.35 % (w/v) BSA) for a maximum of 3 hours 
before being stimulated for 3 minutes in the presence of EGF (section 2.5.7). 
Stimulated MTLn3 cells were then immediately fixed and stained (section 2.5.6.1) with 
either the anti-p34 subunit antibody or the anti-NHS antibody SGI703 and the pre- 
immune serum. Unstimulated MTLn3 cells were fixed and stained with the appropriate 
antiserum once they were approximately 70 % confluent. The actin cytoskeleton was 
visualised by staining with Alexa Fluor 488 phalloidin.
6.23.2.1.1 Localisation o f endogenous Arp2/3 complex
Figure 6.12 shows the immunofluorescent staining pattern observed for Arp2/3 in 
stimulated MTLn3 cells. Arp2/3 localised to the leading edge of the lamellipod, 
indicated by the arrows (figure 6.12 A and B), as previously reported (Bailly et al., 
1999). Alexa fluor 488 phalloidin labelling of the actin cytoskeleton revealed actin rich 
areas at the leading edge of lamellipods, along with stress fibres (figure 6.12, A and B). 
The p34 subunit of the Arp2/3 complex therefore, co-localised with actin at the leading 
edge of stimulated MTLn3 cells (figure 6.12 A and B). There did not appear to be any 
co-localisation of the p34 subunit with stress fibres (figure 6.12 A and B). Some 
cytoplasmic staining was also observed with the anti-p34 subunit antibody (figure 6.12 
A and B).
Unstimulated MTLn3 cells were also immunostained for endogenous Arp2/3 complex 
using the anti-p34 subunit antibody (figure 6.12, C). Immunostaining of the Arp2/3 
complex in unstimulated MTLn3 cells revealed a greater proportion of cytoplasmic 
staining in comparison to stimulated MTLn3 cells (figure 6.12, A-C). In addition, 
strong immunoreactivity was observed at membrane ruffles (indicated by arrows in 
figure 6.12, C).
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A)
Anti-p34 Ab Alexa Fluor 488 Phalloidin Merge
B)
Anti-p34 Ab Alexa Fluor 488 Phalloidin Merge
C)
Anti-p34 Ab Alexa Fluor 488 Phal lokii n Merge
Figure 6.12 Immunofluorescent confocal microscopy of stimulated and unstimulated MTLn3 cells
to detect endogenous Arp2/3
Anti-p34 subunit rabbit polyclonal antibody (1:50 dilution), detected expression o f  endogenous Arp2/3 in 
MTLn3 cells stimulated with EGF to form lamellipods. Labelling o f  the actin cytoskeleton with Alexa 
Fluor 488 phalloidin. Scale bars 10 pm. (A) Endogenous Arp2/3 localised to the leading edge of 
lamellipods in stimulated MTLn3 cells (arrows) (B) Higher magnification o f endogenous Arp2/3 at the 
leading edge o f lamellipods (arrows). (C) Anti-p34 subunit rabbit polyclonal antibody (1 :50 dilution) 
detected expression o f endogenous Arp2/3 in unstimulated MTLn3 cells. Arrows indicate membrane
ruffles
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The cell edge of unstimulated MTLn3 cells was devoid of any staining, consistent with 
the absence of lamellipodia (figure 6.12, C). Immunostaining with secondary antibody 
only, for both stimulated and unstimulated MTLn3 cells, had no signal (data not 
shown).
6.23.2.1.2 Localisation o f endogenous NHS
Localisation of endogenous NHS was investigated in stimulated and unstimulated 
MTLn3 cells (figures 6.13 and 6.14). SGI 703 immunoreactivity was detected in the 
nucleus of both stimulated and unstimulated MTLn3 cells (figures 6.13, A and B and
6.14). Staining of the nucleus was also observed with the pre-immune serum (figure
6.13, C) however, suggesting that this maybe non-specific.
Interestingly, in stimulated MTLn3 cells (figure 6.13, A and B) but not unstimulated 
MTLn3 cells (figure 6.14), NHS immunoreactivity was detected at the edges o f cells, 
which had formed a broad flat lamellipod. The staining pattern for NHS closely 
resembled that of the p34 subunit of the Arp2/3 complex (figure 6.12) at the leading 
edge of lamellipods (indicated by arrows in figure 6.13, A and B). Thus, endogenous 
NHS appeared to localise with actin and was similar to Arp2/3 complex staining at the 
leading edge of lamellipods. No immunofluorescence at the leading edge of 
lamellipods was observed with the pre-immune serum (figure 6.13, C).
Unlike the localisation pattern observed for the p34 subunit of the Arp2/3 complex in 
this study (figure 6.12), SG1703 decorated some actin stress fibres (figure 6.13, B and
6.14, B). Therefore, endogenous NHS appeared to be localised along some of the stress 
fibres (visualised with Alexa Fluor 488 Phalloidin) observed in stimulated MTLn3 cells 
(indicated by green arrows in figure 6.13, B). Co-localisation of NHS with stress fibres 
was also observed on occasion in unstimulated MTLn3 cells (indicated by arrows in 
figure 6.14, B). Decoration of stress fibres was not observed with the pre-immune 
serum (figure 6.13, C and 6.14, C).
Slightly less cytoplasmic immunoreactivity with SGI703 was observed in stimulated 
MTLn3 cells (figure 6.13, A and B) when compared to unstimulated MTLn3 cells 
(figures 6.14). This is analogous to the staining pattern observed for the p34 subunit of 
the Arp2/3 complex in stimulated and unstimulated MTLn3 cells (figures 6.12).
192
Chapter Six -  Functional analyses o f the NHS protein
The cell edge of unstimulated M TLn3 cells was devoid of any staining, consistent with 
the absence of lamellipodia (figure 6.12, C).
6.23.2.1.2 Localisation o f endogenous NHS
Localisation of endogenous N H S  was investigated in stimulated and unstimulated 
MTLn3 cells (figures 6.13 and 6.14). SGI 703 immunoreactivity was detected in the 
nucleus of both stimulated and unstimulated MTLn3 cells (figures 6.13, A and B and
6.14). Staining of the nucleus w as also observed with the pre-immune serum (figure
6.13, C) however, suggesting th a t this maybe non-specific.
Interestingly, in stimulated M TLn3 cells (figure 6.13, A and B) but not unstimulated 
MTLn3 cells (figure 6.14), N H S immunoreactivity was detected at the edges of cells, 
which had formed a broad fla t lamellipod. The staining pattern for NHS closely 
resembled that of the p34 subunit of the Arp2/3 complex (figure 6.12) at the leading 
edge of lamellipods (indicated b y  arrows in figure 6.13, A and B). Thus, endogenous 
NHS appeared to localise with ac tin  and was similar to Arp2/3 complex staining at the 
leading edge of lamellipods. No immunofluorescence at the leading edge of 
lamellipods was observed with th e  pre-immune serum (figure 6.13, C).
Unlike the localisation pattern observed for the p34 subunit of the Arp2/3 complex in 
this study (figure 6.12), SGI703 decorated some actin stress fibres (figure 6.13, B and
6.14, B). Therefore, endogenous NHS appeared to be localised along some of the stress 
fibres (visualised with Alexa F luo r 488 Phalloidin) observed in stimulated MTLn3 cells 
(indicated by green arrows in figure 6.13, B). Co-localisation of NHS with stress fibres 
was also observed on occasion in  unstimulated MTLn3 cells (indicated by arrows in 
figure 6.14, B). Decoration o f  stress fibres was not observed with the pre-immune 
serum (figure 6.13, C).
Slightly less cytoplasmic immunoreactivity with SGI703 was observed in stimulated 
MTLn3 cells (figure 6.13, A a n d  B) when compared to unstimulated MTLn3 cells 
(figures 6.14). This is analogous to  the staining pattern observed for the p34 subunit of 
the Arp2/3 complex in stimulated and unstimulated MTLn3 cells (figures 6.12).
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Alexa Fluor 488 Phalloidin Merge
Figure 6.13 Immunoflurescent confocal microscopy of endogenous NHS following stimulation of
lamellipod formation in MTLn3 cells
Anti-NHS antibody SGI 703 (1:1000 dilution), detected expression o f endogenous NHS in MTLn3 cells 
stimulated with EGF to form lamellipods. Staining of the actin cytoskeleton was achieved using Alexa 
Fluor 488 phalloidin. (A) Endogenous NHS localised at the leading edge of lamellipods in stimulated 
MTLn3 cells (B) Lower magnification of localised endogenous NHS to the leading edge of lamellipods in 
an MTLn3 cell. White arrows indicate localisation of NHS to the leading edge of the lamellipods. Green 
arrows highlight stress fibres. (C) Pre-immune serum for SGI703 (Pre-I, 1:1000 dilution) does not detect 
the leading edges of lamellipods. Scale bars 10 pm.
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Figure 6.14 Immunofluorescent confocal microscopy showing decoration of some actin fibres and 
localisation of NHS to membrane ruffles, in unstimulated MTLn3 cells
Anti-NHS antibody SGI 703 (1:1000 dilution) detected expression of endogenous NHS in unstimulated 
MTLn3 cells (A and B). Staining of the actin cytoskeleton was achieved using Alexa Fluor 488 
phalloidin. (A) Endogenous NHS localised to membrane ruffles (indicated by the arrows); (B) 
Endogenous NHS in unstimulated MTLn3 cells, highlighting co-localization with some actin fibres 
(indicated by the white arrows). (C) Pre-immune serum for SG1703 (Pre-I, 1:1000 dilution) does not 
detect actin stress fibres. Scale bars 10 pm. The non-specific background spots in B, are a result of the
Cy3 labelled secondary antibody.
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SGI 703 Ab Alexa Fluor 488 Phalloidin Merge
Figure 6.14 Immunofluorescent confocal microscopy showing decoration of some actin fibres and 
localisation of NHS to membrane ruffles, in unstimulated MTLn3 cells
Anti-NHS antibody SGI 703 (1:1000 dilution) detected expression of endogenous NHS in unstimulated 
MTLn3 cells. Staining of the actin cytoskeleton was achieved using Alexa Fluor 488 phalloidin. (A) 
Endogenous NHS localised to membrane ruffles (indicated by the arrows); (B) Endogenous NHS in 
unstimulated MTLn3 cells, highlighting co-localization with some actin fibres (indicated by the white 
arrows). Scale bars 10 pm. The non-specific background spots in B, are a result of the Cy3 labelled
secondary antibody.
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Localisation of endogenous NHS to the leading edge of lamellipods in stimulated 
MTLn3 cells (figure 6.13, A and B) was confirmed by generating a phase contrast 
image in parallel to imaging localised endogenous NHS in stimulated MTLn3 cells 
(figure 6.15). The very edges of stimulated MTLn3 cells were clearly defined using 
phase contrast (figure 6.15), and indeed confirmed endogenous NHS localisation at the 
leading edges of lamellipoda in stimulated MTLn3 cells.
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Phase contrast Merge
Figure 6.15 Confocal microscopy of endogenous NHS in stimulated MTLn3 cells with defined
leading edges
SGI 703 (1:1000 dilution) detected expression o f endogenous NHS in MTLn3 cells stimulated with EGF 
to form lamellipods. Staining o f the actin cytoskeleton was achieved using Alexa Fluor 488 phalloidin. 
Phase contrast o f  the same field defines the edges o f stimulated MTLn3 cells. White arrows indicate 
localisation o f NHS to the leading edge o f lamellipods. Scale bars 10 pm.
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6.2.4 Functional analysis of the putative CA domains in NHS
6.2.4.1 Introduction
Actin polymerisation requires the formation of stable nuclei (the lag phase), followed by 
rapid addition of actin monomers to the nuclei (the elongation phase; Pollard et al., 
2000, section 1.9). The Arp2/3 complex alone has very weak intrinsic actin nucleation 
ability. However, when activated, the Arp2/3 complex reduces the lag phase by 
increasing the rate of stable nucleus formation, and increases the rate of the elongation 
phase. Together, this results in an increase in the rate of actin polymerisation.
The identification of a putative actin binding domain (WH2) in the NHS protein implies 
that NHS may interact with actin. The pyrenyl actin polymerisation assay is a suitable 
experiment for testing whether a protein interacts with actin.
The pyrenyl actin polymerisation assay is a very sensitive method for determining if a 
protein activates the Arp2/3 complex. Actin was conjugated to pyrene through a 
covalent bond at the cysteine at 374 position (Cytoskelton, US). As a result, the 
incorporation of pyrene-conjugated actin monomers into an actin filament can enhance 
fluorescence up to twenty-fold and be detected using a spectrophotometer. Thus, the 
ability of a protein to activate the Arp2/3 complex (thereby increasing the rate at which 
actin is polymerised) can be determined by an increase in fluorescence over time. There 
are numerous examples of nucleation promoting factors that bind and activate the 
Arp2/3 complex in the literature (e.g. Welch et al., 1998, Machesky et al., 1999; 
Rohatgi et al., 1999), many of which were determined in part through the use of this 
actin polymerisation assay. A recent example in which the RickA protein (section
1.12.5) was shown to be a weak activator of the Arp2/3 complex compared with ActA 
and the WCA domain of N-WASP, is shown in figure 6.16.
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Figure 6.16 Pyrenyl-actin polymerisation assay
An example o f activation o f the Arp2/3 complex by the WCA domain o f N-WASP, ActA, and RickA, 
resulting in an increased rate o f  actin polymerisation. Adapted from Gouin et al., 2004.
The WASP protein family members are typical examples of nucleation promoting 
factors that have been tested for their ability to activate the Arp2/3 complex via the 
pyrenyl actin polymerisation assay. Indeed the WASP-WCA domain is a commonly 
used positive control in actin polymerisation assays. Both the WASP-WCA and the N- 
WASP-WCA are potent activators of the Arp2/3 complex. The V region binds actin 
monomers, whilst the CA region binds and activates the Arp2/3 complex. Binding of 
the WCA domain to an actin monomer and the Arp2/3 complex results in the actin 
monomer being brought into close proximity with the Arp2, and Arp3 subunits, serving 
as a nucleus for actin filament formation (Kelleher et al., 1995; Machesky and Insall, 
1998; Marchand et al., 2001).
The putative WH2 and CA domains of the NHS protein (section 6.2.1) are not 
contiguous like that of the WASP protein family. In order to test whether the putative 
CA domains (CA1 and CA2) of the NHS protein are functional, a competitive pyrenyl- 
actin polymerisation assay was carried out. If the putative CA domains of NHS proved 
functional, then the presence of such domains in an assay containing the Arp2/3 
complex and WASP-WCA domain, would lead to competition between the NHS-CA 
domain(s) and the WASP-WCA domain for the Arp2/3 complex. Such competition 
would be predicted to result in a decreased rate of actin polymerisation.
198
Chapter Six -  Functional analyses of the NHS protein
6.2.4.2 Results
6.2.4.2.1 Cloning, expression, and purification of the CA domains of NHS
Primers were designed (section 2.2.2, table 6.4) with engineered inframe restriction 
endonuclease sites to PCR amplify (section 2.2.1) the putative CA domains (CA1 and 
CA2) in NHS from genomic DNA. Amplicons were then TA cloned (section 2.3.4) into 
pGEM-T Easy. Clones were sequenced (section 2.2.10) to determine no PCR errors 
had been introduced from the amplification step. Clones with the correct insert 
sequence were then subcloned into pGEX-2T (section 2.3.4.2) in order to generate N- 
terminally tagged GST fusion proteins (figure 6.17). pGEX-2T clones containing the 
correct insert were confirmed through double digests (section 2.2.11) of miniprep DNA 
(section 2.3.3.1) resolved on a 0.5 % (w/v) agarose check gels (section 2.2.5). Clones 
with the correct insert and no sequence errors were then selected for subsequent 
expression of the GST fusion protein (section 2.4.4).
Gene Primer Sequence (5’-3’)
Annealing
temperature
(°C)
Amplicon 
size (bp)
NHS NHS-CA1 F CGGGATCCAGCAGCTCCACGTGCCC 59
NHS-CA1 R CGGAATTCGTAATTCCACTCACTGTCAC 59
j  J  /
NHS-CA2 F CGGGATCCGTTGGCGCTAAACCCTCAG 59 266NHS-CA2 R CGGAATTCCCCACTCCAGTTGCCACT 59
Table 6.4 Primer sequences used to amplify the putative NHS CA1 and CA2 domains. Restriction 
endonuclease sites engineered into the primer sequences are highlighted in bold and underlined 
(GGATCC -  BamHI; GAATTC -  EcoRI).
JM109 competent cells were transformed with the NHS-CA1 and NHS-CA2 constructs 
(section 2.3.2). Transformed cells were then induced to express the GST-fusion 
proteins (section 2.4.4). Total cell lysates, supernatant, and pellet fractions were then 
resolved by SDS-PAGE (section 2.4.1.1) and the protein bands visualised with 
coomassie brilliant blue (section 2.4.2) in order to determine the expression and relative 
solubility of the GST fusion proteins (figures 6.18, A). The molecular weight of the 
two fusion proteins were predicted to be 36.7 kDa and 39.9 kDa for NHS-CA1 and 
NHS-CA2, respectively (see appendix B, table 1). Both the NHS CA1 and CA2 fusion 
proteins were found to be soluble with little or no protein detected in the pellet fraction. 
The GST fusion proteins were then purified by glutathione sepharose
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Figure 6.17 NHS constructs generated throughout this research project.
Putative domains in NHS were cloned either into prokaryotic vectors for subsequent functional analysis. Refer to table 1 in appendix B for more detailed information on the
NHS constructs generated
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affinity chromotography (section 2.4A.2) for use in pyrenyl actin polymerisation assays 
(figures 6.18, B).
GST-NHS-CA1 was purified with little degradation during the purification process 
(figure 6.18, B). The majority of the GST-NHS-CA1 fusion protein was eluted in the 
first fraction. Purification of GST-NHS-CA2 however showed that the protein was 
subject to degradation. Since the GST moiety was N-terminal to the putative NHS CA 
domains, it was likely that the GST-NHS-CA2 fusion protein was being cleaved from 
the C-terminal end resulting in partial loss of the CA2 domain and in particular the 
conserved tryptophan residue residing in the acidic domain. An attempt to repeat the 
purification step of the GST-NHS-CA2 fusion protein resulted in similar degradation 
despite measures to reduce proteolytic activity (section 2.4.4.2). Therefore, only the 
purified NHS-CA1 protein was used for competitive actin polymerisation assays.
JM109 cells were also transformed with empty pGEX-2T (section 2.3.2) and expression 
of GST alone was induced (section 2.4.4) and purified (section 2.4.4.2) for use as a 
negative control in subsequent experiments.
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Figure 6.18 Coomassie brilliant blue® stained SDS PAGE gels showing expression and purification
of NHS CA1.
(A) Induced GST-NHS CA1 expression: Lane 1) empty pGEX-2T expressing GST, induced total cell 
lysate 2) Empty pGEX-2T, uninduced total cell lysate; 3) Induced GST-NHS CA1 expression (total cell
lysate).
(B) Purification of GST-NHS-CA1. 1) Total cell lysate, 2) Supernatant, 3-5) Eluted fractions 1-3.
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6.2.4.2.2 P yrenyl-actin  polym erisation  assay
The pyrenyl-actin polymerisation assay was carried out as described in section 2.6. 
Actin assembly kinetics exhibit an initial lag phase corresponding to the kinetic barrier 
to nucleation, followed by a rapid linear phase. It is during the latter stage that actin 
filaments elongate through the addition of actin monomers (section 1.9). When in the 
presence of the Arp2/3 complex and an Arp2/3 complex activator, the lag phase is 
reduced and the rate of polymerisation increased, as shown in figure 6.19, A (compare 
the actin only curve with that of the WASP-WCA (100 nM) with actin and the Arp2/3 
complex). A GST-WASP-WCA fusion protein was obtained from Cytoskelton Inc. for 
use as a positive control.
Initial results from the pyrenyl-actin polymerisation assay (section 2.6) in which the 
WASP-WCA domain and putative NHS CA1 domain were allowed to compete for 
binding to the Arp2/3 complex, were promising (figure 6.19, A). This experiment was 
conducted in the presence of 1 % (w/w) pyrene-labelled actin. The initial lag phase in 
the competitive assay compared to that of the WASP-WCA was extended and the rate 
of the elongation phase reduced slightly. The total amount of polymerised actin over 
the same time period between the competitive assay and the non-competitive assay was 
found to differ (compare the plateaus of each curve, figure 6.19, A). The total amount 
of polymerised actin was reduced in the competitive assay despite the original 
concentration of actin in each assay being equal. This may be explained by the presence 
of the WASP-WCA domain in the competitive assay, which is unable to bind the 
Arp2/3 complex due to the potential competition for binding by GST-NHS-CA1. Free 
WASP-WCA may be removing the total amount of free actin monomers from the assay 
through its actin-binding domain. Therefore, the rate of elongation was reduced due to 
the reduction in available Arp2/3 complex, which was bound to the NHS-CA1 domain, 
and the total amount of polymerised actin reduced due to the removal of free actin 
monomers from the reaction. The same affect would presumably be observed upon 
decreasing the concentration of Arp2/3 complex in the assay. Since the NHS-CA1 
protein does not contain an actin-binding domain, any
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Figure 6.19 Pyrenyl-actin polymerisation assays.
Labelled pyrene actin with either:
(A) Actin alone (1 % (w/w) labelled, blue), or Arp2/3 complex (13 nM) + WASP-WCA (100 nM, blue), 
or Arp2/3 complex (13 nM) + WASP-WCA (100 nM) + NHS CA1 (100 nM, red)
(B) Actin alone (5 % (w/w) labelled, blue), or Arp2/3 complex (13 nM) + WASP-WCA (100 nM, 
brown), or Arp2/3 complex (13 nM) + WASP-WCA (lOOnM) + NHS CA (100 nM, green), or Arp2/3
complex (13 nM) + WASP-WCA (100 nM) + NHS CA (250 nM, purple).
(C) Actin alone (5 % (w/w) labelled, blue), or Arp2/3 complex (13 nM) + WASP-WCA (100 nM, 
brown), or Arp2/3 complex (13 nM) + WASP-WCA (lOOnM) + GST (100 nM, light blue), or Arp2/3
complex (13 nM) + WASP-WCA (100 nM) + NHS CA1 (250 nM, mustard yellow).
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Arp2/3 complex bound to the NHS-CA1 domain would be unavailable for binding 
WASP-WCA in this assay.
As the WASP-WCA domain is a potent activator of the Arp2/3 complex, it was the last 
component to be added to the competitive assay (i.e. after the addition of the Arp2/3 
complex and NHS-CA1) to allow time for the NHS-CA1 domain to bind the Arp2/3 
complex. Interestingly, as the WASP-WCA domain is such a potent activator of the 
Arp2/3 complex, one might expect the WASP-WCA domain to eventually displace any 
Arp2/3 complex bound NHS-CA1 and, therefore, result in the same total amount of 
polymerised actin, but with a slower and longer elongation step. The resulting 
experimental curve may therefore imply that the potential NHS-CA1 domain binds the 
Arp2/3 complex with an affinity that is not easily displaced by the WASP WCA 
domain.
Following the results obtained from this initial competitive assay, a dose response 
competitive assay was performed to determine how increasing amounts of the NHS- 
CA1 domain, against a constant WASP-WCA domain concentration, affected the lag 
phase, elongation phase, and total amount of actin polymerisation. The amount of 
labelled actin used in subsequent assays was changed from 1 % (w/w, as used in the 
previous assay described above) to 5 % (w/w) following optimisation of the assay. 
Consequently, the Y-axis scale of subsequent graphs (figure 6.19, B and C) differs to 
the that of the previous graph (figure 6.19, A).
In this second competitive assay the initial lag phase and elongation phase, although 
reduced compared to WASP WCA alone, were the same for both concentrations of 
NHS-CA1 (figure 6.19, B). The total amount of polymerised actin was further reduced 
with increasing concentration of NHS-CA1 (in this particular case, a 2.5 fold increase in 
NHS-CA1 concentration, figure 6.19, B). This implied that less Arp2/3 complex was 
available for the WASP-WCA domain to bind at the higher concentration of NHS-CA1 
due to NHS-CA1 sequestering the Arp2/3 complex.
To ensure that the observed affect was due to the NHS-CA1 domain and not an 
experimental artefact, a second assay was designed in which GST alone was placed in
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the assay with the WASP-WCA domain and the Arp2/3 complex (figure 6.19, C). The 
same affect observed in the competitive assay of WASP-WCA and NHS-CA1, was seen 
in this assay with WASP-WCA and GST alone (compare figures 6.19, B and C). It 
would appear, therefore, that the observed affect was a result of the GST moiety and not 
the NHS-CA1 domain. In particular, GST fusion proteins have the potential to 
dimerise, which may affect the actin assay as the WASP-WCA domain was also GST 
bound. However, GTS tagged-proteins have routinely been used in these assays and in 
one case the GST moiety was found to enhance the ability of the WAVE 1-WCA 
domain to activate the Arp2/3 complex compared with His-tagged WAVE 1-WCA 
(Yamaguchi et al., 2002). Another explanation maybe that a contaminant present in the 
purified NHS-CA1 and GST purified fractions had an effect on this very sensitive actin 
polymerisation assay. Overall, determining whether the NHS-CA1 domain was 
functional by competitive assays will require further development.
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6.2.5 Discussion
Little was known about the potential function of the NHS protein following its 
identification in Nance-Horan syndrome. Burdon and colleagues (2003) identified four 
putative monopartite nuclear localisation signals (NLS) at amino acid positions: 371- 
379 (RRRKLRRRK), 438-444 (PSRRRIR), 822-825 (RKPK), 1026-1034 
(PGGSKRKPK), but reported no significant homology to any known protein or class of 
protein (Burdon et al., 2003).
Despite there being no report of a potential function for the NHS protein (Burdon et al., 
2003), Katoh and Katoh (2004) published a report detailing homology identified 
between the NHS and NHSL1 proteins, and the Drosophila Gukh (guanylate-kinase 
holder) protein. Katoh and Katoh sought human homologs of the gukh gene, which 
encodes an adaptor protein bringing together the Drosophila proteins Dig (Disc large) 
and Scrib (Scribble). Dig and Scrib are implicated in the establishment and 
maintenance of epithelial polarity (Johnson and Wodarz, 2003; Tanentzapf and Tepass, 
2003; Humbert et al., 2003). The homology between Drosophila Gukh and the NHS 
family members, NHS and NHSL1, is quite low. Five regions of homology were 
identified, of which three reside within the homology domains 2, 6, 7 and 9 (figures 5.5 
and 5.6) of the NHS protein family. Whether the homology identified implies that NHS 
and NHSL1 share some domains with the Gukh protein will need to be determined.
Through bioinformatic analysis of the protein sequences of the NHS family described in 
this thesis, in particular NHS, NHSL1, and NHSL2, homology to the WASP protein 
family was identified.
The role of the WASP protein family in regulating the actin cytoskeleton is currently a 
vibrant area of research, especially since WASP was shown to activate the Arp2/3 
complex (Machesky and Insall, 1998). The WASP protein family form two subgroups: 
WASP and N-WASP, and WAVE1-3.
The NHS protein family (except NHSL3) share homology at the N-terminus with the 
WHD of the WAVE proteins. At the time of identifying a potential WHD in the NHS 
protein family, little was known about WHD function in the WAVE proteins. Recently,
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two reports have been published describing the WHD as a binding domain for the Abi 
protein family (Echarri et al., 2004; Leng et al., 2005). The critical residues for 
mediating binding to the Abi protein family were mapped within the WHD, through a 
series of binding experiments in which WAVE1 deletion mutants were used (Echarri et 
al., 2004; Innocenti et al., 2004). Abil has been implicated in the translocation of 
WAVE1 and WAVE2 to the leading edge of motile cells (Echarri et al., 2004; Innocenti 
et al., 2004), through binding the WHD in the WAVE proteins. Furthermore, the 
Arp2/3 complex is localised to the leading edge of motile cells (Bailly et a l,  1999), thus 
Abil may translocate the WAVE1 and WAVE2 proteins to the leading edge of motile 
cells bringing these nucleation promoting factors into the vicinity of the Arp2/3 
complex, resulting in localised actin polymerisation at the leading edge.
The Abi-binding domain within the WHD of the WAVEs contains a number of residues 
conserved across species. These residues are either conserved across the NHS protein 
family or are substituted by amino acids with similar chemical properties (figure 6.1). 
The putative WHD in the NHS protein is also highly conserved across species (figure
5.1). Thus, from preliminary analysis, it would appear that NHS, NHSL1, and NHSL2 
may contain an Abi-binding domain. Whether or not this potential Abi-binding domain 
in the NHS protein family is functional remains to be determined. To date, no WHD 
has been identified in NHSL3. NHSL3 appears to be the most distantly related.
In addition to a putative WHD in the NHS protein family, proline rich regions were 
found to reside in all members of the NHS protein family except NHSL2. The length of 
the proline rich regions in the NHS protein family varies considerably from a stretch of 
559 amino acids in NHSL3 at its C-terminus (figure 6.2 and table 6.1), to 65 amino 
acids at the N-terminus of NHS (figure 6.2 and table 6.1). The proline rich region of 
NHS resides within the potential WHD, just prior to the putative Abi-binding domain. 
NHSL1 contains a proline rich region towards its C-terminus, spanning 144 amino 
acids. Proline rich domains are present in all members of the WASP protein family and 
are reported to bind SH3 domain containing proteins such as Grb2/Ash, Nek, and WISH 
(Carlier et al., 2000; Fukouka et al., 2001; Rohatgi et al., 2001). Additional SH3 
domain containing proteins such as Grb2/Ash, Nek, and WISH, are known to regulate 
the activity of N-WASP through its proline rich domain (Carlier et al., 2000; Fukouka 
et al., 2001; Rohatgi et al., 2001). In light of this, the proline-rich domains of the NHS
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protein family may bind SH3 domain containing proteins, which would regulate their 
function within the cell. Since the WAVE proteins bind profilin and the NHS protein 
family share sequence similarity with the WAVE proteins, it will be important to 
determine whether any of the NHS protein family members bind the SH3 domain 
containing protein profilin. Profilin plays an essential role in maintaining a reserve pool 
of unpolymerised actin for subsequent incorporation into existing filaments 
(Goldschmidt-Clermont et al., 1991).
Following the identification of a putative WHD and proline-rich regions in the NHS 
protein family, other WASP protein family domains were sought within the protein 
sequences of the NHS protein family. As a result, potential CA domains were identified 
in all four members of the NHS protein family (figures 6.2 and 6.3). Two potential CA 
domains (CA1 and CA2) were identified in the NHS protein (figures 6.2 and 6.3). CA1 
aligned without interruption with the CA domain of N-WASP. The key tryptophan 
residue within the acidic domain, which is crucial for the binding of the WASP protein 
family to the Arp2/3 complex, was found to be conserved in all the putative CA 
domains of the NHS protein family. In addition, arginine and leucine residues within 
the central domain of the WASP protein family, which facilitate activation of the 
Arp2/3 complex, were conserved in the putative CA domains of the NHS protein family 
(figure 6.3).
A putative G-actin binding (WH2) domain was also identified in three members of the 
NHS protein family (NHS, NHSL1, and NHL2, figure 6.4). The potential WH2 domain 
in NHS, NHSL1, and NHSL2 resides within a highly conserved domain of these three 
NHS protein family members (homology domain 8 in figures 5.5 and 5.6). NHSL3 
does not share this highly conserved domain.
Unlike the WASP protein family, the putative WH2 domain in the NHS protein family 
is not positioned next to the putative CA domains (except for NHSL1, figure 6.2). The 
domain organisation of NHSL1 more closely resembles that of the WAVE proteins, and 
interestingly the putative Abi-binding domain of NHSL1 shares the greatest sequence 
identity with the WAVE proteins Abi-binding domain (figure 6.1). The putative CA 
and WH2 domains of NHSL1 reside close to the C-terminus, as is the case in the WASP 
protein family. The putative WH2 domains of NHS and NHSL2 also reside at the C-
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termini of these proteins, but the putative CA domains are found closer towards the N- 
terminus. It would appear, therefore, that the NHS protein family have undergone 
considerable domain shuffling. Importantly, the NHS proteins are much larger than the 
WASP proteins and therefore, one can envisage that protein folding of the NHS proteins 
could bring the relevant domains in close proximity.
From the known activators (table 1.5) of the Arp2/3 complex, it has become 
increasingly apparent that not all nucleation promoting factors have the same central 
and acidic domain organisation. For example, the bacterial Arp2/3 activator ActA from 
Listeria monocytogenes, contains a central domain downstream of the acidic domain 
(figure 6.3). What is more, the level of conservation between central and acidic 
domains of known activators of the Arp2/3 complex varies considerably (figure 6.3). In 
addition, not all nucleation promoting factors contain a G-actin binding domain but 
instead have domains that bind F-actin, such as cortactin and Abplp (section 1.12.3 and 
1.12.4). Thus, the potential for an F-actin binding domain in NHSL3 (for which no 
WH2 domain could be identified) should still be investigated.
As in the WASP protein family, the NHS protein family were found to contain a basic 
motif residing towards the N-terminus of NHS, NHSL1, and NHSL3, and more 
centrally in NHSL2. The basic region in WASP and N-WASP binds PIP2 enhancing 
their ability to activate the Arp2/3 complex (Higgs and Pollard, 2000; Rohatgi et al., 
2000), whilst the basic region in WAVE2 was recently reported to bind PtdIns(3,4,5)P3, 
which is essential for lamellipod formation (Oikawa et al., 2004). Whether the basic 
regions in the NHS protein family are able to bind either PIP2, PtdIns(3,4,5)P3, or 
another phosphoinositide remains to be determined. Localisation of the NHS protein to 
the leading edges of lamellipods in stimulated MTLn3 cells strongly supports this idea.
Besides the basic domain and the putative WHD, CA, WH2, domains in the NHS 
protein family, all four members were found to contain a serine-rich domain, which is 
not present in the WASP protein family (figure 6.2). The serine-rich region, like the 
proline-rich region in the NHS protein family, varies in size and location. NHS 
contains a serine-rich domain spanning 189 amino acids at the very C-terminus, 
whereas NHSL2 contains a serine-rich domain spanning 24 amino acids and is located 
more centrally (table 6.1 and figure 6.2). A fourth domain found only to be present in
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the NHS protein, was an alanine-rich region residing within the WHD, after the proline- 
rich domain and overlapping with the first 13 amino acids of the putative Abi-binding 
domain.
In order to determine whether or not the putative CA domains in the NHS protein are 
functional and therefore bind and activate the Arp2/3 complex, a pyrenyl-actin 
polymerisation assay was tested. To test the potential function of the NHS CA domains 
a competitive assay was tested. The GST-NHS-CA2 fusion protein was degraded and 
consequently was not used in the competitive assays. Instead, only the ability of the 
CA1 domain to compete with the WASP-WCA domain for binding the Arp2/3 complex 
was tested. Initial results implied that the CA1 domain of NHS could compete with the 
WASP-WCA domain for binding the Arp2/3 complex (figure 6.19, A and B). 
However, upon testing the effect of GST alone in the assay with the WASP-WCA 
domain, a similar result was observed (figure 6.19, C).
A possible way to address the problem observed here, would be to cleave the GST 
moiety from the NHS-CA1 domain using thrombin prior to its use in the assay. 
Alternatively, the portion of the NHS protein containing the entire putative WH2 and 
CA domains should be cloned into pGEX-2T for subsequent testing in a non­
competitive actin polymerisation assay. If a significant increase in fluorescence over 
time was observed for pyrene-conjugated actin when in the presence of the Arp2/3 
complex and a larger NHS construct containing the putative WH2 and CA domains, one 
could propose that the WH2 and one (or both) of the CA domains are functional. Since 
the WASP-WCA domain was obtained from Cytoskeleton Inc., the purification 
procedure may have been different to that used here to purify the NHS-CA1 protein. 
For a more comparable assay, it may be worth expressing and purifying a GST-WASP- 
WCA protein ‘in house’ so as to use the same purification procedures for all fusion 
proteins tested.
The actin polymerisation assays could then be complemented with a competitive assay 
in which the GST moiety is cleaved prior to introducing the CA domains of the NHS 
protein into the assay. Together it may help to clarify which, if  any, of the putative CA 
domains are capable of binding the Arp2/3 complex. GST pull down assays could be
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performed to determine whether NHS directly binds the Arp2/3 complex and globular 
actin.
Once the domains have been identified and characterised, site directed mutagenesis 
could be carried out to generate mutant constructs in which key amino acids (such as the 
conserved tryptophan, figure 6.3) are replaced. If the loss of the conserved tryptophan 
correlates with a loss in ability to bind and/or activate the Arp2/3 complex, then this 
would provide more evidence towards a role for NHS in activating the Arp2/3 complex 
and regulating actin dynamics. Furthermore, if  an NHS construct containing the 
putative WH2, CA1 and CA2 domains is able to activate the Arp2/3 complex, site 
directed mutagenesis will enable the determination of which of the two putative CA 
domains are functional.
An antibody was raised against the C-terminal peptide derived from human NHS 
protein (figure 6.5). The C-terminus of NHS is highly conserved across species (figure
5.1) and, therefore, the anti-peptide antibody should potentially cross react with other 
species. The high conservation at the C-terminus of NHS across species however, had 
the potential to generate problems with trying to raise a C-terminal antibody against the 
NHS protein. It was not known, whether an immune response would be triggered upon 
exposure to the C-terminal peptide of the human NHS protein sequence. Fortunately, of 
the two rabbits immunised with the NHS C-terminal peptide, one (SGI703) produced 
an immune response and the antiserum was used for subsequent immunoblotting and 
immunocytochemistry experiments in this study.
The last 200 amino acids of the NHS protein fused with a GST tag (NHSC1; figure 6.7) 
was generated to characterise the NHS C-terminal anti-peptide antibody. The anti-NHS 
antibody SGI703 detected an immunoreactive band resolving at approximately 50 kDa, 
as anticipated, on immunoblots (figure 6.8, B). The control pre-immune serum did not 
detect this species (figure 6.8, A).
An N-terminally Myc-tagged NHS construct (NHSC2, amino acids 471 to 1630; figure 
6.7) containing the C-terminal epitope for the anti-NHS antibody SGI703, was 
successfully generated for transfection into CHO cells. Counterstaining with the mAb 
9E10, which detects the Myc tag at the N-terminus of the NHSC2 fusion protein, 
confirmed the localisation pattern observed with SG I703 (figure 6.10). SGI 703
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detected expression of NHSC2 in transiently transfected CHO cells (figure 6.10). 
Expression of NHSC2 appeared to be diffuse cytoplasmic and was excluded from the 
nucleus. These results demonstrate that SGI 703 can successfully detect expression of 
the NHS protein through immunoblotting and immunocytochemistry.
Interestingly, the NHSC2 construct contains two of the four putative monopartite 
nuclear localisation signals (822-825 (RKPK), 1026-1034 (PGGSKRKPK)) identified 
in the NHS protein sequence (Burdon et al., 2003). The absence of the NHSC2 
fragment from the nucleus implies that the two putative monopartite nuclear localisation 
signals residing at amino acid positions: 822-825 and 1026-1034, may not be functional 
or could be regulated by another stimuli.
To begin to determine whether the homology between the NHS protein family and the 
WASP protein family was significant, the localisation of endogenous NHS in MTLn3 
cells was investigated. MTLn3 cells have been used extensively to study actin 
cytoskeletal structures and the Arp2/3 complex.
NHS was detected in MTLn3 cells through immunoblotting (figure 6.11). An 
immunoreactive band of approximately 170 kDa was detected by SGI 703 and was not 
detected with the pre-immune serum (figure 6.11). Peptide competition reduced the 
intensity of this immunoreactive band, whilst other non-specific bands remained 
unaffected (figure 6.11). This confirmed the presence of endogenous NHS in MTLn3 
cells, and validated their use for the localisation of endogenous NHS. In addition, other 
cell lines were examined for NHS eexpression. Strong immunoreactive bands of a 
similar size to that detected in MTLn3 cells (approximately 170 kDa) were detected 
with SGI703 in Caco-2, CHO, COS-7, and MDCK cells, and the intensity was 
significantly reduced with peptide competition in all cell lines. Only the 
immunoreactive band at 170 kDa was constant across the different cell lines, whereas, 
nonspecific bands were found to vary between the different cell lines (figure 6.11). Five 
potential NHS isoforms can be identified on the database with predicted molecular 
weights ranging from 160-196 kDa. It is not known which isoform is represented by 
the immunoreactive band resolving at approximately 170 kDa in these cell lines. 
Although these results imply that each of these five cell lines contain a predominant 
NHS isoform, it cannot be ruled out that other NHS isoforms are present.
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MTLn3, Caco-2, and MDCK are all epithelial cell lines derived from rat, human, and 
dog, respectively (table 2.5). COS-7 cells are a fibroblast cell line derived from monkey 
(table 2.5), whilst CHO cells are derived from Chinese Hamster ovaries. Since the anti- 
NHS anti-peptide antibody was raised to a highly conserved peptide at the C-terminus 
of NHS, detection of NHS in other species was expected. COS-7 and MDCK cells are 
derived from kidney, a tissue in which expression of the NHS transcript was 
demonstrated (section 4.2.2.1, figure 4.16). EST sequences on the database, aligning 
with the NHS gene include transcripts derived from colon, the tissue from which Caco-2 
cells are derived. Although expression of NHS in the mammary gland and ovaries have 
not yet been confirmed, endogenous NHS was detected in CHO and MTLn3 cells in this 
thesis.
As described previously for MTLn3 cells (Bailly et al., 1999), the Arp2/3 complex was 
found to localise to the leading edge of the lamellipods in stimulated MTLn3 cells 
(figure 6.12, A and B). Localised polymerisation of actin at the plasma membrane 
results in protrusions such as lamellipodia. Staining of the actin cytoskeleton with 
Alexa Fluor 488 phalloidin revealed actin enriched at the leading edge of the 
lamellipodia in stimulated MTLn3 cells, colocalising with the Arp2/3 complex (figure
6.12, A and B).
Localisation of the Arp2/3 complex in unstimulated MTLn3 cells revealed more 
cytoplasmic staining, with some stronger staining observed at membrane ruffles (figure
6.12, C). This was consistent with previous reports of the localisation of Arp2/3 in 
unstimulated MTLn3 cells (Bailly et al., 1999).
The cellular localisation of endogenous NHS in stimulated MTLn3 cells was 
reminiscent of that seen for the Arp2/3 complex. NHS was found to localise to the 
leading edge of lamellipods in stimulated MTLn3 cells (figure 6.13, A and B). 
Interestingly, the localisation of endogenous NHS in unstilmulated MTLn3 cells also 
revealed some membrane ruffle staining (figure 6.14), as seen in unstimulated MTLn3 
cells stained for Arp2/3 (figure 6.4, Bailley et al., 1999). Ruffles are formed from 
upward folding of lamellipodia. It is interesting that endogenous NHS should localise 
to the ruffles in unstimulated MTLn3 cells as this localisation pattern was observed for
214
Chapter Six -  Functional analyses of the NHS protein
the Arp2/3 complex. The staining pattern of endogenous NHS appears to closely reflect 
that of endogenous Arp2/3 in stimulated and unstimulated MTLn3 cells. These results 
are in agreement with the identified homology between the WASP protein family and 
the NHS protein family (section 6.2.1), which implies a role for NHS in actin 
cytoskeletal dynamics. To further confirm the localisation pattern at the leading edge 
for endogenous NHS in MTLn3 cells, the peptide synthesised to generate the anti-NHS 
antibody SGI703 (section 6.2.2.1) could be used to block the endogenous staining 
observed.
A notable difference in the localisation of endogenous NHS compared to that observed 
for the Arp2/3 complex in this study was the occasional decoration of some stress fibres 
with the anti-NHS antibody (figures 6.13, B and 6.14, B). This was not observed with 
the pre-immune serum (figure 6.13, C), but did occur in both stimulated and 
unstimulated MTLn3 cells (figures 6.13, B, and 6.14, B). This suggests that NHS may 
bind actin directly or through an interaction with another protein.
Taken together, the data imply a function for the NHS protein in actin cytoskeletal 
dynamics. These results also suggest a function for the NHS protein in activating and 
stimulating the Arp2/3 complex. In the future it will be worth directly testing whether 
the NHS protein binds the Arp2/3 complex and actin.
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Cataract is a classic example of a genetically heterogenous disease. It is defined by an 
opacity of the lens, which can dramatically reduce visual acuity. Cataract can vary 
considerably in its morphology and can either be static or progressive in nature. 
Inherited cataract can be non-syndromic, in which case it frequently exhibits an 
autosomal mode of inheritance, or it can form part of a syndrome. Syndromic forms o f 
cataract include the Lowe and Nance-Horan syndromes. The mapping of a five- 
generation family with non-syndromic X-linked congenital cataract (CXN, Francis et 
al., 2002) is one of two reported cases of X-linked inherited cataract. Autosomal 
recessive modes of inheritance have been reported, but are more frequently seen in 
consanguineous families.
Genetic studies have contributed to the idea that genes involved in early onset cataract 
are also implicated in age-related cataract. In particular, mutations in some genes (MIP 
and yC-crystalliri) result in progressive cataracts (Francis et al., 2000; Ren et al., 2000), 
whilst familial adult onset pulverulent cataracts has been linked to the CAAR locus 
(Heon et al., 2001). It is becoming increasing clear therefore, that mutations with 
detrimental effect in certain genes results in congenital cataract, whilst mutations with 
less severe functional consequences in the same genes may contribute to age-related 
cataract in a more complex multifactorial fashion. In the era of the HapMap (section 
1.7.2) it will be interesting to begin to determine which genes are implicated in 
susceptibility to age-related cataract.
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The cataract phenotype observed in affected males of the X-linked congenital cataract 
family (CXN), was of a total opacity of the lens. Total lens opacities usually require 
surgery from an early age. In addition to the cataract phenotype, a few affected males 
of the CXN family were found to suffer from cardiac abnormalities, such as 
ventriculoseptal defect (VSD). Whether or not the cardiac anomalies completely 
segregated with the cataract phenotype in this family is unknown. The CXN disease 
locus was originally mapped to a 3.5 Mb interval on chromosome Xp22.13 -  22.2 
flanked by markers DXS999 and DXS9902. Interestingly, the CXN disease locus was 
found to reside within the disease locus for Nance-Horan syndrome (NHS), which was 
mapped to a 30 cM interval on Xp22.13-22.31 flanked by markers DXS451 and 
DXS143 (Stambolian et al., 1990; Zhu et al., 1990; Bergen et al., 1994).
Nance-Horan Syndrome (MIM 302350) is a rare X-linked disease with affected males 
exhibiting a total opacity of the lens at birth. The total lens opacity phenotype observed 
in affected males with NHS has also been associated with microcomea and/or 
microphthalmia, distinctive dental anomalies including supernumerary incisors and 
crown shaped permanent teeth, characteristic facial features (anteverted pinnae, long 
face, prominent nasal bridge and nose) and mental retardation in approximately a third 
of cases. Carrier females usually have cataracts confined to the posterior Y sutures and 
can exhibit widely spaced cone or screwdriver shaped teeth (Bixler et al., 1984; Seow et 
a l , 1985).
The mapping of CXN and NHS to the short arm of the human X chromosome together 
with the total lens opacities observed in both, implied that the two diseases may have 
been allelic. Strengthening this argument was the mapping of X-linked congenital 
cataract in the mouse (Xcat) to the distal portion of the mouse X chromosome. The 
Xcat mouse exhibited a total opacity of the lens at birth in affected males and 
homozygous females, and a variable cataract phenotype in heterozygous females 
(Stambolian et a l  1994). The distal portion of the mouse X chromosome, to which the 
Xcat locus was mapped, is syntenic with the portion of the human X chromosome 
containing the CXN and NHS disease loci. Thus, the Xcat mouse is a potential model 
for CXN and/or NHS.
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In this study, the causative gene for congenital cataract in the CXN family was 
investigated. Segregation of disease in the CXN family with markers on Xp22.13-22.2 
was confirmed as part of this thesis through genotyping 46 known microsatellite 
markers spanning the human X chromosome. An attempt was then made to refine the 
CXN disease interval through the identification of novel microsatellite markers within 
the CXN disease locus. Novel microsatellite markers S4 and S5 were found to be 
recombinant in individual III.3, and in subsequent generations of the CXN family. As a 
result, the CXN disease interval was successfully refined to approximately 3.2 Mb 
leading to the exclusion of three genes (CDKL5, RSI, and PPEF1).
Due to the possible allelism between CXN and NHS, four British families with NHS 
were recruited to the study. At the time, the interval for NHS had also been refined to 
approximately 1.3 Mb on Xp22.13, flanked by markers DXS1995 and DXS999 
(Toutain et al., 2002). In addition to the refinement, five known candidate genes 
(SCML1, SCML2, CDKL5, RSI, and PPEF1) within the refined NHS disease locus had 
been screened and excluded as disease causative for NHS (Toutain et al., 2002). The 
data described in this thesis and that presented by Toutain and colleagues (2002) still 
pointed towards possible allelism between CXN and NHS. Firstly, the refinement of 
the CXN locus occurred within the newly refined disease interval for NHS leaving an 
overlap of approximately 900 Kb of genomic sequence between the CXN and NHS 
disease loci. Secondly, refinement of the CXN disease locus resulted in the exclusion 
of CDKL5, RSI, and PPEF1 as candidates for disease in this family. This closely 
reflected the report by Toutain and colleagues (2002) who screened and excluded these 
three genes as candidates for NHS.
Three candidate genes (TL1, RBBP7, and CX43-L) were selected for screening in the 
CXN family and NHS families based on expression in relevant tissues, homologies to 
known proteins or classes of proteins, and their positions within the disease intervals for 
CXN and NHS. No sequence changes were identified in any of the three genes 
resulting in their exclusion as candidates for disease in the CXN and NHS families. At 
this point, all known genes residing in the region of overlap between the recently 
refined CXN and NHS disease loci had been screened and excluded for either CXN or 
NHS (this thesis; Toutain et al., 2002).
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A novel gene prediction supported by mRNAs and EST sequences was then identified 
through bioinformatic analysis of the region of overlap between the NHS and CXN loci. 
Upon screening this novel gene truncating mutations were identified in the large exon of 
two of the families with NHS. However, no mutation was identified in the CXN family 
or the remaining two families with NHS, implying that the full coding region of the 
novel gene may not have been fully identified. An article was then published detailing 
findings of a novel gene (NHS) harbouring truncating mutations in 5 families with NHS 
(Burdon et al., 2003). As anticipated, the novel gene in which truncating mutations 
were identified in two families with NHS in this study, was indeed the NHS gene 
reported by Burdon and colleagues (2003). Furthermore, Burdon and colleagues (2003) 
revealed a different 5’ end of the NHS gene when compared to the 5’ end identified in 
this thesis. The alternative 5’ exon (exon la) o f the NHS gene, resided approximately 
350 Kb upstream o f exon 2 (Burdon et al., 2003). It became apparent therefore, that 
bioinformatic analysis alone would have failed to detect this exon, and that RT-PCR as 
done by Burdon et al., 2003, was necessary to detect this alternative transcript.
The NHS gene was reported to be transcribed as two isoforms (A and B; Burdon et al., 
2003), although there are now five putative NHS isoforms on the database (isoforms A- 
E). Isoform A, referred to as the major isoform of the NHS gene (Burdon et al., 2003), 
contained a 5’ exon approximately 350 Kb upstream of exon 2. Isoform B consisted of 
an alternative 5’ exon (exon lb) with predicted translation of the protein product 
beginning at the first methionine of exon 4 (Burdon et al., 2003). Both exon la  and 
exon lb  were screened in the remaining two families with NHS, and the CXN family in 
this study. Truncating mutations in exon la  were identified in the remaining two NHS 
families, but no sequence change was identified in either exon la  or lb  in the CXN 
family.
Ramprasad and colleagues (2005) have since reported the identification of a truncating 
mutation in exon la  of the NHS gene in a family with NHS. The cumulative results of 
the mutations identified in the NHS gene to date (this thesis, Burdon et al., 2003, and 
Ramprasad et al., 2005) have highlighted the loss of isoform A is sufficient to cause 
disease in families with NHS. There does not, however, appear to be any 
genotype/phenotype correlation as yet.
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Truncating mutations within exon la  effect isoform A only, whereas truncating 
mutations identified in exons 2, 3, and 4-8 are predicted to affect all NHS isoforms 
except isoform B where translation begins in exon 4. One might predict therefore, that 
a truncating mutation in an exon predicted to affect all isoforms of the NHS gene (exons 
4-8), would lead to a more severe phenotype. One family reported by Burdon and 
colleagues (2003) opposes this idea. Burdon et al., (2003) identified a truncating 
mutation in exon 6 of a family with NHS. Only two affected males within this family 
exhibited developmental delay, suggesting genetic modifiers may affect phenotype.
Orthologs of the NHS protein were sought and identified in mouse (Mus musculus), rat 
(Rattus norvegicus), chimpanzee (Pan Troglodytes), dog (Canis familaris), orangutan 
(Pongo pygmaeus, partial), chicken (Gallus gallus, partial), cow (Bos Taurus, partial), 
frog (Xenopus laevis, partial), zebrafish (Danio rerio, partial), and pufferfish (Tetradon 
nigroviridis, partial). Alignment of the orthologous protein sequences revealed a high 
degree of conservation. Furthermore, deduced genomic structures of full length NHS 
orthologues revealed a high degree of conservation in genomic organisation. The 
presence of an NHS ortholog in the mouse provides an excellent candidate for the Xcat 
mouse model.
Of the NHS families reported by Burdon and colleagues (2003), one family did not 
harbour a mutation in the coding exons of the NHS gene. The possibility that NHS may 
be heterogenous should not be ruled out. The closely related X-linked developmental 
syndrome Oculofaciocardiodental syndrome (MIM 300166) results from mutations in 
the BCOR gene (Ng et al., 2004). The BCOR gene would make an ideal candidate gene 
for families with apparent NHS for which no mutation in the NHS gene is identified and 
for which linkage to Xp22.13 has not been confirmed. Recently, a family with NHS 
was mapped to the long arm of chromosome X (Xq) by Burdon and colleagues 
(personal communication). It is not known whether the family mapping to Xq is the 
same family for which a NHS gene mutation was not identified (Burdon et al., 2003). 
The identification of NHS paralogs described in this thesis makes NHSL2 (mapping to 
Xql3.1) an ideal candidate for the NHS family linked to Xq.
Expression analysis of the NHS gene described in this thesis revealed the presence of 
transcripts in fetal brain, kidney, lung, and thymus. A detailed investigation into the
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expression of the NHS gene was also carried out by Burdon and colleagues (2003). 
NHS transcripts were detected in human adult and fetal brain, lens, retina, retinal 
pigment epithelium, placenta, lymphocytes and fibroblasts. Developmental expression 
of Nhs in the mouse brain was also investigated revealing varying levels of expression 
of Nhs from E l 7.5 through to 12 months. In situ hybridisation detected expression of 
mouse Nhs in midbrain, lens, retina, tooth primordia, the olfactory epithelium, the 
whisker follicles, the choroid plexus, and heart. To complement these data, a lacZ 
reporter-gene cassette was inserted into intron la  of isoform A of the Nhs gene. This 
allowed Burdon and colleagues to examine the expression of the Nhs gene driven by the 
Nhs promoter. Strong expression was detected in the developing lens and relatively 
high expression was also detected in some tissues of the developing and early postnatal 
brain. Expression in the olfactory bulbs, olfactory epithelium and the limbic system 
were most prominent and expression in the heart, apical ectoderm ridge and the 
olfactory tubercle was observed (Burdon et al., 2003). No phenotype in the lacZ mouse 
(i.e. lens opacities) was reported by Burdon and colleagues (2003).
To date, no mutation within the NHS gene has been identified in the CXN family. It is 
still possible that CXN and NHS are allelic and an attempt to identify alternate 5’ ends 
or cryptic exons of the NHS gene may facilitate the identification of a mutation in the 
CXN family. As with the alternative 5’ exon approximately 350 Kb upstream of exon 2 
of the NHS gene, bioinformatics alone will not be sufficient to identify alternative 5’ 
and cryptic exons. RT-PCR analysis and 5’ RACE of lens and heart mRNA should be 
carried out. Upstream and other regulatory regions of the gene should also be 
considered as potential mutation sites leading to disease. Identification of NHS gene 
expression in the heart (Burdon et al., 2003) provides further support for the NHS gene 
to be disease causative in the CXN family. In addition the Xcat mouse maps to a region 
of the mouse X chromosome syntenic with the interval to which the CXN and NHS loci 
were mapped. Thus, the Xcat mouse may prove to be a model for disease in the CXN 
family and/or NHS families. In the advent that CXN and NHS prove not to be allelic, 
new candidate genes should be sought and screened in the CXN family. It should be 
noted that affected individuals of the CXN family do not exhibit typical NHS features 
(i.e. dental anomalies and facial dysmorphism). If the NHS gene is disease causative for 
CXN, then the variation in phenotype may be a result o f genetic modifiers.
221
Chapter Seven -  Overall discussion and future work
Through this study, the NHS gene has been found to form part of a new gene family. 
The NHS paralogs: NHSLI, NHSL2, and NHSL3, reside on chromosomes 6q24.1, 
Xql3.1, and lp35.1, respectively. Each of the NHS paralogs has a strikingly similar 
genomic structure and their protein products share between 22-28 % sequence identity. 
Initial expression analysis of NHSL1 and NHSL2 in a fetal cDNA panel revealed both to 
be more widely expressed than the NHS gene. NHSL3 appears to be the most distantly 
related of the family. Alignment of the protein sequences for each member of the NHS 
gene family has revealed four conserved homology domains of unknown function. An 
additional five homology domains have been identified between the more closely 
related NHS, NHSL1, and NHSL2 protein sequences. Currently, there are no clues as 
to the function of the various conserved homology domains in the NHS protein family 
apart from homology domains 1 and 8 (both absent from NHSL3). Homology domain 1 
present in NHS, NHSL1, and NHSL2, was found to share sequence identity with the 
WAVE homology domain (WHD), whilst homology domain 8 is predicted to contain a 
putative actin-binding (WH2) domain.
The WHD is located at the N-terminus of the WAVE proteins 1-3. WAVE proteins 
form part of a larger family known as the WASP protein family, which includes 
WAVE1-3, WASP, and N-WASP. Each member of the WASP protein family is a 
known actin-binding protein and activator of the Arp2/3 complex, a seven-subunit 
complex that initiates actin polymerisation at the leading edge of motile cells resulting 
in the formation of protrusive structures such as lamellipodia and filopodia. 
Identification of a putative WHD at the N-terminus of members of the NHS protein 
family (NHS, NHSL1, and NHSL2), prompted a search for additional regions of 
homology shared between the NHS and WASP protein families. This led to the 
identification of at least one putative CA (central/acidic) domain, which is known from 
other proteins to bind the Arp2/3 complex resulting in its activation, in each member of 
the NHS protein family. Two putative CA domains (CA1 and CA2) were identified in 
the NHS protein. A putative actin-binding domain (WH2), present in the WASP protein 
family, was also identified in the protein sequences of NHS, NHSL1, and NHSL2 
within homology domain 8. Together, the WH2 and CA domains of the WASP protein 
family facilitate binding to an actin monomer and the Arp2/3 complex (resulting in its 
activation), bringing the two into close proximity.
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Each member of the WASP protein family also contains a proline-rich region, reported 
to bind SH3 domain containing proteins such as profilin. With the exception of 
NHSL2, each member of the NHS protein family also contains a proline-rich region. 
An additional domain common to all members of the WASP protein family and found 
in all members of the NHS protein family was a basic region. The basic region 
enhances the ability of WASP and N-WASP to activate the Arp2/3 complex through 
binding the phosphoinositide, PIP2 (Higgs and Pollard, 2000; Rohatgi et al., 2000). For 
WAVE2, the basic region was recently reported to bind PtdIns(3,4,5)P3; and is essential 
for the formation of lamellipodia (Oikawa et al., 2004).
Therefore, the NHS protein family appear to share homology with the WASP protein 
family and are more closely related to the WAVE proteins. The presence of putative 
WHD, CA, and WH2 domains implies that the NHS protein family may be able to bind 
actin and activate the Arp2/3 complex.
The function of the WHD in the WAVE proteins was unknown until recently. A 
sequence motif within the WHD has now been identified as an Abelson interactor 
(Abi)-binding domain (Echarri et al., 2004; Leng et al., 2005). Binding of Abil to the 
WHD of WAVE 1 and WAVE 2, results in the translocation of the WAVE proteins to 
the leading edge of motile cells (Echarri et al., 2004; Leng et al., 2005).
Unlike Abi2, which is highly expressed in the lens, Abil is not expressed in the lens 
(Grove et al., 2004). This is of particular interest with regards to the putative Abi- 
binding domain in the NHS protein family. Should the putative Abi-binding domain in 
NHS prove to be functional, its binding partner in the lens is likely to be Abi2. The 
level of homology between the WHD of the WAVE proteins 1 -3 and the N-terminus of 
the NHS, NHSL1, and NHSL2 implies that the NHS protein family may contain an 
Abi-binding domain. Since Abil has been reported to bind and translocate WAVE1 
and WAVE2 to the leading edge of lamellipodia (Echarri et al., 2004; Leng et al., 
2005), the NHS proteins may also bind an Abi protein and be translocated to 
lamellipodia. The variation in amino acid sequence over the putative Abi-binding 
domains in NHS and NHSL2 when compared to the WAVE proteins, may result in their 
specificity for an alternative Abi family member.
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The sub-cellular localisation of NHS in this study supports the notion that NHS may 
bind an Abi protein through its putative WHD and/or actin. NHS was found to localise 
to the leading edge of lamellipods in stimulated MTLn3 cells. The binding of NHS to 
an Abi family member may result in its translocation to the leading edge of motile cells.
To determine whether the putative WHD in the NHS protein family is functional and 
binds one of the Abi protein family members, co-immunoprecipitation and GST-pull 
down assays should be performed.
Interestingly, a recent paper reported the generation of an Abi2 null mutant mouse, 
which developed abnormal phenotypes in the eye and brain (Grove et al., 2004). The 
eyes of adult Abi2‘/" mice were noticeably smaller than those of wild-type mice, and 
appeared to be a result of defective lens development. Primary lens fibres at E l4.4 were 
found to have completely filled the lens vesicle in both wild-type and Abi2 null mice. 
However, the orientation and migration of secondary lens fibres in Abi2 null mice was 
defective at E l6.5 and PI. In addition, the anterior and posterior sutures failed to 
develop in Abi2 null mice. At PI the lens was found to be very deformed and the lens 
capsule to be substantially thicker. Failure for the sutures to form resulted in rupture of 
the posterior region of the lens and subsequent release of primary lens fibres (Grove et 
al., 2004). Grove and colleagues further investigated the defects observed in secondary 
lens fibre migration. They localised the Abi2 protein in wild-type lenses to the tips of 
migrating secondary fibres. In particular they found Abi2 to localise at the transition 
zone where newly differentiated fibres begin migration along the epithelial cell-fibre 
interface (EFI). It is at the EFI that secondary lens fibres form adherens junctions with 
anterior epithelial cells. They also found Abi2 to localise with p catenin along 
secondary lens fibre cell-cell borders. The catenins, a  and p, provide a link between 
cadherins and the actin cytoskeleton. Furthermore, down regulation of Abil and Abi2 
in HeLa epithelial cells, prevented formation of adherens junctions (Grove et al., 2004). 
Thus, Abi2 appears to play a role in adherens junction formation.
Neuronal abnormalities were also observed in Abi2 null mice. Abnormalities in the 
organisation of the neocortex, and mild distortion in the organisation of the 
hippocampus were observed in adult Abi2 null mice. Dendritic spine morphology and 
density were also abnormal in Abi2 null and heterozygous mice, and behavioural tests
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conducted demonstrated deficits in the short and long term memory of Abi2 null mice 
(Grove et al., 2004).
The overlapping phenotype between NHS and Abi2 null mice, and the potential Abi- 
binding domain in the NHS protein along with observed expression of both NHS and 
Abi2 in the lens, suggests a possible role for NHS in adherens junction formation. It 
has already been reported that polymerisation of actin is the driving force behind the 
formation of adherens junctions (Vasioukhin et al., 2000), and therefore, Abi2 may 
bring NHS into the vicinity of the Arp2/3 complex for localised actin polymerisation 
and subsequent generation of adherens junctions.
Investigation of the potential co-localisation of endogenous NHS and junctional 
proteins such as cadherins and a- and p-catenin in MTLn3 cells or another epithelial 
cell line expressing NHS (i.e. MDCK), should be carried out in the future using marker 
antibodies and the anti-NHS antibody described here. This will determine whether or 
not NHS localises to adherens junctions. The junctional proteins cadherins and the a- 
and p-catenin proteins are also expressed in lens fibre cells, and determining whether 
NHS localises to adherens junctions in these lens specific cells will be important, as 
cataract is a hallmark of Nance-Horan syndrome.
Should NHS be found to localise to adherens junctions, its role in adherens junction 
formation should be investigated through RNAi. By transfecting cells with NHS- 
specific siRNAs the affect on adherens junction formation could be determined through 
immunostaining of an junctional protein, such as p-catenin.
Recent reports further support the idea that the NHS protein is related to the WAVE 
proteins and has a function in actin polymerisation. Firstly, the WAVE 1-associated 
GTPase-activating/Mental disorder-associated GAP protein (WRP/MEGAP), which 
terminates Rac signalling in neurons (Soderling et al., 2002; Endris et al., 2002), has 
been identified as the underlying cause in 3p (-) syndrome (Endris et al., 2002). 
Features of the 3p (-) syndrome include hypotonia and severe mental retardation. These 
features are analogous with the symptoms observed in the affected male from NHS 
family 3 in this study (severe developmental delay and hypotonia). Secondly, targeted 
disruption of the Wavel gene in mouse resulted in reduced anxiety, sensorimotor
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retardation, and deficits in hippocampal-dependent learning and memory. These 
symptoms reflect those observed in patients with 3p (-) syndrome (Soderling et al., 
2003), and approximately a third of the cases of NHS suffer mental retardation.
The possible link between the Arp2/3 complex and actin and the NHS protein was 
investigated. MTLn3 cells were confirmed to express endogenous NHS using an anti- 
NHS antibody described in this thesis. These cells have been used extensively by my 
collaborator Dr M. Bailly, to study the actin cytoskeleton and localisation of the Arp2/3 
complex upon stimulation to induce lamellipod formation. To confirm the localisation 
pattern previously observed for Arp2/3 in MTLn3 cells, an anti-p34 subunit antibody 
was used to immunostain stimulated and unstimulated MTLn3 cells.
The Arp2/3 complex localised to the leading edge of lamellipodia in stimulated MTLn3 
cells, as previously reported (Bailly et a l, 1999). Interestingly, the subcellular 
localisation of endogenous NHS in stimulated MTLn3 cells closely resembled that of 
the Arp2/3 complex. Endogenous NHS was found to localise at the leading edge of the 
lamellipods. Both the Arp2/3 complex and the NHS protein were found to localise to 
membrane ruffles in unstimulated MTLn3 cells.
Endogenous NHS was also localised to actin stress fibres in stimulated and 
unstimulated MTLn3 cells. This sub-cellular localisation pattern was not observed for 
the Arp2/3 complex.
The localisation of endogenous NHS to the leading edge of lamellipods and the 
identification of putative WH2 and CA domains, suggest that NHS may be a nucleation 
promoting factor for the Arp2/3 complex.
Other putative domains identified within the NHS protein which are important to the 
function of the WAVE proteins were the proline-rich and basic regions. Proline-rich 
regions of the WAVE proteins are binding sites for SH3 domain containing proteins 
such as profilin. Potential binding of profilin could be addressed for the NHS protein 
through co-immunoprecipitation and GST pull down assays.
PtdIns(3,4,5)P3 was recently shown to bind the WAVE2 protein and is important for 
lamellipod formation (Oikawa et al., 2004), whilst the basic region in WASP and N-
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WASP binds PIP2 enhancing their ability to activate the Arp2/3 complex (Higgs and 
Pollard, 2000; Rohatgi et al., 2000). Sub cellular localisation of NHS to the leading 
edge of MTLn3 cells in this study supports the idea that the basic region of NHS may 
bind either PtdIns(3,4,5)P3, PIP2 or another phosphoinositide. Binding of WAVE2 to 
PtdIns(3,4,5)P3 was determined through enzyme-linked immunosorbent assays (ELISA, 
Oikawa et al., 2004), which could be applied to the NHS protein.
To determine whether the putative CA1 domain in NHS was functional a competitive 
actin polymerisation assay was performed. Unfortunately, the results obtained from the 
competitive actin polymerisation assays were inconclusive. Cloning a larger fragment 
of the NHS protein or the entire protein containing the putative WH2 and CA domains 
for a non-competitive actin polymerisation assay, would be a good approach to 
determine whether the NHS protein is a nucleation promoting factor of the Arp2/3 
complex.
The Arp2/3 complex polymerises actin at the side of pre-existing actin filaments 
resulting in formation of Y-shaped branches (Pollard et al., 2000). Such branches are 
commonly seen in actin meshworks of leading edge lamellipodia in motile cells 
(Svitkina and Borisy, 1999; Bailly et al., 1999). Should the NHS protein prove to 
activate the Arp2/3 complex, it will be important to determine whether its activation 
results in the characteristic branched filaments. This can be achieved through in vitro 
polymerisation of actin in the presence of an NHS construct and Arp2/3 complex and 
labelled phalloidin, which can be fluorescently visualised. Control experiments can also 
be run in parallel consisting of actin monomers on their own (which leads to long 
unbranched filaments) and actin in the presence of the Arp2/3 complex and a known 
nucleation promoting factor construct such as WASP. Disruption of branched actin 
networks could also be determined through use of mutant NHS constructs. If NHS does 
stimulate the Arp2/3 complex thus resulting in branched actin filaments, then the NHS 
protein can be localised in the branched actin networks through high resolution replica 
electron microscopy (Bailly et al., 1999).
The ability of the NHS protein to bind G-actin and the Arp2/3 complex could be 
determined through GST-pull down assays. NHS constructs immobilised on 
glutathione-sepharose beads are incubated with monomeric actin or the Arp2/3
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complex, washed, and the bound protein eluted for Western blot analysis using 
commercially available anti-actin antibodies and the anti-p34 antibody used in this 
thesis. Use of mutant NHS constructs will enable key residues involved in binding 
monomeric actin and the Arp2/3 complex to be identified.
The affect of knocking down NHS expression in cell lines expressing endogenous NHS 
(for example, MTLn3, MDCK, Caco-2) through RNAi should be investigated to see 
what effect reduced or absent NHS expression has on the actin cytoskeleton, and as 
previously mentioned, on adherens junction formation.
It will be important to generate additional antibiodies against the NHS protein, in 
particular against specific isoforms of NHS such as isoform A, which appears to be 
sufficient to cause disease in families with Nance-Horan syndrome and is predicted to 
contain the WHD. Since Nance-Horan Syndrome is a developmental disorder, 
antibodies raised against the NHS protein will provide a valuable resource for 
examining the spatiotemporal expression pattern during development, and subcellular 
localisation of the various NHS isoforms.
Affected males with Nance-Horan syndrome exhibit total cataract whilst heterozygous 
females generally have sutural cataracts. These cataract phenotypes described in 
patients with Nance-Horan syndrome may result from aberrant migration of the lens 
fibre cells and failure to fully form adherens junctions. During lens development, 
secondary lens fibres elongate and differentiate forming sutures at points where they 
come into apposition (section 1.2.1). The failure of secondary lens fibres to form 
adherens junctions with neighbouring secondary lens fibres may result in cataract 
formation at the points of apposition leading to a characteristic Y-sutural cataract 
phenotype observed in heterozygous females. In total cataract, all lens fibre cells are 
affected. Since affected males only have one copy of the NHS gene andno functional 
NHS, adherens junctions may not form in both primary and secondary lens fibres 
providing an explanation for the more severe cataract phenotype observed. Defective 
adherens junction formation is one proposed disease mechanism for cataract in patients 
with Lowe syndrome (Faucherre et al., 2005).
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How mutations in the NHS gene result in the dental anomalies common to Nance-Horan 
syndrome is unclear. Currently there does not appear to be any genotype/phenotype 
correlation between potential loss of certain or all NHS isoforms and the dental 
anomalies observed in NHS families. Genes mutated in human dental disorders include 
transcription factors such as BCOR (Ng et al., 2004), and the signalling molecule 
ectodysplasin (EDA). Disruption of EDA, its receptor EDAR, and the intracellular 
adaptor protein EDARADD in mice results in deviances from the normal number of 
teeth formed (Sofaer, 1969; Sofaer, 1977; Headon et al., 2001), highlighting that defects 
in signalling pathways result in dental anomalies. NHS may act as a scaffolding protein 
downstream of signalling cascades involved in tooth development, which is supported 
by the identification of NHS expression in tooth primordial (Burdon et al., 2003) and 
the dental anomalies that form part of the Nance-Horan syndrome phenotype. In rare 
cases, supernumerary teeth have been observed following loss of Eda or Edar and 
interestingly, supernumerary incisors form part of the dental anomalies seen in Nance- 
Horan Syndrome patients.
If the Nhs gene is disease causative in the Xcat mouse, the absence of dental anomalies 
in Xcat mice is not entirely surprising. Compared to humans who have more tooth 
types (canines and premolars), mice only have one set of teeth, which develop in a 
manner similar to that of human deciduous teeth (milk teeth; Tucker and Sharpe, 2004). 
Thus, the mouse is not a particularly good model for human dental disorders.
The NHS protein may also have a role in modulating gene expression (figure 7.1). Four 
monopartite nuclear localisation signals have been identified in NHS, implying that 
NHS could be imported into the nucleus. Disruption of NHS therefore, may alter the 
regulation of gene expression resulting in the tooth abnormalities observed in patients 
with NHS. Furthermore, craniofacial development is dependent on an intricate pattern 
of gene expression and mutations affecting proteins that modulate gene expression can 
lead to abnormal craniofacial development. If NHS is imported into the nucleus and 
modulates gene expression, then the facial dysmorphism observed in patients with NHS 
may arise from loss of gene modulation in development by the NHS protein.
To summarise, the NHS protein may act as a scaffolding protein bringing together 
various binding partners into one complex (as described for the WAVE proteins; Higgs
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and Pollard, 1999) and activating the Arp2/3 complex for localised actin polymerisation 
(figure 7.1). The Drosophila GUKH protein is also a scaffolding protein and the 
homology identified between NHS and the Drosophila GUKH protein (Katoh and 
Katoh, 2004) may be due to domains that are common to scaffolding proteins. In 
addition to the sequence similarity between the WASP protein family and the NHS 
protein family, homology domains have also been identified in the NHS protein family 
for which a potential function has not been attributed. Further, Burdon and colleagues 
(2003) reported four monopartite nuclear localisation signals (NLS) in the NHS protein, 
although two do not appear to be functional (this study, section 6.2.2.3.2). Bipartite 
nuclear localisation signals have been identified in other members of the NHS protein 
family (except NHSL3), which may localise these proteins to the nucleus under certain 
physiological conditions.
Clearly the research presented in this thesis presents exciting avenues to follow in order 
to elucidate the potential functions of the WASP protein family related domains, and the 
additional homology domains within the NHS protein family. This will aid in gaining a 
greater insight into the disease mechanism underlying Nance-Horan syndrome.
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Lamellipodium
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Adherens
junction
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Modulation of gene expression?
Figure 7.1 Proposed model for the role of NHS
In response to extracellular stimuli, NHS could bind a member o f the Abi protein family and an SH3 domain containing protein, resulting in NHS being translocated to the 
plasma membrane (leading edge) where it binds actin and activates the Arp2/3 complex leading to the formation of a lamellipod. Upon certain stimuli, NHS may be imported 
into the nucleus where it modulates gene expression. The NHS protein could localise to actin stress fibres where it acts as a scaffold, bringing together signalling molecules
and the cytoskeleton.
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Appendices
- Appendix A -
Protein sequences of the NHS paralogs (NHSL1, NHSL2, and 
NHSL3)
Protein sequences of the NHS paralogs are shown below. Putative bipartite nuclear 
localisation signals identified in NHSL1 and NHSL2 are highlighted in red and 
underlined.
NHSL1
MPFHQRTLEPARLRRPEAAGAGAAGAPLFRSLEQVSSHALGCLLAQLADLSRCAGDIFGELEGQ  
AAALGHRTAALHRRLDALQAAAARLDHRRVKIPVSNLDEESRWTVHYTAPWHQQENVFLPTTRP  
PCVEDLHRQAKLNLKSVLRECDKLRHDGYRSSQYYSQGPTFAANASPFCDDYQDEDEETDQKCS  
LSSSEE ERFISIRRPK T PASSDFSDL NT Q TNW T K SL PLPTPEE K M RQ Q AQ TVQ ADW PINITG E  
NFDRQASLRRSLIYTDTLVRRPK KVKRRKTITGVPDNIQKELASGTGQDDADGHSVYTPDHYST 
LGRFNSCRSAGQRSETRDSSCQTEDVKWPPSMRRIRAQKGQGIAAQMGHFSGSSGNMSVLSDS  
AGIVFPSRLDSDAGFHSLPRSGARANIQSLEPRLGALGPAGDMNGTFLYQRGHPQADENLGHLG  
GASGTGTLLRPKSQELRHFESENIM S P A C W S  P H A T Y S T S IIP N A T L S S S S E V IA IP T A Q S A G Q  
RESKSSGSSHARIKSRDHLISRHAVKGDPQSPGRHWNEGHATILSQDLDPHSPGEPALLSLCDS  
AVPLNAPANRENGSQAMPYNCRNNLAFPAHPQDVDGKSESSYSGGGGHSSSEPWEYKSSGNGRA  
SPLKPHLATPGYSTPTSNMSSCSLDQTSNKEDAGSLYSEDHDGYCASVHTDSGHGSGNLCNSSD  
GFGNPRHSVINVFVGRAQKNQGDRSNYQDKSLSRNISLKKAKKPPLPPSRTDSLRRIPKKSSQC  
NGQVLNESLIATLQH SLQLSLPGKSGSSPSQSPCSDLEEPW LPRSRSQ STVSAGSSM TSATTPN  
VYSLCGATPSQSDTSSVKSEYTDPWGYYIDYTGMQEDPGNPAGGCSTSSGVPTGNGPVRHVQEG  
SRATM PQVPGGSVKPKIMSPEKSHRVISPSSGYSSQSNTPTALTPVPVFLKSVSPANGKGKPKP  
K V P E R K S S L IS S V S IS S S S T S L S S S T S T E G S G T M K K L D P A V G S P P A P P P P P V P S P P F P C P A D R S  
P F L P P P P P V T D C S Q G S P L P H S P V F P P P P P E A L IP F C S P P D W C L S P P R P A L S P IL P D S P V S L P L P  
PPLLPSSEPPPAPPLDPKFM K DTRPPFTNSGQPESSR GSLRPPSTKEETSRPPM PLITTEALQ M  
VQLRPVRKNSGAEAAQLSERTAQEQRTPVAPQYHLKPSAFLKSRNSTNEMESESQPASVTSSLP  
TPA K SSSQ G DH G SAAERG G PVSRSPG APSAG EA EAR PSPSTTPLPDSSPSRK PPPISK K PK LFL  
WPPPQKDFAVEPAENVSEALRAVPSPTTGEEGSVHSREAKESSAAQAGSHATHPGTSVLEGGA  
AGSMSPSRVEANVPMVQPDVSPAPKQEEPAENSADTGGDGESCLSQQDGAAGVPETNAAGSSSE  
ACDFLKEDGNDEVMTPSRPRTTEDLFAAIHRSKRKVLGRRDSDDDHSRNHSPSPPVTPTGAAPS  
LASPKQVGSIQRSIRKSSTSSDNFKALLLKKGSRSDTSARM SAAEM LKNTDPRFQRSRSEPSPD  
APESPSSCSPSKNRRAQEEW AKNEGLM PRSLSFSGPRYGRSRTPPSAASSRYSM RNRIQSSPMT  
VISEGEGEAVEPVDSIARGALGAAEGCSLDGLAREEMDEGGLLCGEGPAASLQPQAPGPVDGTA  
SAEGREPSPQ CG GSLSEES
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MPFYRRTWPQRLCPRNPPQQLAELRDVSHLAALSLLRQLADLCGHSLALLEDLEGHLLALGRR  
TDSLYRRTVRLRRRLPCRLLGPEEDEEELGAANSGRENATATAHSRSSWRQPVNVFLSSGRPPS  
VEELLREAQLNLQSLLQEEYEEQYSEARLVGQTFRSSDEATKPTPNPRPQSARRLEFILM PTKR  
Q L SE DE TTT Q G V RAPE ASL SL STT A DK Q TAW NSL FPL PILE EK RW PQ LCSTQ SDIV PINISET R  
MHPSVFILATGQQFDKHASLRHSLFNTETAVNPKSTLRRRRTIIGFSNFSQRDQGHSNSPAGSV  
AHSTTSDIRPSHSVPEGVHGRVAVGQDARFPSLTSPVLRTPSSEPDEPHQARSGPNPPGM ESMG  
MVYSVPSSCNGPTESTFSTSWKGDAFTYMTPSATSQSNQVNENGKNPSCGNSWVSLNKVPPLVP  
KEAATLLVARDNPAGCSGSAGYPERLIQQRHMPERPSKIGLLTSGTSRLETGPGGASRFRERSL  
SVPTDSGTTDVDYDEEQ KANEACALPFASTSSEG SNSADNIASLSAQQEAQHRRQRSKSISLRK  
AKKKPSPPTRSVSLVKDEPGLLPEGGSALPKDQRPKSLCLSLEHQGHHSSHPDAQGHPAIPNHK  
DPESTQ FSHHW YLTDW K SGDTYQSLSSSSTATGTTVIECTQVQGSSESLASPSTSRATTPSQLS  
IE VE AR E ISS P G R P PG L M S P SS G Y S SQ S E T PT P T V SM SL T L G H L P P P SS S V R V R PV V P E R K S SL  
PPTSPM EK FPK SR LSFDLPLTSSPNLDLSG M SISIRSK TK V SRH H SETN FG V K LAQ K TNPNQ PI  
MPM VTQSDLRSVRLRSVSKSEPEDDIESPEYAEEPRAEEVFTLPERKTKPPVAEKPPVARRPPS  
LVHK PPSV PE EY A LT SPTL AM PPRSSIQ H A R PL PQ D SY TV V R K PK PSSFPDG RSPG ESTA PSSL  
V FTPFASSSDAFFSGTQ QPPQGSVEDEGPKVRVLPERISLQSQEEAEKKK GKIPPPVPK KPSVL  
Y LPLT SPT AQ M EAYVAEPRLPLSPIITLEEDTK CPATG DDLQ SLG SSVEPG TEEK SLISDK TAE  
WIAEDDDDVFVASRTTEDLFTVIHRSKRKLLGWKEPGSGSSANLDAGRNDDFKALLQKKGSKAT  
PR SR P SA A E L L K T T N PL A R R IIA Q FSK D Y E T T D N PST
NHSL3
MVVFVGRRLPALLGLFKKKGSAKAENDKHLSVGPGQGPGSAVDEHQDNVFFPSGRPPHLEELHT  
QAQEGLRSLQHQEKQKLNKGGWDHGDTQSIQSSRTGPDEDNISFCSQTTSYVAESSTAEDALSI  
RSEMIQRKGSTFRPHDSFPKSGKSGRRRRERRSTVLGLPQHVQKELGLRNEREAPGTPRAPGAR  
DAVRIPTVDGRPRGTSGMGARVSLQALEAEAEAGAETEAMLQRHIDRVYRDDTFVGRSTGTRAP  
PLTRPM SLAVPG LTG G AG PAEPLSPAM SISPQ ATYLSK LIPH A VLPPTV DW ALG RCSLRTLSR  
C SL H SA SPA SV R SL G R FSSV SSPQ P R SR H P S SS SD T W SH S Q S SD T IV S D G ST L S SK G G S E G Q P E  
S ST A SN SW PPPQ G G SG R G SPSG G ST A E A S D T L S IR SS G Q L SG R S V SL R K L K R P P P PP R R T H S L  
HQRGLAVPDGPLGLPPKPERKQQPQLPRPPTTGGSEGAGAAPCPPNPANSWVPGLSPGGSRRPP  
R SPE RT L SPSSG Y SSQ SG T PT L PPK G L A G PPA SPG K A Q PPK PE R V T SL R SPG A SV SSSL T SL C S  
S S S D P A P S D R S G P Q IL T P L G D R F V IP P H P K V P A P F S P P P S K P R S P N P A A P A L A A P A W P G P V S T  
T D A S P Q S P P T P Q T T L T P L Q E S P V IS K D Q S P P P S P P P S Y H P P P P P T K K P E V W E A P S A S E T A E E P  
L Q DPN W PPPPPPA PE E Q D L SM A D FPPPE E A FFSV A SPE PA G PSG SPE L V SSPA A SSSSA T A L Q I  
QPPGSPDPPPAPPAPAPASSAPGHVAKLPQKEPVGCSKGGGPPREDVGAPLVTPSLLQMVRLRS  
VGAPGGAPTPALGPSAPQKPLRRALSGRASPVPAPSSGLHAAVRLKACSLAASEGLSSAQPNGP  
PEAEPR PPQ SPA STA SFIFSK G SRK LQ L ER PVSPET Q A DL Q R N LV A ELR SISE Q R PPQ APK K SP  
KAPPPVARKPSVGVPPPASPSYPRAEPLTAPPTNGLPHTQDRTKRELAENGGVLQLVGPEEKMG  
LPGSDSQKELA
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Construct
name
Amino
acids
Domains Size (kDa) 
(excluding. N- 
terminal tag)
N-terminally 
tagged with....
Size (kDa) 
(including. N- 
terminal tag)
Functional assay
NHSC1 1430-
1630
Half of putative WH2 domain 
and the C-terminal epitope for 
the anti-NHS antibody
24.12(201 aa) GST 50.12 Characterisation of a c- 
terminal antibody
Subcellular
Localisation
NHSC2 471-
1630
CA domains 1 and 2, WH2 
domain
139.20 (1160 aa) Myc 140.52 GST pull-down/actin 
assay
Subcellular
Localisation
NHS-CA1 616-704 Putative CA domain 1 + 
additional a.a. sequence
10.68 (89 aa) GST 36.68 Actin assay
NHS-CA2 500-615 Putative CA domain 2 + 
additional a.a. sequence
13.92 (116 aa) GST 39.92 Actin assay
Table 1 Cloned domains of the NHS protein in prokaryotic and/or mammalian expression vectors.
Refer to figures 6.7 and 6.19 for a schematic representation of NHS construct
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Publications arising from this study
Identification of the gene for Nance-Horan syndrome (NHS).
J  Med Genet. 2004 Oct;41(10):768-71.
Refinement of the X-linked cataract locus (CXN) and gene analysis for CXN and 
Nance-Horan syndrome (NHS).
Ophthalmic Genet. 2004 Jun;25(2): 121-31.
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